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Endometrial adenocarcinoma, originating from the glandular epithelial cells of the uterine 
endometrial lining, is one of the most prevalent cancers amongst women in the Western 
world.  The prostaglandin F2α (PGF2α) receptor (FP) is upregulated in endometrial 
adenocarcinoma.  A previous microarray analysis of endometrial adenocarcinoma cells 
(Ishikawa) identified numerous targets of PGF2α-FP signalling including angiogenic factors, 
VEGF-A, FGF-2, CXCL1 and CXCL8 and antiangiogenic factors ADAMTS1.  The 
regulation of VEGF-A, FGF-2, CXCL1 and CXCL8 was confirmed by previous studies 
using an in vitro model system, of Ishikawa cells stably expressing the FP receptor to levels 
observed in cancer (FPS cells).  In this thesis, ADAMTS1 expression was found to be 
upregulated in endometrial adenocarcinoma samples compared to normal endometrium.  
Using FPS cells, ADAMTS1 expression was regulated in an extracellular signal regulated 
kinase 1/2 (ERK1/2) independent manner involving activation of nuclear factor of activated 
T cells (NFAT).  Angiogenic and antiangiogenic proteins secreted by epithelial cells, in 
response to PGF2α-FP receptor signalling, could therefore regulate vascular function in a 
paracrine manner.  Hence this thesis examines the role of angiogenic factors FGF2, CXCL1 
and CXCL8, secreted into PGF2α-treated FPS cell conditioned medium (P CM), in the 
regulation of endothelial cell function in vitro. 
 
Firstly, using an in vitro model system, treatment of human umbilical vein endothelial cells 
(HUVECs) with P CM increased endothelial network formation and proliferation, compared 
to control CM.  Immunoneutralisation of FGF2, CXCL1 and CXCL8 from the P CM 
reduced endothelial cell network formation and proliferation (P<0.05).  In addition, 
inhibition of their receptors (FGFR1 and CXCR2) with chemical antagonists decreased 
endothelial cell network formation and proliferation (P<0.05) in response to treatment with P 
CM.  This indicates that FGF2, CXCL1 and CXCL8 are paracrine effectors of FP-mediated 
endothelial cell network formation and proliferation. 
 
Next, the mechanisms by which FGF2 regulates P CM-induced endothelial cell network 
formation and proliferation were investigated. Using specific inhibitors of cell signalling, 
FGF2-FGFR1 was found to regulate endothelial cell proliferation via the mTOR pathway.  
In contrast, FGF2-FGFR1 signalling mediated endothelial cell network formation via the 




Angiogenesis is maintained by a balance of pro-and antiangiogenic factors.  Hence, 
concomitantly with the upregulation of proangiogenic factors, antiangiogenic proteins 
ADAMTS1 and regulator of calcineurin 1 (RCAN1) were upregulated by P CM treatment of 
HUVECs.  They were subsequently shown to limit endothelial cell network formation and 
proliferation in response to P CM. 
 
Finally, the role of PGF2α in angiogenesis was investigated using two in vivo models.  PGF2α 
treatment did not increase angiogenesis in a sponge matrigel mouse model.  In a xenograft 
mouse model, PGF2α-FP signalling increased expression of angiogenic factors in human 
epithelial cells and mouse stroma but this did not enhance microvessel density.   
 
Taken together, this thesis had highlighted that PGF2α-FP receptor signalling stimulates 
expression of pro-and antiangiogenic factors that in turn regulate endothelial cell function. 
However, in vivo studies demonstrate that PGF2α-FP receptor interaction does not impact on 
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1 Literature Review. 
1.1 Introduction 
This chapter intends to review the literature in the context of endometrial cancer, 
prostaglandins and angiogenesis.  It will summarise the multitude of data relating to 
the role of proangiogenic and antiangiogenic factors and the signal transduction 
pathways regulating endothelial cell function.  Endometrial cancer is the most 
common gynaecological cancer among women in the Western world.  Therefore, 
effective antiangiogenic therapy in endometrial cancer could provide curative and 
palliative care for thousands of women.  In order to identify effective targets of 
antiangiogenic therapy in women suffering from endometrial cancer, the pathways 
regulating its initiation and progression must be elucidated. 
1.2 Endometrial adenocarcinoma 
Endometrial adenocarcinoma is the fourth most common cancer and the most 
common gynaecological cancer amongst women in the Western world.  In 2009 the 
American Cancer Society estimated that there would be 42,106 new cases of 
endometrial cancer representing 6% of total new cancer cases for the year (Jemal et 
al., 2009).  In addition, it was estimated that 7,780 deaths will occur from 
endometrial cancer cases contributing to 3% of total female deaths from cancer in a 
year (Jemal et al., 2009).  The five year survival rate for endometrial cancer is 
approximately 83% for all races (Jemal et al., 2008a).  However, the most effective 
form of treatment in use is the surgical removal of the uterus, by hysterectomy or 
laparoscopy.  Perhaps due to the lack of new treatments for endometrial cancer, the 
five year survival rates have not improved over the last 30 years (Jemal et al., 
2008a). 
 
More than 80% of endometrial cancers are endometrial adenocarcinomas which 
originate from the endometrial lining.  There are a variety of methods to group 
endometrial cancers for example; endometrial adenocarcinomas can be defined as 
two different types, Type 1 which are well, moderately or poorly differentiated 
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endometrioid cancers under oestrogen control (Doll et al., 2008).  Type 2 
endometrial cancers are poorly differentiated, non-endometrioid, papillary serous 
carcinomas (Doll et al., 2008).  These two types of endometrial adenocarcinoma 
appear to have distinct gene expression patterns for example, COX-1 was found to be 
upregulated in papillary serous carcinomas compared to endometrioid serous 
carcinomas (Maxwell et al., 2005).  In 1997 it was found that loss of function 
mutations in phosphatase and tensin homolog (PTEN), an essential lipid 
phosphatase, were associated with 55% of endometrial cancers, more so than other 
cancers such as gastric, colorectal and pancreatic cancer (Kong et al., 1997).  Further 
studies have found that Type 1 endometrial carcinomas often exhibit a PTEN 
mutation whereas Type 2 endometrial carcinomas do not commonly exhibit a PTEN 
mutation and more often have mutated TP53 gene which encodes the master cell 
cycle regulator p53 (Doll et al., 2008) (Brosh and Rotter, 2009; Okamoto et al., 
1991).  Approximately 2-4% of endometrial cancers are sarcomas which originate 
from the smooth muscle of uterine wall called mixed mullerian tumours (Maxwell et 
al., 2005). These mixed mullerian tumours are aggressive and associated with a poor 
prognosis (Maxwell et al., 2005).  This thesis will concentrate on endometrial 
adenocarcinomas of Type 1 as the model cell line used in this thesis is the well 
differentiated Ishikawa cell line.  In addition, Type 1 endometrioid, endometrial 
adenocarcinoma biopsy samples will be subdivided into well (grade 1), moderately 
(grade 2) and poorly (grade 3) differentiated samples for analysis in this study.   
However, in spite of the differences in gene expression between endometrial cancer 
types, they share clinical similarities in their association with obesity, race, oestrogen 
and tamoxifen (Doll et al., 2008).  Despite past and present research, the processes 
controlling the initiation and progression of endometrial adenocarcinoma are poorly 
understood.  Further investigations into the mechanisms controlling endometrial 
adenocarcinoma tumourigenesis are required in order to develop new therapeutic 
strategies.   
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1.2.1 Endometrial adenocarcinoma in relation to the normal 
endometrium 
1.2.2  Normal endometrium-form and function 
The normal human endometrium is a dynamic tissue of the uterine corpus 
undergoing continuous menstrual cycles of proliferation, differentiation, breakdown 
and repair in the absence of pregnancy (Gargett and Rogers, 2001).  The average 
menstrual cycle length is between 28 and 32 days although this varies with age 
(Chiazze et al., 1968).  The menstrual cycle can be separated into proliferative and 
secretory stages with each divided into early, mid and late stages.  The progression of 
the menstrual cycle stages is under hormonal control mediated through the 
expression of molecular effectors such as growth factors (Jabbour et al., 2006a).  The 
cycle begins after menstruation, menses, the breakdown and shedding of the 
functional layer of the endometrium.  Rapid proliferation of the functionalis is 
required to replace the tissue lost.  This is stimulated by the circulating ovarian 
steroid oestrogen.  The proliferative effects of oestrogen have been examined in a 
variety of cell types as the regeneration of the functionalis requires the proliferation 
of epithelial and stromal cells, including the endothelial cells lining blood vessels 
(Albrecht et al., 2003a; Albrecht et al., 2003b; Fujimoto et al., 1997; Jabbour et al., 
2006a).   
 
Following the late proliferative stage is the early secretory stage during which the 
endometrium is prepared for embryo implantation (Jabbour et al., 2006a).  The rise 
in progesterone levels counteracts the oestrogenic proliferative effects enabling 
cellular differentiation, although there are still areas of growth around the spiral 
arteries (Jabbour et al., 2006a).  The main blood supply is provided by the spiral 
arterioles which coil in the newly formed functionalis layer to present a larger 
surface area for the exchange of oxygen and nutrients.  The subepithelial capillary 
plexus in the basalis, located just below the functionalis, also develops as an essential 
blood supply that reaches maturity in the early-mid secretory phase (Gargett and 
Rogers, 2001; Krikun et al., 2004).  The endometrium is most receptive to embryo 
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attachment in the early-mid secretory phase (Jabbour et al., 2006a).   In the event of 
the attachment of an embryo, the endometrium undergoes decidualisation, a special 
differentiation event controlled by crosstalk between the embryo and endometrium 
(Jabbour et al., 2006a).  Without embryonic implantation a drop in progesterone 
levels causes an increase in the expression of inflammatory mediators in the 
endometrium, resulting in breakdown and shedding of the upper third layer of the 
endometrium thereby completing the menstrual cycle (Jabbour et al., 2006a). 
 
1.2.3  Factors influencing the transition from normal to diseased state 
Endometrial adenocarcinoma occurs most commonly in post-menopausal women 
(Amant et al., 2005).  Interestingly, a later onset of menopause, after the age of 55, is 
associated with a 79% increased risk of endometrial cancer, compared to women 
whose menopause occurred by age 45 (Setiawan et al., 2007).  The occurrence of 
endometrial adenocarcinoma in post-menopausal women has been shown to be 
facilitated by long term use of oestrogen only hormone replacement treatment (HRT) 
(Pike et al., 1997).  This association led to the use of the combined HRT, oestrogen 
with progesterone, which decreases the risk of HRT inducing endometrial 
adenocarcinoma (Pike et al., 1997).  The unopposed oestrogen hypothesis was 
proposed in the 1980s to increase the mitotic index of the endometrium thereby 
increasing the possibility of cell mutations and tumour growth (Zeleniuch-Jacquotte 
et al., 2001). 
 
Unopposed oestrogen may also be the cause of the increased incidence of 
endometrial cancer in overweight individuals (Calle and Kaaks, 2004; Zeleniuch-
Jacquotte et al., 2001).  In 1949 a cohort study investigating endometrial cancer 
found that there was an increased incidence of endometrial cancer in overweight 
patients (Palmer et al., 1949).  Since this latter study, many more studies have 
confirmed the association of endometrial cancer with obesity.  Some studies have 
suggested that obesity may account for approximately 40% of the incidences of 
endometrial cancer (Bergström et al., 2001; Calle and Kaaks, 2004). Diabetes, an 
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obesity associated disease has also been linked to endometrial cancer further 
suggesting that a disruption in hormonal control may be critical to the onset of 
endometrial cancer (Fig. 1)(Calle and Kaaks, 2004).  In type 2 diabetes and obesity, 
increased levels of insulin are produced to counteract the development of insulin 
resistance.  The increased levels of insulin cause a decrease in the production of 
insulin-like growth factor binding protein 1 (IGFBP1).  This leads to an increase in 
circulating levels of Insulin like growth factor (IGF).  IGF is a growth factor that can 
cause the proliferation of many cell types including endothelial cells and cancer cells 
(Pollak, 2008).  In endometrial cancer increased levels of IGF1 are observed (Soufla 
et al., 2008).  Obesity in post menopausal women can also cause an increase in 
aromatase levels causing higher levels of active oestrogen to be produced 
(Zeleniuch-Jacquotte et al., 2001).  Oestrogen, when unopposed by progesterone can 
promote endometrial cancer, partly through the increased production of IGF1 (Calle 
and Kaaks, 2004; Zeleniuch-Jacquotte et al., 2001).  In pre-menopausal women a 
loss of progesterone production, due to ovarian androgen production or anovulation, 
can result in a decrease in IGFBP1 synthesis which may increase the risk of 
endometrial cancer (Calle and Kaaks, 2004).  It is therefore clear that obesity, 
diabetes and endometrial cancer are inherently linked through their relationship with 
oestrogen, progesterone and IGF (Fig. 1).   
 
IGF is not the only effector of oestrogen-regulated endometrial cancer.  In addition, 
PAX2 is a transcription factor whose expression is under the control of oestrogen and 
tamoxifen (Shang, 2006). The induction of PAX2 expression by oestrogen and 
tamoxifen has been found to enhance in vitro endometrial cancer cell proliferation 
and in vivo endometrial cancer xenograft growth (Wu et al., 2005).  During 
development PAX family proteins are widely expressed however, in most adult 
tissue their expression is switched off by methylation and histone deacetylase 
(HDAC) binding (Shang, 2006).  In endometrial cancer however, the expression of 
PAX2 is high due to loss of methylation along with the HDAC1 binding complex in 
the Pax gene promoter (Wu et al., 2005).  Incidentally, in a different study, 
immunohistochemical analysis of endometrial cancer suggested that the expression 
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of HDAC1 was decreased compared to normal endometrium, suggesting that 
HDAC1 along with Pax are involved in the epigenetic control of endometrial cancer 
(Krusche et al., 2007).    These data indicate that PAX2 is a molecular effector of 
oestrogen and tamoxifen in the progression of endometrial cancer (Shang, 2006).   
 
 
Fig. 1 The relationship between diabetes, obesity and endometrial cancer.  Adapted 
from Calle et al. (2004).  High insulin levels seen in patients with type 2 diabetes and obesity 
can increase in IGF levels through the promotion of bioavaliable oestrogen.  In the 
endometrium an increase in IGF can promote tumour cell proliferation. Pre-menopausal 
women may be genetically predisposed these pathways. Insulin can also increase sex 
hormone binding globulin (SHBG) which increases the bioavailability of oestrogens. 
 
 
In addition to molecular effectors, other regulators may be involved in oestrogen-
regulated endometrial cancer for example, tamoxifen-bound oestrogen receptor can 
interact with p160 steroid receptor coactivators (SRC) (Shang and Brown, 2002; Xu 
et al., 2009a).  There are three forms of SRC 1, 2 and 3 of which SRC3 expression 
has been found to be increased in endometrial cancer (Balmer et al., 2006; Xu et al., 
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2009a).  The interaction of oestrogen and progesterone receptors with SRC enables 
SRC to modulate downstream signalling pathways from the receptors (Balmer et al., 
2006).  For example, SRC3 is involved in EGFR activation and thereby stimulates 
the ERK1/2 pathway involved in proliferation (Xu et al., 2009a).  Interestingly, 
Shang et al. found that in Ishikawa cells treated with tamoxifen, IGF-1 upregulation 
was inhibited by SRC-1 siRNA (Shang and Brown, 2002). 
 
The incidence of endometrial cancer is less in African American, Native Hawaiians, 
Japanese Americans, and Latina women compared to Caucasian American women 
however the reasons underlying this difference are not clear (Setiawan et al., 2007). 
In the US there is a decreased survival rate for endometrial cancer in the African 
female population compared to the Caucasian female population (Jemal et al., 
2008b).  Evidence suggests that this difference is not due to any difference in 
treatments but is due to a higher occurrence of poorly differentiated endometrial 
adenocarcinoma in the African female population suggesting that the more serious 
disease state is responsible for the decrease in survival rate (Maxwell et al., 2006).   
 
Other factors that have been associated with endometrial cancer risk are nulliparity 
and having a first-degree relative with endometrial cancer (Amant et al., 2005).  In 
contrast, oral contraceptive, combined oestrogen and progesterone, use may decrease 
the risk of endometrial cancer (Amant et al., 2005; Calle and Kaaks, 2004).  Also, 
physical activity is known to decrease the risk of many cancer types including breast 
cancer and endometrial cancer (Calle and Kaaks, 2004; McTiernan, 2008).  Due to 
the strong link between endometrial cancer and obesity it is evident that physical 
activity associated with weight loss and a reduction in bioavailable oestrogens may 
help to decrease an individuals risk of endometrial cancer (Calle and Kaaks, 2004; 
McTiernan, 2008).  In a slight contradiction to the healthy lifestyle, smoking may 
also decrease the bioavailability of oestrogens and is associated with a decreased risk 
of endometrial cancer (Amant et al., 2005).  Interestingly, a recent population based 
cohort study suggested that sun exposure, including sun-bed use more than three 
times a year, may decrease the risk of endometrial cancer by as much as 40% 
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(Epstein et al., 2009).  Epstein et al. hypothesise that the decreased risk of 
endometrial cancer could be a result of increasing vitamin D levels although as yet 
there is little evidence for the link between vitamin D deficiency and endometrial 
cancer (Epstein et al., 2009; McCullough et al., 2008). 
 
1.2.4 Current treatments for endometrial adenocarcinoma. 
Patients with localised endometrial adenocarcinoma are treated with standard 
treatment of hysterectomy with or without radiotherapy (Creutzberg et al., 2000).  
For patients with regional and distant metastases the standard treatment is 
inadequate.  Progestrone therapy has been investigated in cancers however it was 
only found to have a beneficial effect if patient cancers expressed the receptors for 
oestrogen and progesterone (Amant et al., 2005).  Alternatively, a phase 3 trial of a 
three-drug treatment of doxorubicin, cisplatin and paclitaxel (TAP) showed 
improved survival rates compared to a two-drug treatment of doxorubicin and 
cisplatin (AP) (Fleming et al., 2004).  Unfortunately, the TAP treatment was 
associated with an increase in peripheral sensory neuropathy due to neurotoxicity 
(Fleming et al., 2004).  Combinations of other drugs including paclitaxel and 
platinum may show as great affects as TAP without the neurotoxicity (Amant et al., 
2005).  A more recent trial found that AP treatment of higher grade cancers 
significantly increased survival compared to whole abdomen radiation (Randall et 
al., 2006).  Due to this, chemotherapy is now used along side radiation in some 
advanced cases of endometrial cancer (Randall et al., 2006).  No molecular therapies 
are approved for the treatment of endometrial adenocarcinoma however, the tyrosine 
kinase inhibitor sunitinib, in combination with radiotherapy, is currently in phase 1 
clinical trials for cancers including endometrial adenocarcinomas.  Sunitinib inhibits 
the angiogenic signalling of tyrosine kinase receptors VEGFR, PDGFRb and c-kit 
(Ellis and Hicklin, 2008).  In vivo experiments found that sunitinib treatment reduced 
tumour xenograft growth and normalised tumour vasculature (Ellis and Hicklin, 
2008) (Hillman et al., 2009).  Therefore, sunitinib could enhance the delivery of 
chemotherapies (Hillman et al., 2009).  Inhibition of sunitinib in colorectal cancer 
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trials increased survival rates hence, sunitinib could be effectively used to treat other 
cancers (Ellis and Hicklin, 2008). 
 
It has recently been suggested that targeting of the biolipid hormone receptors, 
prostaglandin receptors, could be used to treat cancers including endometrial cancer 
(Jain et al., 2008; Sales et al., 2007).  However, the signalling pathways and cell 
functions controlled by prostaglandin receptor signalling must first be thoroughly 
investigated. 
 
1.3 Prostaglandins  
Prostaglandins are bioactive lipids synthesised from arachidonic acid (AA) by steps 
involving cyclooxygenase (COX) enzymes (Dubois et al., 1998). COX-1 and COX-2 
both regulate prostaglandin synthesis (Dubois et al., 1998). COX-1 is a constitutively 
active enzyme responsible for basal levels of prostaglandins and COX-2 is 
considered an inducible enzyme stimulated by growth factors and tumour promoters 
(Cha et al., 2005).  There are four main prostaglandins, PGD2, PGF2α, PGI2 and PGE2 
and seven corresponding receptors, DP, FP, IP and EP1-4 (Jabbour and Sales, 2004).  
Prostaglandin receptors belong to the group of G-protein coupled receptors (GPCRs).  
Once synthesised, prostaglandins can be transported out of the cell, via a 
prostaglandin transporter (PGT) situated in the cell membrane, and act in an 
autocrine/paracrine manner (Jabbour and Sales, 2004). 
1.3.1 Biological action of prostaglandins PLA2 and AA. 
Phospholipase A2 (PLA2) family of enzymes are involved in the rate-limiting step of 
arachidonic acid (AA) release (Nakanishi and Rosenberg, 2006).  For example, 
cytoplasmic PLA2 (cPLA2) translocates to the intracellular membrane upon agonist 
stimulation when intracellular calcium levels are elevated (Alfranca et al., 2006).  
Once at the intracellular membrane, cPLA2 cleaves phospholipids containing AA 
(Fig.2) (Nakanishi and Rosenberg, 2006).   
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Fig.2. Biological action of cytoplasmic phospholipase A2 (cPLA2) on arachidonic 
acid(AA) release. Adapted from Nakanishi et al. (2006). 
 
In the proximity of cyclooxygenases (COX), AA is metabolised into prostaglandin 
precursors: prostaglandin endoperoxide G2 (PGG2) and prostaglandin endoperoxide 
H2 (PGH2) (Nakanishi and Rosenberg, 2006).  Recent research by Herbert et al. 
found that the spatiotemporal co-localisation of cPLA2 with COX-2 at the 
intracellular membrane is crucial for mediating prostaglandin production in 
endothelial cells (Herbert et al., 2007).  Consequently, sequestration of cPLA2 at the 
Golgi apparatus can prevent cPLA2 cleavage of AA and hence inhibit prostaglandin 
production (Herbert et al., 2007).  cPLA2 knockout mice have suboptimal production 
of prostaglandins, including prostaglandin F2α, and reduced fertility due to impaired 
implantation and embryogenesis (Bonventre et al., 1997; Nakanishi and Rosenberg, 
2006).  The negative effects of cPLA2 knockout on implantation in the mouse uterus 
can be partially rescued by the addition of prostaglandin E2 (Song et al., 2002). 
Interestingly, in cPLA2 striated muscle knockout cells there is exaggerated IGF-1 
signalling suggesting that cPLA2 is required for the negative regulation of IGF-1 
(Haq et al., 2003). In the suggested mechanism for this, arachidonic acid recruits 
protein kinase Cζ (PKCζ) to the intracellular membrane and increases the interaction 
of PKCζ with phosphate-dependent kinase-1 (PDK-1), thereby enhancing PKCζ 
activation by PDK-1 phosphorylation (Haq et al., 2003).   PKCζ is a n egativ e 
regulator of IGF-1 signalling and can inhibit ERK1/2 phosphorylation stimulated by 
IGF-1 (Haq et al., 2003).  Therefore, the regulation of AA by PLA2 is critical for 
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determining downstream signalling regulating many physiological processes 
(Nakanishi and Rosenberg, 2006).  PLA2 expression is increased in some types of 
cancer including prostate cancer where it is being considered as a possible 
therapeutic target for cancer treatment (Patel et al., 2008). 
 
Fig. 3 Schematic of the arachidonic acid (AA) metabolic pathway. Adapted from 
Alfranca et al.(2006).  
 
In addition to prostaglandin production, AA can be converted by lipoxygenases 
(LOX) to HETE and leukotrienes (Lötzer et al., 2007).  Additionally, in a non-
enzymatic process involving cytochrome P450, AA can also oxidise into iso-
eicosanoids and epoxides (Alfranca et al., 2006).  A by-product of AA metabolism is 
lysophosphatidic acid (LPA).  LPA and its metabolite 1-O-alkyl-2-acetyl-sn-glycero-
3-phosphocholine (PAF) are known to be involved in the regulation of inflammation 
and cancer (Nakanishi and Rosenberg, 2006).   This thesis however, will focus on the 
cyclooxygenases and their prostaglandin products.   
1.3.2 Cyclooxygenases 1 and 2 
There are three isoforms of cyclooxygenase (COX)-1, -2 and the splice variant of 
COX-1, COX-3, but of these COX-1 and COX-2 have been most extensively 
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characterised (Dubois et al., 1998; Kam and So, 2009).  COX enzymes catalyse the 
production of AA to prostaglandin endoperoxide G2 (PGG2) and from PGG2 to 
prostaglandin endoperoxide H2 (PGH2).  Interest in COX began in the early 1970’s 
when researchers discovered that aspirin inhibition of COX prevented PG secretion. 
Originally identified in during the study of anaphylaxis in guinea pig lungs, RSC 
(rabbit aorta contracting substance now called COX) was found to be inhibited by 
aspirin (acetylsalicylic acid) and indomethacin (Piper and Vane, 1969).  Following 
further studies Vane et al. suggested that COX was responsible for the production of 
prostaglandins and the target of aspirin inhibition (Vane, 1971).  Aspirin, along with 
other COX inhibitors, is a non-steroidal anti-inflammatory drug (NSAID) that 
inhibits both COX-1 and COX-2. 
 
COX-1 is expressed in most tissue under basal conditions and is generally thought to 
be responsible for maintenance of basal levels of prostaglandins regulating 
homeostasis (Cha and DuBois, 2007).  In contrast, COX-2 expression is generally 
absent in basal tissue conditions but increases in response to external stimuli (Cha 
and DuBois, 2007).  As an inducible enzyme, COX-2 is often elevated during 
inflammation and cancer (Dubois et al., 1998).  Due to this, recent research has 
investigated the effects of specific COX-2 inhibitors in the resolution of diseases 
(Cha and DuBois, 2007).   
 
The use of cyclooxygenase inhibitors in therapeutic treatment met with a hurdle 
when in 2004 the COX-2 inhibitor rofecoxib (Vioxx), used in a clinical trial to 
prevent colorectal adenoma, was found to cause cardiovascular problems including 
increased blood pressure (William et al., 2009).  This is due to the fact that COX 
enzymes are essential for normal vascular function and homeostasis through 
regulating the production of a range of different prostaglandins (Dubois et al., 1998).  
Vioxx was immediately withdrawn from the market by its producer Merck, a step 
that affected thousands of people in the UK and US.  Henceforth, new research into 
the targeting of other members of the COX-PG cascade, such as prostaglandin 
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synthases and prostaglandin receptors, may identify alternative therapeutic targets 
(Cha and DuBois, 2007).   
1.3.3 Prostaglandin synthases 
Isomerisation of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2, F2α, 
prostacyclin (PGI2) or D2 is catalysed by prostaglandin synthase (PGS) enzymes 
(Murakami et al., 2002).  In addition, thromboxane endoperoxide synthase catalyses 
the production of thromboxane (TXA2) from PGH2 (Murakami et al., 2002).  The 
prostaglandin produced is determined by the specific PGS that processes PGH2 for 
example, prostaglandin E2 is produced by prostaglandin E2 synthase (PGES) activity 
and prostaglandin F2α is produced by prostaglandin F2α synthases (PGFS). In fact 
there are three isoforms of PGES but of these cytosolic PGES (cPGES) and 
membrane-bound PGES (mPGES) have been most extensively studied (Murakami et 
al., 2002).  cPGES is ubiquitously expressed and catalyses the products of COX-1 
whereas mPGES is inducible and functionally coupled to COX-2 (Murakami et al., 
2002; Murakami et al., 2000).  PGF2α formation by PGFS can occur in three ways, 
from PGH2 catalysed by 9,11-endoperoxide reductase activity, from PGD2 catalysed 
by 11-ketoreductase or from PGE2 catalysed by 9-ketoreductase (Watanabe, 2002).  
Human placental PGF2α synthase (AKR1B1) and human lung PGF2α synthase 
(AKR1C3) are two aldoketoreductase enzymes that synthesise PGF2α (Watanabe, 
2002).  There are three forms of PGFS that have been identified in bovine 
endometrium, liver and lung cells (Waclawik et al., 2006).  PGFS has been found to 
be expressed in the pig endometrium where it is localised to the glandular epithelial 
cells (Waclawik et al., 2006).  In bovine endometrial stromal cells, the presence of 
both oestrogen and progesterone was found to upregulate PGFS expression (Xiao et 
al., 1998).  In 1978 Marcus et al. found that prostaglandins E2, F2α and D2 also 
spontaneously formed from PGH2 via non-enzymatic oxidation whereas prostacyclin 
formation was enzymatic (Marcus et al., 1978).   
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1.3.4 Prostaglandins F2α and E2 
Prostaglandin F2 (PGF2α) is a potent regulator of reproductive function involved in 
promoting luteolysis, parturition, myometrial contractions and cervical ripening 
(Blatchley and Donovan, 1969).  More is known about the role of PGF2α  in 
mammalian species such as sheep, goats and cows than humans (Johnson, 2001). 
Originally prostaglandin F2α secretion was found to be associated with luteolysis in 
guinea pigs (Blatchley and Donovan, 1969).  Prostaglandin E2 (PGE2) has a similar 
role to PGF2α in the female reproductive system although it is luteotrophic.  
However, in comparison to PGF2α, much more is known about the role of PGE2 in 
cell migration, proliferation, apoptosis, vascular formation and cancer.  
 
As prostaglandins regulate reproductive function in many species they therefore have 
multi-species importance.  For example, in the bovine endometrium, prostaglandin 
E2 secretion is increased in endometrial infection, endometritis, upon activation of 
toll-like receptor 4 (TLR4) signalling by bacterial LPS (Herath et al., 2006). The 
increase in PGE2 may be due to PLA2 elevation, rather than an increase in PGES, and 
can disrupt the ovarian cycle and luteolysis (Herath et al., 2006; Herath et al., 2009).  
In the farming industry, the effects of endomitritis on cattle reproduction can be 
devastating due to its detrimental effects on pregnancy and birth rates (Herath et al., 
2006).  Therefore, research into prostaglandin signalling pathways could have 
beneficial effects for many species.  
 
One important species dependent difference of the PGF2α receptor, FP receptor, is 
that the bovine and ovine FP receptor has at least two different splice variants 
including FPA and FPB.  Fujino et al. found that the downstream signalling of these 
two isoforms varies for example, PGF2α can stimulate TNF-alpha promoter activity 
and T-cell factor (Tcf)/β-catenin signalling through the FPB but not the FPA receptor 
in HEK-293 cells stably expressing either the ovine FPA or FPB receptors (Fujino and 
Regan, 2004; Fujino et al., 2004).  In the humans, as well as the hFPA isoform, the 
splice variant hFPS was identified by Regan et al. and is expressed in vascular 
endothelial, trophoblast, and decidual cells from human placenta, although its 
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functional relevance is unknown (Vielhauer et al., 2004).  This thesis will 
concentrate on human PGF2α-FP signalling and therefore focus on the full length 
human FP receptor.  
 
Both prostaglandin E2 and F2α are implicated in tumourigenesis.  In colorectal cancer, 
prostaglandins E2 has been found to be elevated (Wang et al., 2006).  Additionally a 
role for PGF2α and its FP receptor in endometrial adenocarinoma has been 
ascertained (Sales et al., 2005).  An early experiment of phorbol ester (TPA) 
carcinogenesis in rat skin revealed that after TPA treatment a rapid increase in PGE2 
was observed followed by an increase in PGF2α  (Furstenberger et al., 1989).  Tumour 
growth induced by TPA could be inhibited by indomethacin and rescued by the 
addition of PGF2α but not PGE2 to indomethecin treated tumours (Furstenberger et 
al., 1989).  Furstenberger et al. suggested that PGE2 was responsible for initial stage 
of carcinogenesis, involving hyperproliferation and PGF2α upregulation, and 
subsequently PGF2α was responsible for the later stage of carcinogenesis 
(Furstenberger et al., 1989).  A more recent in vitro update of this experiment, 
utilising the COX-2 specific inhibitor NS398, found that PGF2α co-treatment with 
TPA could rescue NS398 inhibited fibroblast cell transformation (Wolfle, 2003).  
Similar to earlier studies, prostaglandin F2α was unable to initiate cell transformation 
therefore it is primarily a promoter of cell transformation in multi-step 
carcinogenesis (Wolfle, 2003).  Previous research published by Sales et al. showed 
PGF2α-FP signalling in endometrial adenocarcinoma stimulates the production of 
growth factors (Sales et al., 2007; Sales et al., 2005).  Similarly, PGE2 signalling 
through the EP2 receptor can stimulate the secretion of growth factors in endometrial 
adenocarcinoma (Sales et al., 2004b).  Recently, Rao et al. published an article 
showing that PGE2 signals through the EP4 receptor to promote blood vessel growth 
in an in vivo sponge assay (Rao et al., 2007). 
1.3.5 Prostaglandins as inflammatory mediators  
Prostaglandins are lipid mediators of inflammation and their role in inflammation has 
been investigated over the last 30 years (Kundu and Surh, 2008).  Both 
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prostaglandins and their catalytic COX enzymes are implicated in the mediation of 
inflammation within and out with the reproductive tract.  As COX-2 is the inducible 
COX enzyme, which increases in prostaglandin production in response to external 
stimuli, it is this isoform that has been most widely studied in inflammation of 
malignant diseases (Kundu and Surh, 2008).  Prostaglandin E2 is the most thoroughly 
studied COX-2 product in inflammation (Kundu and Surh, 2008).  The expression of 
COX-2, along with prostaglandin production, is elevated in inflammatory disorders 
including intestinal cancer, rheumatoid arthritis and endometriosis (Kundu and Surh, 
2008).  COX-2 and PGE2 expression are induced by inflammatory cytokines 
including CXCL1 and CXCL8 in cancer, as well as bacterial lipopolysaccharide 
(LPS) in an inflammatory disease of the bovine endometrium endometritis, and 
phorbol esters (Furstenberger et al., 1989; Herath et al., 2006; Kundu and Surh, 
2008).  mPGES expression is induced by cytokine IL-1β or LPS treatment in a 
variety of cell types (Murakami et al., 2002). Both prostaglandin E2 and COX-2 can 
promote cell proliferation and prevent apoptosis (Jain et al., 2008; Krysan et al., 
2005; Sales et al., 2004c; Tsujii and DuBois, 1995).  In vivo, PGE2 and COX-2 
promote tumorigenesis in experimental animals (Amano et al., 2003; Jain et al., 
2008; Rao et al., 2007).  Additionally, prostaglandins including PGE2 and PGF2α can 
act as an immune cell chemoattractants (Arnould et al., 2001; Kundu and Surh, 
2008).  In malignant oesophageal cells, Abdalla et al. showed that inflammation was 
not necessarily the main cause of COX-2 upregulation but chronic inflammation and 
COX-2 expression in combination contribute to tumour progression (Abdalla et al., 
2005). Prostaglandins can upregulate many inflammatory mediators including 
CXCL1 and CXCL8 as well as COX-2 (Sales, 2009; Wallace et al., 2009; Wang et 
al., 2006).  Therefore, in inflammatory diseases COX-2 and prostaglandins may help 
to maintain a persistent inflammatory state through a positive feedback loop.  This 
may be one mechanism supporting the theory that tumours are wounds that do not 
heal (Dvorak, 1986).   
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1.3.6 Prostaglandins in endometrial adenocarcinoma 
The secretion of prostaglandin E2 is elevated in endometrial adenocarcinoma samples 
compared to normal endometrial samples (Jabbour et al., 2001).  In addition, the 
levels of PGE2 receptors, EP2 and EP4 are also upregulated in endometrial 
adenocarcinomas samples compared to normal endometrial samples (Jabbour et al., 
2001; Sales et al., 2004b).  Jabbour et al. found that COX-2, PGES, PGE2 and EP4 
were expressed in the glandular epithelial and endothelial cells of well, moderately 
and poorly differentiated endometrial adenocarcinomas (Jabbour et al., 2001).  
Research by Sales et al. showed that PGE2 treatment of endometrial adenocarcinoma 
explants increased VEGF-A secretion (Sales et al., 2004b).  Both the FP receptor and 
VEGFA mRNA are upregulated in endometrial adenocarcinoma (Sales et al., 2005).  
In endometrial adenocarcinoma samples, the FP receptor colocalises with VEGF-A 
protein and the endothelial cell marker CD31 (Sales et al., 2005).  The expression of 
prostaglandins and their receptors on the vasculature of endometrial adenocarcinoma 
suggests a direct role for prostaglandin E2 and F2α in the regulation of endometrial 
adenocarcinoma blood vessels.  In addition, the expression of angiogenic proteins 
induced by prostaglandins suggests that PGs may control the paracrine action of 
growth factors on the vasculature.   
 
Both PGF2α and PGE2 can directly stimulate the proliferation of endometrial 
glandular epithelial Ishikawa cells (Milne et al., 2001; Sales et al., 2004c).  
Furthermore, the expression of the potent growth factor FGF2 is also upregulated in 
endometrial adenocarcinoma samples compared to normal endometrial samples 
(Sales et al., 2007).  FGF2 expression is induced by both PGF2α and prostacyclin in 
Ishikawa cell lines (Sales et al., 2007; Smith et al., 2006).  Sales et al. found that 
FGF2 contributed to the autocrine regulation of Ishikawa cell proliferation by PGF2α.  
In addition, Furstenberger et al. found that PGE2 and PGF2α promote cell 
transformation (Furstenberger et al., 1989).  It is therefore possible that 
hyperproliferation of endometrial cells, required for progression to a malignant state, 
could be enhanced by the autocrine/paracrine effects of prostaglandin-receptor 
signalling.   
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PGs may be involved in the mechanisms controlling cell metastasis and invasion 
(Sales et al., 2008).  Recently, Sales et al. found using Ishikawa cells stably 
overexpressing the FP receptor (FPS cells), that prostaglandin F2α signalling through 
the FP receptor stimulated changes in lamellipodia formation, as a result of actin 
cytoskeletal reorganisation, and enhanced cell migration (Sales et al., 2008).  In 
addition, this alteration in cell morphology enhanced cell integrin contacts with the 
extracellular matrix and led to an increase in cell adhesion (Sales et al., 2008).  The 
cellular processes of adhesion and migration are important factors in the invasion and 
metastatic spread of cancers (Avraamides et al., 2008; Bergers et al., 2003). 
 
As mentioned in the previous section, prostaglandins are inflammatory mediators and 
their role as such may influence the initiation and progression of endometrial 
adenocarcinoma (Kundu and Surh, 2008).  Consequently, the evidence from previous 
research suggests that in endometrial adenocarcinoma, prostaglandins may be 
involved in vascular formation, cell proliferation, cell transformation, cell migration 
and inflammation, thereby contributing to tumour progression. 
1.4 Prostaglandin signalling in endometrial adenocarcinoma. 
Prostaglandins increase the transcription of proteins through signalling pathways, the 
contents of which depend on the specific prostaglandin and receptor interacting.  As 
GPCRs, the downstream signalling of the prostaglandin receptor is in the first 
instance determined by the G-protein α subunit to which it is coupled.  For example, 
the FP, EP1 and EP3 receptor couple to the Gαq (Gq) whereas EP2, EP3 and EP4 
couple to Gαs (Gs).  GPCRs do not form stable multiprotein complexes but instead 
activate enzymatic effectors that stimulate second messenger signalling pathways 
(Luttrell and Luttrell, 2004).  Gq is responsible for activating IP3 after binding and 
activation of phospholipase C (PLC).  Alternatively the Gs can bind and activate 
adenylyl cyclase (AC) which subsequently activates cyclic AMP (cAMP).  In 
Ishikawa cells stably overexpressing the FP receptor, PGF2α  interacting with the FP 
receptor stimulates the release of inositol 1, 4, 5-triphosphate (IP3) (Fig. 4).  This is 
via the action of the Gq protein and phospholipase C (Jabbour et al., 2006b).  The 
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activation of IP3 leads to c-Src activation, Epithelial Growth Factor receptor (EGFR) 
signalling and subsequent Ras-ERK1/2 pathway activation. Similarly PGE2 binding 
to an EP receptor causes an increase downstream Ras-ERK1/2 pathway activation 
via the cAMP pathway.  Sales et al. found that cyclic AMP (cAMP) levels were 
increased after PGE2 treatment in Ishikawa cells stably expressing the EP2 receptor 
and cAMP accumulation was similar to that seen in endometrial adenocarcinoma 
explants treated with PGE2 (Jabbour et al., 2001; Sales et al., 2004b).   
 
Fig. 4. PGF2α-FP signaling upregulates angiogenic VEGFA expression.  Prostaglandin 
F2α, synthesized from AA by COX catalytic activity, is transported out of the cell by 
prostaglandin transporter (PGT).  PGF2α bind to Gq-coupled F-prostanoid receptor (FP) 
activating IP phosphorylation and cSRC.  C-Src stimulates MMP cleavage of HB-EGF from 
the plasma membrane or directly phosphorylates EGFR.  HB-EGF ligand activation of EGFR 
activates MAPKinase pathway involving Ras and ERK1/2 phosphorylation.  Dimerised 
ERK1/2 can translocate to the nucleus and enhance VEGF transcription. VEGF secreted 
protein can act in a paracrine manner on endothelial cells to stimulate angiogenesis. 
 
ERK1/2 activation can induce COX2 and subsequently gene transcription and the 
production of other factors occurs.  COX2 has been shown to be upregulated in many 
cancers including colon cancer and endometrial adenocarcinoma (Sales et al., 2007) 
(Tsujii et al., 1998). 
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Prostaglandins, acting via their receptors, can increase the transcription and secretion 
of angiogenic factors in endometrial adenocarcinoma cells and consequently have the 
potential to stimulate angiogenesis (Sales and Jabbour, 2003).  Previous studies have 
shown that treatment of FP-overexpressing Ishikawa cells (FPS cells) with PGF2α 
 promotes the release of angiogenic factors VEGF, bFGF, CXCL1 and CXCL8 (Sales 
et al., 2007; Sales et al., 2005; Sales, 2009; Wallace et al., 2009).  These angiogenic 
factors may in turn function in an autocrine/paracrine manner on cells of the 
endometrium to promote angiogenesis.   
 
In support of the involvement of the prostaglandin pathway in the mediation of 
cancer vascular remodelling, a recent study found that the coordination of COX-2, 
EGFR and MMPs are essential for progression of metastatic mammary tumours 
(Gupta et al., 2007).  Gupta et al. demonstrated that combinational targeting COX-2, 
EGFR, MMP1 and MMP2 with shRNA significantly reduced mammary tumour 
xenograft vessel length, lumen number, vessel branching and vascular permeability 
and stated that it was this mode of action that was responsible for the reduction in 
pulmonary metastasis (Gupta et al., 2007).  As described above, COX-2 activity 
catalyses the formation of prostaglandins which signal via the pathway described 
above. MMPs are a critical part of the transactivation of EGFR involved in the 
prostaglandin pathway as they cleave HB-EGF from the cell surface membrane 
allowing it to bind EGFR and activate downstream signalling such as the ERK1/2 
pathway.  In vitro studies using inhibitors of COX-2, EGFR, Src and MMPs abolish 
prostaglandin signalling (Battersby et al., 2007; Krysan et al., 2005; Sales et al., 
2004a; Sales et al., 2005; Smith et al., 2006).  Therefore, knocking out each of these 
components would perhaps multi-mechanistically apprehend prostaglandin receptor 
signalling and its effects on vascular function.  It would be interesting to compare the 
efficacy of this combinational targeting with the targeting of individual prostaglandin 
receptors.   
 
In addition to prostaglandin F2α-FP signalling via ERK1/2 in glioma cells, Ras/Raf 
activation can trigger Tcf transcription of immediate early response gene Cyr61 (Xu 
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et al., 2009b).  Cyr61 is involved in angiogenesis and has been found to be 
upregulated in endometrial adenocarcinoma (Watari et al., 2009).  Therefore, the 
upregulation of Cyr61 by PGF2α in endometrial adenocarcinoma could be involved in 
the progression of the disease through mechanisms such as the regulation of 
angiogenesis. 
1.5 Initiation and progression of cancer 
To understand the factors affecting the initiation and progression of endometrial 
cancer it is important to be aware of the key processes of tumourigenesis.  There are 
multiple genetic changes that can lead to the transformation of a normal cell into a 
cancer cell, thus factors regulating the initiation and progression of cancers vary 
depending on the cancer type.  However, despite their differences, the progression of 
most invasive cancers can be defined by general steps, the hallmarks of cancer 
(Hanahan and Weinberg, 2000).  These hallmarks, reviewed by Hanahan et al., 
obtained by cells in order to become fully tumourigenic are: insensitivity to anti-
growth signals, self-sufficiency in growth signals, evading apoptosis/limitless 
replicative potential, sustained angiogenesis and tissue invasion and metastasis, 
depicted schematically in Fig. 5 (Hanahan and Weinberg, 2000).  In addition, the 
progression of cancer requires a resistance to hypoxia and acid-mediated toxicity as 
well as the assimilation of inflammation (Colotta et al., 2009; Gatenby and Gillies, 
2008).  Cell-cell competition governed by Darwinian rules, adaptive survival, is also 
proposed to apply in the context of cancer (Moreno, 2008). 
 
Cell transformation from normal non-malignant to malignant cells involves somatic 
cell mutation.  Numerous genes have been identified to be mutated in cancer thereby 
conferring oncogenicity.  Among these are cell cycle regulators such as TP53, BCL-
2 and MYC (Gatenby and Gillies, 2008).  However, there are epigenetic influences 
such as DNA methylation and acetylation that control gene expression and cell 
transformation (Wu et al., 2005). Epigenetic changes have been found in endometrial 
cancer.  For example, in a study by Wu et al., 75% of endometrial cancers were 
found to lack methylation of the Pax2 gene (Wu et al., 2005).  Pax2 is expressed 
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during development but silenced by methylation in most adult cells (Shang, 2006).  
In endometrial cancer cell xenografts, Pax2 expression promotes tumour growth (see 
section 1.2.3 for more details) (Wu et al., 2005). 
 
 
Fig. 5. The carcinogenesis pathway. Adapted from Gatenby et al. (2008). Carcinogenesis 
is the multi-step transformation from normal cells to hyperplasia, atypia (cells show 
abnormalities of the nucleus), ductal cancer in situ (non-invasive), microinvasive cancer 
ending in invasive and metastatic cancer. The microenvironmental barriers to proliferation 
influence the phenotypical strategy of cancer cells and the hallmarks of cancer define each 
step of the progression.   
 
1.5.1 Microenvironmental barriers to proliferation. 
Microenvironmental proliferative barriers shape tumour populations through 
selective adaptation, see Fig. 5 (Gatenby and Gillies, 2008). This is a theory 
described by Gatenby and Gillies in a recent review (Gatenby and Gillies, 2008).  
They hypothesise that the first genetic changes in tumourigenesis must enable the 
clonal expansion of dysplastic cells in situ and therefore involve either a mechanism 
to overcome contact inhibition or detachment-induced apoptosis, that is, anoikis 
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(Gatenby and Gillies, 2008). The initial proliferation of dysplastic epithelial cells in 
an avascular landscape, away from a blood supply and the growth factor gradient, 
requires cells to increase their autocrine-paracrine production of factors, upregulate 
cell surface receptors or increase transduction pathways (Gatenby and Gillies, 2008).  
An increase in signal transduction pathways regulating glucose metabolism helps 
tumour cells to survive in increasingly hypoxic conditions.  Eventually however, the 
need for more oxygen and nutrients promotes in situ tumours to become invasive.  
Microinvasion, the migration of dysplastic cells into adjacent areas of normal cells, 
enables tumour cells to escape the constraints of cell-cell competition for substrates 
that limits their proliferation (Gatenby and Gillies, 2008).  Tumour cells come into 
direct contact with blood vessels further advancing their proliferation.   
Consequently, Gatenby et al. propose that microinvasion is the critical adaptive 
landscape for tumourigenesis that involves the coordination and cooperation of 
tumour cells and neighbouring stromal cells (Gatenby and Gillies, 2008).  
1.5.2 Co-ordination of different cell types  
The progression of cancer requires the collaboration of many different cell types.  
Stromal cells, including immune cells, endothelial cells and fibroblast cells have 
been found to be essential for tumourigenesis in part due to the paracrine action of 
their secretory factors such as cytokines and growth factors (Hanahan and Weinberg, 
2000).  Bone marrow-derived myeloid cells, such as macrophages, neutrophils, 
eosinophils, mast cells and dendritic cells have all been shown to have a role in 
controlling vascular growth in cancers (Murdoch et al., 2008).   For example, tumour 
associated macrophages (TAMs), are attracted to tumours by tumour secretory 
factors such as vascular endothelial growth factor (VEGF) (Murdoch et al., 2008).  
TAMs secrete cytokines such as CCL5 and CCL2 which promote cancer 
progression.  Also, TAMs secrete factors that promote tumour blood vessel growth 
such as VEGF and fibroblast growth factor 2 (FGF2) (Murdoch et al., 2008).  Bingle 
et al. found that in vitro co-incubation of TAMs with breast cancer cells increased 
blood vessel sprouts from spheroids as well as VEGF-A expression, and that in vivo 
increased the number of vessels formed in tumour spheroids (Bingle et al., 2006).  
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Recently, CD4+ T cells were found to enhance malignant mammary breast invasion 
by secreting IL-4 and inducing the secretion of macrophage epidermal growth factor 
(EGF) (McCarthy, 2009). 
1.5.3 The invasive and metastatic phenotype. 
The migration of tumour cells to secondary sites around the body is known as 
metastasis.  Certain tissues of the body are more susceptible to formation of 
secondary tumours, irrespective of blood flow, and these sites are referred to as 
metastatic niches (Psaila and Lyden, 2009).  Current theories of metastasis suggest 
that invasive malignant cells from the primary tumour site can migrate and settle in 
metastatic niches where they form micrometastases (Psaila and Lyden, 2009). Once 
activated by the angiogenic switch, these micrometastases form macrometastases 
(Gao et al., 2009).  Common metastatic niches include the lung, liver and lymph 
nodes.  Recent research by Gao et al. found that bone marrow-derived endothelial 
progenitor cells (EPCs) are necessary for the transition from micro- to 
macrometastases in the mouse lung (Gao et al., 2009).   
 
1.5.4 Evasion of apoptosis  
Approximately 60 billion new cells are generated by the average adult human body 
everyday (Cotter, 2009).  To balance this proliferation, cell death, apoptosis, is 
required.  The evasion of apoptosis is required for cell transformation (Cotter, 2009).  
In order to avoid cell death, tumour cells use a variety of methods such as the 
upregulation of anti-apoptotic factors or the mutation of survival factors.  One of the 
first anti-apoptotic factors identified and investigated was B cell lymphoma gene 2 
(BCL2) (Cotter, 2009).  This anti-apoptotic factor was classified as an oncogene due 
to its ability to enable a cell to survive in uncharacteristic conditions.  In addition, 
TP53, a tumour suppressor gene is mutated in most human cancers, including 
endometrial adenocarcinoma (Doll et al., 2008).  In non-cancerous cells the TP53 
protein product, p53, functions as a transcription factor promoting growth arrest, 
DNA repair and apoptosis through mechanisms including, the activation of apoptotic 
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factor BAX (Brosh and Rotter, 2009).  Therefore, the loss of function mutation of 
TP53 enables cancer cells to evade cell death.   
 
The cell cycle regulator and tumour-suppressor phosphatase with tensin homology 
(PTEN) is frequently found to have loss of function mutations in cancer (Cully et al., 
2006).  In particular, Type 1 endometrioid cancers frequently exhibit PTEN 
mutations resulting in decreased PTEN expression (Kong et al., 1997).  PTEN is a 
negative regulator of PI3K signalling (see section 1.7.2) whose phosphatase action 
converts PIP3 to PIP2, thereby reversing the kinase action of PI3K, shown in Fig. 6.  
As PI3K is involved in promoting cell proliferation stimulated by growth factor-
receptor binding, PTEN acts as an antiproliferative factor (Cully et al., 2006).  In 
addition, PTEN can inhibit cell proliferation dependent on ERK1/2, as well as 
prevent cell spreading and migration (Cully et al., 2006).  Daikoku et al. found that 
the conditional deletion of PTEN, in the endometrium of mice, rapidly induced the 
occurrence of endometrial cancer (Daikoku et al., 2008).  This induction of 
endometrial cancer by PTEN deletion was associated with an increase in COX-2 
expression and increase in Akt phosphorylation (Daikoku et al., 2008).   
 
Fig. 6. PTEN regulation of the PI3K pathway. Adapted from Cully et al. (2006) 
  
It is clear that cell transformation is essential for the transition from normal to 
cancerous cells however, this appears to be a two-way process.  On rare occasions, 
cancer cells can revert back to normal cells (Telerman and Amson, 2009).  For 
example, a survival factor, known as translationally controlled tumour protein 
(TCTP), is down regulated in cancer cells undergoing reversion. TCTP is a highly 
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conserved, ubiquitous, multifunctional, pro-survival factor that controls growth in 
mammalian embryonal stem cells, normal somatic cells and cancer cells (Telerman 
and Amson, 2009).  Inhibition of TCTP in breast cancer cells can cause malignant 
cell growth to revert to normal cell growth (Telerman and Amson, 2009).  
Investigations into the mechanisms governing these rare events suggest that 
activating tumour reversion pathways could be a target for new treatments (Telerman 
and Amson, 2009). 
 
1.6 Vascular function in cancer  
Carmeliet recently stated that, ‘Angiogenesis research will probably change the face 
of medicine in the next decades, with more that 500million people worldwide 
predicted to benefit from pro- or anti-angiogenesis treatments.’ (Carmeliet, 2005).  
This concept has promoted interest in the field of angiogenesis research particularly 
in cancer. 
1.6.1 Angiogenesis/neovascularisation  
One process that is essential for the growth of any cancers larger than 2mm diameter 
is the formation of a sufficient blood supply (Abulafia et al., 1995).  The blood 
supply delivers oxygen and nutrients to a tumour in order to meet its metabolic 
demand.  As shown in Fig. 7, this formation of a new vasculature from existing 
vessels involves the coordination of many different cell types and molecular effectors 
including growth factors and basement membrane proteins. Tumour vascularisation 
is different from vascularisation in normal tissue.  The tumour blood vessels formed 
are often irregularly shaped, dilated and can have dead ends (Bergers and Benjamin, 
2003). 
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Fig. 7 Tumour-induced angiogenesis. Adapted from Dorsam et al. (2007). 
 
As research has increased into the mechanisms of vascularisation a number of 
theories have arisen. The best know mechanism of angiogenesis, endothelial cell 
sprouting also called branching, was described by Auspunk and Folkman in 1977 
(Fig. 7) (Ausprunk and Folkman, 1977).  Sprouting angiogenesis is found in tumours 
and other sites of new vessel growth such as the corpus luteum before ovulation 
(Gargett and Rogers, 2001).  This mechanism involves the degradation of the 
basement membrane surrounding a vessel, followed by the migration of the 
endothelial cells towards a chemotactic stimulus.  The lumen of the new vessel is 
created by one or more endothelial cells curving whilst simultaneously being 
stabilised by reformation of the basement membrane and recruited pericytes (Bergers 
and Benjamin, 2003).  Each step involves the coordination of different angiogenic 
factors (Ausprunk and Folkman, 1977). 
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In the vascular system the sprouting of endothelial cells to form vessel branches can 
be under the regulation of vascular endothelial growth factor-A (VEGF-A), Delta 
like 4 (Dll4) and the Notch pathway, shown in Fig. 8 (Horowitz and Simons, 2008).  
VEGF-A stimulates the secretion of Notch1 ligand Dll4 from endothelial tip cells.  
Dll4 then activates Notch1 which negatively regulates VEGFR2 expression in the 
cells behind the tip cells (phalanx cells) (Hellstrom et al., 2007).  Thus a negative 
feedback loop prevents aberrant endothelial cell sprouting (Horowitz and Simons, 
2008).  This process is likely to be complemented by other signalling mechanisms 
for example, the matrix metalloproteinase MT1-MMP is also crucial for endothelial 
tip cell function and matrix invasion of developing branches (Stratman et al., 2009).     
 
Fig. 8. Branching morphogenesis of blood vessels under the control of VEGF-A-
Notch1 pathway. Adapted from Horowitz et al. (2008). 
 
The schematic in Fig. 9 shows other modes of vessel formation seen in tumours, as 
well as endothelial cell sprouting, including vessel co-option, intussusception, 
vasculogenesis, vascular mimicry and glomeruloid ‘looping’ angiogenesis (Dome et 
al., 2007).  Vessel co-option is defined as the growth of tumours along the existing 
blood vessels (Adams and Alitalo, 2007).  This may occur in the early stages of 
tumour microinvasion or metastatic growth and also in tumours growing in vessel 
rich regions such as the brain (Dome et al., 2007).  It is thought that the use of 
antiangiogenic drugs in the treatment of brain cancers may promote tumour growth 
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by vessel cooption as well as restoring the blood brain barrier and inhibiting the 
distribution of chemotherapy to tumour cells (Claes et al., 2008).  Therefore, the 
tumour context and method of vascularisation is particularly important when 
considering antiangiogenic treatments. 
 
Fig. 9.  Tumour vascularisation mechanisms. Adapted from Hillen et al. (2007).  
 
Intussusceptive microvascular growth (IMG) is a process of vascularisation where 
existing vessels are divided by connective tissue thereby increasing the number of 
vessels (Burri and Djonov, 2002).  This intussusception is seen in the developing 
lung but has also been investigated in the chick chorioallantoic membrane (CAM: 
see section 1.6.2.2) and cancer.  In the CAM, vascularisation is initiated by 
angiogenesis followed by IGM to expand the vascular network (Burri and Djonov, 
2002).  A previous study found intussusception occured complementary to 
angiogenesis in wound healing (Kilarski et al., 2003).  In large mammary tumours 
evidence of intussusceptive vascularisation is indicated by the presence of pillar and 
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mesh formations in a flattened vascular network as described by Djnov et al. in 2001 
(Burri and Djonov, 2002).   
 
Vasculogenesis, blood vessel formation de novo, is the development of new blood 
vessels from circulating endothelial progenitor cells (EPCs) originating from bone-
marrow and EPCs in situ (Eguchi et al., 2007).  This is an important process for the 
embryonic vascular development however its role in tumour angiogenesis is 
disputed.  As mentioned previously, work has shown that bone marrow derived EPCs 
do not play a role in the formation of vessels in tumour vascularisation however; 
previous research has found that EPCs promote macrometastatic tumour growth  
(Gao et al., 2009; Purhonen et al., 2008).  These discrepancies are likely due to 
differences in tumour type, stage and methods used to identify vessel-incorporated, 
BM-derived endothelial cells (Gao et al., 2009).  Stem cell models, either 2D or 3D, 
such as embryoid bodies (EB) can be used to assess molecules regulating 
vasculogenesis from embryonic stem cells (Jakobsson et al., 2007).  
 
Vascular mimicry also called ‘vasculogenic mimicry’ (VM) was a term used by 
Manoitis et al. to describe the process where cancer cells express an endothelial cell 
(EC) phenotype and form vessel-like networks (Dome et al., 2007; Hendrix et al., 
2003).  It is thought that tumour cells can redifferentiate into endothelial like cells 
and take on their roles to aid tumour growth (Hillen and Griffioen, 2007).  Manoitis 
et al. found, using primary human uveal melanoma sections, that in many areas of the 
cancers the cells lining the blood vessels were not immunoreactive for endothelial 
cell markers, CD31, CD34 or von Willebrand factor (VWF) but were positive for S-
100 protein, a characteristic of melanoma cells (Maniotis et al., 1999).  VM 
melanoma networks were found to be unaffected by angiogenic inhibitors such as 
endostatin therefore the molecules regulating VM, such as EphA2, may differ from 
those regulating angiogenesis (Hendrix et al., 2003).  Thus, once again it is important 
to identify the mode of vascularisation utilised by the tumour in order to tailor 
therapeutic treatments for optimum efficacy. 
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The term glomeruloid angiogenesis defines the process whereby tumour cells draw 
capillaries inward resulting in increased vessel loops (Dome et al., 2007).  Recently, 
Kilarski et al. found, in a study of in vivo wound healing and angiogenesis of the 
CAM, that tension mediates rapid expansion of the vasculature by the elongation of 
vessel loops (Kilarski et al., 2009).  This expansion of translocated vessels by 
biomechanical forces can also be called ‘looping vascularisation’ (Benest and 
Augustin, 2009). 
 
Throughout the body there is another network of vessels called lymph vessels that 
maintain normal tissue homeostasis (Adams and Alitalo, 2007).  Fluids that leak out 
of blood vessels and into the tissue, due to intravascular pressure, are collected by the 
lymph vessels and recycled back into the blood (Adams and Alitalo, 2007).  In 
addition, the lymph vessels play an essential role in the regulation of the immune 
system by transporting antigen presenting cells and lymphocytes to the lymphoid 
organs (Rogers et al., 2008).  Interestingly blood vessels developed first in 
evolutionary terms as lymph vessels are only found in amphibians and higher 
organisms (Adams and Alitalo, 2007).  The lymph vessels are lined with lymphatic 
endothelial cells identified by their expression of lymph specific markers such as 
lymphatic vascular endothelial hyaluronan receptor-1 (LYVE-1), podoplanin and 
prox-1 (Rogers et al., 2008).  The growth of lymph vessels also occurs in cancer 
along side angiogenesis (Adams and Alitalo, 2007).  The mechanisms promoting 
lymph vessel growth are thought to be similar to those promoting blood vessel 
growth, mainly lymphangiogenesis in tumours (Avraamides et al., 2008).  In 
endometrial adenocarcinoma peri-tumoural lymphatic endothelial vessels are present 
in larger amounts than in normal endometrial tissue, correlating with VEGF-C and -
D expression, and this is may contribute to tumour progression and metastasis 
(Donoghue et al., 2007). 
 
Although all these methods have been found to facilitate tumour growth, it is 
generally thought that angiogenic sprouting is the rate limiting vascular step involved 
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in the growth of most tumours (Horowitz and Simons, 2008).  Thus, this thesis will 
focus on vascularisation by angiogenesis. 
 
1.6.2 Vascular research in vitro and in vivo 
1.6.2.1 In vitro 
Organ culture assays, such as the rat aortic ring assay, are a commonly used in vitro 
method for the assessment of angiogenesis (Auerbach et al., 2003).  For example, 
isolated rat aorta can be cut into segments and cultured on an extracellular matrix 
such as matrigel.  Over a period of 7-14 days, the effect of exogenous factors, 
including recombinant proteins and cell conditioned medium, on the outgrowth of 
endothelial cells can be assessed (Auerbach et al., 2003).  An advantage of this assay 
is that surrounding non-endothelial cells, such as pericytes, are present to enhance 
endothelial outgrowths (Auerbach et al., 2003).  However, tumour angiogenesis 
primarily involves microvascular cells rather than the aortic endothelial cells. In 
addition, the assay conditions must be optimised so that the angiogenic effects of the 
treatment on endothelial cells can be distinguished from the effects on non-
endothelial cells.  
 
Cell culture models can be used in order to examine the effect of particular 
molecules on individual in vivo processes involved in angiogenesis.  In vitro assays 
of endothelial cell migration, proliferation, differentiation (network formation), 
permeability and adhesion are used to identify the role of specific proteins and their 
receptors in the regulation of endothelial cell function (Auerbach et al., 2003; 
Folkman and Haudenschild, 1980).  Advantages to in vitro cell culture are the ready 
availability of cells and avoiding the use of laboratory animals.  Also assay 
conditions can be carefully monitored to limit variability and enhance 
reproducibility.  However, cells in culture may express different proteins to those in 
vivo and the time period of investigations varies from in vivo situations therefore, in 
vitro results should be viewed with prudence and compared with in vivo data when 
possible (van Beijnum and Griffioen, 2005).  Expression profiles of endothelial cells 
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in vitro has revealed that genes involved in endothelial cell proliferation of 
monolayers are cell cycle regulators whereas genes associated with network 
formation are involved in cell-cell/matrix contacts, cell matrix turnover and 
signalling (van Beijnum and Griffioen, 2005).   
 
The number and scope of studies into endothelial cell biology increased after the 
isolation of endothelial cells from human umbilical cord veins by Nachman and Jaffe 
in the early 1970’s (Nachman and Jaffe, 2004).  Nachman and Jaffe used a set of 
criteria to confirm that the isolated cells were human umbilical vein endothelial cells 
(HUVECs) rather than fibroblasts (Nachman and Jaffe, 2004).  These included: 
examining cell morphology as HUVECs form a monolayer of very flat, polygonal-
shaped cells giving a cobblestone appearance, the presence of Weibel-Palade bodies 
in the cytoplasm, positive reactivity for ABO blood group antigens which was 
consistent with the blood type from the donor umbilical cord, and the expression of 
endothelial cell specific von Willebrand factor vIII (VWF, antihemophilic factor) 
antigen (Nachman and Jaffe, 2004).  The in vitro culture of endothelial cells has 
enabled researchers to investigate the functions of endothelial cells in the normal 
vasculature as well as pathophysiological conditions such as cardiovascular disease 
and cancer.  In the normal vascular system endothelial cells were identified as master 
regulators of blood fluidity due to their thromboregulatory role (Nachman and Jaffe, 
2004).  In cancer, the in vitro study of endothelial cells has identified angiogenic 
factors secreted by tumour cells that promote endothelial cell function (Folkman and 
Haudenschild, 1980; Folkman et al., 1971).  This has led to the development of 
antiangiogenic drugs to target the formation and function of the tumour vasculature 
in order to disrupt tumour growth (Ferrara and Kerbel, 2005).  Research in the past 
30 years has continued to utilise HUVECs due to their ready availability, low cost, 
ease of isolation and identification.   
1.6.2.2 In vivo 
In vivo vascularisation models are used to verify the physiological relevance of the in 
vitro findings. Models include: the chick chorioallantoic membrane (CAM), the rat 
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cornea angiogenesis assay, the matrigel sponge mouse model and the tumour 
xenograft mouse model (Auerbach et al., 2003).  The CAM is commonly used as an 
in vivo model to investigate tumour angiogenesis.  The CAM is a double layer of 
mesoderm in which a rich vascular capillary network develops, connected to the 
embryonic circulation by arteries and veins (Ribatti and Kwang, 2008). The capillary 
plexus of the CAM mediates gas and nutrient exchange for the developing embryo.  
Vascularisation of the CAM is thought to occur initially by angiogenic sprouting 
followed by rapid vascular network expansion by IMG (Ribatti and Kwang, 2008).   
The coordination of endothelial cell functions during angiogenesis can be tested by 
use of agonists and inhibitors to target specific angiogenic pathways.  In this way in 
vitro results can be verified.  One advantage of the CAM is that up until day 10 the 
chick embryo is not immunocompetent so foreign cells grafted into the CAM are not 
rejected (Ribatti and Kwang, 2008).  In the 1980’s Palczak et al. used the CAM to 
graft endometrial adenocarcinoma samples and found that angiogenesis takes place 
during the growth of the grafted tumours (Palczak and Splawinski, 1989).  Recently 
Scavelli et al. used the CAM to show that implanting sponges soaked in bone 
marrow myeloma endothelial cell conditioned medium promotes tumour 
vascularisation which can be inhibited by zoledronic acid, an inhibitor of the VEGF-
A angiogenic response (Scavelli et al., 2007).   
 
More recently, investigations into tumour vascularisation have favoured the use of 
assays including, the matrigel sponge mouse model and the tumour xenograft mouse 
model.  These models allow the monitoring of tumour growth within a 
microenvironment more closely resembling the humans.  The matrigel sponge mouse 
(or rat) model has been extensively used by researchers to assess the proangiogenic 
or antiangiogenic effect of soluble compounds or cells of interest in vivo (Akhtar et 
al., 2002; Auerbach et al., 2003; Kyriakides et al., 2001).  The matrigel sponge 
mouse model involves for example, the injection of an angiogenic protein or cancer 
conditioned medium directly into subcutaneously implanted matrigel sponges.  After 
7-21 days of implantation and treatment in the host mice, the sponges are removed 
and vascular density can be assessed.  
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The tumour xenograft model involves injection of cells with tumourigenic potential, 
such as a cancer cell line, into mice with a compromised immune background to 
allow the formation of tumours in vivo (Curwen and Wedge, 2009).  Immuno-
compromised mice, such as nude mice lacking a thymus, are used so that the hosts do 
not reject the foreign cells (Rygaard and Povlsen, 1969).  Commonly, the 
tumourigenic cells are injected subcutaneously into the flanks of mice because this 
allows the tumour growth to be non-invasively monitored visually and with bilateral 
calliper measurement throughout the course of an experiment.  The tumours formed 
can be extracted from the mice and used to examine proliferation and vessel 
formation.  A frequently used marker of proliferation is Ki-67 protein which is 
present in cell nuclei during all proliferative stages of the cell cycle but absent in 
resting cells (Gerdes et al., 1984). 
 
1.6.2.3 Assessing microvascular density (MVD) 
There are a number of endothelial cell specific markers including, CD31 (PECAM1), 
CD34, CD105 (endoglin) and vWF (Zhang et al., 2002).  Immuno-staining of 
endothelial cell lined vessels with these markers enables the quantification of blood 
vessels, called microvascular density (MVD), within the tissue or tumour of interest.  
There are a variety of methods for the quantification of vessels such as the ‘hotspot’ 
method of counting, the Chalkey vessel count and more recent in vivo computational 
methods. The Chalkey vessel count can be performed on haematoxylin stained or 
endothelial marker stained sections of tissue.  This assessment of angiogenesis has 
been used since the 1940’s as a reproducible method of measuring microvascular 
density (MVD) (Chalkey, 1943).  
 
In the context of tumour growth, MVD was approved by Weidner et al. for the 
assessment of breast cancer and prostate cancer (Weidner et al., 1993; Weidner et al., 
1991).  Weidner et al. associated a poorer prognosis and the progression of cancer 
with an increase in MVD (Weidner, 1993).  This association together with the 
knowledge that tumour angiogenesis is essential for tumour growth led to an 
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increased interest in the possibility of reducing MVD, with antiangiogenic 
compounds, to prevent tumour growth.  The method of MVD assessment used by 
Weidner et al. involved the identification of vessel dense areas (at high 
magnification), ‘hotspots’, in which the number of vessels was then counted per area 
(mm2) (at low magnification) (Weidner et al., 1991).  More recently, computational 
methods of MVD analysis have been performed such as the automated counting of 
vessels in tissue sections after the photographs of sections have been converted to 
bitmaps (Fox et al., 1995).  Despite the advances in technology, the differences in 
accuracy of MVD assessment do not vary significantly with these ex vivo methods 
(Fox et al., 1995).  However, in vivo, non-invasive, 3D-imaging of vessels in 
tumours with the use of fluorescent markers such as rhodamine-dextran, 
macromolecular contrast agents, PET scanning and magnetic resonance imaging are 
providing more informative, context dependent information about the 3D-structure of 
vessels (McDonald and Choyke, 2003).  These methods can be used to quantify the 
number and spacing of blood vessels, measure blood flow and vascular permeability, 
and analyse cellular and molecular abnormalities in blood vessel walls (McDonald 
and Choyke, 2003).     
 
Quantification of blood vessels is not by itself a measure of tumour angiogenic 
activity but it is a useful prognostic indicator in a wide variety of cancers (Hlatky et 
al., 2002).  The minimum MVD relates to the metabolic burden set by the oxygen 
and nutrient consumption rate of the tumour, although MVD can exceed the 
metabolic burden.  Similarly, MVD is not by itself a measure of tumour progression.  
In fact the tissues of some tumours do not appear to have an increase in MVD 
compared to the normal tissue, MVD can even be lower, possibly due to the fact that 
these tumours are better adapted to survive hypoxia (Hlatky et al., 2002).  When 
assessing the effectiveness of antiangiogenic treatments, MVD should not be the 
only indicator as in some cases vessel number may decrease in proportion to tumour 
shrinkage so no overall decrease in MVD would be observed.  Other markers such as 
circulating levels of VEGFR2+ve cells and EPCs should be used alongside MVD 
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counts, as well as in vivo vascular imaging techniques, to indicate the effectiveness 
of inhibiting angiogenesis (Hlatky et al., 2002).   
1.6.3 Pro and Antiangiogenic factors regulating vascular function. 
Increased microvessel density (MVD) and vascular proliferation in cancers, such as 
endometrial cancer, have been shown to be associated with poorer prognosis 
(Czekierdowski et al., 2008; Stefansson et al., 2006).  In endometrial cancer there is 
an increase in microvessel density compared to normal endometrial control (Abulafia 
et al., 1995).  Microvessel density is associated with disease progression as it is 
increased in higher grade (poorly differentiated) endometrial cancers compared to 
lower grades (well differentiated) (Abulafia et al., 1995).  Each mode of 
vascularisation requires different stimulatory factors which may be secreted in part 
by the tumour cells.  The expression and secretion of protein from endometrial 
adenocarcinoma differs considerably from that of normal endometrial cells.  Many of 
the proteins, differentially expressed by endometrial adenocarcinoma, are involved in 
vascular formation and angiogenesis.   
 
This thesis will focus on the angiogenic factors, secreted from endometrial cancer 
cells as a result of the PGF2α-FP receptor signalling, and their paracrine action on 
endothelial cells. Therefore a more detailed understanding of certain signalling 
molecules involved in the growth factor pathways in endothelial cells is required and 
described below.   
1.6.4 Vascular endothelial growth factor-A (VEGF-A) 
The most notorious angiogenic factor, vascular endothelial growth factor-A (VEGF-
A), is expressed and secreted from endometrial adenocarcinoma in levels 
approximately 3-fold more than from normal endometrium (Sales et al., 2005).  In 
addition to its secretion from glandular epithelial cells, VEGF-A secreted from 
neutrophils may regulate both normal endometrial and endometrial adenocarcinoma 
angiogenesis (Gargett et al., 2001).  In the normal endometrium, the precise 
localisation and timing of VEGF-A expression is uncertain due to some conflicting 
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results (Krikun et al., 2004) but the presence of VEGF-A in the endometrium 
suggests that it will have a role in endometrial angiogenesis.  In the endometrium, 
VEGF-A can be secreted apically by glandular epithelial cells (Hornung et al., 1998) 
and from the stroma during the proliferative phase of normal endometrial cycle 
(Gargett et al., 1999).  This coordinates with an increase in VEGFR2 expression in 
capillaries of the proliferative phase (Meduri et al., 2000).  A more recent study 
found that VEGF-A protein was detected only in endothelial cells of the early 
secretory phase of the endometrial cycle (Saito et al., 2007).   
 
VEGF-A, also known as VEGF-165, belongs to a family of VEGF proteins 
consisting of four other members, VEGF-B, VEGF-C (VEGF-121), VEGF-D and 
placental growth factor (PlGF) (Ferrara et al., 2003).  Together with co-receptors 
such as HSPGs, the VEGF proteins bind tyrosine kinase VEGF receptors 1, 2 and 3 
(VEGFR1,2 and 3) (Ferrara et al., 2003).  VEGFR1 and VEGFR2 bind to all the 
VEGF proteins whereas VEGFR3 binds only VEGF-C and VEGF-D.  VEGFR1 and 
VEGFR2 are both commonly expressed on endothelial cells but VEGFR2 is the main 
receptor for transmitting VEGF-A intracellular signalling (Ellis and Hicklin, 2008).  
Studies to differentiate between the roles of VEGF-A to VEGFR1 or VEGFR2 
signalling highlighted, using the rat corneal angiogenesis assay, that VEGFR2 but 
not VEGFR1 is required for angiogenesis in vivo (Gille et al., 2001).  Similarly, in 
guinea pig skin, the Miles assay showed that VEGFR2, but not VEGFR1, was 
essential for increasing vascular permeability (Gille et al., 2001). In contrast, 
VEGFR1 was responsible for mediating VEGF-A induced migration of porcine 
aortic endothelial cells (Gille et al., 2001).  The same group also showed in HUVECs 
that VEGFR2, but not VEGFR1, is responsible for downstream activation of 
phosphoinositide 3-kinase (PI3K), p38 mitogen-activated protein kinase (P38), 
extracellular signal-regulated kinase 1/2 (ERK1/2) and phospholipase C (PLC) (Gille 
et al., 2001).  As shown in Fig. 10, VEGFR2 is a tyrosine kinase receptor and after 
autophosphorylation of Tyr1054 and Tyr1059, can bind to PLCγ and Shb domains in 
receptor substrate proteins (Fig. 10) (Olsson et al., 2006).  An important in vivo 
mouse study demonstrated that VEGFR2 phosphorylation at Tyr 1173 in the PLC 
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binding site is essential for vascular function in mouse embyrogenesis (Sakurai et al., 
2005).  In vitro, the activation of JNK and P38 pathways by VEGF-A has been 
shown to promote HUVEC tube formation and proliferation (Wu et al., 2006).  Also, 
in human intestinal microvascular endothelial cells (HIMEC), the ERK1/2 pathway 
activated by VEGF-A treatment was essential for network formation and 
proliferation (Rafiee et al., 2004).  In addition, VEGF-A to VEGFR2 signalling in 
HUVECs can increase the phosphorylation of focal adhesion kinase (FAK) to 




Fig. 10. Signaling intermediaries interacting with the intracellular domains of VEGFR2.  
Adapted from Ferrara et al. (2003).  
 
VEGFR3 is expressed only on adult lymphatic endothelial cells however; it is widely 
expressed in developing endothelia (Tammela et al., 2008).  Importantly, the 
expression of all VEGF receptors has been shown to be increased in a variety of 
tumours, both on epithelial and endothelial cells.  Recently VEGFR3 has been 
identified as regulating vascular formation via endothelial sprouting, branching and 
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proliferation in mouse tumour xenografts, postnatal retina and embryonic 
development (Tammela et al., 2008).  VEGFR3 is expressed in tip endothelial cells 
and research suggests that VEGFR3 expression can be induced by VEGF-
A/VEGFR2 signalling and decreased by a regulator of angiogenic sprouting, Notch 
(Tammela et al., 2008).  Upon ligand binding, the VEGF receptors can form homo- 
or heterodimers, perhaps explaining any over lap in receptor function.   
 
The VEGFRs and in particular, VEGFR2 can coordinate with other growth factor 
receptors, GPCRs, integrins, neuropilins and cadherins to facilitate downstream 
signalling (Tammela et al., 2005).  For example, transactivation of VEGFR2 by 
CXCR2, the GPCR for CXCL8 and CXCL1, is required to elicit CXCL8 induce 
endothelial cell permeability (Petreaca et al., 2007).  In HUVECs, VEGF-A binding 
to VEGFR2 induces the internalisation of junctional protein VE-Cadherin as part of 
its role in vascular permeability (Gavard and Gutkind, 2006).  Neuropilins can act as 
alternative receptors for VEGF-A and in this manner have been shown to enhance 
tumour angiogenesis (Geretti et al., 2008).    
 
VEGF-A-VEGFR2 can activate integrin alphaVbeta5 which is dependent on Src and 
PKC activation to facilitate angiogenesis (Avraamides et al., 2008; Friedlander et al., 
1995).  In addition, integrin alphaVbeta3 is needed for maximal VEGFR2 activation 
and optimal HUVEC migration, polarisation and proliferation (Soldi et al., 1999).  
Integrin inhibitors have not been as effective as expected at inhibiting angiogenesis 
in various cancers during clinical trials (Reynolds et al., 2009).  A recent research 
article demonstrates, in melanoma and lung carcinoma tumour grafts, that at low 
concentrations alphaVbeta3/beta5 integrin inhibitors actually promote tumour 
angiogenesis (Reynolds et al., 2009).  Reynolds et al. show that VEGFA-VEGFR2 
induced in vitro HUVEC network formation and migration can be enhanced by the 
addition of the alphaVbeta3/beta5 inhibitor which suppresses VEGFR2 degradation 
(Reynolds et al., 2009).  This research highlights the importance of understanding the 
concentration dependent effects of potential inhibitors in vivo and in vitro.   
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In the normal physiological state, the role of autocrine endothelial VEGF is crucial 
for maintenance of vascular homeostasis (Lee et al., 2007).  For example, Lee et al. 
showed in mice lacking endothelial VEGF expression, endothelial cell survival is 
reduced due to absence of intracellular VEGFR2 phosphorylation (Lee et al., 2007).  
This intracellular activation of VEGFR2 may be what distinguishes autocrine VEGF 
signalling from paracrine VEGF signalling.  Their hypothesis that VEGF may act 
through internalised VEGFR2 receptors on endosomes, to initiate signalling 
pathways distinct from the traditional paracrine signalling pathway, is particularly 
interesting (Lee et al., 2007).  
 
The cyclooxygenases and VEGF-A have been linked in pathways leading to 
increased angiogenesis in cancer.  Both COX-2 and VEGF-A expression is increased 
in endometrial adenocarcinoma (Jabbour et al., 2001; Sales et al., 2005).  VEGF-A to 
VEGFR2 downstream signalling can induce both COX-1 and COX-2 expression in 
HUVECs (Murphy and Fitzgerald, 2001).  This results in the secretion of 
prostacyclin (Murphy and Fitzgerald, 2001). Similarly, in HUVECs VEGF-A can 
upregulate prostaglandin E2 secretion by increasing COX-2 expression (Tamura et 
al., 2006).  Alternatively, COX-2 upregulates VEGF-A expression to facilitate 
angiogenesis and tumour growth in a sponge implant model and tumour xenograft 
model (Yoshida et al., 2003). 
 
Receptor tyrosine kinase inhibitors with selectivity for VEGFR, such as sorafenib 
and sunitinib are currently being used in clinical cancer trials (Ellis and Hicklin, 
2008). Bevacizumab (Avastin) is a humanized monoclonal antibody against VEGF is 
approved for treatment of colorectal cancers, metatstatic breast cancer and non-small 
cell lung cancer (Ellis and Hicklin, 2008).  However, combinational treatment of 
chemotherapy and radiotherapy appears to elicit a greater response than any 
individual treatment (Ellis and Hicklin, 2008).  An in vivo investigation using an 
orthotopic mouse model of uterine carcinoma suggested that Bevacizumab treatment 
in combination with docetaxal, an inhibitor of cell division, may be effective at 
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reducing angiogenesis and tumour growth of endometrial adenocarcinoma (Kamat et 
al., 2007).   
1.6.5 Angiopoietins 
In addition to VEGF-A, Angiopoietin 1 (Ang1) and Angiopoietin 2 (Ang2) are 
potent angiogenic growth factors (Augustin et al., 2009).  A study by Krikun found 
that Ang 1 mRNA was expressed mainly in human endometrial stromal cells (HESC) 
rather than glandular epithelial (HEGE) or endothelial (HEEC) cells (Krikun et al., 
2004).  Ang 2 mRNA expression was mainly in HEECs, followed by HEGEs and 
then minimal expression in HESCs (Krikun et al., 2004).  Interestingly, the timing 
and localisation of Ang 1 and Ang2 expression may be related to their functions as 
Ang1 acts later in angiogenesis to stabilise vessels and recruit pericytes, and Ang 2, 
which can be upregulated by VEGF, acts earlier in angiogenesis to promote vascular 
remodelling and enhance vascular permeability (Krikun et al., 2004).  In endometrial 
adenocarcinoma a study by Holland et al. found that there was minimal expression of 
Ang1 and high levels of Ang2 in poorly differentiated cancers (Holland et al., 2003).  
In contrast, a study by Saito et al. showed that Ang2 protein expression was lower in 
moderately and poorly differentiated endometrial adenocarcinoma than normal 
endometrium proliferative samples and there was no difference in the protein 
expression of Ang1 (Saito et al., 2007).  It is possible that the variability of 
angiopoietin expression throughout the course of tumour progression make it hard to 
gain a clear assessment of its expression (Nasarre et al., 2009). 
1.6.6 Tissue Factor 
Tissue Factor (TF), also known as coagulation factor III and CD142, is a 
proangiogenic factor involved in both normal physiological and pathological 
angiogenesis although the mechanisms by which TF regulates these angiogenic states 
differs (Belting et al., 2004).  TF, a transmembrane glycoprotein, is expressed at low 
levels in normal endometrial stroma but is absent from endothelial and glandular 
cells (Krikun et al., 2004).  In contrast TF expression is high in endometrial 
adenocarcinoma and expressed by both epithelial and endothelial cells (Krikun et al., 
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2004).  TF has been associated with leaky vessels and proangiogenic thrombin 
production (Krikun et al., 2004).  Thrombin G-protein coupled receptors known as 
protease activated receptors, PAR 1 and 2, can coordinated with TF to regulate 
angiogenesis in vivo (Belting et al., 2004).  This suggests that in endometrial 
adenocarcinoma TF may be associated with increased angiogenesis and vascular 
permeability and thereby facilitating tumour cell growth and intra/extravasation.    
1.6.7 Fibroblast growth factor 2 (FGF2) 
Proangiogenic factor fibroblast growth factor 2 (FGF2) is one of the most potent 
promoters of epithelial growth and angiogenesis in vitro and in vivo (Presta et al., 
2005).  Research by Sales et al. has shown that FGF2 expression and secretion is 
upregulated in endometrial adenocarcinoma compared to normal endometrial 
samples (Sales et al., 2007).  In addition, increased levels of FGF2 in malignant 
endometrial cancer correlate with the additional angiogenic growth factors IGF and 
EGF (Soufla et al., 2008).  Soufla et al. found FGF2 mRNA overexpression in 75% 
of their endometrial cancer samples examined (Soufla et al., 2008).  FGF2 and its 
receptor FGFR1 are expressed by both the glandular epithelial and vascular cells of 
endometrial adenocarcinoma (Sales et al., 2007).  Sales et al. have shown that 
secretion of FGF2 stimulated by prostaglandin F2α can promote the proliferation of 
endometrial adenocarcinoma cells via its FGFR1 receptor (Sales et al., 2007).  The 
secretion of FGF2 from endometrial adenocarcinoma cells may also be regulated by 
the reproductive hormones oestrogen and progesterone (Fujimoto et al., 1997; Sales 
et al., 2007).  Also, Pollock et al. identified eleven missense mutations at a number of 
locations of the FGFR2 receptor in endometrial cancer (Pollock et al., 2007).  The 
most common mutation was S252W, which is also found in individuals with Apert 
syndrome and has been shown in vitro to enhance FGF ligand binding (Pollock et al., 
2007).  In endometrial adenocarcinoma cells lines FGFR2 inhibition in the context of 
common loss of function mutations such as PTEN result in cell death (Byron et al., 
2008).  These findings suggest that targeting the FGFR receptors could be a therapy 
for endometrial adenocarcinoma (Byron et al., 2008). However, the role of 
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endometrial adenocarcinoma derived FGF2 in the regulation of endometrial 
adenocarcinoma vascular function has yet to be investigated.   
 
FGF2, also known as basic fibroblast growth factor, is one of 18 mammalian proteins 
belonging to the FGF family (FGF1-10 and FGF16-23) (Beenken and Mohammadi, 
2009).  FGF2 shares a homologous core region with the other FGFs but differs from 
them in the N- and C-terminal regions allowing for differential functional activity.  
In contrast to most of the FGFs, FGF2 is secreted through unconventional secretory 
processes involving export via a plama membrane resident transporter or shedding of 
plasma membrane vesicles (Walter Nickel, 2005). Once in the extracellular matrix, 
the FGF proteins signal through FGFRs to elicit a cellular response.  Situated in the 
core region of the FGFs is a heparan sulphate proteoglycan (HSPG) (also known as 
heparan sulphate glycosaminoglycan HSGAG) binding site (HSB).  HSPGs are 
located in the extracellular matrix near the surface of every cell.  Binding of FGF2 to 
HSPG enhances its interaction with the FGFRs, hence enhancing FGFR activation 
and downstream signalling.  There are four FGFR proteins (FGFR1-4) which each 
have various isoforms created by exon skipping and alternative splicing.  Once FGF2 
is bound, FGFRs dimerize enabling a series of auto-phosphorylation events resulting 
in activation of downstream signals.  As shown in Fig. 11, FGFR downstream 
signalling is conveyed through two main interacting proteins, phospholipase C (PLC) 
and FGF receptor substrate 2 (FRS2) (Beenken and Mohammadi, 2009).   
 
Endothelial cells most commonly express FGFR1(3c) and  FGF2-FGFR1 signalling 
is implicated in the basal lamina degradation, migration, proliferation, 
morphogenesis and vessel maturation stages of angiogenesis (Auguste et al., 2003; 
Presta et al., 2005).  Canonical FGF2-FGFR1 signalling in endothelial cells can 
induce many intracellular signal transduction pathways, including phosphoinositide 
3-kinase (PI3K), p38 mitogen-activated protein kinase (P38), c-Jun NH(2)-terminal 
kinases (JNK), signal transducer and activator of transcription 3 (Stat3), mammalian 
target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK)1/2 
pathways (Deo et al., 2002; Kanda et al., 1997; Matsumoto et al., 2002; Murakami et 
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al., 2008).  Negative regulators of the FGF2-FGFR1 canonical signalling pathways 
include SEF, sprouty and MPK3 (Murakami et al., 2008).   
 
Non-canonical signalling stimulated by FGF2 in endothelial cells involves the 
interaction of FGF2 with syndecans, integrins and neural cell adhesion molecules 
(NCAM), see Fig. 11 (Murakami et al., 2008).  For example, syndecans, a member of 
the HSPG family, can act as FGF2 receptors (Murakami et al., 2008).  Syndecans are 
abundant on the cell surface so despite their lower affinity for FGF2 than the FGFRs, 
they can significantly affect FGF2 signalling (Horowitz et al., 2002). In rat fat pad 
endothelial cells mutation of syndecan 4 obstructs FGF2 induced PIP2 activation of 
PKC which disrupts endothelial cell proliferation, migration and network formation 
(Horowitz et al., 2002).  Similarly, FGF2 can bind to vitronectin receptor 
alphaVbeta3 and mediate endothelial cell adhesion and spreading in vitro (Rusnati et 
al., 1997).  
 
Fig. 11. Canonical and non-canonical FGF2 signalling pathways. Adapted from 
Murakami et al. (2008). FGF2 signals through FGFRs in the canonical pathways.  FGFRs 
activate PI3K and MAPK pathways through interaction with receptor substrate proteins PLC 
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and FRS2.  Non-canonical signaling involves FGF2 binding to alternative receptors such as 
syndecans and integrins.   
Studies into anti-angiogenic treatments for cancer have investigated targeting FGF2-
FGFR1 signalling (Beenken and Mohammadi, 2009).  For example thalidomide is an 
FGF2 inhibitor as it increases the degradation of FGF2 mRNA and clinical trial in 
renal cancer patients suggested that it may increase stabilisation of the disease 
(Beenken and Mohammadi, 2009).  More recent research has investigated the use of 
vesicles containing FGF2 in their outer lipid layer to target the delivery of drugs, 
such as thymidine kinase, to FGFR expressing cells in the tumour microenvironment 
(Beenken and Mohammadi, 2009).   
1.6.8 Angiogenic Chemokines CXCL1 and CXCL8 
Chemokines with an ELR motif Glu-Leu-Arg promote angiogenesis whereas those 
lacking the motif in general inhibit angiogenesis (Strieter et al., 2006). The ELR 
motif is a critical factor in determining the structure and hence receptor binding 
specificity for ELR chemokines.  CXCL1, also known as growth related oncogene-α 
(GROα) or melanoma growth stimulatory activity (MSGA), and CXCL8, also known 
as Interleukin 8 (IL8), are both ELR containing angiogenic chemokines.   
 
CXCL1 is a chemokine associated with inflammation, angiogenesis and 
tumourigenesis.  Anisowicz et al. found GRO to be present normal human cells 
where its expression was low however, in human cancer cells its expression was 
increased (Anisowicz et al., 1987). In endometrial adenocarcinoma, CXCL1 
expression is elevated compared to the normal endometrium (Wallace et al., 2009).  
The expression of CXCL1 by endometrial cancer cells may enhance neutrophil 
influx into endometrial adenocarcinoma (Wallace et al., 2009).  Human endometrial 
stromal cells secrete CXCL1 (Nasu et al., 2001).  Earlier research in 1989 identified 
that GRO was secreted by human umbilical vein endothelial cells (Wen et al., 1989).  
It is now established that in cancer the two main functions of CXCL1, secreted by 
tumour cells, endothelial cells, leukocytes and neutrophils, are to enhance immune 
cell tumour cell infiltration, through mechanisms involving chemotaxis and 
transendothelial cell migration, and promote angiogenesis (Kundu and Surh, 2008).   
Chapter 1      Literature Review 47 
 
CXCL8 is an inflammatory chemokine and a proangiogenic factor (Li et al., 2003; Li 
et al., 2005).  In the normal human endometrium, CXCL8 is expressed throughout 
the menstrual cycle with an increase in perivascular staining in the late secretory 
endometrium (Jones et al., 1997).  This increase in CXCL8 expression coincided 
with leukocyte infiltration and COX-2 expression in premenstrual endometrium 
(Jones et al., 1997).  In vitro data suggests that CXCL8 increases MMP 2 and 9 
production in isolated, cultured stromal cells (HESCs) and treatment with CXCL8 
enhances HESCs invasion of extracellular matrix (Mulayim et al., 2004).  CXCL8 is 
also expressed in vascular and glandular cells of first trimester decidua along with 
prokineticin (Maldonado-Perez et al., 2009).  Serum levels of CXCL8 are elevated in 
patients with endometrial cancer (Chopra et al., 1996).  CXCL8 expression is 
increased in endometrial cancer, compared to normal endometrium, where it 
localises to the glandular epithelial and stromal cells (Sales, 2009).  Maldonado-
Perez et al. found that prokineticin treatment of endometrial cancer cells 
overexpressing the prokineticin receptor, increases CXCL8 production (Maldonado-
Perez et al., 2009).  CXCL8 mRNA and protein expression is elevated in endometrial 
cancer cells by nuclear activator of T cells (NFAT:see section 1.7.5) signalling 
(Sales, 2009). Alternatively, the expression of CXCL8 in endometrial microvascular 
endothelial cells can be regulated by lysophosphatidic acid in a p38-NFkB dependent 
mechanism to promote endothelial cell network formation and migration (Chen et al., 
2008).  In human endometrial endothelial cells (HEECs) from normal endometrium, 
the expression of CXCL8 is decreased by oestrogen and progesterone treatment (Luk 
et al., 2005).  In contrast, CXCL8 expression is increased by oestrogen treatment in 
HEECs from women with endometriosis (Luk et al., 2005).  These data, together 
with data showing the role of CXCL8 in angiogenesis, indicate that in an endometrial 
diseased state CXCL8 is an effector of vascular function under hormonal control.  
However, the role of CXCL8 on vascular function in the context of endometrial 
adenocarcinoma requires further investigation. 
 
As chemokines, CXCL1 and CXCL8 modulate cellular functions by binding the 
chemokine receptors (CXCR).  CXCL1 binds with high affinity to CXC receptor 2 
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(CXCR2) and with very low affinity to CXCR1 therefore CXCL1 is generally 
considered to be a CXCR2 specific ligand (Strieter et al., 2005).  CXCL8 can bind 
effectively to CXCR1 and CXCR2 both of which are expressed on HUVECs (Li et 
al., 2003; Li et al., 2002).  It is important to note that CXC receptor expression varies 
among different endothelial cell and human microvascular endothelial cells 
(HMECs) express higher levels of CXCR2 and are more responsive to CXCL8 than 
HUVECs (Salcedo et al., 2000).  Both HMECs and HUVECs express CXCR3 and 
CXCR4 however neither CXCL8 nor CXCL1 act as ligands for either of these 
receptors (Salcedo et al., 2000).  A recent article demonstrated, using a xenograft 
tumour model in mCXCR-/- and mCXCR2+/- mice, that levels of stromal CXCR2 are 
crucial for tumour angiogenesis and growth (Singh et al., 2009).  Similarly, mCXCR-
/- mice exhibit decreased corneal angiogenesis in response to CXCL8 (Addison et 
al., 2000). Also data by Keane et al. have demonstrated in mCXCR-/- mice a role for 
CXCR2 in tumorigenesis and angiogenesis in Lewis lung carcinoma  (Keane et al., 
2004a; Keane et al., 2004b).  These data indicate that CXCL1 and CXCL8 signalling 
to CXCR2 on endothelial cells may be an important part of vascular formation in 
vivo (Singh et al., 2009). 
 
The chemotactic effect of CXCL1 on immune cell migration has been widely studied 
in vitro but CXCL1 also plays a role in the regulation of endothelial cell function and 
angiogenesis (Bechara et al., 2007).  In coronary artery disease, CXCL1 may inhibit 
endothelial vasorelaxation by decreasing the expression of endothelial nitric oxide 
synthase (eNOS) (Bechara et al., 2007).  Recombinant CXCL1 can regulate bovine 
adrenal gland capillary endothelial cell migration and induce angiogenesis in vivo as 
shown using the rat corneal model (Strieter et al., 1995).  In addition, recombinant 
CXCL1 induces endothelial cell proliferation and network formation and addition of 
CXCL1 antibody to HUVECs inhibits thrombin-induced endothelial cell 
proliferation and network formation (Caunt et al., 2006).  In accordance, in the CAM 
angiogenesis assay, CXCL1 induces angiogenesis and thrombin induced 
angiogenesis is inhibited by addition of CXCL1 antibody (Caunt et al., 2006).  Caunt 
et al. proposed a mechanism by which CXCL1 regulates angiogenesis by promoting 
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the expression of angiogenic factors, VEGF-A, VEGFR2, MMP9 and Ang2 (Caunt 
et al., 2006).  Interestingly, CXCL1 expression was not upregulated by FGF2 or 
VEGF-A in HUVECs (Caunt et al., 2006).  In a mouse xenograft model, tumour cells 
in which CXCL1 expression was knocked down with short hairpin RNA, exhibited 
decreased tumour xenogaft growth and microvessel density (Caunt et al., 2006).  
Similarly, in a human colorectal xenograft tumor mouse model, CXCL1-
immunoneutralisation decreased tumour growth and angiogenesis (Wang et al., 
2006).  This was presumably because CXCL1 was required for cancer conditioned 
medium-induced effects on endothelial cell network formation and migration (Wang 
et al., 2006).   
 
Paracrine and autocrine signalling of CXCL8 via the CXCR2 receptor has been 
shown to regulate endothelial cell network formation, proliferation and migration in 
vitro (Li et al., 2003; Li et al., 2005).  Recombinant CXCL8 induces in vitro HUVEC 
proliferation and in vivo vessel growth in the rat corneal model of angiogenesis 
(Koch et al., 1992; Strieter et al., 1995).  Most in vitro and in vivo data suggests that 
CXCR2 is the main CXCL8 receptor of endothelial cell function (Addison et al., 
2000; Strieter et al., 2006).  Addison et al. showed that CXCL8 induction of HMEC 
proliferation, migration and CAM angiogenesis was inhibited to basal levels by 
addition of a CXCR2 antibody (Addison et al., 2000).  CXCL8 binding to CXCR2 
stimulates signalling pathways downstream of this GPCR that regulate gene 
expression.  For example, CXCL8 may promote the migration of HUVECs by 
increasing endothelial secretion of matrix metalloproteinases such as MMP9 and 
MMP2 (Li et al., 2003).  Also, CXCL8 may regulate HUVEC survival by increasing 
the expression of antiapoptotic factor Bcl-xl and decreased the expression of 
antiapoptotic factor Bax (Li et al., 2003).  In vitro and in vivo data by Yao et al. 
suggests that CXCL8 may direct angiogenesis via Sterol regulatory element-binding 
proteins (SREBPs) expression (Yao et al., 2006).  SREBP is an important regulator 
of lipid membrane components and the activation of Rho GTPase, a protein involved 
in cytoskeletal remodelling, by SREBP was shown to be essential for CXCL8 
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induced endothelial cell network formation, proliferation, migration and in vivo 
CAM angiogenesis (Yao et al., 2006).   
 
The differential roles of CXCL1 and CXCL8 have been shown to be due to the 
difference in their receptor binding affinity, as CXCL1 binds only CXCR2 whereas 
CXCL8 can bind CXCR1 or CXCR2.  Interestingly, RhoGTPase was shown by 
Schraufstatter et al. to be downstream of CXCL8-CXCR1 activation regulating 
cytoskeletal arrangement (Schraufstatter et al., 2001).  In contrast, CXCL8 or 
CXCL1 HMEC adhesion was found to be mediated by CXCR2 in a Rac dependent 
manner (Schraufstatter et al., 2001).  However in vivo data suggests that CXCR2 is 
the main receptor mediating tumour progression as recent data by Warner et al. 
indicates that in head and neck tumours CXCL1 and CXCL8 secretion from 
endothelial cells enhances tumour cell invasion by signalling in a paracrine manner 
through CXCR2 on tumour cells (Warner et al., 2008).   
 
As an alternative to directly stimulating intracellular signalling pathways, CXCR2 
can transactivate the VEGFR2 and EGFR tyrosine kinases leading to downstream 
signalling from these receptors.  In ovarian cancer cells, CXCL8 treatment induces 
phosphorylation of EGFR and MAPkinase pathway activation which are proposed to 
be responsible for alterations in cell migration (Venkatakrishnan et al., 2000).  In 
endothelial cells, CXCR2, but not CXCR1, mediated HMEC migration is regulated 
by EGFR transactivation via cathespin and HB-EGF (Schraufstatter et al., 2003).  
Both CXCL1 and CXCL8 binding to CXCR2 can cause EGFR phosphorylation by 
HB-EGF which was also required for HMEC sprout formation in an in vitro model 
of angiogenesis (Schraufstatter et al., 2003). CXCL8 induced human microvascular 
endothelial cell permeability requires the transactivation of VEGFR2 (Petreaca et al., 
2007).  This coordination of CXCR2 and VEGFR2 signalling has recently been 
shown in murine endothelial cells whereby CXCR2 activation by CXCL8 increased 
VEGF-A expression, via  a complex called CBM, and NFκB activation, hence, 
enhancing VEGFR2 activation (Martin et al., 2009).  The effect of CXCL1-CXCR2 
signalling on VEGFR2 transactivation has yet to be verified but is likely to be similar 
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to that induced by CXCL8 as they both activate CXCR2.  A recent in vivo study 
suggests that inhibiting both CXCR2 and VEGFR2 may be an effective treatment to 
block pancreatic cancer growth (Li et al., 2009). 
 
It is important to note that a study by Benelli et al. found that neutrophils are 
essential for CXCL1 and CXCL8 mediated angiogenesis as CXCL1 and CXCL8 
failed to promote angiogenesis, measured by haemoglobin content in matrigel sponge 
implants, in mice lacking neutrophils (Benelli et al., 2001).  This is interesting 
because in vitro CXCL1/CXCL8 and CXCR2 can directly control endothelial cell 
functions (Caunt et al., 2006; Li et al., 2005) and in the rat cornea, an environment 
free from immune cells, CXCL1 and CXCL8 induce angiogenesis (Strieter et al., 
1995).  In tumour angiogenesis the coordination of different cell types, i.e. 
endothelial and immune cells, is likely to be crucial. 
 
A therapeutic antibody against CXCL8, ABX-IL8, has been developed and was 
shown to inhibit HUVEC network formation in vitro as well as inhibiting, in vivo 
melanoma tumour xenograft MMP production, invasion, growth and angiogenesis 
(Huang et al., 2002).  However, the efficacy of ABX-IL8 in inhibiting cancer in 
clinical trials has not been investigated (Yan et al., 2006).  Targeting the 
CXCL1/CXCL8 and CXCR2 receptors might not be an effective form of cancer 
therapy for all tumour types as a recent paper investigating the role of CXCR2 in 
cancer showed that CXCL8 to CXCR2 signalling can actually promote senescence 
thereby inhibiting growth of lung adenocarcinomas (Acosta et al., 2008).  Clearly, 
more work needs to be done to elucidate the role of CXCL1/CXCL8 and CXCR2 in 
individual cancer strains. 
1.6.9 The matrix metalloproteinases (MMPs) 
Factors involved in the degradation of the extracellular matrix such as matrix 
metalloproteinases (MMP) 2 and 9 are also grouped with proangiogenic factors 
(Kalluri, 2003).  The matrix metalloproteinases (MMPs) and Membrane-Type Matrix 
Metalloproteinases (MT-MMPs) are implicated in the regulation of angiogenesis, 
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invasion and metastasis of cancers (Davis and Senger, 2005; Egeblad and Werb, 
2002; van Hinsbergh and Koolwijk, 2008).  A recent microarray study by Du et al. 
found that MMP9 and MMP10 were upregulated in tumour associated endometrial 
endothelial cells (TEECs) compared to normal endometrial endothelial cells 
(HEECs) (Du et al., 2008).  A study by Aglund et al. found that endometrial cancer 
patients with intense MMP9 and MMP2 immunohistochemical staining of tumours 
had a dramatically decreased survival rate than those patients with less intense 
staining for these MMPs (Aglund et al., 2004).   Immunohistochemical analysis has 
also found that in endometrial cancer MMP9 expression is increased and can be 
correlated with increased COX2 and MMP2 expression, along with vascular and 
lymphatic invasion (Karahan et al., 2007).  Park et al. suggest, using a 3D in vitro 
model of invasion with coculture of normal endometrial stromal cells and 
endometrial cancer cells, that MMP9 and MMP2 secreted by endometrial stromal 
cells, in an oestrogen regulated manner, aid endometrial cancer cell invasion (Park et 
al., 2001).  In the normal endometrium, increased MMP9 expression has been 
associated with enhanced angiogenesis and vascular repair after menstruation 
(Plaisier et al., 2004).  In vitro analysis of human microvascular endometrial 
endothelial cells (hMVEECs) found that they express MMP9 mRNA in response to 
various growth factor treatments including VEGF-A (Plaisier et al., 2004).  
Interestingly, in HUVECs, the secretion of MMPs was shown to be temporally 
regulated with a decrease in MMP9 and MMP2 production overtime that could be 
prevented by COX inhibition (Kiran et al., 2006).  The secretion of MT3-MMP from 
endometrial endothelial cells was confirmed by Plaisier et al. using 
immunohistochemical analysis of endometrial tissue (Plaisier et al., 2004).  
hMVEEC network formation could be inhibited by MT3-MMP 
immunoneutralisation (Plaisier et al., 2004).  These data suggest that MMPs, in 
particular MMP9, may be involved in regulation of angiogenesis and tumour 
invasion in endometrial adenocarcinoma.   
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1.6.10 Tissue inhibitors of metalloproteinases (TIMPs) 
Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of MMPs.  
For example, MMP9 activity is regulated by TIMP1, and MMP2 by TIMP2.  Hence, 
TIMPS have been suggested to be antiangiogenic.  In endometrial cancer a decrease 
in TIMP2 histological expression has been found to be associated with an increase in 
MMP2 expression and a poorer prognosis for endometrial cancer patients (Graesslin 
et al., 2006).  Plaisier et al. found that adenoviral overexpression of TIMP1 and 
TIMP3 inhibits VEGF-A induced hMVEEC network formation in vitro (Plaisier et 
al., 2004).  Both TIMP1 and TIMP2 can inhibit VEGFR2 signalling.  For example, 
TIMP2 can inhibit VEGF-A and FGF2 endothelial cell proliferation via a MMP 
independent mechanism involving increasing receptor tyrosine kinase association 
with an endogenous inhibitor SHP1, thereby preventing the downstream signalling 
that stimulates growth (Seo et al., 2003).   TIMPs are often referred to as 
antiangiogenic but this may be a misconception as functional TIMPs are required to 
prevent tubule regression. For example, TIMP2 has been shown to suppress 
endothelial cell tube formation by targeting MT1-MMP but TIMP2 suppression 
destabilises vessels resulting in MMP1 dependent regression (Saunders et al., 2006).  
Similarly, Saunders et al. found that endothelial MT1-MMP, MT2-MMP and ADAM 
15 dependent tube morphogenesis and invasion of collagen was inhibited by TIMP3, 
as was MMP1, MMP10, and ADAM15 dependent tube regression (Saunders et al., 
2006).  TIMP3 interacts with the extracellular matrix components such as heparan 
sulphate, but other TIMPs don’t appear to have this ability therefore this may give 
TIMP3 a unique control mechanism that is important for its role in vessel 
stabilisation (Saunders et al., 2006).  Hence, it is likely that TIMPs have a pluripotent 
role in angiogenesis.   
1.6.11 A disintegrin and metalloproteinase with a thrombospondin 
repeat 1 (ADAMTS1) 
 
A disintegrin and metalloproteinase with a thrombospondin repeat 1 (ADAMTS1) is 
generally recognised as an antiangiogenic factor (Iruela-Arispe et al., 2003).  The 
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role of ADAMTS1 has been investigated in the normal female reproductive tract.  In 
the female reproductive system, ADAMTS1 is essential for ovarian vascular 
medullary formation as ADAMTS1 null mice exhibit severely dysplastic or 
disorganised vascular networks (Shozu et al., 2005).  ADAMTS1 null mice are also 
infertile in part due to their impared ovulation (Mittaz et al., 2004).  ADAMTS1 
expression has been found in the normal and decidual endometrium.  Ng et al. who 
showed that ADAMTS1 expression was restricted to glandular epithelial cells and 
stromal cells surrounding the spiral arteries in the secretory endometrium (Ng et al., 
2006).  They provided evidence to suggest that ADAMTS1 is involved in cytokine 
regulation of endometrial decidualisation (Ng et al., 2006).  Research by Wen et al. 
also showed that the expression of ADAMTS1 by endometrial stromal cells is under 
the control of gonadal steroids DHT and progesterone (Wen et al., 2006).  
ADAMTS1 has also been shown to be essential for healthy follicle growth which has 
been attributed to its metalloproteinase properties (Brown et al., 2006).   
 
A disintegrin and metalloproteinase with a thrombospondin repeat 1 (ADAMTS1) 
(Kuno et al., 1997) is so called because it is closely related to proteins in the a 
disintegrin and metalloproteinase (ADAM) family and has a region which has 40% 
similarity to thrombospondin 1 and 2 containing three TSP type 1 motifs (Kuno et 
al., 1997).  The TSP1 region in ADAMTS1 binds to heparin, as does this region in 
the TSP1 protein, indicating that it is functional (Kuno et al., 1997).  In addition to 
the three TSP1 repeats and metalloprotease region, ADAMTS1 consists of a SP 
region, Prodomain, Disintegrin, Cysteine-Rich region and spacer region, as shown in 




Fig.12. Structure of ADAMTS1. ADAMTS1 contains SP region, Prodomain, 
Metalloprotease, Dinsintegrin, three Thromobospondin repeats (TSR), Cysteine-Rich region 
and a Spacer region. Adapted from Luque et al. (2003). 
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The 121kDa full length ADAMTS1 requires cleavage of the prodomain from the 
zymogen for activation (Rodriguez-Manzaneque et al., 2002).  The active full length 
ADAMTS1 is then further cleaved after the second TSR and then the first TSR 
(Rodriguez-Manzaneque et al., 2002).  This releases 86kDa and 65kDa fragments 
named N and C terminus fragments.  Unlike the ADAM proteins, ADAMTS1 does 
not have a transmembrane binding domain but is instead a secreted protein (Iruela-
Arispe et al., 2003).   
 
ADAMTS1 was originally identified as a protein regulated by inflammatory 
mediators LPS and IL-1 in a murine colon adenocarcinoma cell line (Kuno et al., 
1997).  Extracellular matrix proteoglycans aggrecan and versican were found to be 
substrates for ADAMTS1 in its role as a metalloproteinase (Rodriguez-Manzaneque 
et al., 2002; Sandy et al., 2001).  Recently ADAMTS1 was found to cleave 
transmembrane proteoglycan Syndecan 4 near the N terminus GAG site from the cell 
surface thereby regulating mouse lung endothelial cell adhesion and enhancing 
migration (Rodriguez-Manzaneque et al., 2009).  In addition, the TSP1 region of 
ADAMTS1 was found to be involved in the cleavage and activation of 
antiangiogenic thrombospondin peptides (Lee et al., 2006) and the metalloprotease 
inhibitor Matrix Inhibitor Tissue Factor Pathway Inhibitor-2 can be cleaved from the 
cell membrane by ADAMTS1 (Torres-Collado et al., 2006).  
 
The mechanisms by which ADAMTS1 interacts and regulates the vasculature have 
been investigated in vitro and in vivo.  Recently, the invasion of endothelial cells into 
matrigel was shown to require ADAMTS1 expression (Su et al., 2008).  ADAMTS1 
has been shown to inhibit VEGF-A induced angiogenesis through different 
mechanisms (Iruela-Arispe et al., 2003).  In one angiogenesis inhibitory mechanism 
ADAMTS1 can sequester VEGF-A with two TSP repeats and a spacer region and 
prevent its binding to the VEGFR2 receptor thereby inhibiting human aortic 
endothelial cell proliferation (Luque et al., 2003).  Alternatively, ADAMTS1 inhibits 
angiogenesis by facilitating the cleavage of antiangiogenic thrombospondin peptides 
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which can inhibit FGF2-driven bovine aortic endothelial cell proliferation (Lee et al., 
2006).   
 
A detailed study in vivo by Lui et al. found that the antiangiogenic role of 
ADAMTS1 is dependent on its cleaved N and C terminal fragments (Liu et al., 
2006).  In a Lewis lung carcinoma mouse tumour model, ADAMTS1 N and C 
terminal fragments inhibited tumour proliferation, metastasis and angiogenesis (Liu 
et al., 2006).  Studies in vitro suggested that this was via a mechanism inhibiting the 
shedding of HB-EGF and hence EGFR phosphorylation and ERK1/2 activation (Liu 
et al., 2006).  In contrast, the full length active form of ADAMTS1 promoted tumour 
metastasis and had a weak positive affect on tumour proliferation and angiogenesis 
in vivo and promoted tumour cell invasion through matrigel in vitro (Liu et al., 
2006).  Of note, the full length form of ADAMTS1 was the predominant form in 
LLC conditioned medium perhaps due to the fact that in vivo, heparin inhibits 
ADAMTS1 cleavage (Liu et al., 2006).  This demonstrates that the form of 
ADAMTS1 is critical for determining its function.   
 
ADAMTS1 can be upregulated by growth factor treatment, such as VEGF-A, in 
endothelial cells (Xu et al., 2006).  Apart from VEGF-A, factors regulating the 
expression and secretion of ADAMTS1 are relatively unknown however, HDAC6 
has been found to prevent the expression of ADAMTS1 in human lung carcinoma 
cells (Chou and Chen, 2008).  Protein kinase C was found to be involved in the 
upregulation of ADAMTS1 in endothelial cells (Xu et al., 2006).  Recently, the role 
of early response gene ERG in the regulation of ADAMTS1 was discovered and 
associated with prostate cancer progression (Carver et al., 2009).  This research 
suggests that ADAMTS1 gene expression could be controlled by ERG and HDAC in 
combination.  This thesis will focus on angiogenic factors FGF2, CXCL1 and 
CXCL8 together with the antiangiogenic factor ADAMTS1. 
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1.7 Intracellular signalling molecules regulating endothelial cell 
function 
1.7.1 Extracellular regulated kinase 1/2 (ERK1/2) 
The networks of mitogen-activated protein kinases (MAPKs) are involved in many 
cellular processes such as cell survival, proliferation, migration and differentiation 
(Pearson et al., 2001).  As shown in Fig. 13, MAPK cascades, involving 
phosphorylation of sequential proteins, all share similar components falling into the 
following categories, an initiation kinase (MAP3Ks/MEKK), a MAPKKinase 
(MAPKK/MEK) and a MAPKinase (MAPK).  The activated terminal MAPKinases 
phosphorylate serine/threonine sites on target proteins (Pearson et al., 2001).  These 
target proteins are often transcription factors such as c-fos, c-jun and SP-1(Turjanski 
et al., 2007). In this way, the MAPKinase cascades mediate many signal transduction 
events (Pearson et al., 2001). 
 
 
Fig. 13. The MAPKinase signalling cascades. Adapted from Pearson et al. (2001). 
 
ERK1/2 is part of the classical mitogen cascade which consists of the initiating 
kinase Raf-A, Raf-B or Raf-C, the MAPKK MEK1/2 and subsequent activation of 
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the MAPK ERK1/2.  Although ERK1/2 is a signalling kinase and not an angiogenic 
factor, it is involved in proangiogenic signalling of endothelial cells.  ERK1/2 is 
activated by a phosphorylation cascade after angiogenic ligand-receptor binding 
(Hood et al., 2003).  In the normal endometrium, ERK1/2 phosphorylation is highest 
in glandular epithelial cells of the late proliferative phase and secretory phase (Murk 
et al., 2008).  In stromal cells ERK1/2 phosphorylation is also high in late 
proliferative phase but decreases slightly during secretory phases (Murk et al., 2008). 
This coincides with expression of inflammatory cytokines CXCL8 and COX-2. 
 
The ERK1/2 MAPK cascade is initiated by an extracellular stimulus such as growth 
factor binding to its tyrosine kinase or G-protein coupled receptor (GPCR) (McKay 
and Morrison, 2007).  Guanine nucleotide exchange factor activation by cellular 
receptors generates Ras GTP (Marshall, 1996).  Ras proteins are anchored to the 
inner surface of the plasma membrane where Ras GTP subsequently activates the 
Raf family of MAP3kinases (Vögler et al., 2008).  The Raf family consists of three 
alternatively spliced isoforms A, B and C.  The Raf isoform that activates 
downstream effectors depends on the external stimulus and the cell type.  For 
example in endothelial cells, C-Raf is activated by FGF2 signalling whereas in 
ventricular myocytes TPA activates primarily A-Raf (Wellbrock et al., 2004).  
Phosphorylation of MEK1/2 on two serine sites, S217 and S221, by Raf activates 
MEK1/2.  MEK1/2 is the only known activator of ERK1 and ERK2 which are 
activated by phosphorylation of theronine and tyrosine sites within their activation 
segments (Wellbrock et al., 2004).  The Ras-Raf-ERK1/2 signalling pathway is 
involved in endothelial cell function and angiogenesis (Depeille et al., 2007).  For 
example, Hood et al. found that VEGF-A and FGF2-induced CAM angiogenesis was 
inhibited by ERK1/2 inhibitor PD98059 as well as infection of retroviral vector 
encoding mutationally inactive forms of Ras or C-Raf (Hood et al., 2003).  Recently 
Rap1a, a Ras family small GTPase that can activate Raf, was found to be critical for 
microvascular endothelial cell FGF2-induced ERK1/2 activation, tube formation, 
migration, permeability and proliferation and matrigel plug angiogenesis (Yan et al., 
2008).  Similarly inhibition of ERK1/2 prevents 3D microvascular endothelial cell 
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tube formation, transcription factor Erg-1 activation and matrix metalloproteinase 
MT1-MMP and MMP2 expression suggesting that ERK1/2 mediates endothelial cell 
invasion of extracellular matrix (Boyd et al., 2005).   
  
Activation of ERK1/2 can take place on scaffold proteins which help to 
compartmentalise MAPK signalling and facilitate the phosphorylation cascade 
(Brown and Sacks, 2009).  For example, the scaffold protein kinase suppressor of 
Ras (KSR) present at the plasma membrane, binds to Raf, MEK1/2 and ERK1/2 and 
their proximity enables the rapid activation of ERK1/2 (Brown and Sacks, 2009).  
ERK1/2 dimers bound to KSR subsequently target cytosolic proteins as opposed to 
ERK monomers, not bound to KSR, which translocate to the nucleus (Brown and 
Sacks, 2009).  Therefore, ERK1/2 activation can be regulated through the availability 
of these scaffold proteins (Brown and Sacks, 2009). 
 
Regulation of ERK1/2 can also take place through dephosphorylation of the 
threonine and tyrosine activation sites by protein phosphatases (Raman et al., 2007).  
Phosphatases that act specifically on MAPKs are known as MAPK phosphatases 
(MKPs) (Raman et al., 2007).  A specific ERK2 phosphatase is MKP3.  Inactive 
MKP3 forms a complex with active ERK2 (Zhou et al., 2006).  This enables ERK2 
to activate MKP3 which subsequently dephosphorylates the Thr183 and Tyr185 of 
ERK2 (Zhou et al., 2006).  Alternatively, ERK1/2 activity can be regulated by the 
non-specific protein phosphatase 2A (PP2A).  PP2A can enhance ERK1/2 
phosphorylation indirectly by dephosphorylating inhibitory sites on KSR and Raf 
(Raman et al., 2007).  On the other hand, PP2A can directly dephosphorylate and 
inactivate ERK1/2 (Van Kanegan et al., 2005).  In rat neuronal cultures, the 
calcineurin inhibitor cyclosporin A (CsA) inhibited ERK2 dephosphorylation after 
glutamate treatment suggesting that the phosphatase calcineurin (PP2B) may also 
regulate ERK2 phosphorylation by indirect or direct mechanisms (Paul et al., 2003).      
 
Once activated by phosphorylation, ERK1/2 can phosphorylate cytoplasmic targets.  
For example, ERK1/2 can phosphorylate and inactivate tuberous sclerosis complex 2 
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(TSC2) (Lee and Hung, 2007).  Active TSC2 binds to TSC1 and the TSC1/TSC2 
complex is involved in inhibiting mTOR activation thereby preventing cellular 
proliferation (Guertin and Sabatini, 2007).  ERK1/2 inhibition of TSC2 relieves the 
inhibitory effect of TSC1/2 on the mTOR pathway and allows cellular proliferation 
to proceed (Drakos et al., 2008).  
 
Nuclear targets of ERK1/2 include transcription factors SP1, MSK, RSK and c-fos 
(Turjanski et al., 2007).  For example ERK2 can phosphorylate the ternary complex 
factor family member Elk-1 (Turjanski et al., 2007).  Activated Elk-1 can then bind 
to promoter regions of specific genes as seen with c-fos, part of the AP-1 complex, 
(Monje et al., 2005) or serum response elements (SRE) (Whitmarsh et al., 1995) to 
enhance gene transcription.  ERK1/2 can enhance the expression of vascular 
endothelial growth factor (VEGF-A) by phosphorylating SP1 in fibroblasts 
(Milanini-Mongiat et al., 2002).      
 
The importance of the ERK1/2 pathway in regulating cell functions such as 
proliferation is highlighted by the fact that oncogenic mutations have been found in 
the Ras, Raf  and MEK1/2 stages of this MAPK cascade along with ERK1/2 
hyperactivation in cancers (Roberts and Der, 2007; Wellbrock et al., 2004).  In fact, 
Ras is the most commonly mutated oncogene in cancer (Roberts and Der, 2007).  
Due to this fact, clinical trials of inhibitors of Ras, Raf and MEK1/2 are in progress 
(Roberts and Der, 2007).   
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1.7.2 Phosphatidyl inositide 3 kinase 
In addition to its activating Raf at the start of the ERK1/2 cascade, Ras can also 
directly activate phosphoinositide-3-kinase (PI3K) in vitro (Fig.14) (Marshall, 1996).  
Alternatively PI3K can be phosphorylated directly by binding to receptor tyrosine 
kinases through the SH2 domains (Fig.14) (Vivanco and Sawyers, 2002).  There are 
three classes of PI3K of which class IA is most commonly involved in 
tumourigenesis (Engelman, 2009).  PI3K is made up of two subunits, p85α the 
regulatory subunit and p110 the catalytic subunit as shown in Fig.14. 
 
 
Fig.14. PI3K activation by growth factor receptors at the inner plasma membrane. 
Adapted from Engelman (2009). PI3K can be activated directly by receptor tyrosine kinases 
after ligand binding through phosphorylation of the SH2 regions of the p85α regulatory 
subunit.  Alternatively phosphorylation of p85α can be mediated by an intermediate 
phosphoprotein such as insulin receptor substrates 1/2 (IRS1/2).  Further indirect activation 
of PI3K can take place with the binding of Ras to the catalytic subunit p110.  
 
Once the PI3K catalytic subunit p110 becomes active, its close proximity to the lipid 
substrates in the plasma membrane allows the generation of phosphatidylinositols 
PIP3 from PIP2 (Engelman, 2009).  Interestingly, the PIP phosphatase PTEN, which 
converts PIP3 back to PIP2 is often mutated in cancer, including endometrial cancer, 
suggesting the importance of this PI3K pathway in tumourigenesis (Cully et al., 
2006; Engelman, 2009; Kong et al., 1997; Vivanco and Sawyers, 2002).  Of 
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particular interest is a recent research article which highlights the fact that in 
endometrial neoplastic cell lines insulin receptor substrate 2 (IRS2) expression is 
often upregulated when cells are haploinsufficient for PTEN (Szabolcs et al., 2009).  
In vivo studies by Szabolcs et al. suggest that IRS2 upregulation, in addition to 
PTEN loss of expression, enhances tumour growth either through the 
Akt/TSC/mTOR pathway (see section 1.7.3) or an alternative pathway (Szabolcs et 
al., 2009). 
 
Once generated, PIP3 recruits the cytoplasmic kinase AKT (protein kinase B) 
(Engelman, 2009).  Subsequently, AKT is phosphorylated by 3-phosphoinositide-
dependent protein kinase-1 and -2 (PDK1 and PDK2) on Thr308 and Ser473 for 
maximal activation (Vivanco and Sawyers, 2002).  AKT can be dephosphorylated by 
the previously mentioned phosphatase PP2A.  The most studied roles of AKT 
involve its regulation of tumour cell survival, proliferation and growth (Vivanco and 
Sawyers, 2002). For example, AKT can directly phosphorylate the apoptotic factor 
BAD, preventing BAD’s interaction and inhibition of proapoptotic factor Bcl-xl, 
thereby promoting cell survival (Vivanco and Sawyers, 2002).  Additionally, AKT 
can phosphorylate the oncogenic protein MDM2 (Vivanco and Sawyers, 2002). 
MDM2 is responsible for promoting cell proliferation by targeting cell death factor 
p53 for ubiquitin degradation.  AKT can also directly phosphorylate the central 
regulator of growth mammalian target of rapamycin (mTOR) on Ser2448 (Nave et al., 
1999).  Phosphorylation of mTOR is required for AKTs role in proliferation to be 
elicited (Engelman, 2009).   
 
1.7.3 Mammalian target of rapamycin (mTOR) 
As mentioned above, mTOR activation is an important terminus of the PI3K-AKT 
pathway.  mTOR proteins forms two multiprotein complexes: mTORC1, with Raptor 
and PRAS40 (GβL), and mTORC2, with Rictor, mSIN1 and Protor proteins (Bjornsti 
and Houghton, 2004). However, the precise role of each of these proteins has yet to 
be defined.  Raptor appears to have inhibitory actions on mTOR under nutrient 
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deficient conditions but may also act as a scaffold protein to enhance mTOR function 
(Bjornsti and Houghton, 2004).  As shown in Fig. 15, absence of Raptor inhibition 
allows mTOR to phosphorylate substrates such as translation initiation factor 4E-
BP1 thereby enhancing proliferative signals (Bjornsti and Houghton, 2004).  mTOR 
can also phosphorylate p70S6K1 to enhance the translation of ribosomal proteins 
(Fig. 15) (Vivanco and Sawyers, 2002).  
 
Fig. 15. The mTOR pathway activated by tyrosine kinase receptor ligand binding.  
Adapted from Vivanco et al. (2002).  PI3K binding to IRS results in AKT activation leading to 
mammalian TOR (mTOR) activation and inhibition of mTOR inhibitor complex TSC1/2. 
TSC1/2 inactivation allows RHEB to relieve the inhibitory effect of Raptor on mTOR.  mTOR 
subsequently regulates protein translation via phosphorylation of 4E-BP1and S6K1.  
 
mTORC1 and mTORC2 have different regulatory roles.  For example, in endothelial 
cells, mTORC2 may regulate AKT as rapamycin, the inhibitor of mTOR, can inhibit 
AKT phosphorylation in vivo (Guertin and Sabatini, 2007).  In contrast, mTORC1 is 
thought to be downstream of AKT as AKT can phosphorylate TSC1/2 and PRAS40 
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(Guertin and Sabatini, 2007).  TSC1/2 can inhibit mTOR activity through the 
regulation of small GTP protein RHEB, see Fig. 15.  RHEB is required for mTOR 
activity and this may be because it induces a conformational change in mTOR 
(Wullschleger et al., 2006).   
 
mTOR is also activated by additional pathways such as the ERK1/2 MAPKinase 
pathway.  As previously mentioned ERK1/2 can phosphorylate TSC2 and relieve its 
inhibitory effect on mTOR (Drakos et al., 2008).  In HEK293T cells, evidence 
suggests that the mTOR pathway may additionally be regulated by the binding 
protein 14-3-3β, because 14-3-3β can bind via serine 1210 to phosphorylated TSC2 
resulting in an increase in S6K1 phosphorylation (Shumway et al., 2003). 
 
In vivo studies demonstrate that the mTOR inhibitor, rapamycin, can inhibit 
angiogenesis and enhance blood vessel permeability induced by VEGF-A (Phung et 
al., 2006).  In addition rapamycin reduces xenograft tumour growth and vascular 
permeability suggesting that it could be a useful inhibitor for cancer therapy (Phung 
et al., 2006).  A recent phase 3 trial to investigate the effectiveness of mTOR 
inhibitor Temsirolimus, in patients with mantel cell lymphoma, indicate that 
inhibition of mTOR may be an effective method to increase patient survival rates 
(Hess et al., 2009). 
1.7.4 Cellular Src (c-Src) 
Src was first identified as a viral protein v-Src and later found to be an endogenous 
cellular protein, c-Src (Parsons and Parsons, 2004).  c-Src (Src) is a ubiquitously 
expressed member of the Src-family nonreceptor tyrosine kinases (SFKs) which also 
include Fyn and Yes (Parsons and Parsons, 2004).   SFKs are attached through their 
N terminus to the cytoplasmic membrane from where they interact, through their Src 
homology (SH)2 domain, with tyrosines of activated receptor tyrosine kinases 
(Bromann et al., 2004) and GPCRs.  The activation of Src during recruitment to 
receptor tyrosine kinases such as EGFR may involve small GTPases Ras and 
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Ral.(Bromann et al., 2004).  Src can be activated by tyrosine kinase fibroblast growth 
factor receptor 1 (FGFR1) in endothelial cells (Klint et al., 1999).   
 
Fig. 16. Src domain structure. Adapted from Parsons et al. (2004).  
  
After tyrosine kinase activation Src can activate downstream signalling pathways 
leading to ERK1/2, PI3K, PKC and STAT3 activation (Bromann et al., 2004; Deo et 
al., 2002).   
 
GPCRs for ligands such as LPA, angiotensin and endothelin cause the activation of 
Src (Luttrell and Luttrell, 2004).  Src can interact directly with GPCRs by binding to 
the GPCRs intracellular domains or indirectly by binding to their associated G 
proteins and to scaffold proteins such as β-arrestin (Luttrell and Luttrell, 2004).  
Research by Cao et al. found that the β3 adrenergic receptor can directly bind Src 
and this binding is essential for stimulation of ERK1/2 (Cao et al., 2000).  Src is also 
involved in the transactivation of tyrosine kinase receptors by GPCRs (Petreaca et 
al., 2007).  For example, Petreaca et al. found in microvascular endothelial cells that 
inhibition of Src with the VEGFR2 inhibitor SU6656 also abolished 
CXCR2/VEGFR2 complex formation and VEGFR2 phosphorylation, after treatment 
with CXCR2 ligand CXCL8 (Petreaca et al., 2007).  Also, after prostaglandin F2α 
stimulation of FP receptor GPCR, Src may be involved in the transactivation of the 
tyrosine kinase EGFR leading to ERK1/2 stimulation (Jabbour et al., 2006b). 
Stimulation of endothelial cells with soluble IL6 receptor utilises Src in a mechanism 
upregulating cytokine CXCL1 (Matsumiya et al., 2002).   
 
Src has an essential role in growth factor stimulated endothelial cell function and 
angiogenesis.  For example, Src activation was found to be essential for VEGF-
induced in vivo matrigel plug angiogenesis and vascular permeability (Eliceiri et al., 
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1999).  A recent article by Gavard et al. demonstrated that VEGFR2 activation and 
regulation of endothelial cell junctions requires Src for β-arrestin mediated VE-
cadherin internalisation (Gavard and Gutkind, 2006).  Additionally, VEGF-
A/integrin αvβ5 mediated chick chorioallantoic membrane (CAM) angiogenesis Src 
was required for Raf-ERK1/2 activation (Hood et al., 2003). In immortalised brain 
capillary endothelial cells, FGF-2 treatment can stimulate Src activation as part of an 
essential step in endothelial network formation and proliferation (Klint et al., 1999; 
Larsson et al., 1999).  Src, along with ERK1/2, is also essential for vascular lumen 
formation in vitro (Koh et al., 2009).  Similarly, Kilarski et al. found that Src is 
required for FGF2-induced CAM angiogenesis in vivo (Kilarski et al., 2003).  
Furthermore, Lui et al. found, using time-lapse microscopy, that microvascular 
endothelial cord formation in collagen matrix was inhibited by the Src inhibitor PP2 
(Liu and Senger, 2004). 
1.7.5 Nuclear factor of activated T cells (NFAT)  
NFAT family members are activated when dephosphorylated by calcineurin (Rao et 
al., 1997).  This allows NFAT to translocate to the nucleus where it regulates gene 
transcription (Rao et al., 1997).  In endothelial cells, NFAT has been found to be 
involved in the transcription of growth factors and cytokines.  For example, 
histamine treatment of HUVECs induced the NFAT-dependent expression of 
CXCL8 (Boss et al., 1998).  Cyclosporin A (CsA) is a commonly used inhibitor of 
calcineurin and therefore used to examine the effects of preventing NFAT activity.  
In vitro, CsA can inhibit VEGF-A induced nuclear translocation of the transcription 
factor NFATc1 in human intestinal microvascular endothelial cells (HIMECs) and 
humon pulmonary valve endothelial cells (HPVECs) (Johnson et al., 2003; Rafiee et 
al., 2004).  Similarly, CsA inhibits VEGF-A-induced endothelial cell migration, 
proliferation and network formation (Hernandez et al., 2001; Johnson et al., 2003; 
Rafiee et al., 2004).  In an in vivo model of angiogenesis, the rat corneal 
angiogenesis assay, CsA treatment inhibited VEGF-A-induced, but not FGF2-
induced, vessel formation (Hernandez et al., 2001).  NFAT transcription may 
regulate COX-2 expression and prostaglandin biosynthesis in endothelial cells as 
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CsA inhibits VEGF-A-induced COX-2 expression and NFAT binding to the COX2 
promoter (Hernandez et al., 2001).  In addition CsA inhibition of VEGF-A induced 
angiogenesis could be significantly restored by PGE2 treatment (Hernandez et al., 
2001). 
1.7.6 Regulator of calcineurin (RCAN) 
RCAN1 is also known as Down syndrome critical region 1 (DSCR1), Adapt78 and 
MCIP1 (Davies et al., 2007).  RCAN1 is located on chromosome 21 and individuals 
with Down’s syndrome have an extra copy of this chromosome (Fuentes et al., 
2000).  Individuals with Down’s syndrome have lower rates of many cancers 
(Ryeom et al, 2008).  A recent paper by Baek et al. has provided evidence to show 
that the overexpression of RCAN1 in Down’s syndrome can suppress tumour growth 
(Baek et al., 2009).  RCAN 1 is an inhibitor of calcineurin.  By binding to calcineurin 
and preventing the calcineurin-dependent dephosphorylation of NFAT, RCAN1 can 
impede NFAT induced gene transcription.  Recently, the RCAN1-4 isoform was 
identified as a negative regulator of NFAT dependent CXCL8 expression 
(Maldonado-Perez et al., 2009).   
 
RCAN1 has 4 splice variants from exons 1, 2, 3 and 4 (Harris et al., 2005). Although 
exon 2 is thought to be non functional and exon 3 only contains 3 aminoacids, 
RCAN1-exon1 (RCAN1-1) and RCAN1-exon4 (RCAN1-4) are expressed by 
endothelial cells and affect endothelial cell function (Qin et al., 2006).  For example, 
a study by Minami et al. showed that RCAN1-4 can inhibit NFAT induced VEGF-A 
expression in HUVECs (Minami et al., 2004).  The overexpression of RCAN1-4 
inhibits VEGF-A induced HUVEC network formation and proliferation (Minami et 
al., 2004).  Further in vivo studies using a matrigel plug assay and melanoma 
xenografts indicate that VEGF-A induced angiogenesis is inhibited by RCAN1-4 
overexpression (Minami et al., 2004).   This suggests that RCAN1-4 has anti-
angiogenic actions.   In contrast RCAN1-1 (aka DSCR1-1L) appears to have pro-
angiogenic properties (Qin et al., 2006).  A study by Qin et al. showed that RCAN1-1 
siRNA inhibited VEGF-A induced HUVEC proliferation and in vivo matrigel plug 
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angiogenesis (Qin et al., 2006).  This inhibition in RCAN1-1 was suggested to be due 
to a decrease in NFAT activity since NFAT activity was reduced with RCAN1-1 
siRNA and cyclosporin A inhibited RCAN1-1 induced angiogenesis (Qin et al., 
2006).  Alternatively, the RCAN1-Like1 (RCAN1-L1) isoform has been shown to 
inhibit NFAT activation as well as unstimulated HUVEC network formation and 
VEGF-A induced HUVEC proliferation (Gollogly et al., 2007).   
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1.8 Aims and objectives of the thesis 
 
In this chapter, the role of prostaglandins in endometrial adenocarcinoma has been 
reviewed along with the role of growth factors in angiogenesis and endothelial cell 
function.  FP receptor expression is upregulated, along with angiogenic factor 
expression, in endometrial adenocarcinoma.  Also an increase in microvascular 
density in endometrial cancers is associated with a poorer prognosis for patients.  
Research into the factors mediating the initiation and progression of endometrial 
adenocarcinoma, such as those regulating angiogenesis, could lead to the 
identification of appropriate therapeutic targets.  Further studies are needed, in the 
context of endometrial adenocarcinoma, in order to elucidate the mechanisms by 
which the autocrine and paracrine actions of factors, produced by prostaglandin F2α-
FP receptor signalling, regulate endothelial cell function and angiogenesis.  
Therefore, the specific aims of the research presented herein were to: 
 
1. Determine the expression and localisation of antiangiogenic ADAMTS1 in 
endometrial adenocarcinoma and investigate its regulation by prostaglandin F2α 
signalling.  This was performed using normal and cancer endometrial tissue 
samples and the Ishikawa endometrial adenocarcinoma cell line, stably 
expressing the FP receptor to levels seen in cancer (FPS cells) as described in 
chapter 3. 
 
2. Investigate the paracrine effects of proangiogenic factors FGF2, CXCL1 and 
CXCL8, secreted into conditioned medium from PGF2α treated FPS cells (P CM), 
on endothelial cell functions of differentiation and proliferation.  This was 
performed using conditioned medium and human umbilical vein endothelial cells 
(HUVECs) in network (differentiation) formation and proliferation assays as 
described in chapter 4. 
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3. Investigate the role of prostaglandin F2α and the FP receptor in the regulation of 
endothelial cell network formation and proliferation.  This was achieved by 
assessing endothelial cell network formation and proliferation after treatment 
with exogenous PGF2α or P CM, in combination with the FP receptor inhibitor 
AL8810, and silencing of the FP receptor using short hairpin RNA, as described 
in chapter 5. 
 
4. Identify the role of antiangiogenic ADAMTS1 and regulator of calcineurin 
(RCAN1-4) in P CM-induced endothelial cell network formation and 
proliferation.  This was conducted using viral vector gene silencing and 
overexpression of RCAN1-4 and small interference RNA silencing of 
ADAMTS1 in order to investigate the effects on P CM-induced endothelial cell 
network formation and proliferation as described in chapter 6. 
 
5. Investigate the role of prostaglandin F2α-FP receptor signalling in angiogenesis in 
vivo.  This was carried out by analysing microvessel density and angiogenic 
factor expression in the sponge/matrigel mouse model and tumour xenograft 
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2 General materials and methods 
2.1 Tissue collection 
Endometrial cancer tissue and normal tissue collection was performed with ethical 
approval from Lothian Research Ethics Committee under ethics number 
LREC/1999/6/4. Written informed consent was obtained from all subjects prior to 
tissue collection. Endometrial cancer tissue was obtained from women undergoing 
surgery for removal of endometrial cancer and who had been pre-diagnosed on 
endometrial biopsy to have endometrial adenocarcinoma of the uterus of the 
endometrioid type.  The median age of patients was 60.5 years.  Cancer biopsies 
were assessed by a pathologist and assigned a grade, well differentiated (grade 1; 
n=10), moderately differentiated (grade 2; n=10) or poorly differentiated (grade 3; 
n=10).  Normal endometrium from the proliferative phase and early-mid-late 
secretory phases of the menstrual cycle (n=10), was collected with an endometrial 
suction curette from women undergoing surgery for gynecological procedures 
including surgical sterilisation or abnormal uterine bleeding in whom histological 
examination of endometrium was normal with no underlying endometrial pathology 
(Pipelle, Laboratoire CCD, France).  The median age of women was 30.5 years.  
Biopsies were dated according to stated last menstrual period (LMP) and confirmed 
by histological assessment (Sales et al., 2005). After collection, tissue was placed in 
RNAlater (Ambion) and stored at -70oC (for RNA extraction) or fixed in neutral 
buffered formalin and wax embedded (for immunohistochemical analysis).  
2.2 Cell Culture 
2.2.1 Endothelial cells 
Human umbilical vein endothelial cells (HUVECs) (Lonza, Walkersville, USA) were 
cultured in Endothelial Basal Medium (EBM-2) with 2% FBS and growth 
supplements  (VEGF, FGF, PGDF, IGF, EGF, ascorbic acid, heparin and 
gentamycin) subsequently referred to as Endothelial Growth Medium (EGM) 
(Lonza, Walkersville, USA) at 37oC in a 5% CO2 atmosphere.  Under experimental 
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conditions cells were incubated with EBM-2 plus 1% FBS with the addition of 
ascorbic acid and gentamycin aliquots (Lonza, USA).  When cells reached 70-80% 
confluency, they were passaged by washing three times with Hank's balanced salt 
solution (HBSS), followed by a 5 minute incubation with trypsin.  Trypsinisation 
was stopped by the addition of Trypsin Neutralising Solution (TNS) (1volume 
trypsin: 2volumes TNS) and cells were centrifuged in a 15ml tube at 200rpm for 
5mins.  Cells were counted with a haemocytometer and seeded at the required 
density prior to the start of an experiment.  HUVEC of passages 3-8 were used for all 
experiments. 
 
2.2.2 Ishikawa cells 
A cell line stably overexpressing the FP receptor to levels seen in endometrial cancer 
was constructed by Cytomix Ltd. (Cambridge, United Kingdom) as described by 
Sales et al. 2005.  Briefly, FP receptor cDNA was transfected into wild type Ishikawa 
cells (WT) at passage 10 in the sense direction.  Individual cell populations were 
selected for with addition of 800µg/mL G418.  The clone with the highest level of FP 
receptor expression, FP sense 32 (FPS), as determined by Western blot analysis and 
relative quantification of FP receptor expression, were expanded and stored in liquid 
nitrogen.  Subsequently, WT and FPS Ishikawa cell lines were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen, Paisley, UK) with 10% 
foetal bovine serum (FBS) and 1% penicillin/streptomycin solution, at 37oC in a 5% 
CO2 atmosphere.  Cells were passaged at a confluency of 80-90% by washing three 
times with PBS to remove medium and incubated with trypsin for 5mins at 37°C.  
DMEM was added to quench the trypsinisation, and cells were counted with a 
haemocytometer for use in subsequent experiments.  Under experimental conditions 
cells were serum starved for 24hrs in DMEM containing only 1% 
penicillin/streptomycin and no FBS prior to treatment.  
 
Chapter 2     General Materials and Methods 73 
 
2.2.3 Reagents and cellular signalling inhibitors 
Recombinant CXCL8 (CXCL8), recombinant CXCL1 (CXCL1), Arachidonic acid 
(AA), PGE2, PGF2α, AH6809 and indomethacin were purchased from Sigma 
Chemical Co. (Dorset, UK).  PD98059, SU4984, NS398, SB225002, LY294002, 
PP2, wortmannin and rapamycin were purchased from Calbiochem (Nottingham, 
UK).  AL8810 and SC560 were purchased from Caymen Chemical Company 
(Michigan, USA). Recombinant FGF2 peptide was purchased from PeproTechEC 
Ltd. (London, UK).   
Table 1. Concentration of inhibitors 
























PP2 cSrc 10µM 
AG1478 EGFR 200nM 
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All inhibitors indicated in Table 1 were used at concentrations at or below their IC50 
or working concentrations reported for other systems.  The effect of inhibitors on 
endothelial cell viability was assessed with the proliferation assay (see section 2.9.2) 
using endothelial basal medium (EBM1%) plus inhibitor alone. 
 
To elucidae the intracellular signalling pathways using chemical inhibitors, it is 
important to understand the mode by which the inhibitors prevent their target 
molecules downstream signalling.  For example, AL8810 the antagonist of the FP 
receptor competes with PGF2α for binding to the FP (Griffin et al., 1999).  U73122 
inhibits phospholipases, including PLC which is activated by agonist binding to the 
FP receptor, however the precise mechanism of the action of U73122 is unknown 
(Yule and Williams, 1992).  AH6809, is a competitive antagonist of the 
prostaglandin E2 EP1 and EP2 receptors (Coleman et al., 1994). 
 
The membrane permeable calcium chelator BAPTA-AM sequesters calcium 
rendering it unable to initiate downstream signalling events (Tsien, 1981).   
N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide (W-7) is a calmodulin (CaM) 
antagonist that binds to multiple sites on Ca2+-bound CaM via Van der Waals 
interactions and electrostatic interactions (Osawa et al., 1999).  The binding of W-7 
in the hydrophobic pocket of CaM, and the conformational change caused by W-7 
binding, inhibits the interaction of CaM with target proteins, including calcineurin 
(Osawa et al., 1999).  Cyclosporin A (CsA) is a commonly used inhibitor of 
calcineurin that indiscriminately blocks the activation of all calcineurin targets.  CsA 
enters a cell and complexes with proteins called cyclophilins, enhancing cylophilins 
affinity for calcineurin (Kapturczak et al., 2004).  The CsA-cyclophilin complex 
binds to calcineurin and prevents its activation of target proteins such as NFAT 
(Kapturczak et al., 2004).  The inhibitor of NFAT-calcineurin association 6 (INCA6) 
is a selective inhibitor of the calcineurin-NFAT interaction.  INCA6 binds to 
calcineurin Aα at cysteine 266 which is not in the core calcineurin-NFAT binding 
site (PXIXIT) (Kang et al., 2005).  Therefore, the inhibition of NFAT activation by 
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INCA6 is regulated through an allosteric conformational change of the calcineurin 
PXIXIT docking site (Kang et al., 2005).  
 
 PP2(4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) 
preferentially interacts with Src-family protein tyrosine kinases (SFK) however, it 
can bind to other tyrosine kinases including C-terminal Src kinase (CSK) and  
SAPK2a/p38 (Chong et al., 2005).  PP2 inhibits SFK activation by binding to the 
adenine pocket of the ATP-binding site and via its core hetero-bicyclic region 
thereby preventing SFK activation (Chong et al., 2005).  The aryl substituent of PP2 
inserts into the hydrophobic pocket adjacent to the adenine pocket (Chong et al., 
2005).    
 
AG1478 is a quinazoline synthetic inhibitor highly specific to EGFR.  AG1478 
competes with ATP to bind with EGFR, thereby preventing its activation, but does 
not prevent substrate binding (Levitzki and Gazit, 1995).  
 
PD98059 binds to MEK1/2 (the activator of ERK1/2), at a site unrelated to substrate 
binding, causing a change in tertiary structure which prevents ATP binding and 
therefore MEK1/2 activation.  Consequently, by inhibiting MEK1/2 activation, 
PD98059 prevents ERK1/2 activation (Alessi et al., 1995).  
 
Indomethacin belongs to the structural class of indole and indene acetic acids and 
inhibits both COX-1 and COX-2 with similar efficacy (Mitchell and Warner, 2006).  
NS398 is a selective diarylheterocycle inhibitor for COX-2, as it has only a weak 
effect on COX-1 activity, and is therefore used as a COX-2 specific inhibitor 
(Walker et al., 2001). The binding of NS3983 to the active site of COX-2 results in a 
non-reversible conformational change that prevents substrate binding (Walker et al., 
2001).   
 
The specific COX-1 inhibitor, SC-560, belongs to the diarylheterocycles but lacks 
the phenylsulphonamide moiety common to the COX-2-selective inhibitors, 
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therefore SC-560 binding to the active site of COX-1 is selective but reversible 
(Walker et al., 2001). 
 
Wortmannin is a selective inhibitor of PI3K that binds to the p110 catalytic subunit 
of PI3K and prevents the formation of PIP3 from PIP2 (Arcaro and Wymann, 1993).  
LY294002 is a selective inhibitor of PI3K that competes, with ATP, for the ATP 
binding site of PI3K (Vlahos et al., 1994).  Rapamycin is an inhibitor of the mTOR 
complex 1 (mTORC1) consisting of mTOR, Raptor and mLST8.  Rapamycin 
simultaneously binds to hydrophobic pockets of FKBP12 and the FRB domain of 
mTOR which may interfere with catalytic activity of mTOR by preventing 
phosphatidic acid binding (Ballou and Lin, 2008).  Rapamycin may also interfere 
with the stabilisation of the mTOR-raptor complex and Rheb–GTP activation of 
mTOR (Ballou and Lin, 2008).   
 
SU4984 is an inhibitor of the FGF2 receptor FGFR1 (Mohammadi et al., 1997).  The 
oxindole portion of SU4984 occupies the FGFR1 site in which the adenine of ATP 
binds, whereas the moieties that extend from the oxindole contact residues in the 
hinge region of FGFR1 between its two kinase lobes (Mohammadi et al., 1997).  
SB225002 is an antagonist of the CXCR2 receptor which competes with CXCL1 and 
CXCL8 for binding (Catusse et al., 2003).  The binding of SB225002 occurs through 
epitopes which are disseminated throughout CXCR2.  The epitopes that SB225002 
binds to differ according to the use of CXCL1 or CXCL8 as a competitor and do not 
necessarily overlap with the CXCL1 or CXCL8 binding sites (Catusse et al., 2003). 
 
2.2.4 Conditioned medium 
WT or FPS cells were seeded at a density of 2x106 cells and incubated at 37oC in a 
5% CO2 atmosphere to allow adherence before serum-starvation for 24hrs. 
Thereafter, cells were treated with 20mls of DMEM containing 8.4μM indomethacin 
in the presence of 100nM PGF2α  or vehicle for 24hrs to create PGF2α conditioned 
medium (P) or vehicle conditioned medium (V).  Conditioned medium from three 
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independent experiments was pooled, aliquoted and stored at -20°C until required.  
Fibroblast growth factor 2, CXCL1 and CXCL8 were immunoneutralised from the 
FPS cell PGF2α conditioned medium (FP P CM) by overnight incubation with 
0.5μg/ml FGF2 antibody, 2μg/ml CXCL1 antibody or 2μg/ml CXCL8 antibody. The 
FGF2 antibody recognising the LMW 18kDa isoform and the CXCL1 antibody were 
purchased from Santa Cruz Biotechnology (Autogen-Bioclear, Wiltshire, UK). The 
CXCL8 antibody was purchased from Sigma, UK. The immune complex was 
removed by 4hr incubation with 20-40μl of a 50% protein A plus G slurry 
(Calbiochem, Darmstadt, Germany).  Conditioned medium immunoneutralised with 
Goat IgG was used as a control.  Immunoneutralised CM was stored at -20°C until 
use.  The FGF2, CXCL1 or CXCL8 protein content in the CM before and after 
immunoneutralisation was investigated by ELISA (see section 2.8.2 for further 
details).  An advantage to using conditioned medium, as opposed to recombinant 
ligand alone, is that the concentration of proteins relative to each other, in the CM, is 
representative of the tumour environment (van Beijnum and Griffioen, 2005). 
2.3 RNA analysis 
2.3.1 RNA extraction from tissues and cells 
2.3.1.1 Cells  
RNA was extracted from cells using TRI-Reagent (Sigma-Aldrich, Dorset, UK), 
containing guanidine thiocyanate and phenol in a monophase solution, following 
maufacturers protocols.  Briefly, the RNA, DNA and protein is dissolved in the 
solution following homogenisation or lysis.  Cells were lysed by pipetting the TRI-
Reagent up and down on the cell covered surface of culture dish.  The TRI-Reagent- 
cell mixture was combined with 1-Bromo-3-choloropropane (BCP) and added to 
phase-lock tubes (Invitrogen) to allow for easy separation of the aqueous RNA phase 
from the DNA and protein.  After 30seconds of shaking the phase-lock tubes to mix 
the solutions, the mixture was allowed to stand for 10mins at room temperature, to 
ensure complete dissociation of the nucleoprotein complexes, and then centrifuged 
for 15mins at 14000xg and 4°C.  The colourless, upper aqueous phase (containing 
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RNA), was transferred to a fresh tube containing isopropanol and allowed to stand at 
room temp for 5-10mins followed by centrifugation at 14000xg for 15 mins at 4°C.  
The RNA formed a pellet at the bottom of the tube which was washed with 75% 
ethanol, dried and reconstituted in RNAse-free water by repeated pipetting.   
2.3.1.2 Tissue 
To purify Total RNA from tissue, the RNeasy Mini Kit (Qiagen,) was used according 
to manufacturer’s instructions. For example, 30mg mouse kidney tissue was weighed 
and RNA was extracted for use as a positive control during Quantitative-PCR 
TaqMan reactions (see section 2.4).  Tissue was homogenised in Buffer RLT 
(Qiagen) using a mechanical tissue homogeniser.  The lysed tissue was centrifuged 
and the supernatant collected.  This supernatant was transferred to a new 
microcentrifuge tube and combined with and equal volume of 70% ethanol.  Up to 
700μl of the ethanol mixture was added to an RNeasy spin column in a 2ml tube and 
centrifuged for 15seconds at 8000xg.  This step was repeated until all the ethanol 
mixture had flowed through the spin column and the flow-through was discarded.  
The spin column membrane was washed with 700μl Buffer RW1, followed by two 
washes with 500μl Buffer RPE.  To elute the RNA from the membrane, the spin 
column was placed in a new collection tube, 50μl of RNase free water was added and 
the column was centrifuged to release the reconstituted RNA.   
 
2.3.2 RNA quantification 
The concentration and purity of the reconstituted RNA was measured using the 
Nanodrop-1000 (Labtech International, East Sussex, UK) spectrophotometer.  The 
concentration of RNA was expressed as ng/μl.  RNA absorbance is measured at 
260nm and proteins have a peak absorbance at 280nm. A 260/280 ratio of >1.7 
indicated the RNA was free from protein and DNA contamination as protein 
contamination will reduce this ratio (Gallagher, 2001).   Purified RNA was stored at 
-80°C. 
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2.4 TaqMan® quantitative RT-PCR (QPCR)  
2.4.1 Preparation of cDNA from RNA by reverse transcription. 
Firstly, cDNA reverse transcription was carried out on purified total RNA.  RNA was 
diluted to a concentration of 100ng/μl in RNase-free water.  A 20μl  reaction mixture 
was made as using a mix of TaqMan Reverse Transcription Reagents 
(AppliedBiosystems); 2µl reverse transcription buffer, 5.5mM MgCl2, 2mM dNTPs,  
0.4U/ml RNase Inhibitor, 2.5 µM Random Hexamers, 2mM Oligo dT, 1.25U/ml 
Multiscribe Reverse Transcriptase, volume corrected to 16µl with H2O.  For each 
sample 4μl of 100ng/μl RNA was added to 16μl of the mix to create a 20μl total 
reaction volume.  If a 100μl reaction volume was needed, quantities were increased 
by a factor of 5.   
 
Reverse transcription was carried out using a Techne TC-512 Thermal Cycler 
(Techne Inc., Burlington, NJ, USA).  The thermal profile parameters consisted of 1 
cycle involving 1hour at 42°C, 5minutes at 99°C and 5minutes at 5°C with a 4°C 
hold step. The cDNA was stored at -20°C. 
2.4.2 TaqMan® reaction 
After reverse transcription, the cDNA samples were used to examine the levels of a 
particular gene of interest using a standard TaqMan reaction and the ABI7900HT 
Real-Time PCR System (AppliedBiosystems,FosterCity,CA USA).  The level of 
ribosomal 18S was measured in each sample, as an endogenous control, using an 18S 
standard mix (TaqMan Ribosomal RNA Control reagents, VIC probe, 
AppliedBiosystems). The 18S mix was made using; 18S forward primers, 18S 
reverse primer and 18S probe (~ 840ul total) plus 1260 μl TE Buffer, mixed, 
aliquoted stored at -20°C.  Primers and probes for target sequences were used at a 
concentration of 25nM and 10nM, respectively.  The TaqMan reaction mixture was 
made using TaqMan Universal PCR Master Mix (2✕) (AppliedBiosystems).  A 20μl 
TaqMan reaction mixture in duplicate was made using; 1X TaqMan Universal PCR 
Master Mix, forward primer and reverse primers (25nM), Probe (10nM), 18S 
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standard mix (50nM) and 2μl (40µg) cDNA.  Additionally, negative control samples 
containing no reverse transcriptase enzyme or no cDNA were used.  Samples were 
mixed and centrifuged before transferring to the wells of the TaqMan® Microamp 
Fast Optical 96 well reaction plate (AppliedBiosystems), in duplicate 23μl reaction 
volumes.  The TaqMan reaction volume was set as 20μl on the ABI7900 machine.  
2.4.3 Principles of the TaqMan® quantitative RT-PCR (QPCR) reaction 
TaqMan uses a fluorogenic probe to allow detection of a polymerase chain reaction 
(PCR) product as seen in Fig. 17.  The forward and reverse primers amplify a 
specific sequence of cDNA in a polymerase chain reaction (PCR) and the 
fluorogenic probe hybridises with the PCR product to generate a fluorescent signal 
(Fig. 17).  An internal control of ribosomal 18S standard is added to the reaction 
mixture to normalise for the variation in reaction mixture volume and total RNA 
concentration (see section 2.3.2).  The formation of the PCR product is measured, in 
real time, at multiple time points during the reaction hence Real Time PCR (RT-
PCR) (see Relative Quantitation Using Comparative CT Getting Started Guide, 
AppliedBiosystems 7900HT Real-Time PCR System, www3.appliedbiosystems.com 
for further details.) 
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Fig. 17. A schematic representation of the TaqMan reaction. The Two-Step RT-PCR 
method was used in which total RNA was reverse transcribed (RT) into cDNA followed by 
Real Time PCR (adapted from).  
 
2.4.4 Analysis of results 
Comparative analysis of mRNA quantities was carried out by determining the 
relative quantitation (RQ).  RQ is the quantity of a single nucleic acid target 
sequence within an unknown sample relative to the quantity in a calibrator sample.  
In this thesis, the calibrator sample was a normal endometrial sample when looking 
at gene expression in normal endometrium and cancer.  In cell culture studies, the 
calibrator sample was either an untreated control or a sample at time zero in a time-
course study.  In Real-Time PCR the levels of the target sequence are measured at 
multiple time points throughout the reaction creating an amplification curve, as 
shown in Fig. 18.   
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Fig. 18. Amplification curve data from a TaqMan assay. (adapted from Relative 
Quantitation Using Comparative CT Getting Started Guide, AppliedBiosystems 7900HT 
Real-Time PCR System, www3.appliedbiosystems.com). 
As shown in Fig. 18, a typical amplification curve has a: Plateau phase (a), Linear 
phase (b), Exponential phase (c) - The exponential growth phase of the amplification 
curve, Background (d) – Any reading that falls below the threshold and is not part of 
an amplification curve and Baseline (e) – The initial cycles of the reaction before the 
target sequence is detected, by fluorescence. 
 
Fig. 19. An example amplification curve from one sample (adapted from 
www3.appliedbiosystems.com). 
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In Fig. 19 an example of a single amplification curve can be seen.  The amplification 
curve has regions defined below that are used to determine the relative quantitation 
(RQ) of mRNA in each sample: 
• Normalized reporter (Rn) – The ratio of fluorescence emission intensity 
from the reporter FAM™dye to the fluorescence emission intensity of the 
passive reference VIC™ dye. 
• Delta Rn (ΔRn) – The magnitude of the fluorescence signal generated 
when the probe binds to the target sequence after normalisation and 
baseline correction (ΔRn= Rn-baseline). 
• Threshold cycle (CT)- The cycle number at which the fluorescence signal 
from the target sequence is first detected. This is determined by the point 
at which the threshold line crosses the amplification plot. 
• Threshold- The level used to determine the CT.  It is set within the 
exponential phase automatically determined by the software or manually 
set. 
 
To analyse data in this thesis, the baseline was manually adjusted so that the 
amplification curve began just after the maximum baseline.  The threshold was 
adjusted manually to be in the middle of the exponential phase so an accurate cycle 
number was recorded as the Ct value.  The results were transferred to Excel 
(Microsoft Office) for analysis.  In Excel, the target sequence Ct values were first 
adjusted for variances between RNA and volume using the ribosomal 18S Ct value 
(18S Ct – Gene Ct).  Then an average of duplicates was taken to determine the 
difference (delta) in Ct therefore, delta Ct =Average (18S Ct – Gene Ct) (18S Ct – 
Gene Ct).  The expression levels of the target sequence were normalised to the 
expression levels of the calibrator sample. Therefore, calibrator sample = 0 and gene 
expression = deltadeltaCt.  As this was a log scale, the final fold–expression changes 
were calculated as: Fold change = 2^(-deltadeltaCt) = 2-ΔΔCt  
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2.4.5 Primer/Probe validation 
Primers and probes were designed using the Primer Express® software 
(AppliedBiosystems) to identify suitable sequences.  The following parameters were 
used for identifying nucleotide sequences: 
• Sequence length of approximately 20bp, amplicon size 50-150bases. 
• Avoiding areas of four or more guanines.  
• Keeping the total G-C content within 30-80%. 
• Designing the primers over intron/exon gaps to decrease the possibility of 
genomic DNA contamination. 
• Selecting primers with a melting temperature (Tm) of 58-60°C 
• The five nucleotides nearest the 3’ end should have no more that two 
guanines and/or cytosine bases. 
• Designing the primers as close to the probe as possible. 
 
The sequences of the primers and probes used for mouse and human genes are listed 
below in Table 2 and Table 3 respectively. 
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Table 3. Human gene primers and probes for TaqMan QPCR 
 
 
New primers and probes were initially validated using serial dilutions of control 
cDNA from a range of 40-1.25 ng/μl.  The mouse specific primers and probes, seen 
in Table 2, were validated using mouse kidney cDNA whereas human primers and 





forward primer reverse primer probe 
FGF2 CCG ACG GCC GAG TTG AC 
GAC ACA ACT CCT  
CTC TCT T 
AGA AGA GCG ACC CTC ACA 
CXCL1 
GTT TTC AAA TGT TCT CCA 
GTC ATT ATG 
CCG CCA GCC TCT ATC ACA 
GT 









TAC CTC CAC CAT GCC 
AAG TG 
TAG CTG CGCTGA 
TAG ACA TCC A 
ACT TCG TGA TGA TTC 




ACC TTG AAGGAGT 
CAGGCATG AG 
CGC AAC CGC ATT GCC 
ATG GAG T 
COX2 
CCT TCC TCC TGT 
GCC TGA TG 
ACA ATC TCA TTT GAA 
TCA GGA AGC T 
TGC CCG ACT CCC 
TTG GGT GTC 
FP 
GCA GCT GCG CTT  
CTT TCA A 
CACTGTCATGAAGATTACT 
GAAAA AAATAC 
CAC AAC CTG CCA GAC GGA 
AAA CCG 
EP1 
AGA TGG TGG GCC AGC 
TTG T 
GCC ACC AAC ACC  
AGC ATT G 
CAG CAG ATG CAC GAC 
ACC ACC ATG 
EP2 
GAC CGC TTACCTGCAGC 
TGTA C 
TGA AGT TGC AGG CGA GCA 
CCA CCC TGC TGC TGC 
TTC TCA TTG TCT 
EP3 
GAC GGC CAT TCA 
GCT TAT GG 
TTGAAGATCATT 
TTCAACATCATTATCA 
CTG TCG GTC TGC TGG 
TCT CCG CTC 
EP4 
ACG CCG CCT ACT CCT 
ACA TG 
AGA GGA CGG TGG CGA 
GAA T 
ACG CGG GCT TCA 
GCT CCT TCC T 












CGG CTA CCA CAT CCA 
AGG AA 
GCTGGAATT ACCGCG GCT 
TGCTGGCACCAGACT 
TGCCCTC 




As an example, Fig. 20 and Fig. 21 display primer probe validation graphs for 
ADAMTS1 (Table 3).  Firstly, the Ct values for ribosomal 18S and target sequence 
(ADAMTS1) are plotted in a linear regression graph against the Log values of 
control cDNA concentration (Fig. 20). The y=mx+c equation of the straight line is 
displayed on the graph.  R2 should be close to 1. 
ADAMTS1 primer/probe validation
y = -4.173x + 36.487
R2 = 0.9978
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Fig. 20. Graph displaying the linear equations for target gene sequence and 18S 
control. 
 
Next, as seen in Fig. 21, the deltaCt values for the target gene sequence (ADAMTS1) 
were plotted against the Log of concentration of cDNA (Fig. 21).  The equation of a 
straight line y=mx+c is displayed on the graph.  m, the gradient of the straight line, 
should be close to 0, the gradient for a horizontal line.  Indicating that the 18S and 
gene of interest are present in the same proportions at each concentration of cDNA 
therefore, the primers and probes are reliably relaying the quantities of the target 
sequence.   
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ADAMTS1 primerprobe validation 
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Fig. 21. Graph displaying the linear equation of the deltaCt of the target gene 
sequence. 
2.5 Protein Analysis 
2.5.1 Protein extraction from cells 
HUVEC were seeded at 2x105 cells per 60mm2 dish and left to adhere for 24hrs, at 
37oC in a 5% CO2 atmosphere, before serum starvation overnight.  Growth factor-
starved HUVECs were treated with P CM or V CM for 0, 5, 10, 15, 20, 30 mins in 
the case of a time-course and 10minutes when using a panel of chemical inhibitors.  
HUVEC were rinsed with ice-cold phosphate-buffered saline and lysed on ice for 
20mins with 200μl/dish protein lysis buffer containing inhibitor cocktail mix (see 
section 2.10).  
2.5.2 Protein quantification 
Protein concentration was quantified by a protein assay (BioRad, Hercules, CA) 
following the method of Lowry.  The standard curve for total protein concentration 
in a sample was produced using known dilutions of bovine serum albumin (BSA).  
Standards were made from serial dilutions of 1mg/ml BSA to concentrations of 400, 
300, 200, 100, 75, 50 and 25 μg/ml in water.  25 μl of standards and samples were 
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added in duplicate to the wells of a 96-well plate.  An equal volume of dye reagent 
(Reagent S + Reagent A, 1:50) was added to each well, followed by 100μl of 
Reagent B.  The colour was allowed to develop for 10minutes after which, the plate 
was read at 690nm on a colorimetric plate reader.   
 
Fig. 22. A typical BSA standard curve for the Bio-Rad protein assay, Lowry method. 
 
An example standard curve is displayed in Fig. 22.  The standard curve was 
constructed as an XY linear regression graph in Prism 5 (GraphPad, San Diego, CA).  
The optical density value obtained from each sample was used to calculate the 
unknown protein concentration (μg/ml) from the standard curve.  
2.5.3 Acrylamide gel electrophoresis 
Approximately 16μg of protein was solubilised in Laemmli buffer (see section ) and 
boiled for 5 min.  Protein was resolved using NuPAGE® Novex Bis-Tris Gels.  The 
running buffer was prepared by diluting NuPAGE SDS Running Buffer at a ratio of 
1:20 in deionised water. The running buffer contains SDS (sodium dodecyl sulphate), 
to denature and negatively charge the proteins enabling them to migrate through the 
gel, and EDTA to minimise disulphide bonds which could slow protein migration.  
MES (pKa = 6.15), and MOPS (pKa = 7.20) SDS running buffer (section 2.10) were 
used for small or medium molecular weight proteins, respectively, as proteins 
migrate faster with MES due to its higher acid dissociation constant (pKa) (see 
www.invitrogen.com for further details).  The chambers of the XCell SureLock Mini-
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Cell (Invitrogen) gel box were filled with buffer to a level required to allow the flow 
of current.  In the first well of the gel, 10μl of coloured standard, SeeBlue Plus2 Pre-
Stained Standard (Invitrogen) was loaded.  This coloured standard allowed the 
separation of samples to be monitored.  In the next gel wells 25μl of protein sample 
was loaded.  The current was set at 40 mA/gel and samples were allowed to migrate 
through the gel and separate according to their molecular weight.  
2.5.4 Semi-Dry protein transfer  
Once the loading buffer reached the bottom of the gel, the gel was removed from its 
case and the protein transfer module was assembled, see Fig. 23.  The semi-dry 
method of protein transfer was used.  Blotting paper was soaked in Transfer buffer 
(containing methanol, see section 2.10) and a PVDF (Polyvinylidene Difluoride) 
Immobilon-FL™ membrane (Millipore UK, Watford, UK) was soaked in methanol 
prior to assembly. The methanol enhances the binding of the protein to the 
membrane by decreasing the presence of SDS and also helps to stabilise the gel 
dimensions. Blotting paper was positioned in the transfer module followed by the 
membrane.  The gel was placed on top of the membrane and covered with more 
blotting paper.  The current flowed from the cathode to the anode so that the protein 
was transferred on to the membrane.   
 
Fig. 23. A standard semi-dry protein transfer module (adapted from 
http://www.invitrogen.com). 
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Proteins were allowed to transfer to the membrane for 1.5 hrs at a constant 14volts.  
The successful transfer of protein was indicated by the presence of the coloured 
standard on the membrane.   
2.5.5 Western blotting 
Immunoblots were blocked, to reduce background signals from non-specific 
antibody binding, in Odyssey Blocking bufferTM (LI-COR Biosciences, Cambridge, 
UK). Subsequently, immunoblots were incubated overnight with the primary 
antibodies, listed in Table 4, (diluted 1:1000 in blocking buffer) at 4°C. The 
following day, blots were washed in PBS and incubated with the secondary 
antibodies, listed in Table 5, for 60 minutes at room temperature.  The IRDye® 800 
secondary antibody used is a fluorophore which can be detected with near-infrared 
(IR) wavelengths (800nm).  This longer wavelength helps minimise background 
when visualising proteins.  Simultaneous detection of a control protein was achieved 
by the use of a fluorophore with an emission spectrum in the 680nm range.  
Table 4. Summary of primary antibodies used for Western blotting 
Antibody Source Dilution 
Anti-phospho-
p42/p44 ERK 
Cell Signaling Technologies 1:1000 
Anti-p42/p44 ERK Cell Signaling Technologies 1:1000 
Anti-p85 PI3K Upstate 1:1000 
Anti-phospho p85 
PI3K 
Autogen bioclear  1:1000 
 
Table 5. Summary of secondary antibodies used for Western blotting 
Antibody Source Detection Dilution 
Goat anti-mouse  Rockland, USA 800nm 1:10,000 
Goat anti-rabbit Invitrogen, Paisley, UK 680nm 1:5000 
Donkey anti-goat  Invitrogen, Paisley, UK 680nm 1:5000 
Donkey anti-rabbit Rockland, USA 800nm 1:5000 
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2.5.6 Protein expression analysis  
The chemiluminescence of immunoreactive proteins were detected and quantified 
using the Odyssey infrared imaging system (LI-COR Biosciences).  Subsequently, 
protein phosphorylation was calculated by dividing the value obtained from the 
phosphorylated protein channel (680nm) by the value obtained from total protein 
channel (800nm) and expressed as fold above vehicle controls.  
2.6 Tissue fixation and processing  
Tissue samples were fixed overnight in ten percent neutral buffered formalin, pH 7 
(NBF, see section 2.10). The NBF facilitates the formation of cross-links which helps 
keep in position small molecules such as hormones and prevents degradation of 
proteins whilst preserving their secondary and tertiary structures (see Dako 
Immunohistochemistry staining guide, 4th Edition, http://www.dakousa.com.)  
However, it is important not to over fix tissues as this can result in the masking of 
antigen epitopes.  The next day the tissue samples were transferred to 70% EtOH and 
processed.  From the 70% alcohol, the tissue was alcohol rehydrated by incubation in 
increased concentrations of alcohol, followed by xylene and then samples were 
embedded in hot paraffin wax on plastic block holders.  Sections of tissue samples 
were cut 5 microns thick with a microtome and mounted on glass slides. Slides were 
baked at 55°C overnight to ensure the adhesion of the tissue section to the glass. 
2.7 Tissue staining and Immunohistochemistry 
2.7.1 Haematoxylin and eosin staining 
The initial examination of tissue sections was carried out by staining the sections 
with Harris’s haematoxylin (Triangle Biomedical Sciences) and eosin Y (1% 
aqueous solution mixed with 1% alcohol solution at a ratio of 3:1 - Triangle 
Biomedical Sciences).   Slides were dewaxed in xylene and rehydrated in decreasing 
concentrations of ethanol.  Following this, the slides were incubated for 5 minutes in 
haematoxylin, intense staining was decreased by 20 seconds in scotts tap water, and 
then haematoxylin was ‘blued’ in water.  Two minute incubation in eosin was used to 
stain the collagen fibres.  After optimal staining, sections were dehydrated, incubated 
Chapter 2     General Materials and Methods 92 
 
in xylene and mounted with coverslips (VWR, Poole, UK.) using Pertex (Cell Path, 
Hemel Hempstead, UK).   
2.7.2 The priniciples of Immunohistochemistry 
Antibodies bind to the epitopes of an antigen through ionic interactions, hydrogen 
bonds and Van der Waal forces (see Dako Immunohistochemistry staining guide, 4th 
Edition, http://www.dakousa.com).  The affinity of an antibody for an antigen 
depends on the variable region of its heavy and light chains.   Polyclonal and 
monoclonal antibodies are available for immunohistochemical use.  Polyclonal 
antibody samples contain a range of affinity binding variations due to the multiple 
epitope binding forms.  Polyclonal antibodies are relatively inexpensive and work 
under a variety of conditions.  Monoclonal antibodies are more antigen-specific and 
their use reduces background, due to non-specific binding, and increases consistency.  
Affinity-purified antibodies are produced using immobilised antigen to improve 
antibody specificity.  The binding affinity of an antibody affects the incubation time 
required between the antibody and immobilised tissue antigen.      
 
Below in Fig. 24 is a diagrammatic representation of a primary antibody binding to a 
target antigen, followed by a secondary antibody binding to the primary antibody.   
 
Fig. 24. Target antigen bound to a chain of primary antibody, biotinylated secondary 
antibody and streptavidin enzyme complex. (adapted from Dako Immunohistochemistry 
staining guide, 4th Edition, http://www.dakousa.com ).  
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Slides were washed in phosphate buffered saline (PBS) (section 2.10) because 
streptavidin peroxidase was used as the detection enzyme.  Streptavidin horseradish 
peroxidase (HRP) is a 40 kDa protein that catalyses the oxidation of substrates by 
hydrogen peroxide.  It is most active at a neutral pH and is more stable than the 
alternative detection enzymes.  A commonly used substrate for HRP is 3,3’-
diaminobenzidinetrahydrochloride (DAB).  When DAB is oxidised by HRP, an 
insoluble brown coloured product forms which can be visualised under a microscope.  
Under the correct conditions, the presence of DAB staining will indicate the 
localisation of the target protein.  Whether or not the intensity of DAB staining 
indicates an increased presence of target protein is contentious because so many 
factors could affect the DAB intensity.    
 
As an alternative to DAB staining or when coexpression of two or three proteins is 
required, the method of fluorescent immunohistochemistry can be used. 
Immunofluorescence (IF) protocols vary depending on the sensitivity of the primary 
antibody for the target antigen.  The simplest IF method involves use of a 
fluorophore linked secondary antibody.  If greater sensitivity is required, a 
streptavidin linked secondary is applied followed by a species specific fluorophore 
that will bind to the secondary antibody.  Further sensitivity can be added using a 
tyramide amplification step which lengthens the immunoreactive chain of detection 
thereby creating a larger fluorescent signal. 
 
2.7.3 Antigen Retrieval 
To begin immunohistochemical staining of tissue sections, paraffin embedded 
sections (slides) were dewaxed and rehydrated following a standard protocol: 
5mins in xylene, (x2), 20seconds in 100% ETOH (x2), 20seconds in 95% ETOH, 
20seconds in 75% ETOH, wash in tap water.   Antigen retrieval was then performed 
using Citrate buffer (section 2.10) as the retrieval solution.  Antigen retrieval 
involves the incubation of sections in a hot aqueous retrieval solution such as Citrate 
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buffer.  The aim of antigen retrieval is to recover lost immunoreactivity of target 
antigens which may have been caused by the formalin fixation process. The exact 
mechanism by which protein immunoreactivity is enhanced by heat is uncertain but 
it may reverse the cross linking of formalin sensitive antigenic sites (epitopes) (see 
Dako Immunohistochemistry staining guide, 4th Edition, http://www.dakousa.com).   
Citrate buffer was diluted to a 10mM concentration in deionised water and brought to 
the boil in a pressure cooker.  Slides were boiled for 5minutes, afterwhich the slides 
were taken off the heat and left to sit for 20minutes in the hot Citrate buffer.   
2.7.4 Methanol peroxide block 
A methanol peroxide block was used to minimise background staining that could 
occur due to endogeneous peroxides in the tissue.  Endogenous peroxidises are found 
in a variety of cells including, red blood cells, monocytes and muscle cells. All slides 
were blocked in 300mls of methanol with 3% (v/v) hydrogen peroxide at room 
temperature for 30mins.   
2.7.5 Wash buffer 
After 30minutes incubation, the slides were washed in water followed by a wash in 
phosphate buffered saline (PBS) (section 2.10). Generally PBS was used to wash 
slides after each incubation step.  However, in some cases it may cause a higher 
incidence of nonspecific binding therefore with antibodies that had high levels of 
background binding such as CD31, Tris Buffered Saline (TBS, section 2.10) was 
used as an alternative wash buffer. Tween 0.01% was added to TBS and used for the 
first of three washes as this detergent helps to further decrease non-specific binding.  
In contrast, PBS helps to reduce auto fluorescence during fluorescent 
immunohistochemistry therefore it was the wash buffer used during this process.  
 
2.7.6 Serum block 
Sections were blocked in 4 parts PBS with 1 part normal serum (NS, e.g rabbit) 
(Diagnostics Scotland, Carluke, UK) (v/v) and 5% Bovine Serum Albumin (BSA) 
(Sigma, Poole, Dorset, UK) for at least 30mins at room temp.  The normal serum 
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chosen was usually from the same species that the secondary antibody was raised in 
to help minimise non-specific binding. 
2.7.7 Primary antibodies 
After, blocking in serum block, the block was drained off the slide and excess block 
was wiped from the area around the target antigen.  Polyclonal or monoclonal 
primary antibodies, listed in Table 6, were diluted in serum block (NS/PBS/BSA) 
and incubated with the immobilised target antigens on glass slides overnight at 4°C.  
The optimal dilution of primary antibody was pre-determined in trial runs using 
serial dilutions.    
Table 6. Summary of primary antibodies  
Antibody Source Dilution 
ADAMTS1 Abcam, Cambridge, UK 1:100 
FP CaymenChemicalCompany,USA 1:75 
COX-2 SantaCruz Biotechnology, USA 1:200 
VEGF-A SamtaCruzBiotechnology,USA 1:200 
CXCL1 SantaCruz Biotechnology, USA 1:100 
CD31 Santa Cruz Biotechnology,USA 1:350 
Goat IgG Dako 1:200 
Rabbit IgG Dako 1:200 
 
2.7.8 Secondary antibodies 
The secondary antibody used to detect each antigen was determined according to the 
species that the primary antibody was raised in and the detection method.  
Biotinylated secondary antibodies were used unless otherwise specified (see Table 
7).   For example, a rabbit anti goat biotinylated, at 1:500 in Normal rabbit 
serum/TBS/BSA, was applied after the primary goat anti human CD31 (Santa Cruz, 
sc-1506).  Secondary antibodies were incubated for 30 mins at room temperature. 
 
 
Chapter 2     General Materials and Methods 96 
 
Table 7. Summary of secondary antibodies used for immunohistochemsitry 
Host Target Conjugate Source Dilutions 
Rabbit anti-goat biotinylated Dako 1:500 
Goat anti rabbit biotinylated Dako 1:500 
Swine anti rabbit biotinylated Dako 1:500 
 
2.7.9 Developing, counterstaining and mounting 
Prior to DAB staining, streptavidin horseradish peroxidise (HRP) (DAKO, 
Cambridge, UK) was diluted 1:1000 in PBS (v/v) and was incubated for 30mins with 
slides.  Thereafter, slides were washed three times in PBS for 5 minutes.  The DAB 
substrate (DAKO), 1 drop/ml in diluent, was added to each slide and colour 
development was monitored microscopically.  The reaction was stopped by washing 
in water.  Slides were counterstained with haematoxylin and mounted with coverslips 
in pertex. 
2.7.10 Imaging 
High resolution photographs of DAB stained tissue and cells were taken with the 
Provis microscope (Provis AX70, Olympus America Inc., New York, USA) using 
Axiovision software (Carl Zeiss GmbH, Hamburg, Germany).   
 
2.8 Secreted protein identification and quantification 
2.8.1 Angiogenesis Antibody Array 
A Human Angiogenesis Antibody Array I (RayBiotech Inc, Norcross, GA, USA) kit 
was used to identify angiogenic proteins present in the conditioned medium (section 
2.2.4) from Ishikawa cells as per the manufacturer’s instructions.  Four angiogenesis 
array membranes were used from the kit.  All buffers and reagents were provided in 
the kit (RayBio, recipes undisclosed).  The membranes were incubated in blocking 
buffer before the addition of samples.  Control membranes were treated with 1ml of 
vehicle-treated WT or FPS cell conditioned medium and the test membranes were 
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treated with 1ml of PGF2α-treated WT or FPS cell conditioned medium (DMEM).  
Membranes and samples were incubated for 2hrs at room temperature after which, 
membranes were washed in buffers provided.  The cocktail of biotinylated antibodies 
was added overnight at 4°C. Wash steps were repeated and HRP-streptavidin was 
incubated with the membrane for 2hrs. After further washing, detection of the 
membrane bound proteins was determined with detection buffer and exposure to x-
ray film which was developed using autoradiography film processing equipment 
(Compact, Xograph , Tetbury, UK) in a dark room. 
 
2.8.2 Enzyme-linked immunosorbent assays (ELISA) 
2.8.2.1 VEGF and FGF2 
VEGF and FGF2 protein levels in the conditioned medium were measured using the 
Human VEGF ELISA Kit (Cat. No. QIA51, Calibiochem) and Basic FGF2 ELISA 
Kit (Cat No.QIA64, Calibiochem) according to manufacturers instructions. 
Conditioned medium was diluted 1:10 in assay diluent to detect VEGF and 
conditioned medium was used undiluted to detect FGF2 levels.  
2.8.2.2 CXCL8 and CXCL1 
96 well plates (NUNC™, ThermoFisherScientific, Rochester, NY, USA) were 
coated with 1.8μg/ml capture antibody monoclonal anti-human CXCL8 or CXCL1 
(R&D) and incubated overnight at 4°C.  The next day, excess contents were expelled 
and Dry coat (section 2.10) was added for 1hr.  Excess dry coat was aspirated and 
plates were stored at -20°C.  Before use, plates were washed with ELISA wash 
buffer (section 2.10).  Recombinant human CXCL8 (20ng/ml) was diluted in ELISA 
buffer containing tween (section 2.10) to create standard range of 1000-7.8pg/ml.  
Recombinant CXCL1 (20ng/ml) was diluted in ELISA buffer containing tween to 
create a standard range of 4000-31.2 pg/ml.  100μl/well of standards and samples 
were incubated on plate shaker for 3hrs after which plates were washed with wash 
buffer. Detection antibodies, biotinylated anti-human CXCL8 or CXCL1 antibody 
(R&D) diluted to 0.1μg/ml in ELISA buffer containing tween, were added to the 
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plates at 100μl/well and incubated for 1hr on a plate shaker.  Plates were washed and 
100μl/well Boeringer streptavidin-peroxidase, diluted 1:2000 in ELISA buffer, was 
added for 20mins. After washing, a solution of Tetramethy bezidine (3mg/ml) in 
dimethylformamide (TMB) and urea peroxidase (6mg/ml) was added to 100mM 
sodium acetated buffer pH6. Subsequently, 200μl/well of TMB substrate mixture 
was incubated for 10minutes until colour developed.  The colour reaction was 
quenched with 50μl/well of 2N sulphuric acid and the plate was read at 450M with a 
colorimeter.      
2.8.2.3 PGF2α/PGE2  
HUVECs were seeded at 5x104 cells per 35mm diameter dish and starved overnight.  
V CM or P CM was added to cells and diluted 1:1 (v/v) with EBM1%.  When using 
chemical inhibitors, cells were preincubated with EBM1% and SU4984, SB225002, 
NS3984, Indomethacin, SC560 or PD98059 for 30minutes. Subsequently, cells were 
treated with V CM or P CM in the absence or presence of inhibitors with the addition 
of 3μg/ml arachidonic acid for 6hrs.  After the prescribed time, conditioned medium 
was collected from the HUVECs and frozen until use.  The PGF2α competition 
ELISA was carried out with diluted conditioned medium (diluted 1:4, 1:10, 1:20, 
v/v).  Briefly, 96 well plates (NUNC™,ThermoFisherScientific) were coated 
overnight with donkey anti-rabbit (DAR) capture antibody.  The next day excess 
contents were removed and Dry Coat solution added for 1hr.  Then excess dry coat 
was removed and plates were dried before storage for up to seven days at 4°C.  The 
link was prepared, in the laboratory of R.W. Kelly, by ether extraction and purified 
by reverse phase chromatography using 20mg of synthetic PGE2 or PGF2α, 320µL of 
dry dimethylformamide, 3µl butylchlororomate and 0.05nM biocytin.  Biotin 
labelled PGF2α link was added at 1 in 1.0x106 and antisera (rabbit IgG; 1mg/ml 
diluted in PBS with 1% carbonate buffer, pH 9.6) at 1 in 20 000.   
 
For the PGF2α ELISA, samples, standards, link and antiserum were diluted in ELISA 
buffer without tween (section 2.10) with the highest standard being 5120pg/ml. For 
the PGE2 ELISA samples were incubated with a methyloximating (MOX) solution 
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(Methyloxyamine buffer, pH 5.6, v/v) to stabilise the PGE2 prior to freezing.  The 
PGE2 assay was carried out with 25% MOX buffer and ELISA buffer containing 
tween (section 2.10).  Link was diluted 1:1.5 x 106 in 0.5M P04 pH8 to balance the 
MOX solution pH.  The antiserum was diluted 1:50000 in ELISA buffer.   Standard 
range of the assay was 5120–10 pg/ml.  ELISA plates were washed before use and 
incubated overnight at 4°C with a solution of antiserum, link, buffer and samples or 
standards.  The following day, plates were washed and 100µl/well streptavidin 
peroxidase (0.2U/ml) was added for 25mins at RT on a plate shaker.  After washing, 
200μl/well of TMB substrate mixture was incubated in the wells for 10minutes until 
colour developed.  50μl/well of 2N sulphuric acid quenched the colour reaction and 
the plate was read at 450M with a colorimeter.  As the prostaglandin ELISA is a 
competitive ELISA, in which prostaglandin in samples competes with biotin labelled 
prostaglandin link, less prostaglandin present in the sample media will result in a 
more intense colour reaction.  A standard curve was produced from which the 
concentrations of PGF2α and PGE2 in the sample media were determined using 
AssayZap software (Biosoft, Cambridge, UK).   
2.9 Endothelial cell function assays 
2.9.1 Network formation assay 
The network assay model, seen in Fig. 25, was used to assess endothelial cell 
differentiation in vitro.  Network assays were carried out using 12-well Transwell 
plates (Corning Costar, Cambridge, UK). Growth Factor (GF)-reduced Matrigel (BD 
Biosciences,MA, USA) was liquefied overnight on ice at 4oC.  Pipette tips and plates 
were cooled at -20oC before use.  The upper chambers were coated with 80μl of GF-
reduced Matrigel in the absence/presence of SU4984 (20μM), PD98059 (50μM), 
rapamycin (100ng/ml), wortmannin (200nM), LY294002 (50μM), NS398 (10μM) 
and SC506 (10μM) and incubated at 37oC for 30mins to allow thin gel formation. 
Human umbilical vein endothelial cells were plated onto the gel (2.5x104cells/well) 
in EBM 1% (v/v).  In the lower chamber V CM or P CM was added (Fig. 25).      




Fig. 25. Dual chamber network assay model. 
 
The use of a dual chamber model for network assays (Fig. 25) was chosen because it 
reflected the in vivo environment of angiogenesis.  Secreted factors from tumour 
cells travelling through the cell matrix will come into contact with the abluminal 
surface of endothelial cell which corresponds to the basolateral plasma membrane of 
cultured endothelial cells (Stolz et al., 1992).  Also the distribution of growth factor 
receptors has been shown to differ in an apical/basal orientation on endothelial cells 
(Stolz et al., 1992; Vlodavsky et al., 1987).  Another advantage to using the transwell 
chamber is that two different media can be used to optimise the endothelial and 
epithelial function.  DMEM is the preferred medium for Ishikawa cell culture and 
conditioned medium production, as Ishikawa conditioned medium produced with 
EBM1% resulted in lower concentrations of growth factors.  Vice-versa, culturing 
HUVECs with serum-free DMEM induced cell death.  Pooled conditioned medium 
was used, as opposed to culturing Ishikawa cells in each of the lower chambers, in 
order to reduce experimental variability.   This differentiation assay is referred to in 
this thesis as a network assay so as not to be confused with the tubule formation 
assay, another differentiation assay that takes place over a period of 3-7 days during 
which lumen-containing tubules of endothelial cells form in a synthetic extracellular 
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Transwell plates were incubated at 37oC in a 5% CO2 atmosphere for 16hrs.  
Subsequently, cell networks were fixed with 100% ice cold methanol and stained 
with haematoxylin.   
2.9.1.1 Image analysis 
To assess network formation, each well was divided into 5 sections.  Hotspots of 
each section were photographed, 5 photos per well at x10 magnification, using an 
inverted microscope and camera (Axiovert 200, Carl Zeiss, Germany).  The number 
of network branches was counted blind.  Experiments were repeated at least four 
times.  Fold difference was determined by dividing the value obtained from P CM 
treated cells by the value obtained from V CM treated cells. Data are represented as 
percentage increase in network formation with V=100% and are presented as 
mean+SEM. 
2.9.2 Proliferation assay 
HUVEC in EGM were seeded in 96-well plates at 3000 cells/well.  Following 
attachment, cell medium was replaced with EBM containing 1% FBS (EBM1%;v/v) 
for 3 hours.  Cells were then treated with conditioned medium, diluted 1:1 with 
EBM1%(v/v), in the absence/presence of SU4984, PD98059, rapamycin, 
wortmannin, LY294002 or immunoneutralised conditioned medium.  Treatments 
were replaced three times during the 96hr incubation.  Proliferation was determined 
using the CellTitre96AQueous One Solution Proliferation Reagent (Promega, 
Southampton, UK).  As shown in Fig. 26, this reagent contains a tetrazolium 
compound, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS), which together with an electron coupling agent, 
phenazine ethosulfate (PES), forms a stable compound.  The MTS tetrazolium 
compound is bioreduced by cells undergoing metabolic activity, resulting in a 
soluble coloured formazan compound (Fig. 26).  This is presumed to be a result of 
the increased availability of H+ released by the metabolic dehydrogenation of 
NADPH or NADH to NADP or NAD to respectively. The formation of a soluble 
coloured formazan compound is directly proportional to the availability of H+ and 
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consequently, the number of living cells.  After a 1-4hr incubation period, the 
formation of formazan is recorded by measuring the absorbance at 490nm on a 96-
well plate reader. 
 
Fig. 26. Structures of MTS and its formazan product (adapted from Promega instructions 
for use of products G3580, G3581 and G3582). 
 
The experiments were repeated at least three independent times.  Fold difference was 
determined by dividing the absorbance obtained by P CM treated cells by the 
absorbance obtained by V CM treated cells. Data are represented as percentage 
increase in proliferation with V =100 % and are presented as mean+SEM.  Cell 
proliferation was assessed under EBM1% and inhibitor alone conditions to verify 
that basal endothelial cell proliferation was not affected by the addition of inhibitors.  
This condition was used as a control for normalisation of the results. 
2.9.3 Gene manipulation  
RNA interference (RNAi) can be mediated by the use of short hairpin RNA (shRNA) 
or small interfering RNA (siRNA).  Transfection of siRNA into cells can be 
mediated by transfection agents such a polyamine mixture (see section 2.9.3.5).  The 
use of viral vectors to infect cells can enhance the efficiency of RNAi delivery into 
cells (see sections 2.9.3.2, 2.9.3.3 and 2.9.3.4).  Adenoviruses have been used for 
gene targeting for over a decade.  They can be used as replicating or non-replicating 
vectors (Jaras et al., 2007).  Usually, the E1 and E3 regions are used as gene 
integration sites (Jaras et al., 2007).  Using a host cell, a target sequence, for example 
DNA for a short hairpin RNA in a shuttle plasmid is integrated by homologous 
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recombination into an adenovirus genomic plasmid (Jaras et al., 2007).  
Adenoviruses were used at 100 multiplicities of infection (MOI).  The recombinant 
adenovirus remains epichromosomal in the host cell (Jaras et al., 2007) so the 
adenovirus was re-administered every 48hrs.   
 
Lentiviruses are retroviruses that can infect actively dividing and non-dividing, post-
mitotic cells and are therefore commonly used RNAi vectors (Dykxhoorn et al., 
2003).  The RNAi target-specific insert is made up of a 19-23 nucleotide sequence 
complementary to the target, followed by a short spacer and the reverse complement 
of the same target sequence (Sledz and Williams, 2005).  Once transcribed by the 
cells machinery, a 19-23bp stem-loop structure, termed short-hairpin RNA (shRNA), 
is processed by Dicer into a siRNA that can direct the down-regulation of target gene 
expression (Sledz and Williams, 2005).  Lentiviral vectors stably expressing shRNA 
against any region of mRNA can be targeted; however, sequence sites for mRNA-
binding proteins in the 5′ untranslated region (UTR), 3′ UTR, start codon, or exon –
exon boundaries should be avoided (Dykxhoorn et al., 2003).  Highly specific RNAi 
sequences should be used at the lowest concentration possible to reduce non-specific, 
off-target interactions.    
2.9.3.1 Verification of viral transfection 
Lentivirus or adenovirus transfection efficiency of HUVECs was examined with 
lentivirus or adenovirus constructs expressing LacZ.  HUVECs were seeded at 
1x104cells/well in a 24 well plate.  The next day LacZ virus was added to HUVECs 
at 0, 50 and 100 MOI for adenovirus LacZ and 0, 2, 5 MOI for lentivirus LacZ.  
After 24hrs, the samples were washed in PBS, fixed for 5 minutes in X-gal fixing 
solution (section 2.11.1.4), washed again in PBS and stained with an X-gal staining 
solution (section 2.11.1.4) overnight at 37°C.  Treatments were performed in 
triplicate.  Three photos from each well were taken with the Axiovert 200 
microscope.  The total number of cells and LacZ positive cells were counted. Results 
were expressed as the percentage of LacZ positive cells/total cells.  Transfection 
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efficiency was approximately 80% at 5MOI and 90% at 100MOI for lentivirus and 
adenovirus respectively. 
2.9.3.2 Adenovirus short hairpin FP construct for FP silencing. 
To assess the role of the FP receptor in endothelial cell function, two different short 
hairpin constructs were used, sh306 and sh478 as well as a control scrambled 
sequence, sc1311.  The viral constructs were produced by Dr. P. Brown using the 
human FP receptor sequence as a template.  The start codon of the FP receptor 
(NM_000959) was used as a reference and labelled as basepair 1. Thus, the target 
sequences corresponded to 306 and 478bp downstream and included a scrambled 
(sc1311) negative control: sh306: 5’-GCTGCGCTTCTTTCAAACA; sh478: 5’-
GTGGCCTGGTAATCACTGA; scr: 5’-TTACTCGACGCATGTGCTT.  Three 
25cm2 flasks of HUVECs were seeded at a density of 3x105cells/25cm2flask in EGM 
(need 9x105cells total).  Immediately after, 100MOI of one of the three viruses were 
added to each flask.  The cells were incubated for 24hrs at 37oC in a 5% CO2 
atmosphere.    The next day, the viral infected cells were typsinised, counted and 
used in the network assay (see section 2.9.1) or in the proliferation assay (see section 
2.9.2).  HUVECs were treated for 24hrs with scr, sh306 and sh478 viruses and 
knockdown of the FP receptor was verified with QPCR of FP mRNA expression.  As 
shown in Fig. 27, approximately 50% reduction in FP receptor mRNA expression 
was observed.   
 
Fig. 27. Confirmation of FP receptor reduction with shRNA.  HUVECs were treated for 
24hrs with no virus, scrambled virus (scr) and FPshRNA viruses (sh306 or sh478). After 
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which, FP mRNA expression was assessed by QPCR analysis. Data expressed as fold 
increase in expression over normal HUVEC control. (* represents statistical significance; 
P<0.05). Data are represented as mean ± SEM from at least three independent experiments. 
2.9.3.3 Adenovirus RCAN1-4 for RCAN1-4 overexpression 
The RCAN1-4 adenovirus (Ad-RCAN1), containing the full length RCAN1-4 cDNA 
(ORIGENE, Rockville, MD), was produced as previously described (Maldonado-
Perez et al., 2009).  An empty adenovirus was used as the control (Ad-Control).  
Overexpression of RCAN1-4 was verified and optimized by quantitative RT-PCR 
(Fig. 28.).  Infection of HUVECs with 100MOI of virus increased RCAN1 
expression by more that 100% (Fig. 28.).  Subsequently, HUVECs were seeded at 
4x105cells/25cm2 flask and 100MOI of adenovirus was added to each flask.  Cells 
were incubated for 24hrs at 37oC in a 5% CO2 atmosphere, after which the medium 
was removed, cells were washed and used for network and proliferation assays.  
 
Fig. 28 Adenoviral RCAN1 transfection increases RCAN1 expression in HUVECs. 
HUVECs were untransfected (0MOI) or transfected with 50MOI and 100MOI of adenovirus 
construct containing non-target (Ad-Control) or RCAN1-4 cDNA (Ad-RCAN1).  RCAN1 
mRNA expression was determined by quantitative RT-PCR. 
 
2.9.3.4 Lentivirus RCAN1 for RCAN1 silencing. 
The short hairpin RNA (shRNA) lentivirus for RCAN1-4 was obtained from the 
laboratory of Dr. A.Thompson (Jacksonville, Florida, USA) (Bush et al., 2007).  
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Flasks, of 25cm2 seeded with 4x105 HUVECs, were transfected with 5MOI of virus 
for 24 hrs.  RCAN1 was expressed at very low basal levels in the absence of 
stimulation therefore, to verify the efficacy of lv-RCAN1 transfection, lv-Control 
and lv-RCAN1-4 HUVECs were treated for 3hrs with V CM and P CM.  In lv-
Control cells, RCAN1 mRNA expression was significantly elevated by P CM 
treatment compared to V CM treatment (Fig. 29, P<0.05).  The expression of 
RCAN1 in lv-RCAN1 cells was significantly decreased after P CM treatment 
compared to lv-Control cells treated with P CM (Fig. 29, P<0.05).  This indicates 
that lv-RCAN1 successfully decreased HUVEC RCAN1 expression. After 24hrs at 
37oC in a 5% CO2 atmosphere, the cells were washed and used in the network and 
proliferation assays.   
 
 
Fig. 29. Lenviral RCAN1 shRNA decreases RCAN1 mRNA expression. HUVECs were 
transfected with lentivirus containing a control non-target construct (lv-Control) or RCAN1 
shRNA (lv-RCAN1) prior to the experiment.  Lv-Control and lv-RCAN HUVECs were treated 
with V CM or P CM for 3hrs and RCAN1 mRNA expression was examined by quantitative 
RT-PCR.  (* represents statistical significance; P<0.05). Data are represented as mean ± 
SEM from at least three independent experiments. 
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2.9.3.5 siRNA transfection for ADAMTS1 silencing 
ADAMTS1 siRNA was used to silence ADAMTS1 expression in HUVECs.  
ADAMTS1 Stealth siRNA was purchased from Invitrogen.  Prior to the start of 
experiments the concentration of siRNA and transfection agent was optimised.  A 
scrambled non-target sequence of siRNA was used as a control.  HUVECs were 
seeded at 4x105cells/25cm2 flask.  The next day, cells were transfected with 20nM 
Control siRNA or ADAMTS1siRNA using 5.7μl siPORT Amine Transfection Agent 
(AppliedBiosystems).  As shown in Fig.30, ADAMTS1 siRNA significantly reduced 
ADAMTS1 mRNA expression by approximately 50% compared to a scramble 
control siRNA (Fig.30, P<0.05).  HUVECs were transfected with Control siRNA and 
ADAMTS1 siRNA for 48hrs at 37oC in a 5% CO2 atmosphere after which cells were 
washed and treated for 12hrs with EGM before performing network assays and 
proliferation assays. 
 
Fig.30. ADAMTS1 siRNA decreases ADAMTS1 mRNA expression. HUVECs were 
transfected with Control siRNA or ADAMTS1 siRNA for 48hrs prior treatment.  ADAMTS1 
mRNA expression was determined by quantitative RT-PCR. (* represents statistical 
significance; P<0.05). Data are represented as mean ± SEM from at least 3 independent 
experiments. 
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2.10 In vivo mouse models 
2.10.1 In vivo sponge/matrigel mouse model 
The in vivo sponge/matrigel mouse model was performed by Dr. Hadoke (Centre for 
Cardiovascular Science, Edinburgh).  Mice were divided into two treatment groups 
and each participant was given a number from 1-12 therefore Group 1 contained 
even numbered mice 2, 4, 8, 10 and 12 and Group 2 the odd numbered mice 3, 5, 7, 9 
and 11.  One set of mice from each group, 6 and 1, was discounted because sponges 
were absent or too small.  Group 1 mice were implanted with matrigel soaked 
sponges in their left and right sides which were untreated and vehicle treated 
respectively.  Group 2 matrigel sponges were treated with 100nM PGF2α or vehicle 
in the left and right sides respectively.  After 21 days implantation the sponges were 
excised and divided in two, one half being preserved in RNAlater and the other 
embedded in paraffin wax for microtome sectioning and immunohistochemical 
analysis.  
2.10.1.1 Assessment of sponge vascularity 
Sponge vascularity was examined using paraffin wax embedded sponge sections.  
Firstly, slide sections were given a code so that vessels were counted blind.  
Immunohistochemical analysis of CD31/PECAM-1 was chosen to highlight sponge 
blood vessels as it is a widely used marker for endothelial cells (Donoghue et al., 
2007).  Once CD31 staining was optimised, a 25-point Chalkey eyepiece graticule 
(Graticules Ltd, Edenbridge, Kent, UK) at x250 magnification (the graticule covers 
an area of 0.155 mm2 at this magnification) was used to quantify vessels (Hague et 
al., 2002).  Hotspots, areas of high vessel density, were identified at a higher 
magnification before counting began.  Blood vessels in three hotspots from each 
sponge section were counted as previously described (Hague et al., 2002).  The 
graticule was positioned so the maximum number of points touched vessels in one 
hotspot.  The number of dots touching the vessels in each hotspot was then recorded.  
Individual density was then obtained by taking the mean of three graticule counts.  
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2.10.2  In vivo tumour xenograft mouse model 
The mouse tumour xenograft experiment was performed in the laboratory of Dr 
Rosenburg (Univ. of Connecticut Medical Centre, USA).  FPS or WT cells (5x106 
cells per injection) were subcutaneously injected into the back flanks of adult nude 
mice.  Each day the tumour size was measured none invasively with callipers.  After 
39 days the resulting tumours were removed for analysis. Half the tumours were 
preserved in RNAlater for mRNA analysis and half were embedded in paraffin wax 
for immunohistochemistry analysis. 
 
The tumour xenograft mouse model with CXCL8 immunoneutralisation was 
performed by Dr Martin Wilson in the Jabbour laboratory.  Briefly, a suspension of 
5x106 Ishikawa WT or FPS cells in a total volume of 0.2 ml DMEM was injected s.c. 
into each dorsal flank of CD1-Foxn1nu mice (Charles River).  Tumours were 
monitored twice weekly using digital callipers and 100 µg CXCL8 antibody was 
injected via intra-peritoneal. injection into the mice with FP tumours requiring 
CXCL8 immunoneutralisation.  Control IgG (100µg) was injected into the remaining 
mice containing WT and FPS xenografts.  The animals were maintained under sterile 
conditions in individually vented cages and all animal care and experimental 
protocols were approved by the animal ethics committee of the University of 
Edinburgh and the Home Office of the United Kingdom government.  After four 
weeks, the tumours were removed and divided in two, one half being preserved in 
RNAlater and the other embedded in paraffin wax for microtome sectioning and 
immunohistochemical analysis. 
 
2.10.2.1 Assessment of tumour xenograft vascularity 
Subsequently, immunohistochemical analysis of CD31 in tumour xenograft sections 
was carried out as described in section 2.7.  Firstly, slide sections were given a code 
so that vessels were counted blind.  Microvascular density was assessed by counting 
the number of vessels per mm2 in the outer area of the tumour xenografts, containing 
the fibroblast layer, using a Nikon Eclipse E800 microscope fitted with an automatic 
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stage (Prior Scientific Instruments Ltd.) and video camera (HV-C20; Hitachi).  Data 
were analyzed with Image-ProPlus 4.5.1 software with a Stereology 5.0 plug-in 
(Media Cybernetics).  Vessel diameter was measured (μm) and vessels were 
separated into small (<50μm), medium (50-200μm) and large (>200μm) groups.  
2.11 Statistics 
In accordance with previous published data on similar studies with the same cell 
populations and cell treatments, normal distriubution of data was assumed, i.e. that 
the variance within each population was equal (Sales et al., 2009; Sales et al., 2005; 
Sales et al., 2004c).  Therefore, unless otherwise stated in chapters 3 to 6, statistical 
significance was assessed on untransformed data with one-way ANOVA and 
Dunnett’s post hoc test using Prism 5.0 (Graph Pad, San Diego, CA).  A p-value of 
less than 0.05 (P<0.05) was considered to be statistically significant. 
 
For all cell culture experiments a minimum of three independent experiments, 
preformed on three individual days, was assumed large enough to ensure that the 
power (probability of correctly rejecting a false null hypothesis) was satisfactorally 
high.  On occasion, where stated, the number of experimental repeats was increased 
to ensure minimisation of Type II errors (false null hypothesis failed to be rejected).  
For all experiments the null hypothsis was that the treatment would have no effect on 
the population compared with the reference population. 
2.11.1 Experimental design 
2.11.1.1 Chapter 3 
The Ishikawa cell timecourse experiment (Fig. 33A) was performed in duplicate, 
three independent times (n=3).  Fold difference was determined by dividing the value 
obtained from PGF2α treated cells by the value obtained from vehicle treated cells at 
each individual timepoint.  Statistical significance was assessed on data with one-
way ANOVA and Dunnett’s post hoc test. 
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The Ishikawa cell experiment with inhibitors (Fig. 33B) was performed using one 
well per treatment, three independent times for each inhibitor (n=3).  Data sets from 
multiple treatments were combined for graphical display. Therefore the vehicle and 
PGF2α bars represent nine independent experiments (n=9).  Fold difference was 
determined by dividing the value obtained from PGF2α treated cells by the value 
obtained from vehicle treated control cells.  Statistical significance was assessed on 
data with one-way ANOVA and Dunnett’s post hoc test. 
 
The Ishikawa cell experiment with RCAN1 adenovirus (Fig. 34A) was performed 
using one well per treatment, four independent times (n=4). Ishikawa cell experiment 
with RCAN1 lentivirus (Fig. 34B) was performed using one well per treatment, four 
independent times (n=4).  Fold difference was determined by dividing the value 
obtained from vehicle or PGF2α treated cells by the value obtained from normal 
endometrial control HNJ124.  Data are presented as mean ± SEM.  Statistical 
significance was assessed on data with one-way ANOVA and Dunnett’s post hoc 
test. 
2.11.1.2 Chapter 4 and Chapter 5 
All network formation assays were performed in duplicate (two wells per treatment) 
four independent times (n=4).  Data were blinded before quantification of network 
branches.  Fold difference was determined by dividing the value obtained from P 
CM-treated cells by the value obtained from V-CM treated cells. Data were 
transformed to percentage increase in network formation with V CM =100% and are 
presented as mean ± SEM.  Statistical significance was assessed on untransformed 
data with one-way ANOVA and Dunnett’s post hoc test. 
 
All proliferation assays were performed in quadruplicate (four wells per treatment) 
four independent times (n=4).  Fold difference was determined by dividing the value 
obtained from P CM-treated cells by the value obtained from V CM-treated cells. 
Data were transformed to percentage increase in proliferation with V CM =100% and 
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are presented as mean ± SEM. Statistical significance was assessed on untransformed 
data with one-way ANOVA and Dunnett’s post hoc test. 
 
Western blot experiments were performed using one well per treatment, four 
independent times (n=4).  For Western blot semi-quantitative analysis, ERK1/2 
phosphorylation was calculated by dividing the value obtained from the 
phosphorylated ERK1/2 channel (700nm) by the value obtained from total ERK1/2 
channel (800nm) and expressed as fold above vehicle controls. Data are presented as 
mean ± SEM.  Statistical significance was assessed on data with one-way ANOVA 
and Dunnett’s post hoc test. 
 
To perform endothelial timecouse experiments, HUVECs were seeded sub-
confluently (5x104 cells per 35mm diameter well).  The experiment was performed 
using one well per treatment, five independent times (n=5).  Fold difference was 
determined by dividing the value obtained from P CM-treated cells by the value 
obtained from V CM-treated cells, at each individual timepoint. Data are presented 
as mean ± SEM.  Statistical significance was assessed on data with one-way 
ANOVA and Dunnett’s post hoc test. 
 
Experiments to measure PGF2α and PGE2 secretion from HUVECs (Fig. 49 and Fig. 
50) were performed using single well treatments three independent times (n=3).  
ELISA data are presented as mean ± SEM in pg/ml.  Statistical significance was 
assessed on data with one-way ANOVA and Dunnett’s post hoc test. 
 
Experiments using FP shRNA adenovirus-treated HUVECs (Fig. 59) were performed 
five independent times (n=5) in duplicate or in quadruplicate for the network assays 
or proliferation assays respectively. Data were blinded before quantification of 
network branches.  Fold difference was determined by dividing the value obtained 
from adenovirus (scr, sh306 or sh478)-treated cells by the value obtained from 
adenovirus control cells (scr) treated with V CM (scr V CM).  Data were transformed 
to percentage increase in network formation or proliferation with scr V CM =100% 
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and are presented as mean ± SEM.  Statistical significance was assessed on 
untransformed data with one-way ANOVA and Dunnett’s post hoc test. 
 
2.11.1.3 Chapter 6 
Experiments using ADAMTS1 siRNA-treated HUVECs (Fig. 68) were performed 
four independent times (n=4) in duplicate or in quadruplicate for the network assays 
or proliferation assays respectively. Data were blinded before quantification of 
network branches.   Fold difference was determined by dividing the value obtained 
from treated cells by the value obtained from control siRNA cells treated with V CM 
(control siRNA V CM).  Data were transformed to percentage increase in network 
formation or proliferation with control siRNA V CM =100% and are presented as 
mean ± SEM.  Statistical significance was assessed on untransformed data with one-
way ANOVA and Dunnett’s post hoc test. 
 
Experiments using RCAN1 adenovirus treated HUVECs (Fig. 70 and Fig. 72) were 
performed four independent times (n=4) in duplicate or in quadruplicate for the 
network assays or proliferation assays respectively. Data were blinded before 
quantification of network branches.   Fold difference was determined by dividing the 
value obtained from treated cells by the value obtained from Adnenovirus control 
cells treated with V CM (Ad-control V CM).  Data were transformed to percentage 
increase in network formation or proliferation with Ad-control V CM =100% and are 
presented as mean ± SEM.  Statistical significance was assessed on untransformed 
data with one-way ANOVA and Dunnett’s post hoc test. 
 
Time-course experiments with RCAN1 adenovirus-treated HUVECs (Fig. 71 and 
Fig. 73) were performed using one well per treatment, five independent times (n=5). 
Fold difference was determined by dividing the value obtained from treated cells by 
the value obtained from an untreated HUVEC control sample.  Data are presented as 
mean ± SEM.  Statistical significance was assessed on data with one-way ANOVA 
and Dunnett’s post hoc test. 
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Experiments using RCAN1 lentivirus-treated HUVECs (Fig. 74A and B) were 
performed four independent times (n=4) in duplicate or in quadruplicate for the 
network assays or proliferation assays respectively.  Fold difference was determined 
by dividing the value obtained from treated cells by the value obtained from 
lentivirus control cells treated with V CM (lv-Control V CM).  Data were 
transformed to percentage increase in network formation or proliferation with lv-
Control V CM =100% and are presented as mean ± SEM.  Statistical significance 
was assessed on untransformed data with one-way ANOVA and Dunnett’s post hoc 
test. 
 
Timecourse experiments performed with RCAN1 lentivirus-treated HUVECs (Fig. 
75 and Fig. 76) were performed using one well per treatment, four independent times 
(n=4). Fold difference was determined by dividing the value obtained from treated 
cells by the value obtained from lentivirus control cells treated with V CM (lv-
Control V CM).  Data are presented as mean ± SEM.  Statistical significance was 
assessed on data with one-way ANOVA and Dunnett’s post hoc test. 
2.11.1.4 Chapter 7 
In chapter 7, where an experiment consisted of only two data sets, each bar 
represented 10 independent samples (n=10) (Fig. 82-85).   Data are expressed as fold 
difference over control mRNA.  Control mRNA was either normal endometrial 
sample HNJ124 or mouse kidney sample for the analysis of human mRNA and 
mouse mRNA expression, respectively.  Statistical significance was assessed on 
untransformed data with a Student’s unpaired t-test using Prism (Graph Pad, San 
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2.12 Commonly Used solutions 
2.12.1.1 Protein Analysis 
 
NP40 Lysis Buffer 
• 150mM NaCl 
• 10mM EDTA 
• 50mM Tris pH7.4 
• 0.6% NP40 
• 0.05% sodium deoxycholate 
• 10% Glycerol 
• Make up to 500mls with dH2O 
 
1 Complete Mini Protease Inhibitor Cocktail Tablet (Roche, Mannheim, Germany) 
was added to 10mls of NP40 lysis buffer.   
 
Lammeli Buffer (loading buffer) 
• 125 mm Tris-HCl (pH 6.8) 
• 4% sodium dodecyl sulphate 
• 5% 2-mercaptoethanol 
• 20% glycerol 
• 0.05% bromophenol blue 
 
20x NuPAGE MOPS  
• 50mM MOPS (104.6g) 
• 50mM TRIS base (60.6g) 
• 0.1% SDS (10g) 
• 1mM EDTA (3g) 
• Make up to 500ml with H20 
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20x NuPAGE MES  
• 50mM MES (97.6g) 
• 50mM TRIS base (60.6g) 
• 0.1% SDS (10g) 
• 1mM EDTA (3g) 





• 14.4g Glycine 
• 3g Tris 
• 20% Methanol 
• Make up to 1 litre with dH2O 
 
Tris Buffered Saline (TBS) 
• 60.5g Tris  
• 87.6g NaCl  
• 300mls HCL 
• pH was adjusted to 7.4 using concentrated ethanol 
 
Neutral Buffered Formalin (NBF) 
• 100 mL Formalin (40 percent formaldehyde)  
• 6.5 g Dibasic sodium phosphate 
• 4.0 g Monobasic sodium phosphate 
• 900 mL Distilled water  
• pH was adjusted to 7 
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Citrate Buffer, pH6 (0.1M) 
• Citric acid monohydrate (42.02g) 
• Distilled water (900ml) 
• pH to 5.5 with concentrated NaOH 
• Make up to 2L and pH to 6 
 
 
2.12.1.3 ELISA reagents 
 
Preservatives 
• 200mg/ml 2-Methylisothiazolone 
• 200mg/ml Bromonitro Dioxane 
In dimethyl sulfoxide (DMSO) 1:1 (V/V) 
 
Dry Coat 
• 2% Polyvinyl pyrollidone  
• 5mg/ml BSA 
• 1ml preservatives 
• 5mM EDTA 
• Tris 50mM 
• Make up to 1litre with dH2O 
 
Wash buffer (x20) 
• 20mls Tween 20 
• 360g NaCL 
• 48.4g Tris 
•  200mls dH2O 
• pH to 7-7.5 
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ELISA buffer (x1) 
• 100mM Tris 
• 2mg/ml BSA 
• 9g NaCL 
• 2mM EDTA 
• 300ul phenol red solution 
• 1000mls dH2O 
• pH to 7.2 
Add 1.5mls of 20% Tween 20 solution to 500mls for ELISA buffer with Tween. 
 
2.12.1.4 X-gal staining  
 
Fixing solution 
• 2 % Formaldehyde  
• 0.2% Glutaraldehyde 
 In  PBS 
 
Staining solution 
• 5mM K3Fe(CN)6  
• 5mM K4Fe(CN)7 
• 2mM MgCl2 
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3 The expression and regulation of ADAMTS1 by PGF2α-FP 
signalling in endometrial adenocarcinoma. 
3.1 Abstract  
ADAMTS1 is an antiangiogenic protein responsible for the degradation of 
extracellular matrix.  This chapter demonstrates that ADAMTS1 mRNA expression 
is elevated in the mid-late secretory stage of normal endometrium and provides 
evidence to suggest that ADAMTS1 is elevated in poorly differentiated endometrial 
adenocarcinoma.  Immunohistochemical analysis showed ADAMTS1 is expressed in 
the glandular epithelial cells and vasculature of the normal endometrium and 
endometrial adenocarcinoma.  In addition, using the endometrial cancer cell line, 
Ishikawa, stably expressing the FP receptor to levels seen in endometrial cancer (FPS 
cells), ADAMTS1 expression was found to be regulated by PGF2α signalling in a 
time dependent manner via a pathway involving the FP receptor, EGFR, calmodulin 
and NFAT.  However, this regulation of ADAMTS1 was not mediated by the 
induction of regulator of calcineurin (RCAN1), a negative regulator of NFAT 
signalling.  These data suggest ADAMTS1 may play a role in the regulation of 
vascular function in endometrial adenocarcinoma. 
3.2 Introduction 
Endometrial adenocarcinoma, originating from the glandular epithelial cells of the 
uterine endometrial lining, is one of the most prevalent cancers amongst women in 
the Western world (Jemal et al., 2008a; Westlake and Cooper, 2008). It is a disease 
which particularly occurs in post menopausal women and recent evidence suggests 
that mutations in oncogene expression may play a role in the aetiology of the disease 
(Doll et al., 2008). Data generated by the Jabbour laboratory and others have 
ascertained a role for the cyclooxygenase (COX)-prostaglandin (PG) axis in the 
regulation of endometrial adenocarcinomas by increasing cell proliferation and the 
secretion of angiogenic growth factors (Jabbour et al., 2006b; Tong et al., 2000).  
This is similar to other cancers where over-expression of COX enzymes and 
biosynthesis of prostaglandins has been shown to promote cellular proliferation 
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(Tsuji et al., 1996), inhibit apoptosis (Tsujii and DuBois, 1995) and enhance 
angiogenesis (Tsujii et al., 1998).  
 
A microarray analysis of an endometrial adenocarcinoma cell line, stably expressing 
the FP receptor to levels seen in cancer (FPS cells), identified many possible targets 
of PGF2α-FP signalling including angiogenic genes FGF2, VEGF-A, CXCL1 and 
CXCL8.  The upregulation of these angiogenic genes, along with their protein 
secretion, was subsequently confirmed by in vitro investigations using FPS cells 
treated with PGF2α (Sales et al., 2007; Sales et al., 2005).  In addition to the 
angiogenic genes upregulated, the antiangiogenic factor known as a disintegrin and 
metalloprotease with a thrombospondin repeat (ADAMTS1) was also found to be 
upregulated.   
 
Although, the expression and regulation of ADAMTS1 in endometrial 
adenocarcinoma has not been studied, in the female reproductive system, ADAMTS1 
is essential for ovarian vascular medullary formation as ADAMTS1 null mice exhibit 
severely dysplastic or disorganised vascular networks (Shozu et al., 2005).  
ADAMTS1 null mice are also infertile in part due to their impaired ovulation (Mittaz 
et al., 2004).  ADAMTS1 expression has been found in the normal and decidual 
endometrium.  Ng et al. showed that ADAMTS1 expression was restricted to stromal 
cells surrounding the spiral arteries in the secretory endometrium and glandular 
epithelial cells (Ng et al., 2006).  They provided evidence to suggest that ADAMTS1 
is involved in cytokine regulation of endometrial decidualisation (Ng et al., 2006).  
Research by Wen et al. also showed that the expression of ADAMTS1 by 
endometrial stromal cells is under the control of gonadal steroids DHT and 
progesterone (Wen et al., 2006).  Henceforth, this chapter investigates the expression 
and localisation of ADAMTS1 in endometrial adenocarcinoma.  In addition, the 
signal transduction pathway regulating ADAMTS1 expression was investigated 
using an in vitro model system of Ishikawa endometrial epithelial cells stably 
expressing the FP receptor to levels seen in endometrial cancer (FPS cells),. 
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3.3 Results 
3.3.1 The expression of ADAMTS1 in normal endometrium and 
endometrial adenocarcinoma. 
To evaluate the expression of ADAMTS1 in endometrial adenocarcinoma compared 
to its expression across the normal endometrial cycle quantitative RT-PCR was 
performed.  10 patient samples from each phase of the normal endometrial cycle, 
proliferative, early secretory, mid-late secretory and each stage of endometrial 
adenocarcinoma, well differentiated (well), moderately differentiated (mod) and 
poorly differentiated (poor), were examined for ADAMTS1 mRNA expression (Fig. 
31).  The levels of ADAMTS1 were dramatically increased in the mid-late secretory 
samples compared to samples from the proliferative phase of the endometrial cyclye 
(Fig. 31, P<0.05).  In addition, the levels of ADAMTS1 in poorly differentiated 
adenocarcinoma were significantly increased compared to samples taken from the 
proliferative phase of the endometrial cycle (Fig. 31, P<0.05).   
 
Fig. 31. ADAMTS1 mRNA expression in normal endometrium and endometrial 
adenocarcinoma.  RNA was extracted from 10 patient biopsies from proliferative, early 
secretory, mid-late secretory normal endometrial samples and well, moderately (mod) and 
poorly (poor) differentiated endometrial adenocarcinoma samples.  ADAMTS1 mRNA 
expression was analysed by quantitative RT-PCR analysis. (* represents statistical 
significance compared to proliferative bar; P<0.05). Data are represented as mean ± SEM 
from 10 samples (n=10). 
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No difference was found between the proliferative phase samples and early secretory 
phase, well or moderately differentiated adenocarcinoma samples (Fig. 31).  Since 
ADAMTS1 is elevated in poorly differentiated samples, it may play a role in the 
progression of endometrial adenocarcinoma.   
 
Fig.32. Immunohistochemistry of ADAMTS1 in mid secretory normal endometrium and 
poorly differentiated endometrial adenocarcinoma samples.  The expression of 
ADAMTS1 in samples from proliferative normal endometrium, mid secretory normal 
endometrium and poorly differentiated endometrial adenocarcinoma was immunolocalised 
with ADAMTS1 antibody and DAB, as described in section 2.7.  A mid secretory section with 
rabbit IgG was used as a negative control. White arrows indicate blood vessels.  Black 
arrows indicate glandular epithelial cell layer. Black bars indicate 50μm. 
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Immunohistochemical analysis of ADAMTS1 localisation in mid secretory normal 
endometrium samples suggests ADAMTS1 protein is present in both glandular 
epithelial cells (Fig.32, black arrow) and vascular cells lining blood vessels (Fig.32, 
white arrow).  Similarly, sections of poorly differentiated endometrial 
adenocarcinoma were stained with ADAMTS1 antibody and prominent staining was 
observed in the glandular epithelial cells (Fig.32, black arrow) and vascular cells 
(Fig.32, white arrow). 
3.3.2 ADAMTS1 expression and regulation by PGF2α-FP signalling in 
FPS Ishikawa cells. 
 
Since ADAMTS1 and FP receptor expression (Sales et al., 2007) are localised to 
glandular and vascular compartments and since ADAMTS1 was shown to be a target 
for FP receptor signalling by microarray analysis, the signalling pathway regulating 
ADAMTS1 was investigated (Fig. 33).  A timecourse of FPS Ishikawa cells treated 
with 100nM PGF2α for 2 to 72 hrs revealed that ADAMTS1 mRNA expression was 
significantly upregulated from 4 to 16hrs of PGF2α treatment compared to vehicle 
treatment (Fig. 33A, P<0.05).  ADAMTS1 mRNA expression induced by PGF2α was 
maximal at 6-8hrs (Fig. 33A).  Consequently, the signalling pathway regulating the 
expression of ADAMTS1 after 8hrs of treatment was investigated using a panel of 
small molecule chemical inhibitors (Fig. 33B).  FPS cells were treated with vehicle 
or PGF2α with or without the addition of AL8810 (FP antagonist), YM-254890 (Gq 
inhibitor), AG1478 (EGFR inhibitor), INCA-6 (NFAT inhibitor), PP2 (c-Src 
inhibitor), U73122 (PLC inhibitor), JNK-1 inhibitor, W7 (calmodulin inhibitor), 
BAPTA (Ca chelator), CsA (calcineurin inhibitor) and PD98059 (MEK inhibitor) 
(Fig. 33B).  ADAMTS1 mRNA expression was inhibited by AL8810, YM-254890, 
AG1478, INCA6 and BAPTA (Fig. 33B, P<0.05).  However, ADAMTS1 expression 
was not affection by the addition of PP2, U73122, JNK-1 inhibitor, BAPTA, CsA or 
PD98059 (Fig. 33B).  This indicates that in FPS cells, the upregulation of 
ADAMTS1 involves PGF2α-FP signalling to EGFR, calmodulin and NFAT.  
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However, the fact that neither CsA nor BAPTA had an effect on ADAMTS1 mRNA 
leaves the role of Ca2+ and calcineurin in this pathway unclear (Fig. 33B). 
 
Fig. 33. ADAMTS1 mRNA expression stimulated by PGF2α in FPS cells. A, FPS Ishikawa 
cells were treated with vehicle or PGF2α (100nM) for 0-72hrs and B, FPS Ishikawa cells were 
treated for 8hrs with vehicle or PGF2α in the absence/presence of AL8810 (FPantagonist), 
YM-254890 (Gq inhibitor), AG1478 (EGFR inhibitor), INCA-6 (NFAT inhibitor), PP2 (c-Src 
inhibitor), U73122 (PLC inhibitor), JNK-1 inhibitor, W7 (calmodulin inhibitor), BAPTA (Ca 
chelator), CsA (calcineurin inhibitor) and PD98059 (MEK inhibitor) and mRNA expression of 
ADAMTS1 was determined by quantitative RT-PCR.(* represents statistical significance; 
P<0.05). A, Data are represented as mean ± SEM from 3 independent experiments. B, Data 
are represented as mean ± SEM from 9 (vehicle and PGF2α bars, n=9) and 3 (each inhibitor 
bar, n=3) independent experiments respectively. 
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3.3.3 The role of RCAN1 in regulation of ADAMTS1 expression in FPS 
cells.   
 
Sales et al. found that CXCL8 upregulation by NFAT was negatively regulated by a 
negative regulator of calcineurin, RCAN1-4 (Sales, 2009).  Therefore, to investigate 
if RCAN1-4 could regulate NFAT-induced ADAMTS1 expression in FPS Ishikawa 
cells, cells were infected with control adenovirus (Ad-Control) or adenovirus 
containing the full length RCAN1-4 cDNA (Ad-RCAN1) (Fig. 34A), as described 
and performed by Sales et al. (2009).  Ad-Control FPS cells treated with PGF2α 
(100nM) showed significantly higher ADAMTS1 expression compared with Ad-
Control FPS cells treated with vehicle (Fig. 34A, P<0.05).  Similarly, Ad-RCAN1 
cells treated with PGF2α showed significantly higher ADAMTS1 expression 
compared with Ad-RCAN1 FPS cells treated with vehicle.  There was no significant 
difference between the expressions of ADAMTS1 in Ad-RCAN1 cells treated with 
PGF2α compared to Ad-Control cells treated with PGF2α (Fig. 34A).  These data 
suggest that ADAMTS1 is not regulated by PGF2α via the induction of RCAN1, as 
observed for proangiogenic factors such as CXCL8 (Sales et al, 2009).   
 
To elucidate the effect that decreasing RCAN1-4 expression in FPS cells would have 
on ADAMTS1 mRNA expression, RCAN1-4 expression was inhibited in FPS cells 
using lentivirus containing shRNA against RCAN1 (lv-RCAN1), as described and 
performed by Sales et al. (2009), and compared with a non-target control lentivirus 
(lv-Control) (Fig. 34B).  lv-Control or lv-RCAN1 FPS cells were treated with vehicle 
or PGF2α for 12hrs.  No significant change in ADAMTS1 expression was observed 
between lv-RCAN1 FPS cells treated with PGF2α and lv-Control FPS cells treated 
with PGF2α (Fig. 34B).  However, the basal levels of ADAMTS1 were significantly 
increased in lv-RCAN1 FPS cells treated with vehicle compared to lv-Control cells 
treated with vehicle (Fig. 34B, P<0.05).   
 




Fig. 34. The role of RCAN1-4 in the regulation of ADAMTS1 expression in FPS cells. 
FPS Ishikawa cells were transfected with 5MOI of A, adenovirus construct containing non-
target (Ad-Control) or RCAN1-4 cDNA (Ad-RCAN1) or B, lentivirus containing non-target 
control (lv-Control) or RCAN1-4 shRNA (lv-RCAN1).  Subsequently, cells were treated with 
vehicle or PGF2α (100nM) and ADAMTS1 expression was determined by quantitative RT-
PCR. (* represents statistical significance; P<0.05). Data are represented as mean ± SEM of 
4 independent experiments. 
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3.4 Discussion 
The present study demonstrated elevated expression of ADAMTS1 in poorly 
differentiated endometrial adenocarcinomas compared with normal endometrium 
from the proliferative phase of the menstrual cycle. As the endometrium of post-
menopausal women is no longer under normal hormonal control, the tissue is 
atrophic and often not attainable for analysis, we chose normal proliferative phase 
endometrium as our comparator. This is the phase of the menstrual cycle which 
exhibits rapid cellular proliferation, differentiation and tissue remodelling and is the 
phase of the menstrual cycle with the highest expression of FP receptor (Milne and 
Jabbour, 2003).  ADAMTS1 protein was expressed in endometrial vascular cells and 
glandular epithelial cells.  This was similar to the data by Ng et al. who showed that 
ADAMTS1 expression was localised to the stromal cells surrounding the spiral 
arteries in the secretory endometrium and glandular epithelial cells (Ng et al., 2006).  
They provided evidence to suggest that ADAMTS1 is involved in cytokine, IL-1 and 
TGF, regulation of endometrial decidualisation (Ng et al., 2006).  Research by Wen 
et al. also showed that the expression of ADAMTS1 by endometrial stromal cells is 
under the control of gonadal steroids DHT and progesterone (Wen et al., 2006).  
ADAMTS1 has also been shown to be essential for healthy follicle growth which has 
been attributed to its metalloproteinase properties (Brown et al., 2006).  These 
articles suggest that the metalloproteinase property of ADAMTS1 is involved in 
endometrial remodelling and together with the data presented in this chapter suggests 
that ADAMTS1 could be involved in remodelling of the vasculature of endometrial 
adenocarcinoma and could contribute to its progression.   
 
ADAMTS1 was identified as a target of PGF2α-FP signalling in a previous 
microarray analysis conducted in the Jabbour laboratory.  Since ADAMTS1 was 
expressed in the glandular epithelial and vascular cells of the endometrium, where 
the FP receptor is expressed, the regulation of ADAMTS1 by PGF2α-FP signalling 
was investigated using an Ishikawa cell line stably transfected with the FP receptor 
(Fig. 35).  ADAMTS1 expression was confirmed to be upregulated by PGF2α-FP 
signalling via a Gq-EGFR-calmodulin-NFAT pathway.  In FPS cells, ADAMTS1 
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expression induced by PGF2α -FP signalling was independent of c-Src, PLC, JNK 
and ERK1/2.  The role of calcium in the regulation of ADAMTS1 is unclear because 
although the calmodulin inhibitor inhibited ADAMTS1 expression, the calcium and 
calcineurin inhibitors did not affect ADAMTS1 expression.  This may indicate the 
involvement of co-transcription factor AP-1 which is activated by calmodulin and 
may regulate NFAT induced gene transcription (Rao et al., 1997).    
 
Recently, Sales et al. found the PGF2α-FP signalling upregulates RCAN1-4 
expression in FPS cells (Sales, 2009).  RCAN1-4 has been shown to negatively 
regulate NFAT induced CXCL8 expression (Maldonado-Perez et al., 2009).  To 
further elucidate the pathway controlling ADAMTS1 expression in FPS cells, the 
role of RCAN1-4 in the regulation of NFAT-induced ADAMTS1 in FPS cells was 
investigated.  In FPS cells, RCAN1-4 overexpression had no effect on ADAMTS1 
expression and similarly, decreasing RCAN1-4 expression did not affect ADAMTS1 
expression.  This suggests that ADAMTS1 expression in FPS cells is calcineurin 
independent because neither RCAN1-4 nor the calcineurin inhibitor CsA affected 
ADAMTS1 expression induced by PGF2α-FP signalling.  Therefore, the regulation of 
ADAMTS1 is likely to involve other intermediary factors.  For example, ADAMTS1 
gene expression can be controlled by histone deacetylase (HDAC) binding (Chou 
and Chen, 2008) which can be regulated by calcineurin independent pathways 
(Martin et al., 2007).   
 
Fig. 35. The regulation of proangiogenic (+) and antiangiogenic (-) factors by PGF2α-FP 
signalling. 
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In summary, ADAMTS1 mRNA expression is elevated in the mid-late secretory 
stage of normal endometrium and in poorly differentiated endometrial 
adenocarcinoma compared with proliferative phase endometrium.  ADAMTS1 is 
prominently expressed in the glandular epithelial and vascular compartments in 
endometrial adenocarcinoma.  In addition, using the endometrial cancer cell line, 
Ishikawa, stably expressing the FP receptor to levels seen in endometrial cancer (FPS 
cells), ADAMTS1 expression was found to be regulated by PGF2α signalling in a 
time dependent manner via a pathway involving the FP receptor, EGFR, calmodulin 
and NFAT.  However, this regulation of ADAMTS1 was not affected by the 
absence/presence of the NFAT pathway inhibitor, regulator of calcineurin (RCAN1).  
Data presented in this chapter, together with previous research demonstrating that the 
metalloproteinase property of ADAMTS1 is involved in endometrial remodelling, 
indicates that ADAMTS1 could be involved in remodelling of the vasculature during 
endometrial adenocarcinoma via the mediation of processes such as ECM 
degradation and cell migration.   
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4 The role of proangiogenic factors in the regulation of endothelial 
cell function by PGF2α-FP signalling. 
4.1 Abstract 
 
The research presented in this chapter demonstrates that conditioned medium, from 
PGF2α treated Ishikawa cells stably expressing the FP receptor (Ishikawa FPS cells), 
can increase endothelial cell differentiation (network formation) and proliferation. 
Treatment of Ishikawa FPS cells with PGF2α increases proangiogenic FGF2, CXCL1 
and CXCL8 secretion, which in turn activates FGFR1 and CXCR2 signalling in 
endothelial cells, and induces the phosphorylation of extracellular signal-regulated 
kinase (ERK1/2) leading to increased FGF2, CXCL1, CXCL8 and COX-2 
expression and secretion of PGF2α.  Taken together, these data highlight the 
mechanism by which PGF2α–FP receptor signalling can regulate endothelial cell 
function through the enhancement of an autocrine loop involving FGF2, CXCL1 and 
CXCL8.   
4.2 Introduction 
Data generated in our laboratory and others have ascertained a role for the 
cyclooxygenase (COX)-prostaglandin (PG) axis in the regulation of endometrial 
adenocarcinomas by increasing cell proliferation and the secretion of angiogenic 
growth factors (Jabbour et al., 2006b; Tong et al., 2000).  This is similar to other 
cancers where over-expression of COX enzymes and biosynthesis of prostaglandins 
has been shown to promote cellular proliferation (Tsuji et al., 1996), inhibit apoptosis 
(Tsujii and DuBois, 1995) and enhance angiogenesis (Tsujii et al., 1998).  
 
Numerous growth factors that enhance angiogenesis have been identified in human 
endometrial adenocarcinomas.  For example, vascular endothelial growth factor-A 
(VEGF-A) and fibroblast growth factor-2 (FGF2) expression and secretion are 
elevated in endometrial adenocarcinoma cells (Sales et al., 2007; Sales et al., 2005; 
Soufla et al., 2008) and both VEGF-A and FGF2 can stimulate angiogenesis in 
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xenografts in vivo (Danielsen and Rofstad, 1998; Rofstad and Halsor, 2000).  
However, the molecular mechanisms mediating the role of prostaglandins in 
regulating vascular function and angiogenesis are still poorly defined.  Therefore the 
aim of this chapter was to investigate the paracrine effects of proangiogenic factors 
FGF2, CXCL1 and CXCL8, secreted into conditioned medium from PGF2α treated 
FPS cells (P CM), on endothelial cell functions of differentiation and proliferation. 
 
The data generated in this chapter demonstrates the role of three proangiogenic 
growth factors FGF2, CXCL1 and CXCL8 in mediating the prostaglandin F2α 
stimulated effects on endothelial cell functions defined by network formation and 
proliferation.   
 
4.3 Results 
4.3.1 Detection of angiogenic factors in Ishikawa cell conditioned 
medium 
 
Previous studies using FPS cells have shown that the production of the angiogenic 
factors vascular endothelial growth factor-A (VEGF-A) and fibroblast growth factor-
2 (FGF2) is stimulated by PGF2α treatment but not vehicle treatment and this is not 
seen in similarly treated WT Ishikawa cells (Sales et al., 2007; Sales et al., 2005).  
This suggests that the PGF2α-FP signalling promotes the production of angiogenic 
factors.  To identify additional angiogenic factors that are upregulated by PGF2α in 
FPS cells, a commercially available angiogenic array was used.  The array 
membranes were incubated with conditioned medium taken from WT or FPS cells 
treated with either vehicle or PGF2α.  As shown in Fig. 36A there was no difference 
in secretion of angiogenic proteins between WT cells treated with vehicle (WT V 
CM) or PGF2α conditioned medium (WT P CM).  In contrast, conditioned medium 
from FPS cells treated with PGF2α (FP P CM) contained observably higher levels of 
CXCL8, IL6 and CXCL1 when compared with the vehicle treated FPS cell 
conditioned medium (FP V CM) (Fig. 36B).  
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Fig. 36. Angiogenic array of WT and FPS cell conditioned medium. A, Membranes were 
incubated with vehicle (left; WT V CM) or PGF2α (right; WT P CM) treated conditioned 
medium from WT Ishikawa cells. B, Membranes were incubated with vehicle (left; FP V CM) 
or PGF2α (right; FP P CM) treated conditioned medium from FPS Ishikawa cells.   
 
FGF2, CXCL1 and CXCL8 were chosen as the focal angiogenic proteins for this 
study.  The increase in FGF2, CXCL1 and CXCL8 levels in FP P CM compared to 
FP V CM was confirmed by ELISA (Fig. 37).   In order to investigate the 
contribution of FGF2, CXCL1 and CXCL8 to vascular function, these proteins were 
immunoneutralised from the FPS cell P CM using specific antibodies and the 
efficiency of protein immunoneutralisation was confirmed by ELISA (Fig. 37).   
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Fig. 37. Angiogenic proteins present in Ishikawa cell conditioned medium.  Conditioned 
medium was collected from WT (striped bars) and FPS (black bars) Ishikawa cells treated 
with vehicle (V CM) or PGF2α (P CM) for 24hrs.  The levels of FGF2 (A), CXCL1 (B) and 
CXCL8 (C) in the medium were confirmed by ELISA.  FGF2, CXCL1 and CXCL8 proteins 
were immunoneutralised from the FP conditioned medium using specific antibodies (* 
represents statistical significance P<0.05).  Data are represented as mean ± SEM from at 
least three independent experiments.  
 
As shown in Fig. 37, the incubation of FP P CM with respective antibodies, 
significantly reduced the concentration of FGF2, CXCL1 and CXCL8 in the FP P 
CM (Fig. 37A, B and C respectively, P<0.05).   
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4.4 The role of FGF2, CXCL1 and CXCL8 in P CM–induced 
endothelial network formation and proliferation. 
 
For the progression of any tumour larger that approximately 2mm in diameter, a 
blood supply is needed to provide the tumour cells with enough nutrients and oxygen 
to meet their metabolic demand (Hanahan and Folkman, 1996; Hanahan and 
Weinberg, 2000).  The sprouting of new blood vessels from existing blood vessels, in 
order to form a new blood supply, is known as angiogenesis (Hanahan and Folkman, 
1996).  Endothelial cell network formation and proliferation are two of the processes 
required for angiogenesis (Hanahan and Folkman, 1996; Hanahan and Weinberg, 
2000).  As stated by Folkman et al., in vitro models of angiogenesis are useful for 
identifying the role of individual growth factors or combinations of factors in 
endothelial network formation and proliferation (Folkman and Haudenschild, 1980).  
In Fig. 36 and Fig. 37 the angiogenesis array and ELISA, respectively, identified an 
increased presence of angiogenic FGF2, CXCL1 and CXCL8 in the PGF2α 
conditioned medium from FPS cells (FP P CM).  Since FGF2, CXCL1 and CXCL8 
have been shown to regulate vascular function (Li et al., 2003; Presta et al., 2005; 
Wang et al., 2006), the role of these factors in the FP P CM was examined using 
endothelial cell network formation and proliferation assays. 
 
Firstly, endothelial cell network formation and proliferation assays were performed 
using WT and FPS Ishikawa cell conditioned medium treated with vehicle or PGF2α 
for 24hrs (Fig. 38).  The network formation assay was quantified using a method of 
network branch counting as indicated by the red circle on the photograph in Fig. 
38A.  Fig. 38A shows a representative photograph of each of the four treatments, WT 
V CM, WT P CM, FP V CM and FP P CM.  The quantification of four independent 
experiments is displayed in the form of a bar graph below (Fig. 38B).  No significant 
difference in network formation was seen between V CM and P CM from WT 
Ishikawa cells however the network formation observed with P CM from the FPS 
cells was significantly increased compared to all other treatments (Fig. 38B, P<0.05).   
 








Fig. 38. Endothelial network formation assay with WT and FPS cell conditioned 
medium. HUVECs, plated on growth factor reduced matrigel, were incubated with WT or FP 
conditioned medium for 16hrs. The network connections/branches were counted in 10 fields 
per duplicate A, Images from one representative experiment. Red circle indicates one 
network branch B, Quantification of branches counted from at least four independent 








Fig. 39. PGF2α-treated FPS cell conditioned medium increases endothelial cell 
proliferation.  HUVECs were treated with vehicle or PGF2α conditioned medium from WT or 
FPS cells for 96 hours, after which proliferation was assessed using One Solution Reagent 
(Promega) and absorbance was measured on a spectrophotometer at 490nm.  Data from at 
least four independent experiments. (* represents statistical significance P<0.05).  Data are 
represented as mean ± SEM.  
 
Similarly endothelial cell proliferation was not increased by WT P CM compared to 
WT V CM (Fig. 39).  However, FP P CM induced proliferation was significantly 
increased compared to proliferation in cells treated with FP V CM , WT V CM and 
WT P CM treatments (Fig. 39, P<0.05). 
 
For all further experiments only conditioned medium from the vehicle and PGF2α 
treated FPS cells (henceforth abbreviated as V CM and P CM respectively) was used 
as conditioned medium from WT cells did not significantly influence endothelial 
network formation or proliferation.  To identify the role played by FGF2, CXCL1 
and CXCL8 in P CM induced endothelial cell function, network formation and 
proliferation assays were performed using inhibitors of FGF2, CXCL1 and CXCL8 
receptors.  To confirm the role of FGF2, CXCL1 and CXCL8 in network formation 
and proliferation, these proteins were immunoneutralised from the CM with their 
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respective antibodies as shown in Fig. 37.  FGF2 signals through FGFR1 and 
CXCL1 and CXCL8 share the receptor CXCR2.  Endothelial cell network formation 
induced by P CM was significantly reduced by the addition of FGFR1 tyrosine 
kinase inhibitor, SU4984 and use of FGF2-immunoneutralised P CM (Fig. 40A, 
P<0.05).  Notably, SU4984 reduced endothelial network formation to levels below 
that seen with V CM suggesting it affected basal network formation.   Recombinant 
FGF2 protein (50ng/ml), used as a positive control, increased endothelial network 
formation to the levels observed with P CM (Fig. 40A, P<0.05).  Similarly, P CM 
induced network formation was inhibited by addition of CXCR2 antagonist, 
SB225002 and CXCL1 or CXCL8 immunoneutralisation from P CM (Fig. 40B, 
P<0.05).  Combined immunoneutralisation of CXCL1 and CXCL8 did not have and 
additive inhibitory effect on P CM induced network formation compared with 
CXCL1 or CXCL8 alone.  Recombinant CXCL1 (10ng/ml) and CXCL8 (10ng/ml) 
increased endothelial cell network formation compared to control (Fig. 40B, P<0.05).   
 
Endothelial cell proliferation induced by P CM was significantly reduced by the 
addition of SU4984 or use of FGF2-immunoneutralised P CM (Fig. 41A, P<0.05).  
Recombinant FGF2 protein, used as a positive control, also induced endothelial 
proliferation to a similar level as P CM (Fig. 41A).  Similarly, P CM induced 
proliferation was inhibited, to below basal levels, by addition of SB225002 or 
CXCL1 or CXCL8 immunoneutralisation from P CM (Fig. 41B, P<0.05).  
Recombinant CXCL1 and CXCL8 were used as positive controls and increased 
endothelial cell proliferation to levels seen with P CM treatment (Fig. 41B).   
 
 




Fig. 40. Network formation using immunoneutralised conditioned medium. Network 
formation was assessed with A, HUVECs treated with V CM, P CM, P CM and SU4984 
(FGFR1 inhibitor) or FGF2-immunoneutralised P CM and B, HUVECs treated with V CM, P 
CM, P CM and SB225002 (CXCR2 antagonist) or CXCL1/CXCL8-immunoneutralised P CM. 
Data from at least four independent experiments. (* represents statistical significance 
P<0.05).  Data are represented as mean ± SEM. 
 




Fig. 41. Proliferation using immunoneutralised conditioned medium.  A, HUVECs were 
treated with V CM, P CM, P CM and SU4984 (FGFR1 inhibitor) or FGF2-immunoneutralised 
P CM. B, HUVECs were treated with V CM, P CM, P CM and SB225002 (CXCR2 
antagonist) or CXCL1/CXCL8-immunoneutralised P CM.  After 96hrs proliferation was 
assessed after the addition of One Solution Reagent (Promega) and absorbance was 
measure with a spectrophotometer at 490nm.  Data from at least three independent 
experiments represented at mean ± SEM. (* represents statistical significance P<0.05).   
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4.4.1 The effect of P CM on endothelial ERK1/2 phosphorylation 
 
To further investigate the signal transduction pathways involved in endothelial 
network formation and proliferation initiated after P CM treatment, Western blotting 
for ERK1/2 phosphorylation was performed.  In endothelial cells, increased levels of 
ERK1/2 phosphorylation have been shown after activation of the FGFR1 and 
CXCR2 receptors by their respective ligands (MacManus et al., 2007; Presta et al., 
2005; Shyamala and Khoja, 1998).  To investigate ERK1/2 phosphorylation in 
response to FPS cell conditioned medium, HUVECs were treated with V CM or P 
CM for 0, 5, 10, 15, 20 and 30 mins (Fig.42A).  Treatment of HUVECs with P CM 
significantly increased ERK1/2 phosphorylation in a time-dependent manner which 
was maximal after 10 mins of stimulation, compared to V CM (Fig.42A, P<0.05).  
When FGF2, CXCL1 or CXCL8 were immunoneutralised from the conditioned 
medium using antibodies specific for each respective protein, there was a significant 
reduction in ERK1/2 phosphorylation (Fig.42B, P<0.05).  Goat IgG was used as a 
control for immunoneutralised P CM and did not interfere with P CM induced 
ERK1/2 phosphorylation.  Recombinant FGF2 was used as a positive control as it is 
known to phosphorylate ERK1/2 (Sulpice et al., 2002) as shown in Fig.42B.  This 
suggests that FGF2, CXCL1 and CXCL8 all play a role in the activation of ERK1/2 
by P CM treatment.  
 
ERK1/2 activation is known to be mediated by upstream adapter proteins and 
signalling molecules including c-Src, phosphoinositide-3-kinase (PI3K), Akt, protein 
kinase C (PKC) and raf (Pearson et al., 2001).  To further investigate the signalling 
intermediaries involved in growth factor induced ERK1/2 phosphorylation, HUVECs 
were treated with P CM in the absence or presence of FGFR1 tyrosine kinase 
inhibitor (SU4984), CXCR2 antagonist (SB225002), SU4984 and SB225002 
combined, ERK1/2 inhibitor (PD98059) or c-Src inhibitor (PP2).  All chemical 
inhibitors, listed above, significantly reduced the P CM-stimulated phosphorylation 
of ERK1/2 (Fig. 43, P<0.05).  
Chapter 4    PGF2α-FP paracrine signalling influences endothelial cell function 141 
  
 
Fig.42. Immunoblots of P CM induced ERK1/2 phosphorylation in HUVECs.  A, 
HUVECs were treated with V CM (V) or P CM (P) for 0,5,10,15,20 and 30 minutes. B, 
HUVECs were left untreated (U) or treated for 10 min with V CM, P CM, P CM 
immunoneutralised with FGF2, CXCL8 or CXCL1 antibodies. Cell lysates were subjected to 
immunoblot analysis using antibodies against phosphorylated ERK1/2 (top panel) and total 
ERK1/2 (bottom panel).  A representative Western blot is displayed with a graph of semi-
quantitative analysis of ERK1/2 phosphorylation determined as described in Materials and 
Methods. (* represents statistical significance; P<0.05). Data are represented as mean ± 
SEM from four independent experiments. 
Chapter 4    PGF2α-FP paracrine signalling influences endothelial cell function 142 
  
 
Fig. 43. The effect of conditioned medium on ERK1/2 phosphorylation. HUVECs were 
left untreated (U) or treated with V CM  (V) or P CM (P) for 10 min in the absence/presence 
of SU4984, SB225002, SU4984+SB225002, PD98059, PP2 or LY294002. Cell lysates were 
subjected to immunoblot analysis using antibodies against phosphorylated ERK1/2 (top 
panel) and total ERK1/2 (bottom panel).  A representative Western blot is displayed with a 
graph of semi-quantitative analysis of ERK phosphorylation determined as described in 
Materials and Methods. (* represents statistical significance; P<0.05). Data are represented 
as mean ± SEM from four independent experiments. 
 
However, treatment of HUVECs with P CM in the presence of the PI3K inhibitor 
LY294002 did not significantly reduce the phosphorylation of ERK1/2 by P CM 
(Fig. 43) implying that ERK1/2 activation is independent of PI3K but requires 
FGFR1, CXCR2 and c-Src activation. Recombinant FGF2 was used as a positive 
control for ERK1/2 phosphorylation. 
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4.4.2 The effect of P CM on angiogenic gene expression. 
 
ERK1/2 is a potent regulator of cell proliferation and can increase the transcription of 
genes promoting cell growth in many cell types (Pearson et al., 2001).  In order to 
investigate if P CM treatment induced an upregulation in angiogenic gene expression 
via ERK1/2, which could enhance endothelial cell function in an autocrine manner, 
HUVECs were treated with V CM or P CM for 1,2,3,4,6,16 and 24 hrs.  A 
significant increase in the levels of FGF2, CXCL1 and CXCL8 mRNA expression 
was found after 3hrs of treatment with P CM compared to V CM treatment (Fig. 44 
A, B and C respectively, P<0.05).   
 
To investigate whether the angiogenic factors FGF2, CXCL1 and CXCL8 
autoregulate their own expression in a positive feedback mechanism, HUVECs were 
treated with P CM and small molecule chemical inhibitors against the FGFR1 
receptor (SU4984) and CXCR2 receptor (SB225002) and ERK1/2 (PD98059).  
FGF2, CXCL1 and CXCL8 mRNA expression was significantly decreased when 
HUVECs were treated with P CM in the presence of inhibitors SU4984, SB225002 
and PD98059, compared to P CM treatment alone (Fig. 45 A, B and C respectively, 
P<0.05).  This suggests that the transcription of these angiogenic factors requires the 
activation of FGFR1 and CXCR2, by their respective ligands, as well as activation of 
ERK1/2.  
 





Fig. 44. P CM treatment upregulates angiogenic genes in HUVECs.  HUVECs were 
treated with V CM or P CM for 0.5,1,2,3,4,6,16,24 hrs and mRNA expression of FGF2 (A), 
CXCL1 (B) and CXCL8 (C) was determined by RT-PCR. (* represents statistical significance 
from V CM; P<0.05). Data are represented as mean ± SEM from 5 independent 
experiments. 




Fig. 45. Angiogenic factor mRNA expression is dependent on receptor signalling, 
cyclooxygenases and ERK1/2.  HUVECs were treated for 3hrs with V CM or P CM in the 
absence/presence of SU4984 (FGFR1 tyrosine kinase inhibitor), PD98059 (ERK1/2 
inhibitor), Indomethacin (COX inhibitor) or NS398 (COX-2 inhibitor) and mRNA expression of 
FGF2 (A), CXCL1 (B) and CXCL8 (C) was determined by quantitative RT-PCR. (* represents 
statistical significance; P<0.05). Data are represented as mean ± SEM from 5 independent 
experiments. 
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Previous research has indicated the cyclooxygenase (COX) enzymes (Dubois et al., 
1998) can be involved in an additional step in the upregulation of angiogenic factors 
in endothelial cells and during angiogenesis in vivo (Leahy et al., 2002) (Hernandez 
et al., 2001) (Majima et al., 2000).  For example, Leahy et al. found that VEGF-A 
expression was reduced by COX-2 inhibitor NS389 in endothelial cells.  Research by 
Majima et al., using the sponge angiogenesis rat model, indicates that FGF2-induced 
angiogenesis is augmented by an increase in VEGF-A production which can be 
inhibited by the specific COX-2 inhibitor NS398 (Majima et al., 2000).  It is 
generally understood that COX-1 is the constitutively expressed enzyme regulating 
cellular homeostatic prostaglandin production whereas, COX-2 is the inducible 
enzyme upregulated by growth factor stimulation (Dubois et al., 1998; Masferrer et 
al., 2000), however both COX-1 and COX-2 have been implicated in tumour 
angiogenesis (Sales et al., 2002; Tsujii et al., 1998).  To investigate the possibility 
that COX-1 and COX-2 may be involved in the upregulation of angiogenic genes, a 
general COX inhibitor Indomethacin and a specific COX-2 inhibitor, NS398, were 
used.  HUVECs were co-treated for 3hrs with P CM and Indomethacin or NS398 
after which FGF2, CXCL1 and CXCL8 mRNA expression was examined.  
Interestingly, the addition of Indomethacin a general cyclooxygenase (COX) 
inhibitor to P CM decreased FGF2, CXCL1 and CXCL8 mRNA expression 
suggesting a role for both cyclooxygenases in growth factor production (Fig. 45 A, B 
and C respectively, P<0.05). The use of the specific COX-2 inhibitor (NS398) 
decreased CXCL1 and CXCL8 gene expression (Fig. 45 A, B and C, P<0.05) but not 
FGF2 expression. 
 
As the COX inhibitors prevented FGF2, CXCL1 and CXCL8 mRNA expression, the 
mRNA expression levels of COX-1 and COX-2 in HUVECs treated with V CM or P 
CM were compared.  COX-1 mRNA levels were not elevated at any of the time 
points tested (Fig. 46A). In contrast COX-2 mRNA levels were elevated after 3hrs of 
treatment with P CM compared to V CM treatment (Fig. 46B).  As with the 
angiogenic genes FGF2, CXCL1 and CXCL8, COX-2 mRNA expression was 
inhibited by the addition of inhibitors of FGFR1, CXCR2 and ERK1/2 suggesting 
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that the upregulation of COX-2 is induced by growth factors in the P CM, which then 





Fig. 46. The effect of P CM treatment on COX-1 and COX-2 expression. HUVECs were 
treated with V CM or P CM for 1,2,3,4,6,16,24 hrs and mRNA expression of COX-1 (A) and 
COX-2 (B) was determined by RT-PCR. (* represents statistical significance from V CM; 
P<0.05). Data are represented as mean ± SEM (fold increase V CM/ P CM) from 5 
independent experiments. 
 





















































Fig.47.  P CM growth factor signalling mediates COX-2 expression.  HUVECs were 
treated for 3hrs with V CM or P CM in the absence/presence of SU4984 (FGFR1 tyrosine 
kinase inhibitor), SB225002 (CXCR2 antagonist) or PD98059 (ERK1/2 inhibitor) and mRNA 
expression of COX-2 was determined by quantitative RT-PCR. (* represents statistical 
significance; P<0.05). Data are represented as mean ± SEM from 5 independent 
experiments. 
 
4.4.3 ERK1/2 and cyclooxygenases (COX) are involved in P CM 
induced endothelial cell function. 
 
The previous data demonstrate that ERK1/2, COX-1 and COX-2 are involved in the 
increased expression of angiogenic factors as a result of FGF2, CXCL1 and CXCL8 
signalling in endothelial cells.  Following on from this, the functional relevance of 
ERK1/2 and COX-1 and COX-2 in P CM-induced endothelial cell network 
formation and proliferation was investigated. Specific inhibitors for both COX-1 
(SC560) and COX-2 (NS398) were used in order to clearly identify any differential 
effects these two enzymes may have on endothelial cell network formation and 
proliferation.  HUVECs were treated with V CM or P CM in the presence or absence 
of PD98059 (ERK1/2 inhibitor), SC560 and NS398.  The ERK1/2 inhibitor and both 
COX inhibitors significantly reduced the P CM-mediated increase in network 
formation (Fig. 48A, P<0.05).  Similarly, co-treatment with P CM and PD98059, 
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SC560 or NS398 significantly decreased the P CM-mediated endothelial cell 
proliferation (Fig. 48B, P<0.05).  
 
 
Fig. 48. ERK1/2, COX-1 and COX-2 are involved in endothelial cell function.  A, 
HUVECs were seeded on matrigel containing PD98059 (MEK inhibitor), SC560 (COX-1 
inhibitor) or NS398 (COX-2 inhibitor) and the network assay was performed.  B, HUVECs 
were treated with V CM and P CM plus or minus PD98059, SC560 or NS398 for 96hrs 
afterwhich proliferation was assessed by measuring absorbance (490nm) following the 
addition of One Solution Proliferation Reagent (Promega). (* represents statistical 
significance; P<0.05). Data are represented as mean ± SEM from four independent 
experiments.  
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4.4.4 Endothelial secretion of prostaglandins induced by CM 
treatment. 
 
The cyclooxygenase enzymes catalyse the rate limiting step in the synthesis of 
prostaglandins (PG) (Dubois et al., 1998).  Prostaglandins are secreted by endothelial 
cells and in vitro data along with in vivo data suggests that they can promote 
angiogenesis by enhancing endothelial cell proliferation, migration and network 
formation (Churchman et al., 2007; Finetti et al., 2008; Jabbour et al., 2006b; Majima 
et al., 2003).  Since, COX-2 was upregulated by P CM, the secretion of PGE2 and 
PGF2α was examined.  HUVECs were treated with V CM or P CM for 0, 3, 6, 16, 24, 
48 and 72 hrs and the secretion of PGE2 (Fig. 49A) and PGF2α (Fig. 49B) was 
measured by ELISA.  There was no significant difference in the levels of endothelial 
PGE2 secreted by HUVECs in response to CM at any time point tested (Fig. 49A).  
In contrast, the amount of endothelial PGF2α was elevated in HUVECs at 6hrs 
following P CM treatment compared to both V CM treatment (6hrs) and P CM at 
time 0hrs (Fig. 49B, P<0.05).   
 
To confirm the involvement of COX enzymes in the secretion of PGF2α, HUVECs 
we treated for 6hrs with P CM in the presence of the general COX inhibitor 
Indomethacin, a specific COX1 inhibitor (SC560) or a specific COX-2 inhibitor 
(NS398) (Fig. 50). We found that the P CM-induced secretion of PGF2α was 
significantly reduced by co-treatment of cells with NS398 or Indomethacin (Fig. 50, 
P<0.05).  Interestingly, despite there being no increase in COX-1 mRNA expression, 
the specific COX-1 inhibitor SC560 inhibited endothelial cell prostaglandin F2α 
secretion (Fig. 50, P<0.05) implying COX-1 may be necessary for basal levels of 
prostaglandin production.   
 
 
Chapter 4    PGF2α-FP paracrine signalling influences endothelial cell function 151 
  
 
Fig. 49. Endothelial secretion of prostaglandins stimulated by P CM.  HUVECs were 
incubated with V CM or P CM for 0, 3, 6, 16, 24, 48 and 72 hrs and thereafter conditioned 
medium from HUVECs was collected and used for PGE2 (A) and PGF2α (B) ELISA analysis 
as described in the methods. (* represents statistical significance P<0.05)  Data are 




Fig.47 showed that COX-2 mRNA expression was elevated by P CM via a 
mechanism involving the activation of FGFR1, CXCR2 and ERK1/2.  As COX-2 is 
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the inducible enzyme involved in prostaglandin production, the effect of inhibitors of 
FGFR1 (SU4984), CXCR2 (SB225002) and ERK1/2 (PD98059) on P CM-induced 
endothelial PGF2α secretion was examined.  The addition of SU4984 (FGFR1 
inhibitor), SB225002 (CXCR2 antagonist) and PD98059 (MEK inhibitor) to P CM 
significantly reduced the increase in endothelial PGF2α secretion seen with P CM 
treatment alone (Fig. 50, P<0.05).  This suggests that FGF2, CXCL1 and CXCL8 




Fig. 50. Secretion of endothelial PGF2α inhibited by P CM signalling. HUVECs were 
treated with V CM or P CM with or without SU4984 (FGFR1 inhibitor), SB225002 (CXCR2 
antagonist), PD98059 (ERK1/2 inhibitor), Indomethacin (COX inhibitor), SC560 (COX-1 
inhibitor) and NS398 (COX-2 inhibitor) for 6hrs after which the concentration of PGF2α in the 
HUVEC medium was determined by ELISA. (* represents statistical significance P<0.05)  
Data are represented as mean ± SEM from three independent experiments. 
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4.4.5  Discussion 
 
During tumour angiogenesis, the sprouting of new blood vessels from existing blood 
vessels is augmented by the ability of endothelial cells to proliferate, migrate and 
differentiate (Adams and Alitalo, 2007; Ausprunk and Folkman, 1977; Folkman and 
Haudenschild, 1980; Hanahan and Folkman, 1996). Factors secreted by the tumour 
cells that enhance these endothelial cell functions required for effective blood vessel 
formation, will enable the tumour to better meet its metabolic demand thereby 
enhancing tumour progression (Adams and Alitalo, 2007; Hanahan and Weinberg, 
2000).  The endothelial cell network formation and proliferation assays have been 
extensively used as in vitro models to investigate factors influencing angiogenesis 
(Folkman and Haudenschild, 1980; Goodwin, 2007; Tsujii et al., 1998).   
 
Data in this chapter demonstrate that conditioned medium from endometrial 
adenocarcinoma cells, which stably express the FP receptor to the levels observed in 
endometrial adenocarcinomas (FPS cells) secrete elevated levels of the angiogenic 
factors FGF2, CXCL1 and CXCL8.  Cellular manipulation of receptor expression 
allows individual signalling pathways to be examined (Abramovitz et al., 2000).  
Hence, the overexpression of the FP receptor facilitates the study of the PGF2α-FP 
receptor signalling pathway.  Data herein shows that the angiogenic factors, FGF2, 
CXCL1 and CXCL8, promote endothelial network formation (differentiation) and 
proliferation.  Previous in vitro studies have shown that FGF2, CXCL1 and CXCL8 
can all influence endothelial cell function (Kanda et al., 1997; Li et al., 2003; Li et 
al., 2005; Wang et al., 2006).  For example, Kanda et al. found that recombinant 
FGF-2 treatment of HUVECs enhances endothelial cell network formation and 
proliferation and Li et al. showed that treatment of HUVECs with recombinant 
CXCL8 enhances endothelial cell network formation and proliferation (Li et al., 
2003). Similarly, Wang et al. showed that recombinant CXCL1 induced bovine lung 
microvascular endothelial cell migration and CXCL1 immunoneutralisation from 
colon cancer cell conditioned medium inhibited endothelial cell network formation.  
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In vivo and ex vivo data shows that, FGF2, CXCL1 and CXCL8 are all expressed by 
epithelial and endothelial cells of the human endometrium (Luk et al., 2005; 
Mulayim et al., 2003; Sales et al., 2007; Wallace et al., 2009).  As demonstrated in 
this chapter using a specific FGFR1 tyrosine kinase inhibitor, CXCR2 antagonist and 
FGF2-, CXCL1- and CXCL8-immunoneutralised conditioned medium, the effects of 
conditioned medium on endothelial cell network formation and proliferation could be 
mediated via FGF2-FGFR1 signalling as well as CXCL1/CXCL8-CXCR2 signalling.  
The immunoneutralisation of each of these angiogenic factors inhibited endothelial 
cell function and is in agreement with in vivo data from Rofstad et al., who showed 
that immunoneutralisation of VEGF-A, FGF2 or IL-8 from melanoma cell xenografts 
significantly reduced angiogenesis (Rofstad and Halsor, 2000).  There was no cross 
reactivity between the CXCL1 and CXCL8 antibodies as CXCL8 was not 
immunoneutralised by the CXCL1 antibody and vice versa.  In another study by 
Giavazzi et al. using an endometrial cancer xenograft model, FGF2-induced tumour 
growth and angiogenesis required the expression of VEGF-A (Giavazzi et al., 2003), 
demonstrating that the coordination of growth factors is needed for angiogenesis.  
These data indicate that proangiogenic growth factors synergise to promote 
angiogenesis which is either reinforced by an additive effect of these factors or 
protected by a mechanism of redundancy to ensure the survival of the tumour. 
 
ERK1/2 signalling is known to be a potent regulator of cell growth, differentiation 
and development (Lewis et al., 1998).  ERK1/2 is modulator of gene transcription 
activated by phosphorylation cascades which can be induced by most growth factors 
(Pearson et al., 2001; Turjanski et al., 2007).  FGF2, CXCL1 and CXCL8 have all 
been shown to induce ERK1/2 phosphorylation in a variety of cell types (MacManus 
et al., 2007; Shyamala and Khoja, 1998; Sulpice et al., 2002).  This chapter 
investigated the conditioned medium signalling to ERK1/2 in HUVECs and found 
within this experimental paradigm that ERK1/2 was phosphorylated in a time 
dependent manner via the FGFR1 signalling to c-Src, independent of PI3K.  This is 
in agreement with the observations of Sulpice et al. who showed that, in adrenal 
cortex capillary endothelial cells, ERK1/2 phosphorylation induced by recombinant 
Chapter 4    PGF2α-FP paracrine signalling influences endothelial cell function 155 
  
FGF2 is not mediated via the PI3K pathway (Sulpice et al., 2002).  c-Src is a protein 
tyrosine kinase which co-ordinates a diverse spectrum of receptor-induced signalling 
to ERK1/2 via the phosphorylation of signalling intermediates such as Ras and Raf 
(Thomas and Brugge, 1997).  c-Src has been shown to be involved in FGF2-induced 
angiogenesis (Kilarski et al., 2003) and a recent study has shown that c-Src, Raf and 
ERK1/2 are essential for HUVEC lumen formation in vitro (Koh et al., 2009).  
ERK1/2 phosphorylation was inhibited by CXCL1 or CXCL8 immunoneutralisation 
and the CXCR2 antagonist suggesting that CXCL1/CXCL8 signalling to CXCR2 
promotes ERK1/2 activation.  This ERK1/2 activation via CXCL1 and CXCL8 may 
also involve c-Src as CXCR2 has been shown to co-localise with and transactivate 
VEGF-A receptor tyrosine kinase, VEGFR2 in a c-Src dependent mechanism 
(Petreaca et al., 2007).  If CXCR2 can transactivate VEGFR2 and EGFR it is 
possible it may act similarly with FGFR1.  This could be an interesting focus for 
further investigations.  
 
Once phosphorylated by growth factors, activated ERK1/2 can translocate to the 
nucleus and promote the transcription of additional growth factors (Turjanski et al., 
2007).  For example, ERK1/2 was shown to phosphorylate the transcription factor 
SP1 at two threonine sites leading to increased expression of vascular endothelial 
growth factor (Milanini-Mongiat et al., 2002).  As ERK1/2 was found to be activated 
by FGF2, CXCL1 and CXCL8 in the P CM, the mRNA expression of endothelial 
FGF2, CXCL1 and CXCL8 was examined after P CM treatment.  All three factors 
were upregulated after three hours of P CM treatment.  The use of inhibitors of 
ERK1/2 and growth factor receptors, FGFR1 and CXCR2, confirmed that FGF2 
expression was increased by P CM treatment via FGF2-FGFR1 activating ERK1/2.  
This indicates that ERK1/2 is involved in a positive signalling loop promoting FGF2 
expression.  In support of this, FGF2 was shown to be upregulated in epithelial cells 
via ERK1/2 activation after treatment with recombinant FGF2 as part of an autocrine 
loop (Sales et al., 2007).  Similarly, in this chapter CXCL1 and CXCL8 expression 
was also upregulated by CXCL1/CXCL8 signalling via CXCR2 and activating 
ERK1/2.  Previous studies have shown that, CXCL1 and CXCL8 mRNA is 
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upregulated in an ERK1/2 dependent manner after cytokine treatment (Matsumiya et 
al., 2002; Yang et al., 2008).  For example, in HeLa cells treated with IL-1β, the 
upregulation of CXCL1 and CXCL8 expression is decreased by ERK1/2 inhibition 
(Yang et al., 2008).  In addition, Matsumiya et al. showed that HUVEC expression of 
CXCL1 is stimulated by treatment with a soluble IL-6 receptor in an ERK1/2 
dependent manner (Matsumiya et al., 2002).  The upregulation of FGF2, CXCL1 and 
CXCL8 was transient implying that their activation is tightly regulated.  This could 
be via the regulation of ERK1/2 by phosphatases such as hematopoietic protein-
tyrosine phosphatase (HePTP), mitogen-activated protein kinase phosphatase-3 
(MKP3), and protein serine/threonine phosphatase 2A (PP2A) which can all 
dephosphorylate and hence deactivate ERK1/2 (Turjanski et al., 2007).  For example, 
in a previous report, phosphorylation of ERK1/2 by Epidermal Growth Factor and 
FGF2 stimulation was reversed by PP2A/Bα and Bδ dephosphorylation of ERK1/2 
(Van Kanegan et al., 2005).   
 
The cyclooxygenases are enzymes responsible for production of prostaglandins and 
have been shown to promote growth factor induced angiogenesis in vitro and in vivo 
(Amano et al., 2002; Leahy et al., 2002; Tsujii et al., 1998).  Endothelial expression 
of FGF2, CXCL1 and CXCL8 was inhibited by addition of a general COX inhibitor.  
In addition, CXCL1 and CXCL8 expression was inhibited by a specific COX-2 
inhibitor suggesting that COX-1 and COX-2 may both play a role in P CM induced 
endothelial cell function.  The mRNA expression of COX-2, but not COX-1, was 
upregulated by P CM in an FGFR1, CXCR2 and ERK1/2 dependent manner.  This is 
in agreement with data showing that treatment of microvascular endothelial cells 
with FGF2 upregulates many angiogenic genes including COX-2 whereas no change 
in COX-1 expression was observed (Yue et al., 2006).  In this thesis, data suggest 
that COX-2 is being induced by FGF2, CXCL1 and CXCL8 in the P CM via ERK1/2 
and that this upregulated COX-2 is inducing CXCL1 and CXCL8 production but not 
FGF2. It is likely that FGF2 expression is primarily upregulated by ERK1/2 
modulation of its gene transcription in an autocrine loop as has been reported for the 
role of FGF2 in endometrial epithelial cells (Sales et al., 2007).  As COX-1 controls 
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the basal levels of prostaglandin production (Dubois et al., 1998), it is possible that 
the COX-1 inhibitor is acting to inhibit basal levels of COX-1 production which 
control basal prostaglandin levels.  The basal levels of COX-1 may directly regulate 
the expression of angiogenic proteins as cytoplasmic cyclooxygenases can induce 
PPAR-dependent transcription (Bogatcheva et al., 2005).  
 
To confirm the functional relevance of ERK1/2 in endothelial cells, network 
formation and proliferation assays were performed.  With the use of chemical 
inhibitors, endothelial network formation and proliferation was found to involve the 
activation of ERK1/2.  This confirms the premise that the growth factors FGF2, 
CXCL1 and CXCL8, acting via their receptors on endothelial cells, can activate the 
pathway involving c-Src-ERK1/2 leading to upregulation of endothelial growth 
factors which can facilitate endothelial cell network formation and proliferation in an 
autocrine positive feedback loop (Fig. 51).  Interestingly, FGF2 induced murine brain 
capillary endothelial cell differentiation was found by Klint et al., to be dependent on 
c-Src but independent of ERK1/2 (Klint et al., 1999).  This could support the 
accepted notion that growth factor signalling in endothelial cells is tissue type 
specific or could be a result of the fact that this was an observation and they omitted 
to quantify their endothelial cell differentiation assay by network branch counting, as 
they did in their later studies (Klint et al., 1999). 
 
Fig. 51. A schematic representation of P CM induced FGF2, CXCL1 and CXCL8 
promoting endothelial cell network formation and proliferation. 
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Using a general COX inhibitor and a specific COX-2 chemical inhibitor, COX-1 and 
COX-2 were also found to be involved in P CM-induced endothelial cell network 
formation and proliferation.  Endothelial cyclooxygenase enzymes have previously 
been shown to be involved in endothelial cell network formation and proliferation 
(Hernandez et al., 2001; Kentaro Yazawa et al., 2005).  For example, the COX-2 
inhibitor JTE-522 inhibited HUVEC network formation and proliferation (Kentaro 
Yazawa et al., 2005).  Additionally, Hernandez et al. showed that COX-2 expression 
induced by VEGF-A treatment in HUVECs was required for endothelial cell network 
formation (Hernandez et al., 2001).  Therefore, in an additional level of complexity, 
the cyclooxygenases may further increase the expression of FGF2, CXCL1 and 
CXCL8 facilitating endothelial cell function.  The P CM induced elevation of COX-2 
expression leads to increased levels of prostaglandins.  It is possible that COX-1 is 
involved in the regulation of basal levels of endothelial network formation and 
proliferation as COX-1 is generally thought to maintain homeostasis through the 
production of prostaglandins whereas COX-2 controls the inducible endothelial 
function (Dubois et al., 1998; Masferrer et al., 2000). Alternatively, a previous report 
has suggested that the COX-1 inhibitor may not be as specific to COX-1 as first 
thought because SC560 was found by Brenneis et al. to inhibit TNFα induced PGE2 
production in COX-1 deficient cells (Brenneis et al., 2006).  However, in vitro 
experiments by Tsuji et al. showed that colon cancer cell-stimulated HUVEC 
network formation involved endothelial COX-1 but not COX-2 (Tsujii et al., 1998).  
In contrast, in vivo xenograft tumour growth was inhibited by general COX and 
specific COX-2 inhibitors however, they omitted analysis of the effect of these 
inhibitors on angiogenesis (Tsujii et al., 1998).  Additional in vivo experiments 
suggest that it is COX-2 that is responsible for inducing angiogenesis for example, an 
analysis by Leahy et al. (2002) found that FGF2 increased COX-2 protein expression 
by an estimated 2-3 fold when analysed in an in vivo model (Leahy et al., 2002) and 
FGF2 driven angiogenesis in the rat cornea was COX-2 but not COX-1 dependent 
(Masferrer et al., 2000).  These findings together with those in this thesis suggest that 
the prostaglandins produced by both COX-1 and COX-2 may have a role in P CM-
induced endothelial cell function. 
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Prostaglandins have been shown to be secreted by endothelial cells and directly 
influence endothelial cell function via their receptors on endothelial cells (Finetti et 
al., 2008; Rao et al., 2007; Tamura et al., 2006). Cytokine stimulation of HUVECs 
has been shown to increase the secretion of 16keto-PGF1α and PGE2 in a COX-2 
dependent manner (Parfenova et al., 2001), however in this study no elevation in 
PGE2 biosynthesis in response to P CM was observed. Instead, endothelial cells were 
found to secrete elevated levels of PGF2α following activation by CM from PGF2α-
treated Ishikawa FPS cells and that this PGF2α secretion was regulated via the FGF2-
FGFR1- and CXCL1/CXCL8-CXCR2- ERK1/2–mediated induction of COX-2 (see 
Fig. 52 for a schematic representation).  This finding indicates that prostaglandin F2α 
may be directly involved in endothelial cell network formation and proliferation and 
this will be explored in chapter 5.   
 
Fig. 52. A schematic representation of P CM induced signaling suggesting the 
involvement of COX-2 in endothelial cell network formation and proliferation is via 
prostaglandin F2α.  
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5 The role of PGF2α-FP mediated prostaglandin production on 
endothelial cell function. 
5.1 Abstract  
This chapter contains novel findings about the role of prostaglandin F2α (PGF2α) in 
endothelial cell function.  The direct and indirect role of PGF2α signalling in 
endothelial cells was examined.  Data presented here demonstrates that PGF2α acting 
via the FP receptor on endothelial cells can directly regulate endothelial cell network 
formation but not proliferation.  In the indirect role, PGF2α-FP receptor signalling in 
endometrial epithelial cells upregulates pro-angiogenic factors such as FGF-2.  Data 
herein demonstrates that FGF-2 in PGF2α conditioned medium activates ERK1/2 via 
its endothelial FGFR1 receptor resulting in two divergent signalling pathways, one of 
which leads to mTOR activation to promote endothelial cell proliferation.  The 
second unique pathway leads to an increased production of endothelial PGF2α which 
enhances endothelial cell differentiation.   
5.2 Introduction 
 
In chapter 4, it was found that P CM treatment of endothelial cells not only induced 
endothelial cell network formation and proliferation but also induced the secretion of 
prostaglandin F2α.  Following on from this, the direct and indirect role of 
prostaglandins in regulating endothelial cell network formation and proliferation will 
be examined.  
 
Prostaglandins E2 has been shown to influence endothelial cell function in vitro and 
promote angiogenesis in vivo (Finetti et al., 2008; Rao et al., 2007; Tamura et al., 
2006).  PGF2α is secreted by endothelial cells which express the FP receptor (Finetti 
et al., 2008; Taylor et al., 1987) however, its role in angiogenesis is unknown as 
current research has concentrated on the important role of PGF2α in regulating 
vasoconstriction (Errasti et al., 2009; Wong et al., 2009).  Addition of exogenous 
Prostaglandin E2 to endothelial cells can increase proliferation, migration and tube 
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formation (Jain et al., 2008; Wang et al., 2006; Zhao et al., 2007).  Jain et al. showed 
that exogenous PGE2 stimulates the migration of HUVECs in an EP2 dependent 
manner and also showed using a matrigel plug assay that PGE2 treatment causes an 
increase in CD31 stained vessels as well as an upregulation in NF-kB and Akt 
staining (Jain et al., 2008).  In addition Jain et al., suggest that using EP receptor 
antagonists may be a rational way of overcoming the need for COX inhibitors (Jain 
et al., 2008).  The use of cyclooxygenase inhibitors in therapeutic treatment met with 
a hurdle when in 2004 the COX-2 inhibitor celecoxib, used in a clinical trial to 
prevent adenomas, was found to cause cardiovascular problems including increased 
blood pressure (William et al., 2009).  This is due to the fact that COX enzymes 
regulate the production of a number of prostaglandins which are essential for 
different mechanisms controlling normal vascular function and homeostasis (Dubois 
et al., 1998).  Ideally, new research may be able to identify alternative COX-related 
therapeutic targets, such as individual prostaglandin receptors (Cha and DuBois, 
2007).  Targeting a specific prostaglandin pathway involved in cancer may be a way 
of preventing a specific downstream effect of COX, rather than ablating all COX-
related functions.   
 
Although the role of prostaglandin E2 in angiogenesis is reasonably well studied, the 
role of prostaglandin F2α has been neglected.  Therefore, in this chapter the 
mechanisms by which PGF2α-FP epithelial signalling stimulates endothelial cell 
proliferation via the FGFR1-mTOR pathway and endothelial cell network formation 
via the endothelial FP receptor are revealed. 
5.3 Results 
5.3.1 The direct effect of prostaglandin F2α and E2 on endothelial cell 
function. 
In order to investigate whether prostaglandin F2α and E2 directly regulate endothelial 
cell network formation and proliferation, endothelial cells were treated with 
exogenous PGF2α and PGE2 and proliferation (Fig. 53) and network assays (Fig. 54) 
were performed.  Firstly, to examine the effects of PGF2α on proliferation, HUVECs 
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were treated with 1μM PGF2α or 0.1 μM PGF2α for 24, 48, 72 and 96hrs. No 
difference was observed in proliferation rates of HUVECs treated with either 
concentration of PGF2α at any of the time points tested (Fig. 53A).  Similarly, 
treatment of HUVECs with 1μM PGE2 or 0.1 μM PGE2 did not significantly increase 
proliferation rates above that seen with control medium (EBM1% plus vehicle) alone 
(Fig. 53B).  
 
Fig. 53. HUVEC proliferation is not affected by prostaglandin E2 and F2α treatment. 
HUVECs were treated with exogenous (A) prostaglandin F2α (PGF2α) or (B) prostaglandin E2 
(PGE2) for 24, 48, 72 and 96hrs after which proliferation was measured by reading 
absorbance (490nm) following the addition of One Solution Proliferation Reagent (Promega).  
(* represents statistical significance P<0.05)  Data are represented as mean ± SEM from 
three independent experiments. 
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 Next to investigate the effect of PGF2α and PGE2 on network formation, HUVECs 
were treated with 1μM PGF2α or 1μM PGE2 for 16hrs after which network formation 
was assessed (Fig. 54).  The addition of exogenous PGF2α and PGE2 significantly 
increased network formation above the levels seen with vehicle control medium 
alone (Fig. 54).  This indicates that the prostaglandins signalling via their receptors 
may enhance network formation.  To verify the role of the prostaglandin receptors, 
chemical antagonists of the FP receptor AL8810 and EP2 receptor AH6809 were 
added to the network assays in addition to the PGF2α and PGE2 treatment 
respectively.  Co-treatment of HUVECs with PGF2α and AL8810 significantly 
reduced network formation compared to that seen with PGF2α alone (Fig. 54).  Also, 
co-treatment of HUVECs with PGE2 and AH6809 significantly reduced network 
formation in comparison to HUVECs stimulated by PGE2 alone (Fig. 54).  These 




Fig. 54. Endothelial network formation with prostaglandin treatment. HUVECs were 
plated on growth factor reduced matrigel with or without 50µM AL8810 (FP receptor inhibitor) 
or 50μM AH6809 (EP2 receptor inhibitor) and incubated with 1µM exogenous PGF2α or 
PGE2 for 16hrs. The network connections/branches were counted in 10 fields per duplicate. 
Quantification of branches counted from at least four independent experiments. (* represents 
statistical significance P<0.05).  Data are represented as mean ± SEM from five independent 
experiments.  
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5.3.2 Prostaglandin receptor mRNA expression induced by P CM in 
HUVECs. 
Prostaglandin F2α and prostaglandin E2, signalling via their FP and EP2 receptors 
respectively, can directly stimulate HUVEC network formation and the inhibition of 
COX-2 prevents P CM network formation.  Hence, the contribution of prostaglandin 
F2α and E2 receptors to P CM-induced endothelial cell function was investigated.  
Firstly, the expression of the prostaglandin receptors after P CM treatment was 
examined in order to identify which receptors may play a part in P CM induced 
endothelial cell function.  HUVECs were incubated with V CM or P CM for 1, 2, 3, 
4, 6, 16 and 24hrs. 
 
Fig. 55. Expression of prostaglandin receptors EP2 and FP after P CM treatment. 
HUVECs were treated with V CM or P CM for 1,2,3,4,6,16,24 hrs and mRNA expression of 
EP2 (A) and FP (B) was determined by RT-PCR. (* represents statistical significance from V 
CM; P<0.05). Data are represented as mean ± SEM from 5 independent experiments. 
Treatment of HUVECs with P CM for 3hrs significantly elevated the mRNA 
expression of FP (Fig. 55A) and EP2 (Fig. 55B) receptors compared to V CM 
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treatment (P<0.05).  However, no upregulation of EP1 (Fig. 56A), EP3 (Fig. 56B) or 
EP4 (Fig. 56C) receptor mRNA expression by P CM treatment was observed at any 
of the timepoints tested.   
 
Fig. 56. Expression of endothelial cell EP receptors after P CM treatment. HUVECs 
were treated with V CM or P CM for 1,2,3,4,6,16,24 hrs and mRNA expression of EP1(A), 
EP3 (B; EP3 mRNA was not detectable after 6hrs of treatment.) and EP4 (C) was 
determined by RT-PCR. (* represents statistical significance from V CM; P<0.05). Data are 
represented as mean ± SEM from at least 5 independent experiments. 
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Subsequently, the signalling pathways leading to the increased expression of FP and 
EP2 mRNA were examined with the use of small molecule chemical inhibitors.   
  
In chapter 4 the endothelial FGFR1 and CXCR2 receptors have been shown to be 
involved in the P CM induced network formation via the paracrine action of 
epithelial FGF2, CXCL1 and CXCL8.  To examine whether FGF2-FGFR1 and 
CXCL1/CXCL8-CXCR2 signalling may be involved in the regulation of the FP and 
EP2 receptors, a small molecule chemical inhibitor against the FGFR1 receptor 
(SU4984) and chemical antagonist against the CXCR2 receptor (SB225002) (Fig. 
57) were used.  HUVECs were treated for 3hrs with V CM and P CM in the absence 
or presence of the chemical inhibitors after which FP (Fig. 57A) and EP2 (Fig. 57B) 
mRNA expression was examined.  Both SU4984 and SB225002 significantly 
inhibited P CM-induced FP (Fig. 57A) and EP2 (Fig. 57B) mRNA expression.  
SU4984 and SB225002 used in combination did not have an additive affect of 
reducing FP (Fig. 57A) or EP2 (Fig. 57B) expression.  This indicates that FGF2, 
CXCL1 and CXCL8, signalling via their respective receptors, are involved in the 
increase in FP and EP2 receptor expression induced by P CM treatment. 
 
According to data in chapter 4 FGF2, CXCL1 and CXCL8 signalling to their 
receptors FGFR1 and CXCR2 respectively can activate ERK1/2 and the 
cyclooxygenases.  In agreement, using the inhibitors, PD98059 (ERK1/2 inhibitor), 
Indomethacin (COX inhibitor) and NS398 (COX-2 inhibitor) in combination with P 
CM, significantly reduced levels of both FP (Fig. 57A) and EP2 (Fig. 57B) receptor 
mRNA expression compared to that seen with P CM alone (P<0.05).  This suggests 
that FGF2-FGFR1 and CXCL1/CXCL8-CXCR2 induced endothelial cell signalling 
regulates endothelial cell PG receptor expression. 




Fig. 57. FP and EP2 expression regulated by P CM induced signalling. HUVECs were 
treated for 3hrs with V CM or P CM in the absence/presence of SU4984 (FGFR1 tyrosine 
kinase inhibitor), CXCR2 (SB225002), PD98059 (ERK1/2 inhibitor), Indomethacin (COX 
inhibitor) or NS398 (COX2 inhibitor) and mRNA expression of FP (A) and EP2 (B) was 
determined by quantitative RT-PCR. (* represents statistical significance; P<0.05). Data are 
represented as mean ± SEM from 5 independent experiments. 
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5.3.3 The role of the FP and EP2 receptors in P CM-induced endothelial 
cell function 
 
Previously in this chapter, endothelial cell network formation (Fig. 54) but not 
proliferation (Fig. 53) was found to be stimulated by exogenous PGF2α and PGE2.  
To verify the role of the FP and EP2 receptors in P CM induced endothelial cell 
function, network assays and proliferation assays were performed firstly using 
inhibitors of the FP and EP2 receptors.  Treatment of HUVECs with P CM and 
antagonists of FP and EP2 receptors, AL8810 and AH6809 respectively, 
significantly reduced network formation compared to that seen with P CM treatment 
alone (Fig. 58A, P<0.05).  Co-treatment of HUVECs with P CM and AL8810 and 
AH6809 had a slight but not significant additive affect on preventing endothelial cell 
network formation (Fig. 58A).  In contrast, P CM induced proliferation was not 
inhibited by the addition of AL8810 or AH6809 even when used in combination 
(Fig. 58B).   
 
As shown in chapter 4, only PGF2α secretion was increased by P CM treatment.  This 
suggests a prominent role for PGF2α-FP autocrine signalling in P CM-induced 
endothelial cell network formation.  As the role of the FP receptor in endothelial cell 
network formation is a novel finding, to support the chemical inhibitor data, two 
short hairpin RNA (shRNA) constructs of the FP receptor, sh306 and sh478 in 
adenovirus, were used to knockdown FP receptor signalling (section 2.9.3.2).  Once 
the FP receptor knockdown was verified (see section 2.9.3.2), HUVECs were 
infected with scrambled control virus (scr), sh306 and sh478 and network formation 
and proliferation rates were assessed. HUVECs infected with the control scr virus 
showed an increase in network formation with P CM treatment compared to V CM 
treatment (Fig. 59A, P<0.05).  In contrast, network formation in sh306 and sh478 
infected cells did not increase after P CM treatment compared to V CM treatment 
(Fig. 59A).  This suggests that P CM induced endothelial cell network formation 
requires the endothelial FP receptor.  In support of the results collected with use of 
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AL8810, knocking down the FP receptor with sh306 and sh478 did not prevent P 
CM-mediated endothelial cell proliferation (Fig. 59B).  Therefore, it is likely that 
endothelial PGF2α-FP signalling is not involved in P CM induced proliferation.   
 
Fig. 58. The role of FP and EP2 in P CM-induced endothelial cell function. A, HUVECs 
were seeded on matrigel, with or without 50µM AL8810 (FP receptor inhibitor) or AH6809 
(EP2 receptor inhibitor), and the network assay was performed with V CM and P CM.  B, 
HUVECs were treated with V CM and P CM plus or minus AL8810 or AH6809 for 96hrs after 
which proliferation was measured by reading absorbance (490nm) following the addition of 
One Solution Proliferation Reagent (Promega). (* represents statistical significance; P<0.05). 
Data are represented as mean ± SEM from four independent experiments.  




Fig. 59.  Decreasing FP receptor with shRNA expression affects endothelial cell 
network formation. HUVECs were infected with scrambled adenovirus (scr) or short hairpin 
adenovirus targeted against the FP receptor (sh306 and sh478) and treated with V CM or P 
CM. Endothelial network formation (A) and proliferation (B) were determined as described in 
the methods. (* represents statistical significance P<0.05)  Data are represented as mean ± 
SEM from five independent experiments. 
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5.3.4 The regulation of endothelial cell proliferation by proangiogenic 
factor signalling. 
 
The previous data in this chapter shows that endothelial PGF2α plays a role in 
promoting P CM-induced endothelial cell network formation but is not involved in 
endothelial cell proliferation.  This leads to the suggestion that it is the growth factors 
in the conditioned medium, identified in chapter 4, that are controlling P CM induced 
proliferation independently of endothelial prostaglandin secretion.  In support of this, 
HUVECs treated with P CM immunoneutralised with FGF2, CXCL1, CXCL8 all 
showed reduced proliferation rates compared to cells treated with P CM alone (Fig. 
60A).  Equally, recombinant FGF2, CXCL1 and CXCL8 can all stimulate 
endothelial cell proliferation above that seen with basal cell medium control 
(EBM1%).  FGF2 has been shown to promote the secretion of VEGF-A facilitating 
tumour growth and angiogenesis, in vivo using an endometrial cancer xenograft 
model (Giavazzi et al., 2003).  This demonstrates that the coordination of growth 
factors is needed for angiogenesis.  To shed some light on the mechanism by which 
growth factors in the P CM are involved in endothelial cell proliferation, the pathway 
stimulated by fibroblast growth factor 2 was chosen as FGF2 is a potent growth 
factor involved in proliferation of many cell types including endothelial cells (Presta 
et al., 2005; Sales et al., 2007; Seghezzi et al., 1998).  Using chemical inhibitors of 
FGFR1, PP2, ERK1/2 shown in Fig. 60B, as found in chapter 4, the P CM induced 
proliferation, was found to be regulated by FGF2 signalling to FGFR1 and activating 
ERK1/2 via c-Src. Therefore, the pathways controlling network formation and 
proliferation could diverge after ERK1/2 activation or else before via another 
alternative pathway from FGFR1.    
 
One pathway that has been implicated in cellular proliferation is the mTOR pathway 
(Bjornsti and Houghton, 2004).  mTOR can be activated via the PI3K pathway 
therefore, chemical inhibitors of mTOR (rapamycin) and PI3K (LY294002 and 
wortmannin) were used to examine the role of the PI3K-mTOR pathway in P CM 
induced proliferation (Fig. 61).  Interestingly none of the inhibitors, rapamycin, 
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LY294002 or wortmannin inhibited endothelial cell network formation (Fig. 61A).  
In contrast, rapamycin was found to inhibit P CM-induced proliferation but neither 
LY294002 nor wortmannin had an effect on P CM-induced endothelial cell 
proliferation (Fig. 61A). 
 
Fig. 60. Growth factors in P CM control endothelial cell proliferation. A, HUVECs were 
treated with V CM, P CM or P CM immunoneutralised with antibodies for FGF2, VEGFA, 
CXCL1, CXCL8, IL6 or PDGFA.  FGF2, VEGFA, CXCL1 and CXCL8 were used as a 
positive control.  B, HUVECs were treated with V CM, P CM, P CM plus SU4984 (FGFR1 
inhibitor), PD98059 (ERK1/2 inhibtor) or PP2 (c-Src inhibitor).  After 96hrs, proliferation was 
assessed after the addition of One Solution Reagent (Promega) and absorbance was 
measured with a spectrophotometer at 490nm.  Data from at least three independent 
experiments represented at mean ± SEM. (* represents statistical significance P<0.05).   





Fig. 61. The role of PI3K-mTOR pathway in P CM induced endothelial cell function. A, 
HUVECs were seeded on matrigel containing rapamycin (mTOR inhibitor), LY294002 (PI3K 
inhibitor) or wortmannin (PI3K inhibitor) and the network assay was performed.  B, HUVECs 
were treated with V CM and P CM plus or minus rapamycin, LY294002 or wortmannin for 
96hrs afterwhich proliferation was measured by reading absorbance (490nm) following the 
addition of One Solution Proliferation Reagent (Promega).  (* represents statistical 
significance; P<0.05). Data are represented as mean ± SEM of at least three independent 
experiments.  
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 To confirm whether PI3K plays a role in P CM signalling, HUVECs were treated 
with V CM and P CM for 0, 5, 10, 15, 20 and 30 minutes (Fig. 62).  Western blot 
analysis of the PI3K regulatory subunit p85 alpha, which is activated by FGFR1 in 
murine brain endothelial cells  (IBECs) (Cross et al., 2002), showed that P CM 
treatment did not induced PI3K phosphorylation at any of the time points tested 
compared to V CM treatment (Fig. 62).  These data along with that of Fig. 61B 
indicates that activation of the PI3K regulatory subunit p85 is not involved in P CM 
induced endothelial cell proliferation. 
 
 
Fig. 62. PI3K p85α phosphorylation is not induced by P CM treatment. HUVECs were 
treated with V CM (V) or P CM (P) for 0,5,10,15,20 and 30 minutes. Cell lysates were 
subjected to immunoblot analysis using antibodies against phosphorylated PI3K (top panel) 
and total PI3K (bottom panel).  A representative Western blot is displayed with a graph of 
semi-quantitative analysis of PI3K phosphorylation determined as described in Materials and 
Methods. (* represents statistical significance; P<0.05). Data are represented as mean ± 
SEM of three independent experiments. 
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 To confirm the position of rapamycin in the signalling cascade resulting from P CM 
treatment and leading to endothelial cell proliferation, HUVECs were treated with V 
CM, P CM and P CM and rapamycin for 10 minutes and ERK1/2 phosphorylation 
was assessed by immunoblot analysis (Fig. 63).  Rapamycin did not inhibit P CM 
induced ERK1/2 phosphorylation indicating that it is downstream of ERK1/2 
activation (Fig. 63).  
 
Fig. 63. P CM induced ERK1/2 phosphorylation is independent of mTOR activation. 
HUVECs were treated for 10minutes with V CM, P CM or P CM and rapamycin. FGF2 was 
used as a positive control for ERK1/2 phosphorylation. Cell lysates were subjected to 
immunoblot analysis using antibodies against phosphorylated ERK1/2 (top panel) and total 
ERK1/2 (bottom panel).  A representative Western blot is displayed with a graph of semi-
quantitative analysis of ERK1/2 phosphorylation determined as described in Materials and 
Methods. (* represents statistical significance; P<0.05). Data are represented as mean ± 
SEM of three independent experiments. 
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5.3.5 Confirmation of the FGF2 induced network formation and 
proliferation pathways. 
 
In order to confirm that the divergent pathways involved in P CM induced HUVEC 
network formation and proliferation are mediated by FGF2, HUVECs were treated 
with recombinant FGF2 in the absence or presence of the c-Src inhibitor PP2, the 
ERK1/2 inhibitor PD98059 and the mTOR inhibitor rapamycin (Fig. 64).   
 
Fig. 64. The signalling pathways involved in FGF2 induced endothelial cell function. A, 
Endothelial network formation and B, proliferation in HUVECs treated with vehicle or 
recombinant FGF2 protein (50ng/ul) in the absence/presence of PD98059 (ERK1/2 inhibitor), 
PP2 (c-Src inhibitor) or rapamycin (mTOR inhibitor). (* represents statistical significance 
P<0.05) Data are represented as percentage increase compared to EBM1% and presented 
as mean ± SEM of at least three independent experiments.  
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Recombinant FGF2 significantly increased endothelial cell network formation (Fig. 
64A, P<0.05) and proliferation (Fig. 64B, P<0.05).  Addition of PP2 and PD98059 to 
recombinant FGF2 treatment inhibited both network formation (Fig. 64A, P<0.05) 
and proliferation (Fig. 64B, P<0.05) however, rapamycin significantly inhibited only 
FGF2 induced proliferation (Fig. 64B, P<0.05) and had no significant effect on 
network formation (Fig. 64A), similar to the results seen for CM (Fig. 61). 
 
Previous studies have been uncertain about whether or not c-Src is required for FGF2 
induced endothelial cell ERK1/2 activation as Kilarski et al. showed using 
immortalised brain endothelial cells (IBECs) that overexpressing an inhibitor of Src 
did not prevent ERK1/2 phosphorylation by FGF2 (Kilarski et al., 2003).  As both c-
Src and ERK1/2 are involved in P CM- and FGF2-induced proliferation and c-Src 
inhibits P CM induced ERK1/2 activation (as shown in chapter 3), the effect of the c-
Src inhibitor, PP2 on recombinant FGF2 induced ERK1/2 activation in HUVECs 
was assessed (Fig. 65).   
 
Fig. 65. c-Src is involved in FGF2 induced ERK1/2 phosphorylation. HUVECs were 
treated for 10 minutes with EBM1%, FGF2 (50μg/μl) or FGF2 plus PP2. Cell lysates were 
subjected to immunoblot analysis using antibodies against phosphorylated ERK1/2 (top 
panel) and total ERK1/2 (bottom panel).  A representative Western blot is displayed with a 
graph of semi-quantitative analysis of ERK1/2 phosphorylation determined as described in 
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Materials and Methods. (* represents statistical significance; P<0.05). Data are represented 
as mean ± SEM of three independent experiments. 
Co-treatment of HUVECs with FGF2 and PP2 significantly reduced ERK1/2 
activation seen with recombinant FGF2 treatment alone (Fig. 65, P<0.05).  This 
confirms that c-Src is involved in the FGF2-FGFR1 induced activation of ERK1/2 in 




At the end of chapter 4, data showed that PGF2α and PGE2 were biosynthesised by 
HUVECs however only PGF2α secretion was increased, along with cyclooxygenase-2 
expression, by P CM treatment.  This suggests that prostaglandin F2α may be 
important in the regulation of endothelial cell function.   
 
In order investigate the direct effects of PGF2α and PGE2, HUVECs were treated with 
exogenous PGF2α or PGE2 and network formation and proliferation were examined.  
Exogenous prostaglandin F2α treatment was compared with prostaglandin E2 
treatment as previous data has shown that PGE2 can influence endothelial cell 
network formation, proliferation and migration (Jain et al., 2008; Wang et al., 2006; 
Zhao et al., 2007).  A study by Tamura et al. showed in HUVECs, that exogenous 
PGE2 induced network formation and implicated PGE2  and COX-2 in the regulation 
of VEGF-A induced network formation  (Tamura et al., 2006).  A recent study by 
Finetti et al. showed that PGE2 treatment of endothelial cells causes EP3 and c-Src 
activation followed by FGF2-FGFR1-ERK1/2 signalling which enhances endothelial 
cell migration (Finetti et al., 2008).  Also previous research has shown that 
endothelial cell proliferation inhibited by COX-2 siRNA was partially rescued by 
addition of PGE2 (Zhao et al., 2007).  However, in a study investigating the role of 
EP4 receptor in endothelial cell network formation, proliferation, and migration, 
PGE2 treatment did not increase murine endothelial cell proliferation in EP4-null 
cells or the control cells (Rao et al., 2007).  Data presented in this thesis showed that 
neither exogenous PGF2α nor exogenous PGE2 could induce endothelial cell 
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proliferation at the concentrations tested.  This in vitro investigation does not rule out 
the fact that these prostaglandins may be involved in proliferation in vivo.  For 
example, Leahy et al. found that the addition of COX-2 inhibitor celecoxib to an 
FGF2-induced mouse corneal model of angiogenesis inhibited endothelial cell 
proliferation which was attributed to a decrease in PGE2 production (Leahy et al., 
2002).  However, as it may be difficult to distinguish between endothelial cell 
proliferation and migration using in vivo models, perhaps the action of celecoxib 
could have also been inhibiting the chemotactic role of prostaglandins in stimulating 
endothelial cell migration (Rao et al., 2007).   
 
In accordance with previous data, exogenous PGE2 was found to stimulate HUVEC 
network formation in an EP2 dependent manner.  In vivo data by Jain et al. has 
shown that the EP2 receptor is involved in PGE2 stimulated angiogenesis (Jain et al., 
2008).  Additionally, this chapter presents the novel finding that exogenous PGF2α 
stimulates endothelial cell network formation in an FP dependent manner since the 
FP inhibitor significantly reduced PGF2α-induced endothelial cell network formation.  
This suggests that PGF2α present in the P CM could be acting directly to promote 
endothelial cell network formation in a paracrine and autocrine manner via the 
endothelial FP receptor.  
 
To assess the direct role of the prostaglandins and their receptors in P CM-induced 
endothelial cell function, the levels of prostaglandin receptors after P CM treatment 
were investigated.  All the EP receptors 1-4 have been shown to be involved in 
tumourigenesis, angiogenesis or endothelial cell function (Amano et al., 2003; 
Dorsam and Gutkind, 2007; Jain et al., 2008; Kamoshita et al., 2006).  In this study, 
the FP and EP2 receptors were upregulated after P CM treatment indicating these 
receptors are involved in the P CM-induced network formation and proliferation.  
Data herein demonstrates that the FP and EP2 receptors, the receptors for PGF2α and 
PGE2 respectively, are regulated in a manner requiring FGF2-FGFR1 or 
CXCL1/CXCL8-CXCR2 signalling, the activation of ERK1/2 and cyclooxygenases 
1 and 2.  In line with these data, a previous study by Kuwano et al. showed in a 
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mouse corneal model that the regulation of angiogenesis by cytokine signalling 
involved increasing COX-2 resulting in elevated prostaglandin E2 signalling through 
endothelial EP2 and EP4 receptors (Kuwano et al., 2004).  Additionally, 
prostaglandin F2α secretion was shown to be induced via COX-2 after IL-1 treatment 
of endometrial stromal cells (Kawano et al., 2001) and TNFα stimulates PGF2α 
secretion via ERK1/2 activation in bovine luteal cells (Sakumoto R et al., 2000). 
 
Using the in vitro indicators of angiogenesis, endothelial cell network assays and 
proliferation assays, data in this thesis demonstrate that P CM-induced endothelial 
cell network formation is regulated by PGF2α signalling through the FP receptor.  In 
contrast, P CM-induced endothelial cell proliferation was not inhibited by the FP 
receptor antagonist suggesting that, as seen with the exogenous PGF2α, PGF2α-FP 
signalling does not directly regulate endothelial cell proliferation.  The apparent 
increase in proliferation seen with the addition of AL8810, is likely due to the fact 
that AL8810 can act as an agonist when in excess (Griffin et al., 1999).  The 
evidence for the role of the FP receptor in P CM-induced endothelial cell network 
formation was further supported by use of a specific FP receptor short hairpin RNA 
in an adenoviral delivery system for targeted ablation of endothelial FP receptor.  
Reducing the FP receptor levels in endothelial cells, reduced endothelial cell network 
formation induced by P CM but had no effect on endothelial cell proliferation. 
 
The EP2 receptor antagonist also significantly inhibited P CM-induced network 
formation.  This suggests that even though the PGE2 secretion is not upregulated by 
P CM, the upregulation of the EP2 receptor is enough to contribute to the P CM-
induction of endothelial cell network formation.  No evidence was found here to 
indicate that PGE2-EP2 receptor signalling is involved in P CM-induced 
proliferation.  One interesting explanation for the role of the EP2 receptor in the P 
CM-induced network formation is the possibility that PGF2α could act through the EP 
receptors.  For example, in a recent study involving mast cells which don’t express 
the FP receptor, PGF2α treatment was found to increase cytokine secretion in an EP 
receptor dependent manner (Kaneko et al., 2008).  The affinity of PGF2α for the EP2 
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receptor is Ki 119nM, much less than that for the FP receptor (Abramovitz et al., 
2000), but enough to promote robust cellular signalling via the EP2 receptor.  In 
accordance, in endometrial epithelial cells, PGE2 can signal via the FP receptor to 
enhance COX-2 expression (Sales et al., 2008b) demonstrating the flexibility of 
prostaglandins for PG receptors. 
 
Alternatively, another explanation for the role of the EP2 receptor in the P CM-
induced network formation is that conventional intracellular prostaglandins may 
signal through PG receptors expressed on the nuclear membrane.  All the 
prostaglandin E2 receptors EP1-4 are present on the nuclear membrane in cerebral 
microvascular endothelial cells and the EP1 receptor has been shown to be able to 
induce Ca2+ signalling when situated on the nuclear membrane indicating that it is 
functional (Bhattacharya et al., 1998).  Another study showed that agonist activation 
of perinuclear EP3 caused an increase in nuclear eNOS expression indicating that 
nuclear prostaglandin receptors can regulate gene expression (Gobeil et al., 2002).  In 
addition, COX-2 has been shown to be localised to the perinucleus and nucleus in a 
stimulation regulated manner in HUVECs (Parfenova et al., 2001).  It is possible that 
due to the proximity of intracellular COX and PGE2 to nuclear EP receptors, an 
increase in nuclear EP receptor number could efficiently enhance PGE2 stimulated 
gene transcription, even in the absence of elevated PGE2 secretion.   
 
The data in chapter 4 showed that the COX inhibitors inhibit endothelial cell 
proliferation however, as we found no involvement in the EP2 or FP receptors in 
endothelial cell proliferation it is possible that the COX-dependent endothelial 
proliferation is reliant on a different COX product.  One possibility is that 
prostacyclin is the COX product involved in endothelial cell proliferation. The IP 
receptor has been implicated in the regulation of endometrial angiogenesis (Smith et 
al., 2006).  Prostacyclin treatment can induce angiogenesis and vascular permeability 
(Pola et al., 2004).  For example, in guinea pigs, intradermal injection of VEGF-A, 
but not FGF2, upregulated PGI2 expression and increased vascular permeability both 
of which could be inhibited by the addition of the COX inhibitor Indomethacin 
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(Murohara et al., 1998).  An alternative COX product is thromboxane, TxA2 which 
signals through the TxA2 receptor expressed on endothelial cells.  Inhibition of the 
TxA2 receptor inhibits IL1β induced mouse corneal angiogenesis (Kuwano et al., 
2004). Further investigations are required to elucidate the roles of prostacyclin and 
thromboxane in endometrial adenocarcinoma angiogenesis. 
 
Prostaglandin F2α and the FP receptor were found to directly regulate endothelial cell 
network formation however, they were not found to directly regulate endothelial cell 
proliferation.  Therefore, the indirect role of PGF2α in regulating HUVEC 
proliferation was investigated further as PGF2α-FP signalling in epithelial cells 
causes the secretion of growth factors.  These growth factors (as shown in chapter 4) 
FGF2, CXCL1 and CXCL8, are responsible for endothelial cell proliferation and 
network formation but the intracellular pathways regulating proliferation have yet to 
be elucidated.  Although, immunoneutralisation of FGF2, CXCL1 and CXCL8 all 
reduced P CM dependent proliferation, FGF2 was chosen to investigate the P CM-
induced proliferation, as it is a potent growth factor in many cell types and there is an 
abundance of in vivo data supporting its role in angiogenesis (Presta et al., 2005).  
FGF2 binds FGFR1 and signals through c-Src and ERK1/2 to regulate P CM-
induced proliferation.  As shown in chapter 4, both proliferation and network 
formation involve the FGF2 activation of ERK1/2 therefore it is likely that the 
divergent proliferation pathway occurs after this signalling intermediate or before via 
an alternative proliferation pathway activated by FGFR1. 
   
One possible proliferation pathway is the phosphatidylinositol 3-kinase (PI3K) -Akt-
rapamycin (mTOR) pathway (Vivanco and Sawyers, 2002).  FGF2 signals to the 
PI3K pathway in endothelial cells (Cross et al., 2002; Sulpice et al., 2002), which can 
activate mTOR (Bjornsti and Houghton, 2004), to promote endothelial cell 
proliferation (Zheng et al., 2008).  Data presented in this chapter show that mTOR is 
involved in P CM-induced proliferation but not network formation.  This is in 
agreement with the observations of Kanda et al., who demonstrated in murine brain 
endothelial cells that FGF2-induced endothelial network formation is not dependent 
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on activation of the mTOR pathway (Kanda et al., 1997).  Interestingly, neither P 
CM-induced proliferation nor network formation involved the PI3K pathway as 
inhibitors of PI3K did not affect these endothelial functions.  To confirm the absence 
of PI3K activation, PI3K phosphorylation was investigated and was not found to be 
activated by P CM treatment.  The p85α regulatory subunit investigated was the 
regulatory subunit which can be phosphorylated by FGF2 signalling through the 
FGFR1 tyrosine kinase as well as other growth factors signalling through their 
receptors (Gesbert et al., 1998; Ong et al., 2001; Wu et al., 2001).  Recent studies 
into the role of PI3K in tumourigenesis have involved the investigation of the p110 
catalytic subunits but evidence suggests that these subunits are activated by GPCRs 
rather than tyrosine kinases (Jia et al., 2008).  As shown in chapter 4, ERK1/2 
phosphorylation was not inhibited by treatment with a PI3K inhibitor and these data 
together with the fact that PI3K inhibitors had no effect on endothelial cell 
proliferation indicate that P CM induced proliferation is independent of PI3K but 
dependent on mTOR signalling.  Similar results were found by Kanda et al. in 
murine brain capillary endothelial cells who showed that the cell cycle regulator, 
p70S6kinase, was activated by mTOR independently of PI3K (Kanda et al., 1997).  
The opposite scenario also occurs after angiotensin II treatment in rat smooth muscle 
cells where proliferation is PI3K dependent but mTOR independent indicating that 
proliferative responses are cell type and stimulus specific (Dugourd et al., 2003).  
Data herein demonstrates that mTOR is downstream of ERK1/2 activation by P CM 
as the mTOR inhibitor had no effect on ERK1/2 phosphorylation.   
 
To confirm that FGF2 in the P CM can stimulate this pathway to proliferation, 
endothelial cell proliferation stimulated by recombinant FGF2 was shown to  involve 
the activation of c-Src, ERK1/2 and mTOR.  In contrast, inhibiting mTOR activity 
had no effect on recombinant FGF2-induced endothelial cell network formation.  The 
involvement of c-Src in FGF2-induced ERK1/2 activation was unclear because one 
study showed, in murine brain endothelial cells, that FGFR1 activation of ERK1/2 
was independent of c-Src (Cross et al., 2002) but other studies have shown that c-Src 
is needed for FGF2-induced HUVEC proliferation (Deo et al., 2002) and endothelial 
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cell network formation (Klint et al., 1999).  To clarify the role of c-Src in ERK1/2 
activity in HUVECs, the c-Src inhibitor, PP2, was used in combination with 
recombinant FGF2 to demonstrate that FGF2 induced ERK1/2 phosphorylation is 
dependent on c-Src activity.  This is in accordance with research by Kho et al. 
showing that c-Src and ERK1/2 are essential for vascular lumen formation in vitro 
(Koh et al., 2009). 
 
Following ERK1/2 activation, mTOR has been shown to be regulated via the 
tuberous sclerosis complex 1 and 2 (TSC1/2 also called Hamartin and Tuberin) 
(Guertin and Sabatini, 2007; Lee and Hung, 2007).  Phosphorylation of TSC2 by 
ERK1/2 results in its dissociation from TSC1 and its subsequent degradation via the 
ubiquitin pathway. This inactivates the inhibitory effect of TSC1/2 on the mTOR 
pathway and allows cellular proliferation to proceed (Drakos et al., 2008).  
 
Taken together, these data confirm that the P CM-induced proliferation can be 
mediated by FGF2 in a c-Src, ERK1/2, mTOR dependent pathway.  Endothelial cell 
proliferation and network formation pathways are both stimulated by FGF2 
signalling to FGFR1 but diverge after ERK1/2 activation. After which, the 
upregulation of COX-2 enhances P CM-induced endothelial cell network formation 
by increasing PGF2α signalling via endothelial cell FP receptor (see Fig. 66 for a 
schematic).  
 
In summary, this chapter demonstrates that pro-angiogenic factor FGF-2, produced 
in endometrial epithelial cells via the PGF2α-FP receptor signalling, can regulate the 
endothelial cell functions of differentiation and proliferation, required for 
angiogenesis.  Epithelial FGF-2 binds to endothelial FGFR1 receptors and activates 
ERK1/2 resulting via two divergent signalling pathways, one of which leads to 
mTOR activation to promote endothelial cell proliferation.  The second unique 
pathway leads to an increased production of endothelial PGF2α which directly 
enhances endothelial cell differentiation.   
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Fig. 66. Schematic representation of the divergent pathways regulating P CM-induced 
endothelial cell network formation and proliferation. 
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6 The role of antiangiogenic ADAMTS1 and RCAN-1 in P CM-
induced endothelial cell function. 
6.1 Abstract  
Data presented in this chapter demonstrates P CM-induced endothelial cell network 
formation and proliferation is regulated by antiangiogenic proteins known as a 
disintegrin and metalloproteinase with a thrombospondin repeat 1 (ADAMTS1) and 
regulator of calcineurin 1-4 (RCAN1-4).  ADAMTS1 overexpression significantly 
inhibited P CM-induced network formation and proliferation.  RCAN1-4 
overexpression in HUVECs inhibited P CM-induced endothelial cell network 
formation and proliferation possibly through a dual mechanism involving the 
inhibition of angiogenic cytokine CXCL8 expression and the upregulation of 
antiangiogenic protein ADAMTS1.  In contrast, RCAN1-4 deficient HUVECs 
exhibited an increase in P CM-induced network formation but a decrease in P CM-
induced endothelial cell proliferation occurs possibly resulting from signalling to 
apoptotic pathways.  These data implicate ADAMTS1 and RCAN1-4 as regulators of 
vascular remodelling in endometrial pathologies where the FP receptor is aberrantly 
expressed.   
 
6.2 Introduction 
Endothelial cell function and angiogenesis are tightly regulated by a balance between 
proangiogenic factors and antiangiogenic factors.  Antiangiogenic factors such as 
thrombospondin and endostatin have been shown to counteract proangiogenic 
VEGF-A-induced endothelial cell function in vitro and angiogenesis in vivo 
(Kyriakides et al., 2001; Lee et al., 2006; Margosio et al., 2008) (Abdollahi et al., 
2004; Schumacher et al., 2007).  In the preceding chapters, the role of proangiogenic 
FGF2, CXCL1 and CXCL8 in P CM-induced endothelial cell network formation and 
proliferation was investigated.  In this chapter the role of antiangiogenic factors 
disintegrin and metalloproteinase with a thrombospondin repeat 1 (ADAMTS1) and 
regulator of calcineurin-1-4 (RCAN1-4) in P CM-induced endothelial cell network 
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formation and proliferation was investigated.  In chapter 3, ADAMTS1 expression 
was localised to the vasculature in endometrial adenocarcinoma. Previous studies 
have demonstrated that VEGF-A-induced angiogenesis is negatively regulated by 
secretion of a ADAMTS1 and RCAN1-4 (Iruela-Arispe et al., 2003; Minami et al., 
2004).  In 1997 ADAMTS1 was first identified as an inflammatory regulated gene in 
a murine colon adenocarcinoma cell line (Kuno et al., 1997).  ADAMTS1 has been 
shown to inhibit VEGF-A-induced angiogenesis through different mechanisms 
(Iruela-Arispe et al., 2003).  In one angiogenesis inhibitory mechanism ADAMTS1 
can sequester VEGF-A and prevent its binding to the VEGFR2 receptor thereby 
inhibiting human aortic endothelial cell proliferation (Luque et al., 2003).  
Alternatively, ADAMTS1 inhibits angiogenesis by facilitating the cleavage of 
antiangiogenic thrombospondin peptides which can inhibit FGF2-driven bovine 
aortic endothelial cell proliferation (Lee et al., 2006).  ADAMTS1 can also be 
upregulated by growth factors treatment, such as VEGF-A, in endothelial cells (Xu et 
al., 2006) and thereby acts as a negative regulator mediating the actions of VEGF-A.  
These studies indicate that ADAMTS1 may act as a regulator of angiogenesis in 
endometrial cancers.   
 
RCAN1, also known as Down’s syndrome candidate region-1, was originally 
identified on chromosome 21 in individuals with Down’s syndrome (Fuentes et al., 
2000).  Individuals with Down’s syndrome have an extra copy of chromosome 21 
and have lower rates of many cancers.  A recent study by Baek et al. has provided 
evidence to show that the overexpression of RCAN1 in Down’s syndrome can 
suppress tumour growth (Baek et al., 2009). RCAN1 has 4 splice variants from exons 
1, 2, 3 and 4 (Harris et al., 2005).  Although exon 2 is thought to be non functional 
and exon 3 only contains 3 aminoacids, RCAN1-exon1 (RCAN1-1) and RCAN1-
exon4 (RCAN1-4) are expressed by endothelial cells and affect endothelial cell 
function (Qin et al., 2006).  RCAN 1-4 is an inhibitor of calcineurin and by binding 
to calcineurin and preventing the calcineurin-dependent dephosphorylation of NFAT, 
RCAN1-4 can impede NFAT-induced gene transcription (Baek et al., 2009).  
Recently, the RCAN1-4 isoform was identified as a negative regulator of NFAT-
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induced CXCL8 in endometrial epithelial cells (Maldonado-Perez et al., 2009).  
RCAN1-4 isoform has previously been shown to inhibit CXCL8 expression and 
increase ADAMTS1 expression in VEGF-induced angiogenesis (Minami et al., 
2004).  In chapter 4 CXCL8 was found to regulate P CM-induced network formation 
and proliferation in a CXCR2 and ERK1/2 dependent manner.  In addition, CXCL8 
expression has also been shown to be regulated by NFAT in endothelial cells (Boss 
et al., 1998).   Therefore, the role of RCAN1-4 in regulating P CM-induced 
endothelial cell network formation and proliferation via CXCL8 was investigated.   
 
The data presented in this chapter demonstrate that antiangiogenic factors such as 
ADAMTS1 and regulators such as RCAN1-4 balance the proangiogenic factors 
mediating endothelial cell network formation and proliferation to control vascular 
cell function.   
6.3 Results 
6.3.1 Timecourse of ADAMTS1 mRNA expression in CM treated 
HUVECs.  
 
In order to investigate if ADAMTS1 could be involved in regulating P CM-induced 
endothelial cell network formation and proliferation; HUVECs were treated with V 
CM or P CM for 0.5, 1, 2, 3, 4, 6, 16 and 24hrs after which ADAMTS1 expression 
was investigated (Fig. 67).  The expression of ADAMTS1 was significantly 
upregulated at 1 and 4hrs after treatment with P CM compared to V CM (Fig. 67A, 
P<0.05).  To confirm that ADAMTS1 is regulated by angiogenic factors such as 
CXCL8, HUVECs were treated with recombinant CXCL8 (10ng/ml) for 1, 3 and 
4hrs after which mRNA expression of ADAMTS1 was examined (Fig. 67B).  
ADAMTS1 mRNA was significantly upregulated after 3hrs of treatment with 
recombinant CXCL8 compared to control EBM1% treatment (Fig. 67B, P<0.05).  
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Fig. 67. ADAMTS1 mRNA expression is increased by P CM and CXCL8. A, HUVECs 
were treated with V CM or P CM for 0.5,1,2,3,4,6,16,24 hrs and B, HUVECs were treated 
with EBM1% or recombinant CXCL8 for 1, 3, 4hrs and mRNA expression of ADAMTS1 was 
determined by quantitative RT-PCR. (* represents statistical significance; P<0.05). Data are 
represented as mean ± SEM from 5 independent experiments. 
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6.3.2 The effect of ADAMTS1 siRNA on P CM-induced endothelial cell 
network formation and proliferation. 
 
ADAMTS1 has been shown to inhibit endothelial cell proliferation and in vivo 
angiogenesis (Iruela-Arispe et al., 2003).  Therefore, it is possible that the 
antiangiogenic properties of ADAMTS1 are partially responsible for regulating P 
CM-induced endothelial cell functions.  In order to investigate this proposed 
antiangiogenic effect of ADAMTS1 in P CM-induced endothelial cell network 
formation and proliferation, ADAMTS1 siRNA, as shown in chapter 2, was used to 
inhibit ADAMTS1 expression in HUVECs. 
 
HUVECs were infected with Control siRNA and ADAMTS1 siRNA for 48hrs.  
Thereafter, cells were incubated with V CM or P CM and network formation and 
proliferation assays were performed.  Addition of ADAMTS1 siRNA to HUVECs 
significantly increased P CM-induced network formation (Fig.68A, P<0.05) and 
proliferation (Fig.68B, P<0.05) compared to Control siRNA cells treated with P CM.  
This suggests that an increase in ADAMTS1 expression levels will negatively affect 
endothelial cell network formation and proliferation as ADAMTS1 is a negative 
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Fig.68. ADAMTS1 siRNA increases endothelial cell network formation and 
proliferation.  HUVECs were incubated with Control siRNA or ADAMTS1 siRNA for 48hrs 
prior to treatment. Subsequently, Control siRNA or ADAMTS1 siRNA HUVECs were treated 
with V CM or P CM and network formation (A) and proliferation (B) assays were performed. 
(* represents statistical significance; P<0.05). Data are represented as mean ± SEM from 4 
independent experiments. 
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6.3.3  RCAN1 mRNA expression is upregulated in P CM treated 
HUVECs. 
 
RCAN1-exon4 (RCAN1-4) is expressed by endothelial cells and regulates 
endothelial cell function (Qin et al., 2006).  In order to investigate the role of 
RCAN1-4 in endothelial cell network formation and proliferation, HUVECs were 
treated with P CM for 0.5, 1, 2, 3, 4, 6, 16 and 24hrs after which RCAN1 expression 
was investigated (Fig.69A).  The expression of RCAN1 was significantly 
upregulated at 3hrs after treatment with P CM compared to V CM (Fig.69A, 
P<0.05).   
 
NFAT has been shown to upregulate RCAN1-4 expression and this can negatively 
regulate CXCL8 (Maldonado-Perez et al., 2009). In addition, CXCL8 can activate 
NFAT (Boss et al., 1998) therefore, RCAN1-4 could itself be upregulated by 
CXCL8.  As shown in chapter 4, CXCL8, in the P CM, activates MEK-ERK1/2 via 
the CXCR2 receptor which increases the endothelial expression of CXCL8.  To 
examine if this signal transduction pathway is involved in P CM induction of 
RCAN1 by CXCL8, HUVECs were treated with P CM in the absence or presence of 
inhibitors of CXCR2 (SB225002) and ERK1/2 (PD98059) (Fig.69B).  After 3hrs of 
treatment, the expression of RCAN1 was analysed (Fig.69B).  The CXCR2 inhibitor, 
SB225002, significantly reduced RCAN1 expression (Fig.69B, P<0.05) however, the 
inhibitor of ERK1/2, PD98059, had no effect on RCAN1 expression (Fig.69B).  This 
indicates that the signal transduction pathway induced by CXCL8 and regulating 
RCAN1 expression are different to those regulating the production of P CM-induced 
proangiogenic growth factors, as seen in chapter 4.   
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Fig.69. RCAN1 mRNA expression after P CM treatment.  A, HUVECs were treated with V 
CM or P CM for 0.5,1,2,3,4,6,16,24 hrs and B, HUVECs were treated for 3hrs with V CM or 
P CM in the absence/presence of SB225002 (CXCR2 antagonist) or PD98059 (ERK1/2 
inhibitor) and mRNA expression of RCAN1 was determined by quantitative RT-PCR. (* 
represents statistical significance; P<0.05). Data are represented as mean ± SEM from 5 
independent experiments. 
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6.3.4 Overexpression of RCAN1-4 negatively regulates endothelial cell 
network formation and proliferation. 
 
As RCAN1-4 overexpression can inhibit angiogenesis (Minami et al., 2004), and it is 
upregulated in HUVECs treated with P CM, its role in HUVEC network formation 
and proliferation was investigated using an adenoviral construct to overexpress 
RCAN1-4.  As shown in section 2.9.3.3, the addition of 100MOI of adenovirus 
RCAN1-4 (Ad-RCAN1) increased the expression of RCAN1 more than 100 fold 
above the control.  Control adenovirus (Ad-Control) did not alter RCAN1 basal 
levels.  Therefore, HUVECs were infected with 100MOI of an adenovirus control or 
adenovirus RCAN1 and subsequently treated with V CM or P CM to examine 
endothelial cell network formation and proliferation.  In the Ad-Control treated 
HUVECs, P CM significantly increased endothelial cell network formation (Fig. 
70A, P<0.05) and proliferation (Fig. 70B, P<0.05).  However, in HUVECs infected 
with Ad-RCAN1 to overexpress RCAN1-4, the P CM-induced increase in network 
formation (Fig. 70A, P<0.05) and proliferation (Fig. 70B, P<0.05) was inhibited 
compared to Ad-Control cells treated with P CM.  This suggests that an increase in 
the levels of RCAN1-4 negatively regulates endothelial cell network formation and 
proliferation.   
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Fig. 70. The effect of RCAN1-4 overexpression on endothelial cell network formation 
and proliferation.  HUVECs were transfected with 100MOI of adenovirus construct 
containing non-target (Ad-Control) or RCAN1-4 cDNA (Ad-RCAN1).  Subsequently, cells 
were treated with V CM or P CM and network formation (A) and proliferation (B) were 
assessed. (* represents statistical significance; P<0.05). Data are represented as mean ± 
SEM of 4 independent experiments. 
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6.3.5 The effect of RCAN1-4 overexpression on CXCL8 mRNA 
expression in endothelial cells. 
 
In chapter 4, CXCL8 in the P CM was found to regulate endothelial cell network 
formation and proliferation via the CXCR2 receptor.  In addition, CXCL8 mRNA 
expression was upregulated in a CXCR2 dependent manner suggesting that CXCL8 
acting via the CXCR2 receptor regulates a positive feedback loop promoting CXCL8 
expression and endothelial cell function.  RCAN1-4 has previously been shown to 
negatively regulate CXCL8 expression (Maldonado-Perez et al., 2009).  Therefore, 
to determine if RCAN1-4 overexpression was preventing endothelial cell network 
formation and proliferation via the inhibition of CXCL8 expression, HUVECs were 
infected with Ad-Control and Ad-RCAN1 adenovirus and treated with V CM or P 
CM after which CXCL8 mRNA expression was examined (Fig. 71).  CXCL8 mRNA 
expression in Ad-Control cells was significantly elevated after 3hrs of P CM 
treatment compared to V CM treatment (Fig. 71A, P<0.05).  In Ad-RCAN1 cells, 
this increase in CXCL8 mRNA induced by P CM was inhibited compared to Ad-
Control cells treated with P CM (Fig. 71A, P<0.05).  To confirm the possibility that 
RCAN1-4 overexpression could negatively regulate CXCL8-induced expression of 
endothelial CXCL8, adenovirus infected HUVECs were treated with recombinant 
CXCL8 or control media (EBM1%) and CXCL8 expression was examined.  In Ad-
Control cells the addition of CXCL8 recombinant protein significantly increased 
CXCL8 expression, compared to Ad-Control cells treated with EBM1% (Fig. 71B, 
P<0.05).  In Ad-RCAN1 cells, the induction of CXCL8 expression by recombinant 
CXCL8 was inhibited (Fig. 71B, P<0.05). 
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Fig. 71. CXCL8 mRNA expression is decreased by RCAN1-4 overexpression at 3hrs. 
HUVECs were transfected with 100MOI of adenovirus construct containing non-target (Ad-
Control) or RCAN1 cDNA (Ad-RCAN1).  Subsequently, cells were treated with V CM or P 
CM (A) or EBM1% and CXCL8 (B) and CXCL8 expression was determined by quantitative 
RT-PCR. (* represents statistical significance; P<0.05). Data are represented as mean ± 
SEM of 5 independent experiments. 
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Next, the possibility that addition of recombinant CXCL8 to RCAN1-4 
overexpressing HUVECs could rescue P CM-induced endothelial cell network 
formation and proliferation was investigated (Fig 72). 
 
Fig. 72. Addition of CXCL8 to RCAN1-4 overexpressing cells does not rescue network 
formation or proliferation.  HUVECs were transfected with 100MOI of adenovirus construct 
containing non-target (Ad-Control) or RCAN1-4 cDNA (Ad-RCAN1).  Subsequently, cells 
were treated with V CM, P CM or P CM plus recombinant CXCL8 (10ng/ml) and network 
formation (A) and proliferation (B) were assessed. (* represents statistical significance; 
P<0.05). Data are represented as mean ± SEM of at least 4 independent experiments. 
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Ad-Control and Ad-RCAN1 HUVECs were treated with V CM and P CM with or 
without recombinant CXCL8 (Fig. 72).  There was no significant difference in 
HUVEC network formation (Fig. 72A) or proliferation (Fig. 72B) seen with Ad-
RCAN1 cells treated with P CM and CXCL8 compared to Ad-RCAN1 cells treated 
with P CM alone.  This demonstrates that the addition of recombinant CXCL8 did 
not rescue the RCAN1-4 overexpressing cells.  Therefore, it is possible that RCAN1-
4 is regulating the expression of other angiogenic proteins which may mediate P CM-
induced endothelial cell proliferation.  
 
The overexpression of RCAN1-4 in HUVECs has been shown to decrease 
angiogenic protein expression but it may also increase the expression of 
antiangiogenic proteins.  For example, data by Minami et al. found that RCAN1-4 
overexpression in HUVECs increases ADAMTS1 expression (Minami et al., 2004).  
As ADAMTS1 expression is increased after P CM treatment (Fig. 67) and 
ADAMTS1 expression inhibits P CM-induced endothelial cell network formation 
and proliferation (Fig.68), it is possible that RCAN1-4 may regulate endothelial cell 
function via ADAMTS1 expression.  Hence, to investigate the role of RCAN1-4 in 
the regulation of ADAMTS1, Ad-Control and Ad-RCAN1 HUVECs were treated 
with V CM or P CM and ADAMTS1 mRNA expression was examined (Fig. 73A).  
ADAMTS1 mRNA expression was significantly increased in Ad-RCAN1 HUVECs 
treated with P CM compared to control HUVECs treated with P CM (Fig. 73, 
P<0.05).  This indicates that RCAN1-4 is augmenting P CM upregulation of 
ADAMTS1.   Recombinant CXCL8 treatment was found to increase ADAMTS1 
expression (Fig. 67B) therefore, the effect of RCAN1-4 overexpression on 
ADAMTS1 expression induced by recombinant CXCL8 was examined (Fig. 73B).  
In Ad-RCAN1 HUVECs treated with recombinant CXCL8 had elevated levels of 
ADAMTS1 mRNA but this was not significantly different to Ad-Control cells 
treated with recombinant CXCL8 (Fig. 73B).  
 
 




Fig. 73. ADAMTS1 expression increased by RCAN1 overexpression. HUVECs were 
transfected with 100MOI adenovirus control (Ad-Control) or adenovirus RCAN1-4 (Ad-
RCAN1) for 24hrs prior treatment.  Ad-HUVECs were treated with for 4hrs with V CM or P 
CM (A) or for 3hrs with EBM1% and recombinant CXCL8 (10ng/ml) (B).  After treatment, 
mRNA expression of ADAMTS1 was determined by quantitative RT-PCR. (* represents 
statistical significance; P<0.05). Data are represented as mean ± SEM from 4 independent 
experiments. 
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6.3.6 Decreasing endothelial RCAN1-4 expression differentially 
regulates P CM-induced endothelial cell network formation and 
proliferation. 
 
Next the effect of reducing endothelial RCAN1 expression, with use of a lentiviral 
construct containing RCAN1-4 short hairpin RNA (shRNA), on P CM-induced 
endothelial cell network formation and proliferation, was investigated.  As increasing 
RCAN1-4 expression in HUVECs decreased endothelial cell network formation and 
proliferation (Fig. 70), decreasing RCAN1-4 could possibly increase endothelial cell 
network formation and proliferation.  Therefore, HUVECs were infected with a non-
target control lentivirus (lv-Control) or lentivirus containing RCAN1-4 shRNA (lv-
RCAN1).  As shown in section 2.9.3.4, the expression of RCAN1 in lv-RCAN1-4 
cells was significantly decreased compared to lv-Control cells.  To examine the 
effect of decreased RCAN1-4 expression on endothelial cell network formation and 
proliferation, lv-Control and lv-RCAN1 HUVECs were treated with V CM and P 
CM (Fig. 74).  The lv-Control cells exhibited normal response to P CM because P 
CM treatment significantly increased endothelial cell network formation (Fig. 74A, 
P<0.05) and proliferation (Fig. 74B, P<0.05) compared to V CM treatment.  In lv-
RCAN1 HUVECs the addition of P CM significantly increased endothelial cell 
network formation above the levels seen in lv-Control cells treated with P CM (Fig. 
74A, P<0.05).  However, contrary to what was observed for the network formation, 
inhibition of RCAN1 expression with shRNA did not elevate cellular proliferation 
(Fig. 74B).  lv-RCAN1 HUVECs treated with P CM exhibited a decrease in 
proliferation compared to lv-Control P CM (Fig. 74B, P<0.05).  There was also a 
significant decrease in the proliferation of lv-RCAN1 HUVECs treated with V CM 
compared to lv-Control HUVECs treated with V CM (Fig. 74B, P<0.05).  This was 
an unexpected finding because HUVEC proliferation was proposed to increase in lv-
RCAN1 cells.   
Chapter 6     ADAMTS1 and RCAN1-4 in P CM treated HUVECs 202 
  
 
Fig. 74.  The effect of decreasing RCAN1 expression on endothelial network formation 
and proliferation.  HUVECs were transfected with 5MOI of lentiviral control (lv-Control) or 
lentivirus RCAN1 (lv-RCAN1) for 24hrs and allowed to recover for 12hrs prior to 
experiments.  Lentivirus HUVECs were treated with V CM or P CM and network formation 
(A) and proliferation assays (B) were performed. (* represents statistical significance; 
P<0.05). Data are represented as mean ± SEM from 4 independent experiments. 
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6.3.7 The effect of RCAN1-4 shRNA on P CM induced mRNA 
expression of COX-2, CXCL8 and ADAMTS1. 
 
As mentioned previously, RCAN1-4 is a negative regulator of NFAT gene 
transcription (Baek et al., 2009).  In endothelial cells, one angiogenic target of NFAT 
is cyclooxygenase 2 (Hernandez et al., 2001). As shown in chapter 4, the increase in 
angiogenic gene expression of FGF2, CXCL1 and CXCL8 was partially dependent 
on COX-2 expression.  In addition, data in chapter 5 show that the COX-2 product, 
PGF2α promotes endothelial cell network formation.  Therefore, the possibility was 
investigated that the elevation in network formation, seen after a reduction in 
RCAN1-4 expression, was due to an enhancement of COX-2 expression.  The 
expression of COX-2 was examined in lv-Control and lv-RCAN1 HUVECs treated 
for 3hrs with V CM, P CM, EBM1% or CXCL8 (Fig.75).  In lv-RCAN1 cells treated 
with P CM, there was a significant increase in COX-2 mRNA expression compared 































































Fig.75. The effect of lv-RCAN1 on COX-2 mRNA expression in HUVECs. HUVECs were 
transfected with 5MOI of lentiviral control (lv-Control) or lentivirus RCAN1 (lv-RCAN1) for 
24hrs and allowed to recover for 12hrs prior to experiments.  lv-Control and lv-RCAN1 
HUVECs were treated with V CM, P CM, EBM1% or CXCL8 for 3hrs after which COX-2 
mRNA expression was analysed by quantitative RT-PCR.  (* represents statistical 
significance; P<0.05). Data are represented as mean ± SEM from 4 independent 
experiments. 
 
Chapter 6     ADAMTS1 and RCAN1-4 in P CM treated HUVECs 204 
  
COX-2 expression in lv-Control cells treated with P CM was not significantly 
different to lv-Control cells treated with V CM (Fig.75) although as shown in chapter 
4, P CM treatment does significantly increase COX-2 mRNA levels in untransfected 
cells.  The level of COX-2 mRNA expression was also significantly increased in 
untreated lv-RCAN1 cells (lv-RCAN1 EBM1%) compared to untreated lv-Control 
cells (lv-Control EBM1%) (Fig.75, P<0.05) further suggesting that COX-2 mRNA 
expression is increased when RCAN1-4 expression is decreased.   
 
Earlier in this chapter, it was shown that CXCL8 mRNA expression was decreased 
by RCAN1-4 overexpression suggesting that RCAN1-4 negatively regulates 
endothelial CXCL8 expression.  In order to investigate whether decreasing RCAN1 
expression would increase CXCL8 expression, HUVECs were infected with lv-
Control and lv-RCAN1 and treated for 1, 3 and 4 hrs with V CM and P CM after 
which the expression of CXCL8 was examined (Fig.76A).  Unexpectedly, the 
expression of CXCL8 was significantly decreased in lv-RCAN1 cells treated with P 
CM compared to lv-Control cells treated with P CM after 1 and 4 hrs of treatment 
(Fig.76A, P<0.05).  This indicates that contrary to the expected increase in NFATc1-
regulated gene expression, due lack of RCAN1-4 negative feedback, CXCL8 
expression was not increased.  To confirm the role of calcineurin-NFAT signalling in 
CXCL8 mRNA expression, lv-Control and lv-RCAN1 cells were coincubated with P 
CM and the calcineurin inhibitor cyclosporin A (CsA) (Fig.76A).  The expression of 
CXCL8 in lv-RCAN1 cells treated with P CM was significantly decreased by the 
addition of CsA (Fig.76A, P<0.05) after 1 hr of treatment, compared to P CM alone.  
This suggests that even when gene transcription is decreased, calcineurin-NFAT 
activation is still regulating gene transcription of CXCL8 as cyclosporin A can 
inhibit these low levels of endothelial CXCL8 expression.   
 
Previously in this chapter, it was shown that ADAMTS1 mRNA expression was 
increased by RCAN1-4 overexpression (Fig. 73).  Conversely, it may be expected 
that decreasing RCAN1-4 expression would decrease ADAMTS1 expression.  
Therefore, the expression of ADAMTS1 in lv-Control and lv-RCAN1 cells was 
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examined.  Contrary to expectations, the expression of ADAMST1 was significantly 
increased in lv-RCAN1 cells treated with P CM compared to lv-Control cells treated 
with P CM (Fig.76B).  To investigate the role of calcineurin-NFAT transcription in 
ADAMTS1 expression, cells were co-treated with P CM and cyclosporin A 
(Fig.76B).  Cyclosporin A treatment did not decrease ADAMTS1 mRNA expression 
induced by P CM (Fig.76B).  These data suggest that an increase or decrease in 
NFAT gene transcription alone may not affect ADAMTS1 expression.  
 
Fig.76. The effects of lv-RCAN1 on CXCL8 and ADAMTS1 mRNA expression.  HUVECs 
were transfected with 5MOI of lentiviral control (lv-Control) or lentivirus RCAN1 (lv-RCAN1) 
for 24hrs prior to experiments.  Subsequently, lv-Control and lv-RCAN1 HUVECs were 
treated for 1, 3 and 4 hrs with V CM, P CM or P CM plus cyclosporin A (P CM+ CsA).  After 
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which, CXCL8 (A) and ADAMTS1 (B) expression was analysed by quantitative RT-PCR. (* 
represents statistical significance; P<0.05). Data are represented as mean ± SEM from at 
least 3 independent experiments. 
6.4 Discussion 
 Angiogenesis is regulated by a balance between pro- and antiangiogenic factors.  
Data in chapters 4 and 5, of this thesis have established a proangiogenic role for 
FGF2, CXCL1 and CXCL8 in P CM-induced endothelial cell network formation and 
proliferation.  In this chapter, the role of antiangiogenic ADAMTS1 and RCAN1-4 
in P CM-induced endothelial cell network formation and proliferation was 
investigated.  Antiangiogenic ADAMTS1 has been shown to inhibit VEGF-A 
induced angiogenesis through a variety of mechanisms (Iruela-Arispe et al., 2003).  
In one angiogenesis inhibitory mechanism, ADAMTS1 can sequester VEGF-A and 
prevent its binding to the VEGFR2 receptor thereby inhibiting human aortic 
endothelial cell proliferation (Luque et al., 2003).  Alternatively, ADAMTS1 inhibits 
angiogenesis by facilitating the cleavage of antiangiogenic thrombospondin peptides 
which can inhibit FGF2-driven bovine aortic endothelial cell proliferation (Lee et al., 
2006).  ADAMTS1 can also be upregulated by growth factor treatment, such as 
VEGF-A, in endothelial cells (Xu et al., 2006).  In this chapter, the expression of 
ADAMTS1 in HUVECs by P CM treatment was investigated and ADAMTS1 was 
found to be elevated after 1hr and 4hrs of P CM treatment compared to V CM.  This 
elevation of ADAMTS1 was in a reciprocal manner to the expression observed for 
proangiogenic growth factors CXCL1 and CXCL8 which were maximally induced at 
3hrs (see section 4.4.2).  These findings indicate that angiogenic factors in the P CM 
may regulate ADAMTS1 expression.  To confirm this, recombinant CXCL8 was 
used and found to stimulate endothelial ADAMTS1 expression after 3hrs of 
treatment, suggesting that CXCL8 in the P CM could induce ADAMTS1 expression.  
 
To verify the antiangiogenic role that ADAMTS1 may play in P CM-induced 
endothelial cell network formation and proliferation, ADAMTS1 siRNA was used to 
inhibit HUVEC ADAMTS1 expression.  Inhibition of ADAMTS1 expression in 
HUVECs increased P CM-induced endothelial cell network formation and 
proliferation.  This is in agreement with data from Iruela-Arispe et al. who 
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demonstrated that ADAMTS1 inhibits bovine aortic endothelial cell proliferation and 
angiogenesis in vivo (Iruela-Arispe et al., 2003; Luque et al., 2003).  These data 
indicate that ADAMTS1 negatively regulates endothelial cell network formation and 
proliferation induced by P CM.   
 
RCAN1 is also known as Down syndrome critical region 1 (DSCR1), Adapt78 and 
MCIP1 (Davies et al., 2007).  RCAN1 has 4 splice variants from exons 1, 2, 3 and 4 
(Harris et al., 2005).  Although exon 2 is thought to be non functional and exon 3 
only contains 3 amino acids, RCAN1-exon1 (RCAN1-1) and RCAN1-exon4 
(RCAN1-4) are expressed by endothelial cells and regulate endothelial cell function 
(Qin et al., 2006).  RCAN 1-4 binding to calcineurin prevents the calcineurin-
dependent dephosphorylation of NFAT hence, RCAN1-4 can impede NFAT-induced 
gene transcription (Baek et al., 2009).  A study by Minami et al. showed that 
RCAN1-4 overexpression can inhibit NFAT-induced VEGF-A expression in 
HUVECs and thereby inhibit VEGF-A-induced HUVEC network formation and 
proliferation (Minami et al., 2004).  Further in vivo studies using a matrigel plug 
assay and melanoma xenografts indicate that VEGF-A-induced angiogenesis is 
inhibited by RCAN1-4 overexpression (Minami et al., 2004).  This suggests that 
overexpression of RCAN1-4 has antiangiogenic actions.  These antiangiogenic 
actions are further supported by the observation that individuals with Down’s 
syndrome, who have an extra copy of the RCAN1 gene locus, display reduced 
incidences of solid tumours and reduced tumour growth rates (Baek et al., 2009). 
 
To investigate the possibility that RCAN1 may be regulating endothelial cell network 
formation and proliferation, the expression of RCAN1 in HUVECs was determined 
by quantitative RT-PCR.  RCAN1 was upregulated after 3hrs of treatment with P 
CM compared to V CM. This suggested that growth factors in the P CM are 
increasing RCAN1 expression.  Using the CXCR2 antagonist together with P CM 
decreased HUVEC expression of RCAN1, indicating that CXCL8 signals through 
the CXCR2 receptor to upregulate RCAN1.  In contrast to the expression of growth 
factors which are upregulated via the ERK1/2 pathway, RCAN1 expression was 
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found to independent of ERK1/2 activation.  This is in agreement with data by Iizuka 
et al. who found that RCAN1 upregulation by VEGF-A treatment was independent 
of ERK1/2 activation (Iizuka et al., 2004). Similarly, treatment of HUVECs with 
PLC, PI3K, P38 and JNK inhibitors had no effect on the expression of RCAN1 
induced by P CM (data not included).  In addition, Yao et al. showed using HUVECs 
that VEGF-A-induced RCAN1 expression was independent of ERK1/2, P38 and 
PI3K (Yao and Duh, 2004).  Iizuka et al. also found that in HUVECs, RCAN1 
upregulation by VEGF-A was independent of PI3K and P38 but dependent on 
calcium-calcineurin signalling (Iizuka et al., 2004).  It is important to note that the 
cytokine receptors such as CXCR2, a GPCR, are not assumed to activate NFAT 
unless they can stimulate calcium pathways leading to calcineurin (Rao et al., 1997).  
However, the CXCR2 receptor can transactivate the tyrosine kinase receptor 
VEGFR2 in human microvascular endothelial cells (Martin et al., 2009) (Petreaca et 
al., 2007) which previous research has shown can activate endothelial cell 
calcineurin-NFAT signalling (Schweighofer et al., 2007).  Therefore, it is possible 
that CXCL8, in the P CM, signalling through the CXCR2 receptor on endothelial 
cells could regulate NFAT activation via a mechanism involving the transactivation 
of tyrosine kinase receptors such as VEGFR2.  
 
Next to examine the effect that increasing RCAN1-4 expression would have on P 
CM-induced endothelial cell network formation and proliferation, an adenovirus 
RCAN1-4 construct was used.  As the RCAN1-4 isoform has previously been shown 
to inhibit CXCL8 expression (Maldonado-Perez et al., 2009) and angiogenesis 
(Minami et al., 2004), this was the isoform investigated.  Data herein demonstrates 
that P CM-induced endothelial cell network formation and proliferation was reduced 
in HUVECs infected with RCAN1-4 adenovirus.  This is in line with previous data 
showing that RCAN1-4 overexpression inhibits VEGF-induced endothelial cell 
network formation and proliferation (Minami et al., 2004).    
 
The mechanism by which RCAN1-4 regulated endothelial cell network formation 
and proliferation was further investigated.  Ligand binding to membrane receptors 
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such as GPCRs can elevate intracellular calcium which activates calcineurin (Rao et 
al., 1997).  Activated calcineurin dephosphorylates cytoplasmic NFAT allowing its 
translocation to the nucleus where it stimulates gene transcription (Rao et al., 1997).  
RCAN1-4 can inhibit NFAT induced transcription because RCAN1-4 and NFAT 
compete for binding to calcineurin (Martinez-Martinez et al., 2009). This would 
imply that with more RCAN1-4 there would be more competition for calcineurin, 
which may decrease NFAT-induced gene transcription.  CXCL8 has been identified 
as a target of NFAT gene transcription negatively regulated by RCAN1-4 
(Maldonado-Perez et al., 2009).  In chapter 4, CXCL8 activation of the CXCR2 
receptor was shown to regulate CXCL8 expression and endothelial cell network 
formation and proliferation suggesting that CXCL8 is regulated by a positive 
feedback loop.  Therefore, the possibility was investigated that the inhibitory effect 
of RCAN1-4 on endothelial cell network formation and proliferation was due to a 
decrease in NFAT-dependent endothelial CXCL8 expression.  Subsequent in vitro 
investigations found that in HUVECs, RCAN1-4 overexpression with adenovirus 
inhibited P CM-induced CXCL8 expression.  Similarly, HUVEC CXCL8 expression 
induced by recombinant CXCL8 treatment was also inhibited by RCAN1-4 
overexpression.  In agreement, a previous report by Minami et al. showed that 
CXCL8 expression is downregulated in HUVECs overexpressing RCAN1-4 
(Minami et al., 2004).  This indicates that the CXCL8 autocrine loop enhancing 
endothelial cell network formation and proliferation is regulated by RCAN1-4.  
However, addition of recombinant CXCL8 to RCAN1-4 overexpressing cells did not 
counteract the effects of RCAN1-4 overexpression as it did not rescue P CM-induced 
endothelial cell network formation and proliferation.  This indicates that either 
RCAN1-4’s inhibitory effect on endothelial cell function is not regulated solely by 
CXCL8, or the concentration of CXCL8 was not sufficient to overcome the action of 
RCAN1-4 overexpression in HUVECs.  Previous studies have shown that RCAN1 
can regulate the expression of eNOS in HUVECs (Riper et al., 2008). Additionally, 
Hesser et al. showed that RCAN1-4 overexpression in HUVECs decreases 
inflammatory modulators such as COX-2, TF, E-selectin and VCAM-1 (Hesser et al., 
2004).   
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Interestingly, as well as down-regulating angiogenic molecules, RCAN1-4 can up-
regulate antiangiogenic molecules (Minami et al., 2004).  In RCAN1-4 
overexpressing cells treated with P CM, ADAMTS1 expression was significantly 
upregulated compared to control cells treated with P CM.   This is in agreement with 
data from Minami et al. who showed that ADAMTS1 expression is increased in 
RCAN1-4 overexpressing HUVECs treated with VEGF-A or thrombin (Minami et 
al., 2004). These data suggest that ADAMTS1 expression is either negatively 
regulated by calcineurin-NFAT signalling or RCAN1-4 promotes ADAMTS1 
expression via an alternative pathway. 
 
Furthermore, it could be proposed that the induction of ADAMTS1 by RCAN1-4 
together with its inhibition of CXCL8 expression maintains the balance of 
endothelial cell function by preventing excessive endothelial network formation and 
proliferation in the presence of proangiogenic growth factors (see Fig. 77).   
 
Fig. 77. Possible mechanism regulating endothelial cell network formation and 
proliferation in RCAN1-4 overexpressing cells.  RCAN1-4 overexpression inhibits 
endothelial cell CXCL8 expression and increases endothelial ADAMTS1 expression resulting 
in a decrease in endothelial cell network formation and proliferation. 
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Since the overexpression of RCAN1-4 decreased endothelial cell network formation 
and proliferation, it was expected that decreasing the levels of RCAN1-4 expression, 
by lentiviral introduction of short hairpin RCAN1-4 to decrease endogenous 
RCAN1-4 in endothelial cells, would increase P CM-induced endothelial cell 
network formation and proliferation.  Decreasing RCAN1-4 expression did increase 
P CM-induced endothelial cell network formation.  However, contrary to 
expectations, P CM-induced endothelial cell proliferation was decreased with 
decreased RCAN1-4 expression. One explanation for this is that the calcineurin-
NFAT pathway inhibited by RCAN1-4 is involved in cellular proliferation and the 
regulation of apoptosis.  Hyperactivation of calcineurin can activate transcription 
dependent and transcription independent apoptotic pathways (Ryeom et al., 2008).  
For example, a transcription dependent mechanism regulated by calcineurin involves 
the activation of NFAT.  NFAT family members are activated when 
dephosphorylated by calcineurin (Rao et al., 1997).  This allows NFAT to translocate 
to the nucleus where it regulates gene transcription (Rao et al., 1997).  An excess of 
calcineurin results in an excess of dephosphorylated NFAT which translocates to the 
nucleus and activates the apoptotic pathways via Fas-ligand genes (Latinis et al., 
1997).  The transcription independent pathway regulated by calcineurin involves the 
dephosphorylation of pro-apoptotic protein BAD.  Both these calcineurin pathways 
can be regulated by the inhibition of calcineurin either by RCAN1 or a small 
chemical inhibitor, cyclosporin A.  Therefore, the addition of cyclosporin A (CsA) to 
endothelial cells undergoing proliferation in normal circumstances will result in a 
decrease in proliferation but in an environment where calcineurin is hyperactivated, 
when used at the correct concentration, could result in an increase in proliferation 
(Ryeom et al., 2008).  Hyperactivation of calcineurin can cause excessive NFAT 
nuclear transcription and activation of apoptotic genes.  Alternatively, hyperactivated 
calcineurin can cause transcription independent apoptosis via dephosphorylation of 
apoptotic protein BAD.  A recent study by Ryeom et al. investigated the effects of 
RCAN1-4 deficiency in tumorigenesis and found that in vivo tumour growth and 
angiogenesis was suppressed in RCAN null mice (Ryeom et al., 2008). Their premise 
was that endothelial cell proliferation was inhibited by the loss of RCAN1-4 due to 
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hyperactivation of calcineurin leading to apoptotic pathways (Ryeom et al., 2008).  
Ryeom et al. showed that VEGF-A stimulated proliferation in RCAN1-4 null 
endothelial cells could be restored by the addition of 10nM low dose of calcineurin 
inhibitor cyclosporin A (CsA) (Ryeom et al., 2008).    
 
Although decreasing RCAN1-4 expression inhibited endothelial cell proliferation, it 
had the opposite effect and increased endothelial cell network formation.  This 
suggests that as seen in chapter 4, network formation and proliferation are regulated 
by separate pathways induced by growth factors.  Thus, the expression of angiogenic 
factors was investigated by QPCR.  COX-2 expression was upregulated in RCAN1-4 
deficient endothelial cells. In support of this, RCAN1-null mouse endothelial cells 
exhibited an increase in COX-2 protein levels after VEGF-A treatment (Ryeom et 
al., 2008).  Additionally, data by Yao et al. showed in HUVECs overexpressing 
RCAN1-4, treated with VEGF-A, that NFATc1 activation increases COX-2 
expression (Yao and Duh, 2004).  This suggests that COX-2 expression can be 
regulated by calcineurin-NFAT and RCAN1-4 levels could affect COX-2 expression. 
In line with this, data by Loster et al. show that NFAT is responsible for COX-2 
upregulation and secretion of prostaglandins by HUVECs (Lötzer et al., 2007).  The 
network formation in chapter 5 was found to involve PGF2α signalling and the 
production of PGF2α was dependent on COX-2.  This indicates that in RCAN1-4 
deficient cells, if there is an increase in COX-2 expression, the production of PGF2α 
could also be upregulated and may be responsible for the increase in network 
formation seen in HUVECs infected with lentivirus shRNA to decrease RCAN1-4 
expression.   
 
Interestingly, CXCL8 expression was not upregulated in RCAN1-4 deficient cells 
despite the evident increase in COX-2 expression and the presumed increase in 
NFAT activity.  The reasons for this contradiction are unclear but it indicates that 
endothelial CXCL8 expression is not essential for autocrine signalling to enhance 
network formation as the lack of CXCL8 upregulation does not inhibit network 
formation.  Addition of the calcineurin inhibitor CsA to the RCAN1-4 deficient cells 
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further decreased CXCL8 expression indicating that calcineurin-NFAT signalling is 
still needed for low levels of CXCL8 expression.   
 
The expression of ADAMTS1 is further upregulated in RCAN1-4 deficient cells and 
this increase in ADAMTS1 expression was not prevented by calcineurin inhibition 
with CsA, in fact a trend towards an increase in ADAMTS1 expression was 
observed.  This indicates that RCAN1-4 may play an additional role in the regulation 
of ADAMTS1 independently of calcineurin inhibition rather than suggesting that 
calcineurin may negatively regulate ADAMTS1 expression.  This increase in 
ADAMTS1 did not prevent the increase in network formation seen in HUVECs, 
infected with lentiviral shRNA to deplete endogenous RCAN1-4, indicating that 
although a lack of ADAMTS1 enhances network formation, the inhibitory effect of 
an increase in ADAMTS1 on network formation must be counteracted by growth 
factors in the P CM.  This is possible because data in chapter 4 showed that in 
untransfected HUVECs, P CM treatment increased network formation even though 
endothelial ADAMTS1 expression was upregulated.   
 
It is evident that the mechanisms regulating endothelial cell network formation differ 
from those regulating endothelial cell proliferation.  As seen in chapter 5, P CM-
induced endothelial cell network formation was regulated by prostaglandin F2α 
secretion whereas proliferation was not.  In this chapter, decreasing endothelial 
RCAN1-4 expression inhibited CXCL8 expression but increased endothelial cell 
network formation (Fig. 78).  Thus it is possible that the initial paracrine signalling 
of CXCL8 could be needed to stimulate ERK1/2 and increase COX-2 and 
prostaglandin production, as the CXCR2 inhibitor inhibited PG production, and this 
may be enough to support network formation even without additional endothelial 
CXCL8 expression.  Alternatively, the prostaglandin production, needed for network 
formation, requiring CXCR2 activation could be regulated by CXCL1 primarily and 
CXCL8 secondarily.  CXCL1 also signals through the CXCR2 receptor therefore 
PGs will still be produced and able to promote network formation even with a 
reduction in endothelial CXCL8 expression.  Data herein found that antiangiogenic 
Chapter 6     ADAMTS1 and RCAN1-4 in P CM treated HUVECs 214 
  
endothelial ADAMTS1 expression was increased, along with P CM-induced network 
formation, when endogenous levels of endothelial RCAN1-4 were decreased.  
Hence, the upregulation of ADAMTS1 and its negative effect on network formation 
may be counteracted by growth factor signalling such as FGF2 which enhances 
COX-2 network formation (see Fig. 78).  Furthermore, previous research suggests 
that network formation can be enhanced despite a decrease in proliferation as 
apoptosis has been shown to enhance endothelial network formation through the 
pruning of endothelial cells not essential for the structure of the networks (Segura et 
al., 2002).   Research by Segura et al. demonstrated that HUVEC network formation 
is inhibited by anti-apoptotic gene expression and inhibition of apoptotic proteins 
(Segura et al., 2002).  As RCAN1-4 deficient cells are undergoing apoptosis, this 
process of cell network pruning could be enhanced in RCAN1-4 deficient cells and 
facilitate network formation.  Whereas on the other hand, the decrease in CXCL8 and 
increase in ADAMTS1 expression along with activation of apoptosis by 
hyperactivated calcineurin signalling pathways could overthrow any positive effects 
that growth factor signalling has on proliferation, leading to cell death.  
 
 
Fig. 78. Possible mechanism for the disregulation of network formation and 
proliferation in RCAN1-4 deficient cells. In RCAN1-4 deficient cells an increase in NFAT 
results in increased COX-2 and ADAMTS1 but decrease in CXCL8.  The inhibition of 
proliferation is possibly due to calcineurin hyperactivation and induction of apoptosis.  An 
increase in COX-2 would lead to increased prostaglandin-stimulated network formation. 
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The data in this chapter discussed so far have revealed evidence to indicate that the 
expression of RCAN1-4 is crucial for the outcome of growth factor stimulated 
endothelial cell function.  Furthermore, it could be hypothesised that a certain level 
of RCAN1 is needed to facilitate calcineurin-NFAT induction of CXCL8 therefore, 
rather than being known as an antiangiogenic protein, RCAN1-4 may more 
accurately be called a regulator of angiogenesis.  Some of the most compelling 
research for this idea is that, in vivo, RCAN1 knockout mice exhibit a very similar 
phenotype to the calcineurin knockout mice (Sanna et al., 2006).  RCAN1 null mice 
exhibit hyperactivity in the brain similar to those seen in the calcineurin knockout 
mice suggesting that RCAN1 facilitates calcineurin signalling in vivo (Sanna et al., 
2006).  In vitro research suggests that calcineurin signalling may be enhanced by 
RCAN1 via phosphorylation (Hilioti et al., 2004).  Hilioti et al. demonstrate in yeast 
that the phosphorylation of RCAN1 by GSK3 converts it from an inhibitor to an 
enhancer of calcineurin (Hilioti et al., 2004).  In this way, RCAN1 may be regulated 
by multiple pathways, the outcome of which will decide if RCAN1 is an activator or 
deactivator of calcineurin dependent gene transcription. 
 
Alternatively, the bimodal role of RCAN1-4 in the regulation of endothelial cell 
angiogenic and antiangiogenic gene expression could be a result of the fact that 
calcineurin has a dual role as an activator and deactivator of transcription signals (Im 
and Rao, 2004).  The role of calcineurin in inactivation of gene transcription may 
explain the increase in ADAMTS1 seen with the increase in RCAN1.  For example, 
previous research has shown that protein phosphatases, such as PP2A and 
calcineurin, may dephosphorylate gene transcription silencers known as histone 
deacetylases (HDACs) thereby promoting their translocation to the nucleus (Martin 
et al., 2008).  Once in the nucleus HDAC binds histones in specific regions of the 
DNA and deacetylates them thus inhibiting gene transcription (Martin et al., 2007).  
HDAC6 has been found to prevent the expression of ADAMTS1 in human lung 
carcinoma cells (Chou and Chen, 2008).  HDAC inhibition can also increase the 
expression of RCAN2 in HUVECs (Wang et al., 2008).  Additional regulation may 
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take place involving 14-3-3, a protein binding partner which can bind phosphorylated 
HDACs and promote their nuclear export or prevent nuclear import, hence 
promoting gene transcription (Im and Rao, 2004; Martin et al., 2007).  Interestingly, 
RCAN1 can bind 14-3-3, which relieves its inhibitory effect on calcineurin however, 
the effect this has on HDAC regulation of gene transcription has yet to be explored 
(Abbasi et al., 2006).  This dual regulatory role of calcineurin and RCAN1 on the 
activation and deactivation of gene transcription is not unique to these proteins.  For 
example, the calcium/calmodulin-dependent protein kinases (CaMK) are responsible 
for 14-3-3 phosphorylation which promotes gene transcription (Martin et al., 2007) 
and recent research has shown that CaMKII can inhibit NFAT-induced transcription 
by inhibiting calcineurin through phosphorylation (Macdonnell et al., 2009).  
Evidently more research is needed to understand the precise mechanism of RCAN1 
gene transcription and the cross talk between RCAN1-4 and calcineurin signalling.   
 
In addition RCAN1 may act independently of calcineurin and NFAT to regulate 
endothelial cell functions by either transcription independent or dependent 
mechanisms.  For example, RCAN1 was found to interact directly with integrin 
αvβ3, inhibiting FAK phosphorylation thereby regulating cell spreading and 
migration (Iizuka et al., 2004).  Alternatively, in HUVECs RCAN 1-4 can bind Raf-
1, located upstream of ERK1/2 in angiogenic signalling pathways, however the 
physiological significance of this has yet to be elucidated (Cho et al., 2005). 
 
In summary, this chapter has investigated the role of antiangiogenic factors 
ADAMTS1 and RCAN1-4 in the regulation of P CM-induced endothelial cell 
network formation and proliferation.  ADAMTS1 overexpression inhibits P CM-
induced endothelial cell network formation and proliferation.  In addition, RCAN1-4 
overexpression inhibits P CM-induced endothelial cell network formation and 
proliferation, possibly via the inhibition of CXCL8 expression and the upregulation 
of ADAMTS1 expression.  In contrast, RCAN1-4 deficient cells display an increase 
in endothelial cell network formation in response to P CM treatment possibly due to 
increased COX-2 expression.  However, RCAN1-4 deficient cells exhibit a dramatic 
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decrease in endothelial cell proliferation possibly due to altered gene expression of 
CXCL8 and ADAMTS1 as well as calcineurin hyperactivation activating apoptotic 
pathways.  Data herein demonstrate that the level of endothelial antiangiogenic 
proteins such as ADAMTS1 and regulators such as RCAN1-4 are crucial for the 
outcome of P CM-induced endothelial cell function. 
Chapter 7  The effect of PGF2α on angiogenesis in vivo 218 
  
 
7 The in vivo analysis of prostaglandin F2α stimulated 
angiogenesis. 
7.1 Abstract  
Data in this chapter investigate the direct action of PGF2α on endothelial F-
Prostanoid (FP) receptors, and the indirect, paracrine action of angiogenic growth 
factors produced as a result of PGF2α-FP receptor signalling, in angiogenesis, using 
two in vivo models.  Directly, PGF2α did not increase angiogenesis in an in vivo 
sponge matrigel angiogenesis mouse model.  Indirectly, PGF2α-FP signalling 
increased angiogenic factor expression in human epithelial cells and in mouse stroma 
but this did not enhance microvessel density.  These data indicate that PGF2α-FP 
signalling may not directly regulate angiogenesis however, it may influence 
angiogenic gene expression and regulate alternative vascular functions in vivo. 
7.2 Introduction 
In vitro data presented in this thesis have demonstrated that prostaglandin F2α can 
regulate endothelial cell function through two mechanisms, a direct mechanism and 
an indirect mechanism.  Firstly, via a direct mechanism, the prostaglandin F2α acting 
through the FP receptor on endothelial cells was found to stimulate endothelial cell 
network formation but not proliferation.  Secondly, via an indirect mechanism 
prostaglandin F2α treatment of endometrial adenocarcinoma epithelial cells induces 
the secretion of proangiogenic growth factors FGF2, CXCL1 and CXCL8 which can 
promote endothelial cell network formation and proliferation via a paracrine action. 
The P CM-induced effects are, in part, regulated by endothelial cell expression of 
antiangiogenic ADAMTS1 and regulator RCAN1-4.  Additionally ADAMTS1 
secreted into the FPS conditioned medium via PGF2α-FP signalling could regulate 
cell function in a paracrine mechanism. 
 
Previous in vivo studies suggest that prostaglandin E2 can promote angiogenesis via 
direct and indirect mechanisms.  For example, using EP3 null mice, Amano et al. 
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found that stromal cell signalling of prostaglandin E2 to the EP3 receptor is crucial 
for tumour angiogenesis (Amano et al., 2003).  In addition, these researchers 
revealed that VEGF-A growth factor secretion stimulated by PGE2 treatment is 
crucial for angiogenesis in a rat sponge model (Majima et al., 2000).  Similarly, Jain 
et al. showed using a matrigel plug assay of angiogenesis that PGE2 treatment causes 
an increase in number of CD31 stained vessels (Jain et al., 2008).  However, the 
effect of prostaglandin F2α has not yet been thoroughly investigated.   
 
Experiments were performed using two in vivo models, the matrigel sponge mouse 
model and the tumour xenograft mouse model, to assess the direct and indirect effect 
respectively, of prostaglandin F2α on angiogenesis in vivo. 
 
7.2.1 The direct effect of PGF2α on angiogenesis in the matrigel sponge 
mouse model. 
The matrigel sponge mouse (or rat) model has been extensively used by researchers 
to assess the proangiogenic or antiangiogenic effect of soluble compounds or cells of 
interest in vivo (Akhtar et al., 2002; Auerbach et al., 2003; Kyriakides et al., 2001).  
Therefore, the matrigel sponge mouse model (sponge model) was used to examine 
the effect of PGF2α treatment on vascular formation in vivo.  The matrigel sponge 
mouse model involved the injection of PGF2α directly into subcutaneously implanted 
matrigel sponges.  This experiment was carried out in the laboratory of Dr. P 
Hadoke.  After 21 days of implantation and treatment in the mice, the sponges were 
removed and vascular density was assessed with the Chalkey vessel count on CD31 
stained sponge sections (Fig.79).  This assessment of angiogenesis has been used 
since the 1940’s as a reproducible method of measuring microvascular density 
(MVD) (Chalkey, 1943). 
 
Although there was a dramatic difference in redness of the sponges from the PGF2α 
treatment compared to the vehicle control treatments from the same mice, which was 
visible by eye on excision but not after paraffin embedding, no significant difference 
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in MVD was found between any of the treatments after Chalkey counting (Fig.80).  
Participants from Group 1 untreated sponges and vehicle treated sponges had very 
similar MVD counts (Fig.80) suggesting that vehicle treatment had no effect on 
angiogenesis.  Two participants out of the five mice in Group 2, 100nM PGF2α and 
vehicle treated sponges, showed a significant increase in MVD in the PGF2α treated 
sponges however, as there was no difference in the other three participants there was 
no significant difference between groups overall (Fig.80).  Immunohistochemical 
analysis of sponge sections for various growth factors including FGF2, CXCL1 and 
COX2 showed no observable differences in immunoreactivity from sections between 
the groups and treatments (data not included).  Similarly, QPCR analysis of 
angiogenic mRNA expression with RNA extracted from 20 sponge halves embedded 
in RNAlater showed no conclusive differences in mRNA expression between 
treatments (data not included). 
 
Fig.79.Immunohistochemistry of CD31 in mice matrigel sponge implants. Mice were 
implanted subcutaneously with matrigel sponges in the left and right flanks and were treated 
in two groups for 21 days.  Group 1 implants were untreated or treated with vehicle.  Group 2 
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implants were treated with vehicle or 100nM PGF2α.  Immunhistochemical analysis was 
performed, on sections from five sponges of each treatment, with an antibody for endothelial 
cell marker CD31.  Black bar represents 50μm. 
 
 
Fig.80. Chalkey vessel counts in mouse matrigel sponge implants. Mice were implanted 
subcutaneously with matrigel sponges in the left and right flanks and were treated in two 
groups for 21 days.  Chalkey count data Group 1 (even groups) implants were untreated 
(blue squares) or treated with vehicle (green triangles).  Group 2 (odd groups) implants were 
treated with vehicle (green triangles) or 100nM PGF2α (red circles).  A Chalkey graticule was 
used to count vessels in three hotspots from each sponge implant.  Five sponges from each 
treatment were analysed.  Results are displayed as mean ±SEM vessels per hotspot from 
each sponge.   
 
7.2.2 Mouse tumour xenograft model. 
A mouse tumour xenograft model was used to investigate the indirect role of FP 
signalling on the vasculature.  The tumour xenograft model involves injection of 
cells with tumourigenic potential, such as a cancer cell line, into mice with a 
compromised immune background to allow the formation of tumours in vivo 
(Curwen and Wedge, 2009).  Commonly, the tumourigenic cells are injected 
subcutaneously into the flanks of mice because this allows the tumour growth to be 
non-invasively monitored visually and with bilateral calliper measurement 
throughout the course of an experiment.  Immuno-compromised mice, such as nude 
mice lacking a thymus, are used so that the hosts do not reject the foreign cells 
(Rygaard and Povlsen, 1969).  The tumours formed can be extracted from the mice 
and used to examine proliferation and vessel formation.  A frequently used marker of 
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proliferation is Ki-67 protein which is present in cell nuclei during all proliferative 
stages of the cell cycle but absent in resting cells (Gerdes et al., 1984).  In vitro 
FGF2, CXCL1 and CXCL8 growth factors are secreted by the epithelial PGF2α -FP 
signalling, as demonstrated in chapter 4, and these growth factors act in a paracrine 
manner on endothelial cells to promote network formation and proliferation.   In this 
tumour xenograft model WT and FPS Ishikawa cells injected subcutaneously into 
nude mice formed tumours.  The comparison of WT tumour xenografts to FP tumour 
xenografts allows an examination of the effects of growth factors secreted from the 
epithelial cells on vascular formation.     
 
The WT and FP tumour xenograft experiment was carried out by researchers in the 
laboratory of Dr. Daniel Rosenberg (Univ. of Connecticut Medical Centre, USA).  
Initial analysis from forceps measurements (Fig. 81A) and KI67 staining (Fig. 81B) 
indicated that the growth rate of the FP tumours was slightly higher than that of the 
WT tumours (Fig. 81).  Ten WT and ten FP tumour xenografts were subsequently 
analysed by QPCR and immunohistochemistry.  As expected the expression of FP 
mRNA was dramatically elevated in FP tumours compared to WT tumours since the 
FP tumours originated from FPS cells stably transfected with FP receptor cDNA 
(Sales et al., 2005) (Fig. 82A, P<0.05).  There was a significant increase in COX-2 
mRNA expression (Fig. 82B, P<0.05) but no significant increase in COX-1 
expression (Fig. 82C) in FP tumours compared to WT tumours.  Analysis of 
angiogenic mRNA expression with primers and probes that recognised both human 
and mouse (total) mRNA showed that FGF2 (Fig. 82D), CXCL1 (Fig. 82E), CXCL8 
(Fig. 82F) and IL6 (Fig. 83D) mRNA expression was significantly upregulated in FP 
tumours compared to WT tumours (P<0.05).   
 
















































Fig. 81. WT and FP tumour xenografts growth after subcutaneous injection. A, The 
growth of WT and FP tumours in mice was monitored by measurement with a calibrated 
forcep throughout their development. B, Ki-67 immunohistochemical staining of WT and FP 
tumour xenografts. The Ki-67 staining of 3 WT and 4 FPS tumours was quantified using a 
computer imaging system (Image pro plus).   




Fig. 82. QPCR of WT and FP mRNA.  WT and FP tumour xenograft RNA was extracted 
and mRNA expression of FP (A), COX-2 (B), COX-1 (C), FGF2 (D), CXCL1 (E) and CXCL8 
(F) was analysed using specific primers and probes by RT-PCR (QPCR).  Data are 
expressed as fold increase in tumour xenograft mRNA expression over normal endometrial 
control tissue mRNA expression. Data are represented as mean ± SEM from ten tumours in 
each group. (* represents statistical significance from WT tumours; P<0.05). 
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 The role of other factors previously found to be involved in angiogenesis was also 
investigated by QPCR analysis of WT and FP tumours.  Surprisingly the potent 
angiogenic growth factor VEGF-A (Fig. 83A) was not increased in FP tumours 
compared to WT tumours.  Angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2) have 
been shown to be involved in angiogenesis in vitro and in vivo (Augustin et al., 
2009).  Interestingly mRNA expression of Ang1 (Fig. 83B) and Ang2 (Fig. 83E) 
were both significantly decreased in FP tumours compared to WT tumours (P<0.05).   
Matrix metalloprotease 9 (MMP9) is a protease that is involved in degradation of the 
extracellular matrix during angiogenesis (Egeblad and Werb, 2002; Roy et al., 2006).  
MMP9 levels were not significantly different between WT and FP tumours (Fig. 
83C).  Bcl-2 is a well known antiapoptotic factor involved in tumorigenesis (Cotter, 
2009) however, its expression was not found to be increased in FP tumours 
compared to WT tumours (Fig. 83F).  
 
In chapter 6, data shown indicate that antiangiogenic ADAMTS1 negatively 
regulates endothelial cell network formation and proliferation induced by P CM.  
Therefore, the expression of antiangiogenic ADAMTS1 was investigated and found 
to be significantly decreased in FP tumours compared to WT tumours (Fig. 84A, 
P<0.05).  RCAN1 was found to be a regulator of P CM-induced endothelial cell 
network formation and proliferation and so the expression of RCAN1 in WT and FP 
tumours was investigated (Fig. 84B).  RCAN1 expression was slightly elevated in FP 
tumours compared to WT tumours but this elevation was not significant (Fig. 84B).  
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Fig. 83. QPCR of angiogenic factor mRNA expression in WT and FP tumour 
xenografts. WT and FP tumour xenograft RNA was extracted and mRNA expression of 
VEGF-A (A), Ang1 (B), MMP9 (C), IL6 (D), Ang2 (E) and Bcl-2 (F) was analysed using 
specific primers and probes by RT-PCR (QPCR).  Data are expressed as fold increase in 
tumour xenograft mRNA expression over normal endometrial control tissue mRNA 
expression. Data are represented as mean ± SEM from ten tumours in each group. (* 
represents statistical significance from WT tumours; P<0.05). 
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Fig. 84. ADAMTS1 and RCAN1 mRNA expression in WT and FP tumour xenografts. WT 
and FP tumour xenograft RNA was extracted and mRNA expression of ADAMTS1 (A) and 
RCAN1 (B) was analysed using specific primers and probes by RT-PCR (QPCR).  Data are 
expressed as fold increase in tumour xenograft mRNA expression over normal endometrial 
control tissue mRNA expression. Data are represented as mean ± SEM from ten tumours in 
each group. (* represents statistical significance from WT tumours; P<0.05). 
 
Since the in vitro data in chapter 4 showed that CM from FPS cells treated with 
PGF2α enhanced endothelial COX-2, FGF2, CXCL1 and CXCL8 expression in vitro, 
primers and probes specific to mouse genes were designed for COX-2, COX-1, 
FGF2, CXCL1, IL6 and VEGF-A.  This allowed the expression of these factors in 
mouse stromal cells and vascular cells to be investigated in vivo.  Human CXCL8 
can bind to mouse CXCR2 (IL8RA) and mouse CXCR1 however, the mouse 
homologue of CXCL8 is uncertain for example, one known ligand of mouse CXCR2 
is MIP2 which is more closely related to human CXCL2 (Fan et al., 2007). Due to 
the uncertainty of mouse CXCL8 homologue, the stromal CXCL8 production was 
not investigated in this model.  A significant increase in mouse COX-2 (Fig. 85A), 
COX-1 (Fig. 85D), IL6 (Fig. 85C), CXCL1 (Fig. 85E) and VEGF (Fig. 85F) was 
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found in FP tumours compared to WT tumours.  The difference between FP and WT 
tumour expression of mouse FGF2 was not significant (Fig. 85B). 
 
Fig. 85. QPCR of mouse angiogenic mRNA expression in WT and FP xenografts. WT 
and FP tumour xenograft RNA was extracted and mRNA expression of  mouse COX-2 (A), 
FGF2 (B), IL6 (C), COX-1 (D), CXCL1(E) and VEGF (F) was analysed, using specific 
primers and probes, by RT-PCR (QPCR).  Control was RNA from normal mouse kidney.  
Data are represented as mean ± SEM from ten tumours in each group. (* represents 
statistical significance from WT tumours; P<0.05). 
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Sections from WT and FP tumours were stained with an antibody recognising the N-
terminus of the FP receptor. The large differences in FP mRNA between the WT and 
FP tumours indicate that there should be more FP protein in the FP tumours 
compared to WT tumours. However, immunohistochemical analysis of FP staining 
did not reveal a clear difference in staining between WT and FP tumours (Fig. 86).  
 
Fig. 86. Immunohistochemical staining of FP and WT tumour xenografts for FP 
receptor protein.  Sections from FP and WT tumour xenografts embedded in paraffin wax 
were stained for FP receptor protein with a specific FP antibody.  Representative 
photographs at x10 and x40 magnification from FP tumours and WT  tumours are displayed 
above. Sections of normal endometrium late secretory (LS) and endometrial cancer-poorly 
differentiated (poor) were used as positive controls.  Goat IgG was used as a negative 
control. Black bar represents 50µm. 
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Both total and mouse COX-2 mRNA expression was increased in FP tumours 
compared to WT tumours and there was an observable difference in COX-2 staining 
in FP tumours compared to the WT tumours (Fig. 87).   
 
 
Fig. 87.  COX-2 immunohistochemistry of WT and FP tumour xenografts. Sections from 
FP and WT tumour xenografts embedded in paraffin wax were stained for COX-2 protein 
with a specific COX-2 antibody.  Representative photographs at x10 and x40 magnification 
from FP tumours and WT tumours are displayed above, taken with Provis, Canon 10D. 
Sections of normal endometrium were used as a positive control.  Goat IgG on a endometrial 
cancer section was used as a negative control. Black bar represents 50µm. 
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No observable difference in VEGF-A immunoreactivity was seen between the WT 
and FP tumours (Fig. 88) similar to the VEGF mRNA expression pattern seen in Fig. 
83 in the WT and FP tumours.   
 
Fig. 88. Immunohistochemistry of VEGF-A staining in FP and WT xenografts.  Sections 
from FP and WT tumour xenografts embedded in paraffin wax were stained for VEGF-A 
protein with a specific VEGF-A antibody.  Representative photographs at x10 and x40 
magnification from FP tumours and WT tumours are displayed above, taken with Provis, 
Canon 10D. Sections of normal endometrium and endometrial cancer were used as positive 
controls.  Rabbit IgG was used as a negative control. Black bar represents 50µm. 
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In accordance with mRNA expression data in Fig. 83, which showed that total 
CXCL1 mRNA was increased in FP tumours compared to WT tumours, there 
appeared to be a difference between WT and FP tumour immunoreactivity for 





Fig. 89. Immunohistochemistry of CXCL1 in WT and FP tumour xenografts. Sections 
from FP and WT tumour xenografts embedded in paraffin wax were stained for CXCL1 
protein with a specific CXCL1 antibody.  Representative photographs at x10 and x40 
magnification from one FP tumour and one WT tumour are displayed above. Goat IgG was 
used as a negative control. Black bar represents 50µm. 
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7.2.3  The role of CXCL8 in tumour xenograft vascular formation. 
In vitro data in chapter 4 suggest that CXCL8 is involved in regulating P CM-
induced endothelial cell function.  In accordance, CXCL8 has been shown to be 
involved in vascular formation in vivo (Caunt et al., 2006; Li et al., 2003).  Previous 
data in this chapter shows that human CXCL8 was upregulated in vivo in FP tumour 
xenografts compared to WT tumour xenografts (Fig. 82) confirming in vitro data.  
Therefore, to investigate the role of CXCL8 in blood vessel formation in FP tumours 
compared to WT tumours, CXCL8 was immunoneutralised from the FP tumour 
xenografts using a specific CXCL8 antibody.  
 
These tumour xenograft experiments were performed by Dr Catalano and Dr Wilson 
in our laboratory.  As observed previously, there was an increase in CXCL8 
expression in FP tumours compared to WT tumours.  A stereologer was used to 
assess CD31 stained sections of the tumours and count number of vessels per mm2 in 
the outer region of the tumour including the fibroblast layer.  The numbers of small, 
medium and large vessels were quantified as well as the fibroblast area.  No 
significant difference in the number of small (Fig. 90A), medium (Fig. 90B) or large 
(Fig. 90C) vessels was found between the WT and FP tumour although there was a 
trend towards a decrease in large vessel size in FP tumours compared to WT tumours 
(Fig. 90C).   There was no difference in total number of vessels per mm2 in WT and 
FP tumours, when results from small, medium and large vessel counts were 
combined (Fig. 90D).  The fibroblast layer around the tumours appeared larger in the 
FP tumours compared to the WT tumours however; this difference was not 
significant (Fig. 90E).   
 
Immunoneutralisation of CXCL8 with its antibody from the FP tumours (CXCL8Ab) 
did not reduce CXCL8 expression compared to FP tumours with IgG control (FP 
IgG), nor did it affect the expression of any other proteins assessed.  An initial count 
of microvascular density in three tumours from each treatment group indicated that 
perhaps addition of the CXCL8Ab was affecting MVD.  Therefore, MVD was 
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assessed in all ten tumours from WT IgG, FP IgG and CXCL8Ab treatment groups 
(Fig. 90). However, no significant difference in small (Fig. 90A), medium (Fig. 90B) 
or large (Fig. 90C) vessels was found between the CXCL8Ab tumours and FP IgG 
tumours.  There was no difference between CXCL8Ab tumours and FP IgG tumours 
in total number of vessels per mm2 (Fig. 90D).  The fibroblast layer area was not 
different in CXCL8Ab tumours compared to FP IgG tumours (Fig. 90E).   
 
Fig. 90. Microvascular density analysis of WT, FP and CXCL8Ab tumour xenografts. 
The number of small (A), medium (B) and large (C) vessels was counted from the periphery 
of  CD31 stained sections of  WT, FP and CXCL8 Ab tumours using a stereologer 
microscope and camera (Nikon) at x20 magnification.  Total number of vessels (D) was 
calculated as well as fibroblast area (E). Results are expressed as mean number of vessels 
per mm2 ±SEM from ten tumours in each group.  (* represents statistical significance) 
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7.3 Discussion 
To investigate the direct and indirect role of prostaglandin F2α on angiogenesis in 
vivo, two mouse models were used.  The matrigel sponge mouse model is frequently 
used as an in vivo model of angiogenesis (Akhtar et al., 2002).  Studies by the 
laboratory of Majima have shown using the matrigel sponge model in rats, that 
topical injections of PGE2 can enhance angiogenesis (Majima et al., 2000). In this 
chapter, the matrigel sponge mouse model involved the injection of PGF2α directly 
into subcutaneously implanted matrigel sponges.  After 21 days of implantation and 
treatment in the mice, the sponges were removed and vascular density was assessed 
with the Chalkey vessel count on CD31 stained sponge sections. The Chalkey count 
method has been found to be as effective at assessing microvascular density as 
computational methods (Fox et al., 1995). No significant difference in vessel count 
was found between treatments however, this method does not take into account any 
differences in size of the vessels in the sponges. For example, some growth factors 
such as Angiopoietin 2, affect vessel lumen diameter rather than vessel density 
(Nasarre et al., 2009).  The absence of a difference in vessel number may also 
indicate that although PGF2α enhances endothelial cell network formation, this is not 
sufficient for vessel formation in vivo because it does not promote endothelial cell 
proliferation.  A recent study by Herbert et al. demonstrated that inhibition of 
cytosolic PLA2α, an enzyme involved in arachidonic release, prevented HUVEC 
proliferation but not network formation (Herbert et al., 2009).  Herbert et al. 
subsequently showed that this cPLA2 inhibition of proliferation was sufficient to 
block angiogenic tubule formation, and concluded that endothelial proliferation is 
essential for angiogenesis (Herbert et al., 2009). PGF2α has been shown to have a 
chemotactic role in enhancing the migration of neutrophils and epithelial cells but 
size of the granuloma of the sponges appeared to be similar between treatments 
(Arnould et al., 2001) (Sales et al., 2008a) signifying that there was no increase in 
infiltrating cell number.   
 
The data presented in this thesis indicates that it is a combination of growth factors 
and prostaglandins acting in concert that enhance vascular function therefore a 
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second in vivo model, the mouse tumour xenograft model was investigated.  In this 
model WT and FPS Ishikawa cells were injected subcutaneously into nude mice to 
allow the formation of tumours. Tumours were excised and analysed by 
immunohistochemistry and quantitative-RT-PCR.  The comparison of WT to FP 
tumour xenografts allowed the examination of the effects of growth factors secreted 
from the epithelial cells on vascular formation.  This could be likened to comparing 
the effects of WT V CM and FP V CM on endothelial cell function as seen in chapter 
4.  Although no significant difference in endothelial cell network formation or 
proliferation was seen between these treatments in vitro, the in vivo situation is very 
different in terms of time span and cell-cell interaction.  As expected, the levels of FP 
mRNA expression were significantly upregulated in the FP tumours compared to the 
WT tumours.  The expression of angiogenic growth factors, was also elevated in the 
FP tumours for example, FGF2, CXCL1, CXCL8 and IL6 were all increased along 
with COX-2 mRNA. This is in agreement with data from the angiogenic array and 
ELISA experiments in chapter 4 showing FGF2, CXCL1, CXCL8 and IL6 were 
secreted in increased quantities into PGF2α treated FPS Ishikawa cell conditioned 
medium.  Therefore, one could infer that the addition of PGF2α to FPS Ishikawa cells 
in vitro merely enhances the processes that are seen with the autocrine signalling in 
vivo.  A difference in FP receptor protein level was not apparent from  the 
immunohistochemical analysis however; COX-2 and CXCL1 immunoreactive 
staining appeared to be increased in the FP tumours compared to the WT tumours.   
 
The discrepancy between the in vivo and in vitro data occurred when VEGF-A 
expression was analysed because it was not upregulated, as would be expected from 
the in vitro data (Sales et al., 2005), in FP tumours compared to WT tumours.  
Similarly, there appeared to be no obvious difference between the WT and FP 
tumours in the immunohistochemical analysis of VEGF-A protein.  VEGF-A is a key 
angiogenic factor whose expression and secretion is upregulated in a variety of 
cancers and subsequently associated with poorer prognosis of disease through the 
promotion of tumour progression via angiogenesis and metastasis (Danielsen and 
Rofstad, 1998; Hainaud et al., 2006; Rofstad and Halsor, 2000; Sales et al., 2005; 
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Takei et al., 2004; Wei et al., 2003).  The in vitro data in this thesis indicated that the 
balance of growth factors secreted into the P CM was critical as 
immunoneutralisation of any individual factor from the CM prevented endothelial 
cell function.  In addition, in a previous in vivo tumour xenograft analysis, the 
immunoneutralisation of VEGF could not be compensated for by the other factors 
and resulted in a decrease in tumour angiogenesis and metastasis (Rofstad and 
Halsor, 2000).  In endometrial adenocarcinomas, VEGF-A is elevated and has been 
shown to be regulated by PGF2α-FP signalling (Sales et al., 2005).  Therefore, the 
lack of VEGF-A upregulation in the FP tumours could be critical to the use of this 
experiment as a model for endometrial adenocarcinoma angiogenesis in vivo.  
 
Mouse mRNA expression was examined with specific primers and probes for mouse 
genes.  The mouse mRNA expression was detected in the mouse stroma containing 
endothelial cells, immune cells and fibroblasts, that have infiltrated the tumour 
xenografts.  Mouse COX-1, COX-2, CXCL1, IL6 and VEGF expression was 
upregulated in FP tumours compared to WT tumours but there was no change in 
mouse FGF2 mRNA expression.  The upregulation of stromal angiogenic factors in 
FP tumours supports the in vitro data in chapter 4 showing that paracrine signalling 
from factors secreted by PGF2α-FP signalling in epithelial cells can enhance the 
expression of growth factor in endothelial cells. Further more, the upregulation of 
mouse COX-2 indicates that in vivo as seen in vitro, the production of stromal 
angiogenic factors could involve stromal COX-2 and prostaglandin autocrine 
signalling. These stromal and epithelial angiogenic factors upregulated in the FP 
tumours could be enhancing tumour angiogenesis however, the absence of mouse 
FGF2 upregulation indicates that there is a discrepancy between in vivo and in vitro 
signalling.  This could be explained by the fact that mRNA expression was examined 
after six weeks of tumour growth in vivo therefore, the time frame of analysis differs 
greatly from in vitro experiments. 
 
In light of these in vivo data, the specific role of CXCL8 was chosen to be examined 
in the tumour xenograft model in order to observe the effects on tumour 
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angiogenesis.  CXCL8 and the receptor CXCR2 have all been implicated in tumour 
angiogenesis using in vivo models (Payne and Cornelius, 2002; Pold et al., 2004; 
Strieter et al., 2006; Zhou et al., 2005).  For example, tumour xenografts from two 
different prostate cell lines were found to increase angiogenesis in a CXCL8 
dependent manner (Moore et al., 1999).  Also, a previous report found using a 
tumour xenograft model of non-small cell lung cancer (NSCLC) that COX-2 
overexpressing tumours relied upon the upregulation of CXCL8 to enhance tumour 
angiogenesis and growth (Pold et al., 2004).  In vitro supporting data indicated that 
this was a PGE2 and CXCR2 dependent regulation (Pold et al., 2004).  In mouse-
CXCR2 receptor knockout mice, the growth of human melanoma xenografts is 
reduced indicating that host CXCR2 and its ligands, including CXCL8, are essential 
for tumour growth and angiogenesis (Singh et al., 2009).  
 
To examine the role of CXCL8 in the tumour xenograft model, CXCL8 was 
immunoneutralised from the FP tumours with a specific CXCL8 antibody.  Although 
CXCL8 is not expressed in murine cells, mouse CXCR2 and CXCR1 receptors are 
expressed, through which human CXCL8 can act (Fan et al., 2007 516).  CXCL8 
mRNA expression was increased in FP tumours compared to WT tumours.  
Immunoneutralisation of CXCL8 has been shown in various mouse models of 
tumourigenesis to decrease vessel density (Inoue et al., 2000; Kim et al., 2001).  
Examination of mRNA expression as with the previous WT and FP tumours showed 
that addition of the CXCL8 antibody had no effect on mRNA expression of any of 
the angiogenic genes of interest (data not shown).  In addition, tumour growth rates 
examined throughout the experiment were not affected by CXCL8 
immunoneutralisation.  
 
No difference in microvessel density, assessed from CD31 stained vessels, was found 
between WT, FP or CXCL8 immunoneutralised tumours suggesting that vascular 
function is not affected by PGF2α-FP signalling to CXCL8 in this model.  One theory 
for this, being explored by Dr. Catalano and Dr.Wilson, is that the WT cells 
implanted in vivo upregulate their basal FP receptor levels so that the levels of FP 
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receptor in WT cells are similar to FPS cells prior to xenografting (Catalano et al. 
unpublished data).  This would suggest that sufficient growth factors are being 
produced to regulate angiogenesis in WT tumours, and elevating the expression 
further in FP tumours does not benefit tumourigenesis.  In support of this theory, 
microRNA against the FP receptor, added to FP tumours to decrease FP receptor 
levels results in a decreased number of small vessels (A.Wallace, PhD thesis 2009).  
This indicates that the FP receptor may play a role in regulating vessel size during 
angiogenesis in vivo.  Two angiogenic factors that have previously been found to 
play a role regulating tumour vessel size are angiopoietin 1 (Ang 1) and angiopoietin 
2 (Ang2) (Augustin et al., 2009).  A recent in vivo experiment by Nassare et al. 
demonstrated that stromal expression of angiopoietin 2 regulates vessel size and 
tumour growth (Nasarre et al., 2009).  In the first WT and FP xenograft in this 
chapter, the levels of Ang 1 and Ang 2 were found to be downregulated in FP 
tumours compared to WT tumours however, the levels of stromal angiopoietins were 
not investigated due to the availability of mouse specific primers and probes.  
Perhaps investigating the levels of stromal Ang1 and Ang2 could shed some light on 
vascular morphogenesis within the FP tumours however, angiopoietin expression is 
inherently linked to time span and examining the expression of angiogeneic proteins 
at one time point may provide mRNA information which could be open to 
misinterpretation.  
 
Although CXCL8 immunoneutralisation had no effect on tumour microvascular 
density, it is possible that the immunoneutralisation of CXCL8 had an effect in the 
tumour xenografts that affected a different physiological process other than 
microvascular density investigated in this study.  For example, a recent study by 
Wallace et al., showed that CXCL1 Ab immunoneutralisation from FP endometrial 
adenocarcinoma tumour xenografts, significantly reduced neutrophil infiltration into 
the FP CXCL1Ab tumours compared to FP tumours treated with Goat IgG control 
(Wallace et al., 2009).  This indicates that PGF2α-FP signalling can stimulate the 
migration of immune cells towards a tumour. Also, prostaglandin F2α is known to be 
secreted by HUVECs (Watanabe et al., 1997) and other endothelial cells (Arnould et 
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al., 2001; Shirasuna et al., 2008) and this endothelial PGF2α has been shown to 
induce the migration of neutrophils towards endothelial cells (Arnould et al., 2001). 
Therefore, it is possible that stromal PGF2α stimulated by paracrine PGF2α-FP 
signalling in epithelial cells, may directly enhance stromal cell infiltration.  Recently, 
Sales et al. found that CXCL8 immunoneutralisation from the FP tumours 
significantly reduced tumour epithelial cell proliferation but increased stromal cell 
infiltration compared to FP IgG tumours (Sales, 2009).   
 
In addition, there appeared to be a slight difference, although not significant, in 
fibroblast layer size around the tumours.  This could be due to the way in which the 
tumours were excised or it could be that PGF2α-FP signalling is attracting the 
infiltration of fibroblasts.  Another possible chemoattractive factor is ADAMTS1 
which was recently shown to stimulate the influx of fibroblasts into xenograft 
tumours (Rocks et al., 2008). Although ADAMTS1 is not upregulated in FP tumours 
compared to WT tumours, in vitro studies show it is upregulated in endothelial cells 
by PGF2α-FP signalling (chapter 6) suggesting that as seen by Rocks et al., stromal 
ADAMTS1 could promote the influx of fibroblasts (Rocks et al., 2008). 
 
In vitro and in vivo evidence suggests that CXCL1 and CXCL8 influence the 
invasiveness of certain tumours.  For example, increased CXCL1 expression was 
associated with increased invasiveness of glioma tumours (Zhou et al., 2005).  Bcl-2 
was elevated although not significantly in FP tumours compared to WT tumours and 
research by Warner et al. demonstrated that endothelial CXCL1 and CXCL8 
expression induced by Bcl-2 upregulation, enhanced head and neck tumour cell 
invasion through a matrigel layer in vitro, which corresponded to a increase in Bcl-2 
expression and correlated with head and neck tumour invasion in vivo (Warner et al., 
2008).  This suggests that the invasiveness of FP tumour xenografts is a further 
avenue for research. 
 
In summary, these in vivo tumour xenograft data support the role of PGF2α-FP 
paracrine upregulation of angiogenic factors in endothelial cells.  However, in vivo 
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matrigel sponge mouse data together with the previous in vitro data would suggest 
that the role of PGF2α-FP signalling in inducing angiogenesis may be limited by its 
inability to induce endothelial cell proliferation. Therefore, it could be the 
combination of epithelial growth factors signalling together with PGF2α-FP receptor 
signalling that is needed to an elicit angiogenic response.  Hence prostaglandin F2α 
may not initiate but may potentiate tumour angiogenesis.  This research provides 
evidence to suggest that targeting of the FP receptor in addition to the targeting of 
growth factor receptors, such as FGFR1, could provide a possible therapeutic avenue 
in diseases, such as endometrial cancer, where the FP receptor is aberrantly 
expressed.  In accordance with this, recent in vitro and in vivo research suggest that 
endothelial FP receptor may be involved in vascular function through the regulation 
of vasoconstriction and vascular hypertension (Errasti et al., 2009; Yu et al., 2009).  
However, further research is required to optimise the xenograft mouse model of 
endometrial adenocarcinoma angiogenesis. 
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8 Summary, conclusions and future perspectives 
8.1 The regulation of angiogenic and antiangiogenic proteins by 
PGF2α-FP signalling in epithelial cells. 
In endometrial cancer the FP receptor along with angiogenic factors VEGF-A, FGF2, 
CXCL1 and CXCL8, have been found to be upregulated compared to normal 
endometrium.  A previous microarray analysis of endometrial adenocarcinoma cells, 
stably expressing the FP receptor to the levels observed in cancer (Ishikawa FPS 
cells), treated with prostaglandin F2α (PGF2α) identified these proteins VEGF-A, 
FGF-2, CXCL1 and CXCL8 as targets of PGF2α-FP signalling.  Further in vitro 
research, using Ishikawa FPS cells, has found that PGF2α signalling via the FP 
receptor upregulates the secretion of VEGF-A, FGF2, CXCL1 and CXCL8, in an 
ERK1/2 dependent manner.  Therefore, these angiogenic proteins potentially act on 
endothelial cells in a paracrine manner to regulate endothelial cell function. 
 
In addition to the regulation of proangiogenic proteins, the antiangiogenic protein a 
disintegrin and metalloproteinase with thrombospondin repeat 1 (ADAMTS1) was 
also identified as a target for PGF2α-FP signalling in the microarray analysis.  In this 
thesis ADAMTS1 expression was found to be upregulated in endometrial 
adenocarcinoma samples compared to normal endometrium and localised to 
glandular epithelial cells and endothelial cells.  Using Ishikawa FPS cells, as a model 
system, the upregulation of ADAMTS1 by PGF2α-FP signalling was found to be 
regulated in an ERK1/2 independent manner involving activation of calmodulin and 
nuclear factor of activated T cells (NFAT).  Therefore, the expression and secretion 
of antiangiogenic ADAMTS1 into PGF2α-treated Ishikawa cell conditioned medium 
(P CM) could potentially regulate endothelial cell function in a paracrine manner.  In 
the context of endometrial adenocarcinoma, ADAMTS1 could regulate vascular 
remodelling and angiogenesis.  This is because ADAMTS1 can inhibit proangiogenic 
endothelial cell proliferation and network formation as well as promote ECM 
degradation and endothelial cell sprouting.  Additionally, ADAMTS1 could act in a 
paracrine manner on epithelial cells and fibroblasts to regulate cell migration and 
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invasion via mechanisms mediating the degradation of extracellular matrix (see 
section 8.7.5).   
 
These findings, as summarised in Fig.91, indicate that PGF2α regulates the expression 
of both pro- and antiangiogenic factors via the FP receptor in endometrial 
adenocarcinoma.  In turn, these factors can act in a paracrine manner on endothelial 
cells to regulate vascular function. An imbalance between pro-and antiangiogenic 
factors could enhance angiogenesis in endometrial cancers. 
 
Fig.91. A schematic diagram summarising angiogenic (+) and antiangiogenic (-) factor 
secretion induced by F-Prostanoid signalling in epithelial cells. 
 
8.2 The paracrine action of FGF2, CXCL1 and CXCL8 on endothelial 
cell function. 
Using an endothelial cell model system of HUVECs incubated with conditioned 
medium from PGF2α-treated Ishikawa FPS cells (P CM), the proangiogenic proteins 
FGF2, CXCL1 and CXCL8 in the P CM were found to act in a paracrine manner via 
their respective endothelial receptors, FGFR1 and CXCR2, to promote endothelial 
cell network formation and proliferation.  Activation of FGFR1, via FGF2, and 
CXCR2, via CXCL1/8, resulted in the upregulation of endothelial FGF2, CXCL1 
and CXCL8 creating an autocrine positive-feedback loop.  In addition, activation of 
FGFR1 and CXCR2 regulated COX-2 and FP receptor expression in endothelial cells 
and promoted the release the PGF2α, as shown schematically in Fig. 92.   
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Fig. 92. A schematic representation of mechanism by which P CM regulates 
endothelial cell network formation, proliferation and PGF2α secretion. 
 
8.3 The role of the FP receptor in P CM-induced endothelial cell 
network formation and proliferation. 
The effects of prostaglandin F2α secretion by endothelial cells , induced by FGF-2 in 
the P CM, on endothelial cell network formation and proliferation were investigated.  
PGF2α, secreted from endothelial cells after P CM treatment, increased endothelial 
cell network formation via the endothelial FP receptor but did not regulate 
endothelial cell proliferation. Further investigations into the intracellular signal 
transduction pathway mediated by FGF2, revealed that P CM-induced endothelial 
cell proliferation was regulated in an FGFR1, c-Src, ERK1/2 and mTOR dependent 
manner.  A schematic diagram displaying the divergent signalling pathways 
controlling P CM-induced endothelial cell network formation and proliferation is 
shown in Fig. 93. 
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Fig. 93. A schematic representation of P CM-induced endothelial cell network 
formation and proliferation stimulate via FGF2-FGFR1. 
 
8.4 The role of ADAMTS1 and RCAN1-4 in the regulation of P CM-
induced endothelial cell network formation and proliferation. 
 Antiangiogenic proteins, a disintegrin and metalloproteinase with a thrombospondin 
repeat 1 (ADAMTS1) and regulator of calcineurin 1-4 (RCAN1-4) were found to be 
upregulated in endothelial cells after P CM treatment.  ADAMTS1 silencing 
enhanced P CM-induced endothelial cell network formation and proliferation, 
whereas the overexpression of RCAN1-4 inhibited P CM-induced endothelial cell 
network formation and proliferation.  Overexpression of RCAN1-4 decreased 
CXCL8 expression and increased ADAMTS1 expression. As summarised in Fig. 94, 
this suggests that RCAN1-4 may mediate P CM-induced endothelial cell network 
formation and proliferation by regulating endogenous expression of proangiogenic 
CXCL8 and antiangiogenic ADAMTS1 in endothelial cells.  In contrast decreasing 
RCAN1-4 expression enhanced endothelial cell network formation but inhibited 
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endothelial cell proliferation, indicating that a certain level of RCAN1-4 expression 
is needed for endothelial cell proliferation.  These data suggest ADAMTS1 and 
RCAN1-4 could function as regulators of vascular function by preventing excessive 
endothelial cell differentiation (network formation) and proliferation in conditions 
where growth factors are abundant. 
 
Fig. 94. A schematic represenatation of the regulation of P-CM induced endothelial 
cell network formation and proliferation by CXCL8, RCAN1 and ADAMTS1. 
 
8.5 In vivo investigations of PGF2α-FP signalling in angiogenesis. 
The role of prostaglandin F2α in angiogenesis was investigated using two in vivo 
models.  PGF2α did not increase angiogenesis directly in an in vivo sponge matrigel 
mouse model.  In a xenograft mouse model the indirect, paracrine signalling of 
PGF2α-FP increased angiogenic factor expression in human epithelial cells and in 
mouse stroma but this did not enhance microvessel density.  These data highlight the 
possibility that PGF2α may not regulate angiogenesis directly in vivo; however, it is 
possible the PGF2α -FP signalling regulates alternative vascular functions such as 
vasoconstriction which could determine vessel diameter.  
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8.6  The relevance of PGF2α-FP signalling in angiogenesis and 
vascular function of endometrial adenocarcinoma. 
In vitro studies from this thesis indicate that angiogenic factors secreted from 
endometrial adenocarcinoma cells as a result of PGF2α-FP signalling can act in a 
paracrine manner on endothelial cells to regulate endothelial cell network formation 
and proliferation, processes involved in angiogenesis.  In line with this evidence, 
endometrial adenocarcinoma endothelial cells have been found to produce more 
networks in vitro compared to normal endometrial endothelial cells (Du et al., 2008).  
However, in vivo data in this thesis suggests that angiogenesis assessed by 
microvessel density (MVD) counts are not affected by PGF2α-FP signalling.  Early 
research using the chick chorioallantoic membrane (CAM) assay found that 
endometrial adenocarcinoma samples grafted to the CAM induced angiogenesis 
(Palczak and Splawinski, 1989).  However, similar CAM and rat corneal 
angiogenesis assays in which prostaglandins were injected into the CAM or cornea, 
found that PGF2α could not induce angiogenesis (Barnhill and Ryan, 1983; BenEzra, 
1978; Form and Auerbach, 1983; Ziche et al., 1982).  In addition, in mice lacking the 
FP receptor (FP-/- mice), using the retinopathy of prematurity (ROP) model of 
neovascularisation, no difference was found in levels of vascularisation in FP-/- mice 
compared to WT mice (personal communication from Dr Ying Yu, 2009, University 
of Pennsylvania, USA).  These data suggest that although PGF2α is secreted by 
endometrial cancers, it is not the primary factor involved in initiating angiogenesis.  
 
It is therefore possible that PGF2α-FP signalling could mediate vascular function by a 
mechanism independent of angiogenesis that cannot be assessed by MVD counting.  
Recent in vitro and in vivo data suggests that prostaglandin F2α signalling through the 
FP receptor may regulate vascular contractility and vascular hypertension (Errasti et 
al., 2009; Yu et al., 2009).   For example, a study by Errasti et al. found that 
prostaglandin F2α signalling through the FP receptor on endothelial cells, mediates 
vascular contractility in the human umbilical vein (Errasti et al., 2009).  This 
suggests that the endothelial FP receptor may regulate vessel diameter. In fact, in 
chapter 7 data showed there was a slight trend towards a decrease in vessel diameter 
Chapter 8  Summary and conclusions 248 
  
seen in FP tumour xenografts compared to WT tumour xenografts.  Similarly, in vivo 
studies by Yu et al. showed that FP-/- mice exhibited a decrease in vascular 
hypertension and blood pressure compared to WT mice (Yu et al., 2009).  In 
addition, studies by Wong et al. on human and hamster renal arteries suggest that an 
increase in endothelial COX-2, increases endothelial PGF2α secretion, which acts in a 
paracrine manner on vascular smooth muscle cells (VSMCs), via the thromboxane 
receptor (TP) to mediate endothelium-dependent contractions (Wong et al., 2009).  
This paracrine action of endothelial cell PGF2α could also occur in the context of the 
tumour microenvironment to mediate tumour vessel contractions and regulate 
intratumoural blood pressure.  Intratumoural blood pressure is an important 
consideration when investigating tumourigenesis as an increase in interstitial 
pressure, due to rapidly proliferating cells and leaky vessels, can cause collapse of 
blood vessels leading to hypoxia, if the intratumoural blood pressure is not sufficient.  
Additionally, intratumoural blood pressure must be considered when investigating 
blood vessel-mediated delivery of therapeutic drugs to the tumour, as an increase in 
intratumoural blood pressure may aid therapeutic delivery. 
8.7 Future work 
Further investigations using more sophisticated technical methods to examine 
vascular morphology in the WT and FP xenografts could better elucidate the role of 
the FP receptor in vascular functions of endometrial adenocarcinoma.  By employing 
in vivo bioimaging techniques, vascular perfusion of endometrial adenocarcinoma 
models could be investigated (McDonald and Choyke, 2003).  Vascular permeability 
is an important consideration when proposing to utilise the blood supply for 
therapeutic drug delivery into cancers (Fidarova et al., 2008).  As prostaglandin F2α 
secretion from endothelial cells may increase in endometrial adenocarcinoma, the 
role of endothelial PGF2α in vascular permeability could be investigated in vitro and 
in vivo.  Similarly, as PGF2α-FP signalling regulates epithelial cell secretion of 
vascular endothelial cell growth factor, a vascular permeability factor, and VEGF-A 
secretion is elevated in endometrial cancer compared to normal endometrium, the 
paracrine effects of these factors on vascular permeability could be investigated. 
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In addition, Corrosion casting is one method by which whole tumour xenograft 
vascular morphology can be examined to assess parameters such as vessel diameter, 
number of vessel branches and vessel ‘dead ends’ (Konerding et al., 1999).  For 
example, in an endometrial adenocarcinoma xenograft mouse model, corrosion 
casting was used to assess the impact of FGF2 on vessel morphology (Konerding et 
al., 1998).  In complement, in vivo bioimaging monitoring the growth of tumours and 
their blood supply would also provide useful information about the rate and nature of 
vasculogenesis and vascular morphogenesis (McDonald and Choyke, 2003).   
 
8.7.1 Use of the FP-/- mouse for in vivo corneal angiogenesis assay. 
To definitively determine the role of PGF2α and the FP receptor during in vivo 
angiogenesis, the corneal angiogenesis model could be performed using mice lacking 
the FP receptor (FP-/- mice).  The FP-/- mouse was found to have severe defects in 
parturition contributing to decreased fertility and recently, the FP-/- mouse was 
found to have defects in vascular function resulting in vascular hypotension (Yu et 
al., 2009).  Using the FP-/- mice and corneal angiogenesis assay various 
experimental parameters could be tested including, the effect of PGF2α  administered 
in FP-/- mice compared to WT mice which would investigate the potential of PGF2α 
to initiate angiogenesis specifically via the FP receptor present on epithelial and 
endothelial cells.  This would identify the specific role of PGF2α-FP signalling since 
PGF2α can also bind to and activate other PG receptors such as the EP receptors as 
discussed in section 4.4.5  Also by administering PGF2α along with angiogenic 
proteins such as FGF-2 and VEGF-A, the possibility that PGF2α acting via the 
endothelial FP receptor could potentiate angiogenesis in combination with other 
factors could be investigated.  Similarly, conditioned medium from WT and FPS 
Ishikawa cells could be administered onto the mouse cornea so that the corneal 
angiogenesis experiments could be performed to investigate the role of angiogenic 
factors, produced by FP signalling in FPS cells, in mediating angiogenesis in vivo.   
Chapter 8  Summary and conclusions 250 
  
8.7.1.1 Use of the conditionally deleted PTEN mouse to assess the 
contribution of the FP receptor in endometrial tumour 
angiogenesis and vascular function.   
Recently, a model involving the conditional deletion of PTEN from the mouse uterus 
was used to investigate the initiation and progression of endometrial cancer (Daikoku 
et al., 2008).  Endometrial cancer developed in 100% of the conditionally deleted 
PTEN mice (Daikoku et al., 2008).  An increase in COX-2 expression was seen in 
the early stages of tumour formation suggesting the possible involvement of 
prostaglandins (Daikoku et al., 2008).  A previous study showed that PGF2α-FP 
signalling in Ishikawa FPS cells upregulates COX-2 expression and PGF2α release to 
promote a positive feedback system (Jabbour et al., 2005).  Hence it is plausible that 
conditional deletion of PTEN and the increase in COX-2 expression could increase 
the secretion of PGF2α thereby promoting tumourigenesis and mediating vascular 
function via mechanisms described in this thesis.  As the FP receptor is upregulated 
in endometrial cancer and may be involved in promoting the progression of 
endometrial cancer (Sales et al., 2005), the contribution of the FP receptor could be 
investigated in vivo by mating FP-/- mice with conditionally deleted PTEN mice to 
generate an in vivo model which could provide information as to whether or not FP 
receptor expression in the uterus affects either the rate of occurrence or growth rate 
of PTEN-induced endometrial cancer.  As demonstrated by in vitro data in this 
thesis, the endothelial cell FP receptor may mediate endothelial cell function, 
therefore the physiological role of the FP receptor in the vascular function of 
endometrial cancer could be assessed.  Vascular morphology of tumours could be 
assessed, using corrosion casting methods, along with the assessment of vascular 
perfusion.  Additionally, microvessel density and angiogenic factor expression could 
be investigated by immunohistochemical analysis.  Investigations into the role of the 
FP receptor in vascular morphology and perfusion could provide valuable 
information to facilitate drug delivery to endometrial adenocarcinomas.  In addition, 
data would highlight whether FP receptor expression is essential in promoting 
tumour progression, in a PTEN background, of endometrial adenocarcinoma.  This 
could perhaps identify the relevance of using the FP receptor antagonists for 
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endometrial adenocarcinoma therapy in a situation where PTEN is deleted and the 
FP receptor is overexpressed.  As mentioned above, there is a possibility that 
endothelial PGF2α, secreted when endothelial COX-2 is elevated, can act in a 
paracrine manner on other PG receptors such as the TP receptors of VSMCs to 
regulate vascular function (Wong et al., 2009).  Therefore the extent to which FP 
expression is needed for tumour growth may not be as high as expected, as there may 
be a level of receptor redundancy or compensation occurring.   
 
8.7.2 Integrins as mediators of P CM induced endothelial cell function. 
Previous research suggests that integrins play a role in angiogenesis and are 
implicated as key regulators of endothelial cell migration (Avraamides et al., 2008).  
Integrins are a family of transmembrane glycoprotein heterodimers consisting of 
non-covalently bound α and β subunits.  The function of each integrins is defined by 
their subunits for example, the β3 subunit of integrin αvβ3 can interact with 
VEGFR2 receptor in the endothelial extracellular membrane to mediate VEGF-A 
binding and VEGFR2 activation, an interaction not found with the β1 subunit (Soldi 
et al., 1999).  Integrins interact with the extracellular matrix to transmit ‘outside-in’ 
signals that regulate endothelial cell sprouting from capillaries and adhesion.  
Previous research found that extracellular matrix component alpha-type IV collagen 
non-collagenous 1 domains (α3(IV)NC1), is an inhibitor of in vitro endothelial 
proliferation and network formation and in vivo tumour angiogenesis due to its 
interaction with integrin α3β1 (Boosani et al., 2007). α3(IV)NC1 interacts with α3β1, 
but not αvβ3, to prevent hypoxia induced-endothelial COX-2 expression which 
Boosani et al. suggest is the mechanism by which α3(IV)NC1 inhibits angiogenesis 
(Boosani et al., 2007).  Interestingly, the induction of COX-2, and therefore 
prostaglandin production, by other integrin α3β1-dependent pathways could also be 
inhibited by α3(IV)NC1 interaction with α3β1.  For example, the role of extracellular 
matrix-integrin interactions in mediating the FGF2-FGFR1 production of 
prostaglandin F2α and resulting HUVEC differentiation, induced by P CM treatment 
is a possible further avenue of investigation.  Along this line, a recent study 
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presented findings that in HUVECs, integrin α3β1 binding to fibronectin induces a 
p38-MAPKinase intracellular signalling pathway that upregulates COX-2 expression 
along with subsequent secretion of PGE2 (Viji et al., 2008).  Similarly, HUVEC 
spreading and migration on vitronectin, mediated by αvβ3, was found to be 
dependent on COX-2 activation and PGE2 production (Dormond et al., 2001).  Also 
the αvβ3-mediated activation of ERK1/2 is essential for FGF2 mediated angiogenesis 
in the in vivo CAM model (Eliceiri et al., 1998).  These data indicate that integrins 
may be involved in mediating the ERK1/2, COX-2-PGF2α pathway induced by 
FGF2-FGFR1 signalling after P CM treatment. 
 
 Alternatively, integrin α9β1 was recently found to directly bind VEGF-A and 
promote angiogenesis.  In addition, α9β1 binds to the N terminus of thrombospondin 
1 fragments to promote angiogenesis.  Inhibition of α9β1 prevents angiogenesis. It 
would be interesting to investigate if ADAMTS1, which is a negative regulator of 
VEGF-A and responsible for the release of TSP1 fragments into the cellular matrix, 
may interact with or mediate integrin-dependent angiogenesis via integrins such as 
α9β1.  
8.7.3 The role of IP receptor and PPAR in P CM-induced endothelial 
cell proliferation. 
The data in chapter 4 showed that the COX inhibitors inhibit endothelial cell 
proliferation however, involvement of the EP2 or FP receptors in endothelial cell 
proliferation was not found.  Hence, it is possible that the COX-dependent 
endothelial proliferation is reliant on an alternative COX product.  One possibility is 
that prostacyclin is the COX product involved in endothelial cell proliferation. The 
IP receptor has been implicated in the regulation of endometrial angiogenesis (Smith 
et al., 2006).  Prostacyclin treatment can induce angiogenesis and vascular 
permeability (Pola et al., 2004).  For example, in guinea pigs, intradermal injection 
of VEGF-A, but not FGF2, upregulated PGI2 expression and increased vascular 
permeability both of which could be inhibited by the addition of the COX inhibitor 
Indomethacin (Murohara et al., 1998).  However, as well as signalling through the IP 
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receptor, prostacyclin can also signal through PPAR alpha nuclear receptors to  
upregulate VEGF expression and induce angiogenesis in vivo (Pola et al., 2004).  In 
fact this previous study found using a mouse cornea neovascularisation assay that a 
prostacyclin analogue which acts only through the IP receptors in the cell can not 
facilitate angiogenesis in vivo (Pola et al., 2004). This study was recently verified 
using PPAR-/- mice which exhibit reduced corneal angiogenesis in response to 
iloprost, a stable prostacyclin analogue (Biscetti et al., 2009).  Therefore it is possible 
that prostacyclin acting through the nuclear PPAR receptor or the IP receptor may be 
involved in the regulation of P CM-mediated endothelial cell proliferation.  Further 
in vitro investigations to evaluate the role of the IP receptor in endothelial cell 
proliferation could utilise methods of IP receptor antagonists, gene silencing or IP 
receptor overexpression in endothelial cells.  Additionally, in vivo investigations 
could involve the use of WT and FP conditioned medium in the corneal angiogenesis 
assay in PPAR-/- mice to determine whether vascular function, as investigated in this 
thesis, is mediated via signalling mechanisms that coactivate nuclear receptors such 
as PPAR.  
 
8.7.4 The role of non-conventional cyclopentanone prostaglandins in 
COX-regulated endothelial cell proliferation. 
An alternative intriguing explanation of the fact that COX inhibitors inhibited 
endothelial cell proliferation (see chapter 4), although the EP2 or FP receptors were 
not involved in endothelial cell proliferation (see chapter 5), is that COX-dependent 
endothelial proliferation could be regulated by non-conventional cyclopentanone 
prostaglandins (cPGs) such as PGAs and PGJ2 which may regulate gene transcription 
without exiting the cell.  However, most evidence from macrophages suggests that 
cPGs are involved in the down-regulation of gene transcription via PPARγ activation 
(Ricote et al., 1998) and 15d-PGJ2 has been shown to inhibit rat corneal 
angiogenesis, HUVEC network formation and proliferation (Xin et al., 1999).  On 
the other hand, HUVEC apoptosis is stimulated by PGJ2 treatment upregulating p53 
in a PPARγ independent mechanism (Ho et al., 2008).  Therefore, it is likely that 
Chapter 8  Summary and conclusions 254 
  
these cPGs will be antiproliferative rather than proliferative although further studies 
are needed to confirm their role in P CM-induced endothelial cell proliferation.   
8.7.5 The role of ADAMTS1 in endometrial adenocarcinoma. 
In this thesis, antiangiogenic ADAMTS1 was found to localise to the glandular 
epithelial and endothelial cells of endometrial cancer sections.  Also, ADAMTS1 
was found to inhibit P CM-induced endothelial cell network formation and 
proliferation.  ADAMTS1 is secreted by endothelial cells and controls endothelial 
cell network formation and proliferation however, ADAMTS1 may mediate other 
vascular functions such as endothelial cell invasion.  For example, Su et al. found 
that ADAMTS1 was responsible for enhancing endothelial cell sprouting in an in 
vitro cell model (Su et al., 2008). Additionally, ADAMTS1 can enhance endothelial 
cell migration (Krampert et al., 2005).  A possible further experiment investigating 
the effect of ADAMTS1 on endothelial cell matrix invasion could be performed by 
attaching endothelial cells to microcarrier beads, embedding them in a 
collagen/matrigel matrix and coculturing with WT and FPS cells.  In this model, the 
role of ADAMTS1, both paracrine and autocrine, could be examined with 
ADAMTS1 siRNA transfection of Ishikawa cells or endothelial cells.   
 
Alternatively, as highlighted in chapter 3, ADAMTS1 is also released from epithelial 
cells in response to PGF2α-FP signalling.  Consequently, ADAMTS1 could regulate 
other aspects of tumourigenesis in addition to vascular function.  For example, data 
by Rocks et al. demonstrated that cancer conditioned medium from ADAMTS1 
overexpressing bronchial epithelial tumour cells can regulate the migration of 
fibroblast cells (Rocks et al., 2008).  Similary, Krampert et al. found that ADAMTS1 
mediated fibroblast cell migration in an in vivo mouse model of wound healing 
(Krampert et al., 2005). As ADAMTS1 expression was elevated in endometrial 
adenocarcinoma and increased by PGF2α-FP signalling, the paracrine actions of 
ADAMTS1 in mediating fibroblast migration of endometrial cancer could be 
investigated.   
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8.7.6 Elucidating the mechanism by which RCAN1-4 may regulate 
ERK1/2 induced gene expression. 
 
It is clear from the data in chapter 6 and previous studies that RCAN1-4 can prevent 
and enable endothelial cell proliferation perhaps due to the fact that changes in the 
levels of RCAN1-4 can inhibit and promote gene expression (Hilioti et al., 2004; 
Sanna et al., 2006).  For example, RCAN1-4 overexpression appeared to inhibit 
calcineurin-NFAT induced gene expression of VEGF-A and CXCL8 but increase 
ADAMTS1 expression (Hesser et al., 2004).  RCAN1-4 may regulate endothelial 
cell function by transcription dependent mechanism, i.e. through the inhibition of 
calcineurin-NFAT mediated transcription (Hesser et al., 2004) or transcription 
independent mechanisms, i.e. through the regulation of second messenger activation 
by binding Raf (Cho et al., 2005).  As Raf is an important molecule involved in the 
activation of MEK1/2 and therefore ERK1/2, it would be interesting to investigate 
the role of RCAN1-4 in the regulation of ERK1/2 activation.  ERK1/2 is activated by 
MEK and deactivated by phosphorylation and dephosphorylation events (Raman et 
al., 2007).  ERK1/2 activity can be regulated by the non-specific protein phosphatase 
2A (PP2A) (Raman et al., 2007; Van Kanegan et al., 2005).  PP2A can enhance 
ERK1/2 phosphorylation indirectly by dephosphorylating inhibitory sites on Raf 
(Raman et al., 2007).  On the other hand, PP2A can directly dephosphorylate and 
inactivate ERK1/2 (Van Kanegan et al., 2005).  In rat neuronal cultures, the 
calcineurin inhibitor cyclosporin A (CsA) inhibited ERK2 dephosphorylation after 
glutamate treatment suggesting that the phosphatase calcineurin (PP2B) may also 
regulate ERK2 phosphorylation by indirect or direct mechanisms (Paul et al., 2003).  
Therefore, as hypotheses for further investigations, RCAN-1 may interact with the 
ERK1/2 pathways in a number of ways by a) interfering with the activation of Raf by 
PP2A, b) interacting with the PP2A mediated dephosphorylation and inactivation of 
ERK1/2, or c) inhibiting ERK1/2 dephosphorylation mediated by calcineurin 
(PP2B). 
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